i a a p anthroposophic pharmaceutical codex apc second edition 11
TRANSCRIPT
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
4rd EDITION2017
International Association of Anthroposophic PharmacistsGoetheanumMedical Section4143 DornachSwitzerland
www.iaap.org.ukemail: [email protected]
IAAP International Association of Anthroposophic Pharmacists
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Introductory Note APC 4th edition, 2017
International Association of Anthroposophic Pharmacists, IAAP
The IAAP is the international umbrella organisation of the national associations of Anthroposophic Pharma- cists.
Its purpose, objective and tasks are, in detail:
• To represent anthroposophic pharmacy in the anthroposophic-medical movement and in public life on an international level: Anthroposophic pharmacy is understood as an extension of conventional phar- macy.
• To establish standards regarding further education and training as well as practice in anthroposophic pharmacy (including but not limited to retail phar-macy).
• To establish quality standards regarding manufactu-ring methods and substances used for anthroposo-phic medicinal products.
• To promote research in anthroposophic pharmacy.• To achieve international recognition by specialised
publications as well as training material for anthro- posophic pharmacists.
• To establish a cooperative network between anthro- posophic pharmacists to exchange information and best practice throughout the world.
• To initiate / coordinate international activities.
According to these aims the Board is pleased to publish the 4th edition of the Anthroposophic Pharmaceutical Codex (APC). Since this edition will only be presented in an electronic version, it has been possible to add more information, by giving easily accessible links to additional information.
Several manufacturing procedures have been adjusted to the wording and the requirements of the European Pharmacopoeia (Ph.Eur.) 9.2 (including the declaration of ethanol concentration in % V/V), especially because many methods have been adopted by the Ph.Eur. The changes are marked by a line to the side of the text. A new appendix (2.7) has been added to describe the production of some stocks by specific methods. The lists of starting materials used have been updated and widened to include for each substance 1) the manufacturing methods in use, 2) all relevant monographs of the Commission C and 3) the name of the monograph of the pharmacopoeia referred to.
In addition, several new substances, missing in the 3rd edition have been added. Further, the literature
references, which demonstrate that the substance is generally known and used in anthroposophic pharmacy / medicine, have been extended.
The APC is reviewed and updated by an anthropo-sophic pharmaceutical committee reporting to the IAAP board.
The changes in summary:
NEW TEXTS Part IIa: Production methods3.3.33.8.2
Part IV: AppendicesAppendix 2.2Boswellia speciesCampanula rotundifoliaCrataegus laevigata, C. monogyna, dried leavesIllicium verumLedum palustre Ph.fr.Malus domesticaOnonis spinosaOriganum majorana Ph.fr.Passiflora alataPinus sylvestris (essential oil DAB)Polygala senegaPrimula farinosaPrimula veris DAC (dried flowers)Solanum dulcamara Ph.fr.Veratrum album (fresh, underground parts)Veronica officinalis (fresh aerial parts) Viscum album L. 7 new substances
Appendix 2.3Arteria vertebralisCartilago (rabbit)Colon (rabbit)Cor (rabbit)Corpora quadrigemina (pig)Corpus ciliareCortex cerebriCutis (feti) (pig)Disci intervertebrales (pig)Gingiva (pig)Glandula suprarenales (rabbit)Globus oculiHypothalamus (rabbit)Lamina quadrigemina (rabbit)Larynx (rabbit)Lens cristallina (rabbit)Lien (rabbit)Mamma (rabbit)Mandibula (feti) (pig)
• Introductory N
ote
2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Maxilla (feti) (pig)Medulla spinalis (rabbit)Mucosa sinusalis (rabbit)Nervus oculomotorius (pig)Nervus ophtalmicus from the calfNervus opticus (pig)Nervus parasympathicus (rabbit)Ovarium (rabbit)Periodontium (pig)Retina (et chorioidea) (pig)Retina (et chorioidea) (rabbit)Stomachus (rabbit)Thymus (glandula) (rabbit)Truncus cerebri (rabbit)Truncus sympathicus (rabbit)Vaginae synovialis tendinum (pig)Vena cava (rabbit)
Appendix 2.4Calcarea phosphorica (calcium phosphate Ph.Eur.)Calcii lactasHepar sulfurisSulfur ad usum externum
Appendix 2.6Equisetum hyemale-RubellitOnopordon comp. praeparatum (CH)Rubellit comp.Viscum …: 8 new preparations
New appendix 2.7with 15 new preparations
REVISED TEXTS List of abbreviations and SymbolsPart IIa: Production methods"Correlation table ..." changed to "Survey of general methods for the manufacturing of anthroposophic medicinal products and related specific production methods in pharmacopoeias"
All concerned monographs: The test on 2-propanol has been deleted.All concerned monographs: The unit for the ethanol concentration was changed from m/m to V/V.Method 3.6 was changed to be in accordance with HAB 2016.Method 3.8 was changed to be in accordance with Ph.Eur. 9.0.Methods 7.2.3 and 7.2.4: "water for injections" was replaced by "purified water".
• In
trod
ucto
ry N
ote
3
Part IV: AppendicesFor each substance, preparation methods and all monographs have been added. The "references to standards" have been updated. The names of many substances have been changed in accordance with changes to the pharmacopoeias.
Appendix 2.6Quercus robur/petrae e cortice cum Calcio carbonico changed in Quercus e cortice cum Calcio carbonicoFor many compositions the potentising method has been added to the preparation method.
DELETED TEXTS Appendix 2.1:CalciteCalx jurassicaCarnelianDiamondPyrolysitSulfurSulfur selenosumTerra rubraVanadiniteZircon
Appendix 2.2: Acorus calamus (Volatile oil from the underground parts)Adonis vernalis (fresh flowers)Aethusa cynapiumAilanthus altissimaAjuga reptansAlchemilla xanthochloraAmaryllis belladonnaAnagallis arvensis (fresh aerial parts)Anagallis arvensis Ph. fr. (not fresh aerial parts)Angelica archangelica (fermented juice from roots)Armoracea rusticanaArmoracea rusticana Ph.fr.Arundo donax Aspidosperma quebracho-blancoAtropa belladonna Ph.fr. (now Ph.Eur.)Atropa bella-donna DACBallota nigraBambusa arundinacea, Bambusa vulgarisBoswellia species ( Olibanum DAC)Botrychium lunariaCentaurium erythraeaChamaelirium luteumCheiranthus cheiriChondodendron tomentosumCichorium intybus (dried root)Coffea arabica Ph.fr.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
4
Colchicum autumnale Ph.fr.Collinsonia canadensis L.Croton tiglium L.Cupressus sempervirensEuphorbia resiniferaFilipendula ulmaria (fresh inflorecence)Fraxinus americanaFucus vesiculosusGalium odoratumGlechoma hederacea Ph.fr.GramineaeHeracleum mantegazzianumHibiscus sabdariffaHippophaë rhamnoides (fresh branches with fruits)Hoya carnosaHumulus lupulusLaurus nobilisLavandula angustifolia HAB (fresh flowers)Lavandula angustifolia Ph.fr. (flowering stems)Leptandra virginicaLevisticum officinale, whole fresh plantLevisticum officinale, fresh flowersLevisticum officinale, fresh leavesLilium lancifolium Ph.fr. (whole fresh flowering plant)Linum usitatissimum (linseed)Lophophora williamsiLycopersicon lycopersicum, fresh ripe fruitsMalus sylvestris (core from fresh fruit)Malus sylvestris (fresh unripe fruit)Malva sylvestris Ph.fr.Medicago sativaMelilotus officinalisMenyanthes trifoliataMomordica balsaminaMonotropa unifloraOcimum basilicum (dried flowering aerial parts)Ornithogalum umbellatumPetroselinum crispum (dried roots)Phyllanthus niruriPicea nigra (dried resin)Piper nigrum (dried fruit)Plantago lanceolata DAB 1999Plantago lanceolata Ph.Eur.Podophyllum peltatumPollenPolygala amaraPolypodium vulgare (fresh underground parts)Primula veris Ph.fr. (dried flowers)Ptelea trifoliateRhamnus purshianaRhododendron ferrugineum L. (Ph.fr. remains)Robinia pseudoacacia (HAB/Ph.fr. remains)Rosa caninaSambucus nigra (dried inflorescence)Sanicula europaea HAB
Saponaria officinalisSarcopoterium spinosumScrophularia nodosaScutellaria laterifoliaSedum acre (HAB remains)Sedum telephiumSenecio vulgarisSerenoa repens HABSmilax species Ph.fr.Solanum dulcamara HABSpigelia anthelmia Ph.fr.Stellaria mediaSyzygium jambosTanacetum vulgareTeucrium marum HABTriticum aestivum (fresh flowers)Urginea maritima var. rubra (HAB remains)Urtica dioica, fresh leavesUrtica dioica: Urticae folium Ph.Eur.Urtica dioica (dried leaves)Vaccinium myrtillus Ph.Eur.Vaccinium vitis-idaeaValeriana officinalis (fresh flowers)Veratrum album Ph.fr. (fresh)Verbascum densiflorum HABVerbascum densiflorum (dried fruit)Vinca minorViola tricolor Ph.fr.Viola tricolor (Violae herba cum flore Ph.Eur.)Viscum album (Fresh plant excluding haustorium (Host tree: Oak))Viscum album (Fresh plant excluding haustorium (Host tree: e.g. Ulmus caprinifolia Gled., Elm))Viscum album HABViscum album (Fresh shoots collected in summer and flowers collected in winter (Host tree: Salix alba))Viscum album (Fresh aerial parts including fruit of Viscum album L. (Host trees: Apple, Birch, Fir, Pine, Lime))Zea mays
Appendix 2.3Asterias rubens BadiagaBlatta orientalisBothropsBufo ranaDuctus deferensElapsFavusFel: Bile from gall bladder from the rabbitGlucogenumJejunumKeratinum EquiLachesis lanceolatus
• Introductory N
ote
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
5
MoschusNervus trigeminus from the rabbitOssa (Bones from the pig)Ossa longa from the calfPelvis renalis (et Ureter) from the calfPortio vaginalis from the cowSepiaTarantula hispanicaTestes from the rabbitThalamus from the rabbitTruncus encephali (brain stem)Truncus encephali (hypothalamus and other organs)Uterus from the pigVena tibialis
Appendix 2.4Acidum benzoicum Acidum benzoicum e resina Acidum citricum (Citric acid)Acidum formicicumChinini sulfasFerrum gluconicumHydrargyrum stibiato-sulfuratumHydrargyrum sulfuratum nigrumKalium arsenicosum pphStannum silicicumStibium sulfuratum nigrum
Appendix 2.6Hepar sulfuris (now in app. 2.4)Lapis Cancri praeparatusOnopordon comp. praeparatum (D)Quarz cum Ferro sulfuricoViscum Pini cum ArgentoViscum Pini cum Cupro
Members of the APC committee
Gabriele Jones, pharmacist, Germany, member of the Further Education Committee of GAPiD.
Jakob Maier, pharmacist, Switzerland, Board member of VAEPS and member of the Committee on Comple- mentary Medicinal Products of the Swiss Pharmaco- poeia (Ph.Helv.) until April 2017.
Peter Pedersen, pharmacist, Denmark (chairman), former member of the Committee on Manufacturing Methods of the German Homoeopathic Pharmacopoeia (GHP/HAB).
René Schwarz, biology technician, former head of production Weleda Switzerland, Board member of VAEPS.
Responsible person of the IAAP:
Mónica Mennet-von Eiff, pharmacist, Switzerland, President of the Swiss association VAEPS, Board member of the IAAP; member of the Working Group HOM on Homoeopathic Raw Materials and Stocks of the European Pharmacopoeia (Ph. Eur. HOM WP).
The committee appreciates substantial help from Anne Vernet (Weleda, France), Elke Heid (WALA), Wolfram Engel (Weleda, Germany) and Anja Glockmann (ESCAMP, Germany).
The APC is recognised by the following national anthroposophic pharmaceutical associations:
the French Association AFERPA (Association Française d'étude et de recherche sur la pharmacie anthroposophique – French Association for Studies and Research on Anthroposophic Pharmacy);the Brazilian Association Farmantropo (Associação Brasileira de Farmácia Antroposófica – Brazilian An- throposophic Pharmacy Association);the German Association GAPiD (Gesellschaft Anthroposophischer Apotheker in Deutschland – Society of Anthroposophic Pharmacists in Germany);the Austrian Association ÖGAPh (Österreichische Gesellschaft anthroposophischer Pharmazeuten – Austrian Society of Anthroposophic Pharmacists);the Italian Association SOFAI (Società di farmacisti antroposofi in Italia – Society of Anthroposophic Pharmacists in Italy);the pharmacist section of the Swiss association VAEPS (Verband für Anthroposophisch Erweiterte Pharmazie in der Schweiz – Association for Anthroposophically Extended Pharmacy in Switzerland).
Dr. Manfred Kohlhase, President IAAP, 30.06.2017For full details of the IAAP Guidelines, see website www.iaap.org.uk
• In
trod
ucto
ry N
ote
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• Fo
rew
ord
7
Foreword
Pharmacy extended by the principles of anthroposophy began to be developed at the beginning of the 20th century by Rudolf Steiner (founder of anthroposophy, 1861 – 1925) and Oskar Schmiedel (Austrian chemist, 1887 – 1959), in collaboration with a number of physicians. Their aim was to reinterpret and complement the results of pharmaceutical and medical research with insights gained from anthroposophic research of the human being and nature.The basis of the anthroposophic approach to pharmacy is the “holistic” knowledge of mankind and nature, which recognizes the notion that human beings and the kingdoms of nature are related through a common evolution1.This perception leads to a comprehensive view of substances in their relationship to health, illness and to a specific approach to pharmacy.
Therefore anthroposophic pharmacy uses substances from the mineral, plant and animal kingdoms2,3.
Anthroposophic medicinal products have been on the market world-wide and prescribed by qualified medical practitioners since 1921.
The range of anthroposophic medicinal products is partially determined by the physical characteristics of substances, whereby allopathic, phytotherapeutic and homoeopathic criteria are taken into consideration. Most particularly, anthroposophic medicinal products are characterised by their manufacturing processes involving specific anthroposophic and typical homoeopathic pharmaceutical procedures. The range of anthroposophic medicinal products includes potentised medicinal products, manufactured by using the methods of the official homoeopathic pharmacopoeias, as well as concentrated mineral, herbal or animal substances or preparations and compounded medicinal products. Considering this diversity, anthroposophic medicinal products, cannot be defined under a single substance classification.
1 Jos Verhulst: „Der Erstgeborene“ (The first-born), publisher Verlag Freies Geistesleben, Stuttgart, D 2001.2 Rudolf Steiner/Ita Wegman: „Grundlegendes für eine Erweiterung der Heilkunst nach geisteswissenschaftlichen Erkenntnissen.“ GA 27, publisher Rudolf Steiner Verlag, Dornach, CH, 1992.In English: „Extending Practical Medicine – Fundamental Principles based on the Science of the Spirit“. Rudolf Steiner Press , London, GB, 1996.3 Rudolf Steiner: „Geisteswissenschaft und Medizin“, 20 Vorträge für Ärzte (1920), Rudolf Steiner Verlag, Dornach, CH 1985.In English: „Introducing Anthroposophical Medicine“ (previously published as: Spiritual Science and Medicine). Twenty lectures to doctors. Dornach 21 March – 9 April 1920, GA 312. Anthroposophic Press, Hudson, NY, USA, 1999.
The Anthroposophic Pharmaceutical Codex APC gives an overview of substances and methods used in the manufacture of anthroposophic medicinal products as well as of the related quality parameters.
Legal SituationToday the European Union Directive 2001/83/EEC and amendments contain the main legislation concerning medicinal products. The legal status of anthroposophic medicinal products in the EU is closely related to that of homoeopathic medicinal products (see below).
Preamble of Directive 2001/83/EEC n° (22) refers to anthroposophic medicinal products as follows:“Anthroposophic medicinal products, which are described in an official pharmacopoeia and prepared by a homoeopathic method are to be considered, as regards to registration and marketing authorization, as homeopathic medicinal products.”
From a regulatory point of view anthroposophic medicinal products can be devided into two categories:• anthroposophic medicinal products manufactured
according to a homoeopathic manufacturing method within the meaning of Directive 2001/83/EEC, article 1, 5.: “Any medicinal product prepared from substances called homoeopathic stocks in accordance with a homoeopathic manufacturing procedure described by the European Pharmacopoeia or, in absence thereof, by the pharmacopoeias currently used officially in the Member States. (...)”
• anthroposophic medicinal products other than those manufactured by a homoeopathic manufacturing method.
These are equally important and have never been included in any pharmacopoeia.
The definitions of anthroposophic medicinal products given in the Swiss and German Drug Laws take both categories into account (translations by APC Committee):
Switzerland: Regulation of Swissmedic concerning the simplified Authorisation of Complementary and Herbal Medicinal Products (Verordnung des Schweizerischen Heilmittelinstituts über die vereinfachte Zulassung von Komplementär- und Phytoarzneimitteln) Art. 4,2 f: Anthroposophic medicinal product: Medicinal product, whose active substances are manufactured by a homoeopathic manufacturing procedure, or according to an anthroposophic manufacturing procedure described in the German Homoeopathic Pharmacopoeia or in the British
• Forew
ord
Homoeopathic Pharmacopoeia or according to a special anthroposophic manufacturing procedure and that is formulated and developed according to the anthroposophic knowledge of man, animal, substance and nature and is meant to be used according to these principles.
Germany: Medicinal Products Act (Gesetz über den Verkehr mit Arzneimitteln) Art. 4, (33) An anthroposophic medicinal product is a medicinal product that has been developed according to the anthroposophic knowledge of man and nature and that is manufactured according to a homoeopathic manufacturing procedure described in the European Pharmacopoeia or in absence thereof in a pharmacopoeia officially used in the Member States or according to a special anthroposophic manufacturing procedure and that is meant to be used according to the anthroposophic principles concerning man and nature.
In many EU countries, and also world-wide, medicinal products used for the anthroposophic therapeutics are thus partially integrated in legislation.
In Brazil as well as in Australia the APC has been officially recognised as quality standard and reference for anthroposophic medicinal products (RESOLUÇÃO RDC No – 26, DE 30 DE MARÇO DE 2007; amendments to the Australian Therapeutic Goods Act, 2009).
In summary anthroposophic medicinal products as a whole are step by step gaining legal recognition in the EU as well as world-wide, and among other things this requires comprehensive publication of their pharmaceutical quality.
The publication of the Anthroposophic Pharmaceutical Codex is to provide transparency of anthroposophic pharmaceutical quality for pharmacists and bodies requiring an appreciation of anthroposophic medicinal products and pharmacy. Furthermore it provides a basis for the maintenance of existing and development of new anthroposophic medicinal products.
The relationship of the APC to the European Pharmacopoeia, to other existing official Pharma-copoeias and non official pharmacopoeias
The APC is published by the IAAP, an independent association of professional pharmacists, within the context of official existing pharmacopoeias. It is the intention of the APC to refer where possible to existing pharmacopoeias. In fact anthroposophic medicinal
8
products are often manufactured and controlled according to existing specifications and standards.A part of the reference pharmacopoeias for the APC are published by official Authorities, in particularThe European PharmacopoeiaThe French PharmacopoeiaThe German Homoeopathic Pharmacopoeia (which is a part of the German Pharmacopoeia);The Swiss Pharmacopoiea has implemented two texts concerning anthroposophic pharmacy in the last eight years:• in 2009 (Suppl. 10.1) with the general Ph.Helv.-mo-
nograph “Praeparationes anthroposophicae (Anth-roposophic Preparations)” (Ph.Helv. CH 306); it was the first time that anthroposophic preparations ap-peared as a monograph in an official pharmacopeia. This monograph includes the paragraphs definitions, starting materials, methods of preparation and dosa- ge forms, by analogy with the Ph.Eur.-monograph Homoeopathic preparations Ph.Eur. 1038.
• in September 2013 (Suppl. 11.1) the new Ph.Helv.-chapter “17.7 Manufacturing methods for anthropo-sophic preparations” came into force. This chapter gives an overview on the general manufacturing processes and describes in more detail some manu-facturing methods which are more frequently used in anthroposophic pharmacy and had not been described in an official pharmacopoeia before.
The APC served as important basis to establish both of these Ph.Helv.-texts. Therefore it can be concluded, that the continuing work of the APC supports the establishment of the pharmaceutical quality standards and the regulation of anthroposophic medicinal products in Switzerland.
Further official pharmacopoeias of reference:The Austrian PharmacopoeiaThe British Pharmacopoeia
In particular the European Pharmacopoeia today represents and for the future will represent a reference of paramount importance for the APC.
Therefore in part IV of the APC containing the lists of the various substances used in anthroposophic pharmacy reference is made where possible to the European Pharmacopoeia and other official pharmacopoeias.
Particularly important Ph.Eur. monographs are:Herbal drugs for homoeopathic preparations (2045)Homoeopathic preparations (1038)Methods of preparation of homoeopathic stocks and potentisation (2371)Minimising the risk of transmitting animal spongiform
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• Fo
rew
ord
9
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
encephalopathy agents via human and veterinary medicinal products (50208)Mother tinctures for homoeopathic preparations (2029)Tinctures (chapter in 0765 Extracts)Viral safety (50107)Other pharmacopoeias referred to in the APC are not officially recognised. Nevertheless they provide reliable standards accepted e.g. by regulatory authorities, in particular the British Homoeopathic Pharmacopoeia.
The IAAP understands its task to sustain anthro-posophic pharmaceutical activities at any level (e.g. manufacturing, quality control, regulatory affairs), worldwide, that is, beyond the countries of the European Pharmacopoeia Convention. Therefore during the evolution of the APC other official pharmacopoeias (or reliable private pharmacopoeias) will possibly be referred to, e.g. the Brazilian Pharmacopoeia.
• Table of C
ontent
10
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Table of ContentStructure of the Anthroposophic Pharma ceutical Codex, APC ...................................................................................12List of Abbreviations and Symbols ....................................................................................................................................13Glossary ................................................................................................................................................................................14
PART IDefinitions ......................................................................................................................................................... 151. Anthroposophic medicinal product .............................................................................................................................162. Starting materials, general information .......................................................................................................................16
2.1. Minerals, rocks, including natural waters ...........................................................................................................162.4. Starting materials that can be described chemically..........................................................................................162.5. Starting materials that have undergone special treatment ................................................................................162.6. Compositions (for further information see “Glossary”) ...................................................................................16
3. Vehicles and excipients ...................................................................................................................................................184. Active substances .............................................................................................................................................................18
4.1. Starting materials ...................................................................................................................................................184.2. Preparations ............................................................................................................................................................18
PART IIa General monographs of preparations and specific production methods (Pharmaceutical processes) .......... 19Introduction .........................................................................................................................................................................20Survey of general methods for the manufacturing of anthroposophic medicinal products and related specific production methods in pharmacopoeias .........................................................................................................................221. SPECIAL TREATMENTS OF RAW MATERIALS....................................................................................................24
1.1. Vegetabilisation methods (“vegetabilised metals“) ............................................................................................242. METAL PREPARATIONS .............................................................................................................................................25
2.1. Metal mirrors ..........................................................................................................................................................253. TINCTURES, MOTHER TINCTURES, GLYCEROL MACERATES AND VISCOUS EXTRACTS .................26
3.1. Cold treated mother tinctures and liquid preparations thereof .......................................................................263.2. Tinctures and mother tinctures made by macerations with water or ethanol/water ....................................273.3. Glycerol macerates .................................................................................................................................................283.4. Liquid preparations made by maceration with oil .............................................................................................303.5. Mother tinctures made by percolation ................................................................................................................303.6. Buffered aqueous mother tinctures manufactured under exclusion of oxidative influence ..........................313.7. Fermented mother tinctures .................................................................................................................................323.8. Tinctures and mother tinctures made by digestion (Digestio) ........................................................................333.9. Tinctures and mother tinctures made by infusion (Infusum) .........................................................................343.10. Tinctures and mother tinctures made by decoction (Decoction) .................................................................353.11. Viscous extracts with heat treatment .................................................................................................................363.12. Preparations made by distillation (Distillates) .................................................................................................373.13. Mother tinctures obtained by rhythmic application of heat and cold...........................................................38
4. SOLID STARTING MATERIALS OBTAINED BY HEAT .......................................................................................394.1. Toasted preparations – Tosta .................................................................................................................................394.2. Carbons – Carbo .....................................................................................................................................................404.3. Ashes – Cinis ...........................................................................................................................................................40
5. SOLID PREPARATIONS FROM PLANTS (DRYING ONTO A VEHICLE) .......................................................415.1. Solid preparations from fresh plants ...................................................................................................................415.2. Solid preparations from liquids, plant juices or aqueous extracts ...................................................................41
• Ta
ble
of C
onte
nt
11
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
6. LIQUID DILUTIONS .....................................................................................................................................................427. COMPOSITIONS ...........................................................................................................................................................43
7.1. Compositions made by treating two or more starting materials by one or more pharmaceutical processes .................................................................................................................437.2. Compositions made by treating two or more extracts or mother tinctures of one plant by one or more pharmaceutical processes ............................................................................................437.3. Compositions made by treating one or more starting materials with one or more mother tinctures which undergo one or more pharmaceutical processes together ..........................................................457.4. Compositions made by treating two or more extracts or mother tinctures and/or dilutions by one or more pharmaceutical processes ....................................................................................457.5. Compositions made by co-potentising................................................................................................................46
8. POTENTISED PREPARATIONS .................................................................................................................................468.1. Co-potentised preparations ..................................................................................................................................478.2. Potentising in an ointment base ...........................................................................................................................478.3. Triturations..............................................................................................................................................................48
9. MIXTURES ......................................................................................................................................................................48
PART IIb Individual monographs of starting materials and preparations ..................................................................... 50CYDONIA OBLONGATA, FRUIT ..................................................................................................................................51CYDONIA OBLONGA, FRUIT, HEAT TREATED AQUEOUS TINCTURE 1:2.1 .................................................51CYDONIA OBLONGATA, FRUIT, GLYCEROL EXTRACT WITH HEAT TREATMENT 1:2.1 ..........................52CYDONIA OBLONGATA, FRUIT, MOTHERTINCTURE OBTAIND BY RHYTHMIC APPLICATION OF HEAT AND COLD CYDONIA OBLONGATA E FRUCTIBUS FERM 33B .........................53LEVICO WATER .................................................................................................................................................................54
PART III Dosage forms ..................................................................................................................................................... 56INDEX LIST OF TERMS OF PART I, II AND III .........................................................................................................60
PART IVAppendices ........................................................................................................................................................ 64Note concerning appendix 2.3. ..........................................................................................................................................65 Note concerning appendices 2.1., 2.4. and 2.6. ................................................................................................................65 References concerning nomenclature in appendices 2.1. to 2.7 ....................................................................................65 Note concerning the references for use in anthroposophic medicine in appendices 2.1. to 2.7 ...............................65 References concerning the use in anthroposophic medicine in appendices 2.1. to 2.7 .............................................66
Appendix 2.1. List of minerals, rocks and natural waters ...............................................................................................73Appendix 2.2. List of starting materials of botanical origin ...........................................................................................83Appendix 2.3. List of starting materials of zoological origin ...................................................................................... 135 Appendix 2.4 List of starting materials that can be described chemically ............................................................... 167Appendix 2.5. List of starting materials that have undergone special treatment ..................................................... 185Appendix 2.6. List of compositions ................................................................................................................................ 189Appendix 2.7. Stocks with special manufacturing methods ....................................................................................... 201Appendix II .................................................................................................................................................................... 205Correlation table: Ph.Eur. / HAB manufacturing methods used in anthroposophic pharmacy and corresponding manufacturing methods in the HPUS ........................................................................................... 205
• Structure of A
PC
Structure of the Anthroposophic Pharma ceutical Codex, APC
Part I “Definitions” provides definitions and describes quality aspects as well as parameters related to anthroposophic medicinal products. The different stages incurred in the obtaining of a medicinal product, from the starting material to the dosage form, are described in this part.
Part IIa “General Monographs of specific production methods (Pharmaceutical processes)” contains general monographs concerning the types of preparations/ active substances that are prepared by specified procedures. Beneath the relevant general monograph(s), different specific production methods by which a particular type of a starting material can be prepared are either quoted from other pharmacopoeias or an APC production method is set out.
In this way, the relationship between the APC and other pharmacopoeias, as well as the option to define substances through their production methods are outlined.
Schematically the following order is applied:
General monographs
Definition, Identification, Tests, Assay, Storage, Recommended Designation
Specific production methods related to the particular general monograph
Ph.Eur. Methods
HAB Methods
Ph.fr. Methods
B.Hom.P. Methods 1, 2, 3, 4, 5a, 5b, 6,
8a, 12
APC Methods
12
Part IIb “Monographs of starting materials and preparations” sets standards for specific starting materials and preparations. In their last section the monographs of the starting materials list a) Some existing anthroposophic preparations that utilise the starting material and/ or b) Manufacturing methods, described in the Ph.Eur., the HAB or the APC commonly used for the processing of the particular starting material. That list is not meant to be exhaustive.
Part III, information about dosage forms in anthroposophic pharmacy as well as production methods of specific dosage forms for anthroposophic medicinal products.
Part IV “Appendices”
In appendix I starting materials for the preparation of anthroposophic medicinal products are listed (not excipients and vehicles). The appendices are numbered according to the related chapter in part I: 2.1., 2.2., 2.3., 2.4., 2.5., 2.6.
In appendix II a link to the HPUS is given:• Correlation table: Ph.Eur./HAB manufacturing
methods used in anthroposophic pharmacy and corresponding manufacturing in the HPUS.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• St
rucr
ure
of A
PC
13
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
List of Abbreviations and Symbols
* see p. 65
1 CH Symbol for the first centesimal potency, see also C1 and 1C
1 DH Symbol for the first decimal potency, see also D1 and 1X
1C Symbol for the first centesimal potency, see also 1 CH and C1
1X Symbol for the first decimal potency, see also 1 DH and D1
ABMA-Vade-mecum
Gardin NE, Schleier R: Medicamentos Antroposóficos: Vademecum. Associação Brasileira de Medicina Antroposófica. São Paolo:Editor João de Barro; 2009
APC Anthroposophic Pharmaceutical Codex
aph ad preparationes homoeopathicae
API Active Pharmaceutical Ingredient
B.Hom.P. British Homoeopathic Pharmacopoeia
B.P. British Pharmacopoeia
Br1 Numbering of the production methods of the B.Hom.P.
C1 Symbol for the first centesimal potency, see also 1 CH and 1C
CVD Chemical Vapour Decomposition
D1 Symbol for the first decimal potency, see also 1 DH and 1X
DAB Deutsches Arzneibuch(German Pharmacopoeia)
DAC Deutscher Arzneimittel-Codex(German Codex of Medicinal Products)
DER Drug extract ratio
EU European Union
fhp for homoeopathic preparations
GHP German Homoeopathic Pharmacopoeia. Unauthorized translation of the HAB. In case of differences between the GHP and the HAB the latter is decisive
Gl Symbol for mother tinctures prepared by HAB method 41 using glycerol
H 2.2.6 Analytical method specified in the HAB
HAB Deutsches Homöopathisches Arzneibuch(German Homoeopathic Pharmacopoeia)
HPUS The Homœopathic Pharmacopœia of the United States
IAAP International Association of Anthroposophic Pharmacists
IVAA statement2013
see p. 67
KC Mono-graph
Monograph of the “Kommission C” (Commission of the German Ministry of Health for the anthroposophic therapeutic system and substances), published in the official Gazette of the German government (in German: “Bundesanzeiger”)
Liste HAS Liste der Homöopathischen und Anthropo- sophischen Stoffe (Anhang 4 zurVerordnung des Schweizerischen Heilmittelinstituts über die vereinfachte Zulassung von Komplementär- und Phytoarzneimitteln (List of Homoeopathic and Anthroposophic Subtances (Appendix 4 in the Regulation of the Swissmedic concerning the simplified Authorisation of Complementary and Herbal Medicinal Products in Switzerland))
LM Symbol for potencies prepared according to Ph.Eur. (2371) 5.2
MT Mother tincture
Ph.Eur. European Pharmacopoeia
Ph.Eur. (2371)
Ph.Eur. Monograph 2371 “Methods of preparation of homoeopathic stocks and potentisation”
Ph.fr. Pharmacopée Française (french Pharma copoeia), including monographies de souches pour préparations homéopathiques (monographs of the stocks for homoeopathic preparations)
Ph.Helv. Pharmacopoea Helvetica(Swiss Pharmacopoeia)
pph pour préparation homöopathiques
• Structure of A
PC
Glossary
In this glossary only those terms are referred to, that need extra clarification prior to the definitions given in part I.
Composition Definition given in the monograph “Anthroposophische Zubereitungen”, (Anthroposophic preparations), Swiss Pharmacopoeia, Supplement 10.2, (translation by Swissmedic): “Compositions are active substances which are obtained, when two or more starting materials or preparations, with or without excipients, are processed together in a pharmaceutical process of anthroposophic pharmacy (e.g. Ferrum-Quarz).”
Excipient Excipients are auxiliary substances, which may be used for the production of pharmaceutical dosage forms. Excipients may beused in the production of mixtures.
Pharmaceutical process General term for substance transformations at different stages to obtain starting materials for medicinal products or a medicinal product.
Preparation/active substance
A class of processed starting material specified in the monographs of part II.
Production method A general manufacturing procedure specified in a pharmacopoeia (see e.g. HAB).
Raw material Substance which has not undergone any pharmaceutical process and meets a general quality characterisation, e.g. an optical identification.
Starting material A substance or a composition that meets a specification and can be used as active substance or can be further processed.
Vehicle Vehicles are auxiliary substances which may be used to produce an active substance. Vehicles may be used in the production of mixtures.
14
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Q Symbol for potencies dilutedby the ratio 1: 50 000
Rh Symbol for mother tinctures prepared by HAB methods 21 and 22 (rhythmic procedure)
Vade-mecum
Gesellschaft Anthroposophischer Ärzte in Deutschland (ed.)Vademecum Anthroposophische Arzneimittel3.erg. Aufl. Der Merkurstab 2013; 66 (Suppl.)
• A
PC P
art I
15
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IDefinitions
Table of ContentPart I1. Anthroposophic medicinal product .................. 162. Starting materials, general information ............ 16 2.1. Minerals, rocks, including natural waters . 16 2.2. Starting material of botanical origin .......... 16 2.3. Starting materials of zoological origin ....... 16 2.4. Starting materials that can be described chemically ........................................... 16 2.5. Starting materials that have undergone special treatment .............................. 16
2.6. Compositions (for further information see “Glossary”) .......... 163. Vehicles and excipients........................................ 184. Active substances ................................................. 18 4.1. Starting materials .......................................... 18 4.2. Preparations................................................... 18
• A
PC Part I
1. Anthroposophic medicinal product
definitionAn anthroposophic medicinal product is conceived, developed and produced in accordance with the anthroposophic knowledge of man, nature, substance and pharmaceutical processing1. The application within anthroposophic medicine results from that knowledge².
According to anthroposophic principles, active substances may be starting materials which are used as such or starting materials which have been transformed into active substances by a process of anthroposophic pharmacy, including compositions.
An anthroposophic medicinal product can contain one or more active substances (see also part I, chapter 4).
An anthroposophic medicinal product can fundamentally be employed in every dosage form, including external (topical), internal and parenteral dosage forms (see also part III).
productionThe active substances or dosage forms of anthroposophic medicinal products are produced:
• in accordance with classical homoeopathic or anthro-posophic-homoeopathic manufacturing methods as described in the Ph.Eur., HAB, Ph.fr., and B.Hom.P. (Methods 1, 2, 3, 4, 5a, 5b, 6, 8a, 12)
• in accordance with anthroposophic pharmaceutical codex production methods, i.e. “APC Methods”
and/or• in accordance with anthroposophic manufacturing
methods described in the individual monograph.
An anthroposophic medicinal product complies with the relevant specifications/ monographs set out in parts I and II.
1 See IAAP brochure: “Basic Information on the Working Principles of Anthroposophic Pharmacy”, 2005, http://www.iaap.org.uk/downloads/principles.pdf2 For clarification it has to be mentioned here, that anthroposophic medicine from the beginning includes “Over the Counter” products (OTC). A part of its medicinal products had been conceived right from the start for broad use for typical health disorders; see Chapter XX, “Typical Remedies”, in Rudolf Steiner/Ita Wegman: “Grundlegendes für eine Erweiterung der Heilkunst nach geisteswissenschaftlichen Erkenntnissen.” GA 27, publisher Rudolf Steiner Verlag, Dornach, CH, 1992.In English: “Extending Practical Medicine – Fundamental Principles based on the Science of the Spirit”. Rudolf Steiner Press , London, GB, 1996.
16
recommended designation Concerning the designation of anthroposophic medicinal products a reference to the APC is recommended.
2. Starting materials, general information
Starting materials for the production of anthroposophic medicinal products are:
2.1. Minerals, rocks, including natural waters
2.2. Starting materials of botanical origin Dried or fresh plants or parts of plants, including algae, fungi and lichens; Plant secretions, juices, extracts, oleoresins, essential oils or distillation products.
2.3. Starting materials of zoological origin Whole animals, organs, parts of organs dried or fresh; Animal secretions, extracts, blood products, calcareous products.
2.4. Starting materials that can be described chemically
2.5. Starting materials that have undergone special treatment
2.6. Compositions (for further information see “Glossary”)
Starting materials for the production of anthroposophic medicinal products comply with any relevant monograph in the European Pharmacopoeia or in the absence thereof, with the relevant monographs in national pharmacopoeias used in the Member States, or in absence thereof with the individual monograph.
Starting materials can be active substances themselves or can be processed into preparations (see also Part I, chapter 4).
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
17
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
2.1. Minerals, rocks, including natural watersMinerals are solid, crystalline components of natural origin belonging to the earth’s crust and other celestial bodies. A mineral has a defined crystal system and crystal class. Minerals are chemically and physically homogeneous to a significant extent. In reality, however, there are always deviations from the theoretical mineral formula. Many minerals may show differences in their colours. Form and habitus may be significantly different within the same type.
Rocks are composed of one or more minerals having a geological definition and distribution in their natural deposit with a certain statistical homogeneity.
Pieces that will be used for production should be big enough to allow mineralogical identification. If a powdered mineral is used, adequate documentation should ensure the quality and natural origin. In fact pieces used for production must be free from visible foreign matter. They have not undergone any unwanted mechanical or chemical treatment: in particular any chemical reaction, colouring, varnishing, heating and artificial radiation must be excluded. The amount of foreign matter accepted after chemical analysis is specified in the respective monograph.
Natural waters can come from a natural source (e.g. Levico), from the sea (e.g. aqua maris) or from mineral cavities (e.g. agate water).
List of minerals, rocks, including natural waters: see part IV, appendix 2.1.
2.2. Starting materials of botanical originStarting materials of botanical origin are:• Dried or fresh plants or parts of plants,
including algae, fungi and lichens;• Plant secretions, juices, extracts, oleoresins,
essential oils or distillation products.
Fresh plants should be used shortly after harvest. If this is not possible, the quality is guaranteed by appropriate measures, e.g. freezing.
If material from cultivated plants is used preference should be given to materials from plants cultivated by biodynamic cultivation (“Demeter” certified) or by other certified organic cultivation methods in accordance to the relevant European regulations ruling organic agricultural products (see also Council Directive (EEC) n° 2092/91).If wild plants are harvested protection of species according to relevant regulations is granted and special care is taken of the eco-system concerned.
Plants or parts of plants are, as far as possible, free from impurities such as soil, dust, dirt and other contaminants such as fungal, insect and other animal contaminations. They are not decayed.
Harvested plants or the mother tinctures made thereof are analysed for content of heavy metals and pesticides.The range and frequency of this testing can occur according to a monitoring plan based on risk assessment.
Unless otherwise stated, the collecting or harvesting times are generally:
Whole plants with underground partsand plants without underground parts
at flowering time
Leaves and shoots when fully developed
Flowers shortly after opening
Bark throughout the year
Underground parts of annual plants
at seed ripening time
Underground parts of biennial and perennial plants
in spring
Fruits and seeds at the time of ripening
Fungi when the fruiting bodies are fully developed
Particle size: according to Ph.Eur. 2.1.4 Sieves.
Starting materials of botanical origin see part IV, appendix 2.2.
2.3. Starting materials of zoological originStarting materials of zoological origin are:• Whole animals, organs, parts of organs
dried or fresh;• Animal secretions, extracts, blood products,
calcareous products. Lower animals as well as warm-blooded animals are used.
• A
PC Part I
Animal husbandry and keeping must be adequate for the animal species (see also Council Directive (EEC) n° 2092/91). In particular in the case of warm-blooded species animals from well-monitored “Demeter” or biodynamic herds are preferentially used.
The starting materials of zoological origin must meet the requirements of the European and/ or relevant national pharmacopoeias regarding the preparation of medicinal products from materials of animal origin and with EU directives and/or national guidelines of the appropriate regulatory authorities.In particular the Ph.Eur. monographs on TSE safety (Ph.Eur. 50208), and viral safety (Ph.Eur. 50107) apply.
Animals must be healthy and in good hygienic condition. The intervals given in legislation after the administration of drugs to animals must be observed before the animals are used.
Health requirements, animal keeping, protection of species and processing of animals must comply with the relevant guidelines of responsible national authorities and those of the European Union, where applicable.
List of starting materials of zoological origin see part IV, appendix 2.3.
2.4. Starting materials that can be described chemicallyStarting materials that can be described chemically are inorganic and organic substances.Organic substances are generally of natural origin, e.g. purified fractions.
Preference should be given to clearly traceable substances, that comply with the quality standards in 2.1, 2.2, 2.3.
List of starting materials that can be described chemically see part IV, appendix 2.4.
2.5. Starting materials that have undergone special treatmentStarting materials that have undergone a special treatment are: e.g. plants, parts of plants cultivated by special treatment (see part IIa, chapter 1.1. Vegetabilisation methods of substances used for mother tinctures).
List of starting materials that have undergone special treatment see part IV appendix 2.5.
18
2.6. CompositionsDifferent starting materials described in 2.1, 2.2, 2.3, 2.4, 2.5 undergo one or more pharmaceutical processes that will lead to a substance that cannot be described as an addition of its ingredients. The rationale for the synthesis is an anthroposophic formula, in accordance with the anthroposophic understanding of man and nature1.
List of compositions see part IV, appendix 2.6.
3. Vehicles and excipients
Vehicles are auxiliary substances, which may be used for the production of active substances (e.g. ethanol to obtain an extract or lactose monohydrate to obtain a potentised preparation). Vehicles are also used in the production of mixtures (see part IIa, chapter 9).
Excipients are auxiliary substances, which may be used for the production of the pharmaceutical dosage forms (e.g. NaCl to obtain an isotonic solution for parenteral preparations). Excipients are also used in the production of mixtures (see part IIa, chapter 9).
Vehicles and excipients used in the manufacture of anthroposophic medicinal products comply with the relevant requirements of the European Pharmacopoeia or of the national pharmacopoeias used in the EU Member States.
4. Active substances
4.1. Starting materialsActive substances can be starting materials themselves or preparations.Starting material used directly as active substances may be the final dosage form, e.g. a herbal tea.
4.2. PreparationsPreparations are obtained from one or more starting materials.
Preparations comply with the specifications described in part II or in the individual monograph.
Preparations can be the final dosage form or can be processed further, e.g. to obtain mixtures.
1 As an example see: “Biodoron/Kephalodoron” , in Persephone N° 12, M. Kohlhase editor; publisher Verlag am Goetheanum, Dornach, CH, 1998.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
19
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IIaGeneral monographs of preparations and specific production methods (Pharmaceutical processes)
Table of Content Part IIa1. SPECIAL TREATMENTS OF RAW MATERIALS .........................................................24 1.1. Vegetabilisation methods ............................242. METAL PREPARATIONS ..................................25 2.1. Metal mirrors ................................................253. TINCTURES, MOTHER TINCTURES, GLYCE- ROL MACERATES, VISCOUS EXTRACTS ...26 3.1. Cold treated mother tinctures and liquid preparations thereof .................................26 3.2. Tinctures and mother tinctures made by macerations with water or ethanol/water ....27 3.3. Glycerol macerates .......................................28 3.4. Liquid preparations made by maceration with oil ..............................................30 3.5. Mother tinctures made by percolation ......30 3.6. Buffered aqueous mother tinctures manufactured under exclusion of oxidative influence ...............................................31 3.7. Fermented mother tinctures .......................32 3.8. Tinctures and mother tinctures made by digestion (Digestio) .............................33 3.9. Tinctures and mother tinctures made by infusion (Infusum) .........................................34 3.10. Tinctures and mother tinctures made by decoction (Decoction) ........................35 3.11. Viscous extracts with heat treatment .......36 3.12. Preparations made by distillation .............37
3.13. Mother tinctures obtained by rhythmic application of heat and cold .........38 4. SOLID STARTING MATERIALS OBTAINED BY HEAT ........................................39 4.1. Toasted preparations – Tosta .......................39 4.2. Carbons – Carbo ...........................................40 4.3. Ashes – Cinis .................................................405. SOLID PREPARATIONS FROM PLANTS .....41 5.1. Solid preparations from fresh plants ..........41 5.2. Solid preparations from liquids, plant juices or aqueous extracts .........................416. LIQUID DILUTIONS .........................................427. COMPOSITIONS ................................................43 7.1. Compositions made by treating two or more starting materials by one or more pharmaceutical processes ...................................43 7.2. Compositions made by treating two or more extracts or mother tinctures of one plant by one or more pharmaceutical processes ........43 7.3. Compositions made by treating one or more starting materials with one or more mother tinctures which undergo one or more pharmaceutical processes together ..........45 7.4. Compositions made by treating two or more extracts or mother tinctures and/or dilutions by one or more pharmaceutical processes ........45 7.5. Compositions made by co-potentising ......468. POTENTISED PREPARATIONS ......................469. MIXTURES ..........................................................48
• A
PC Part IIa
20
IntroductionBrief description of the main pharmaceutical processes applied in anthroposophic pharmacy
Several pharmaceutical processes are described in existing homoeopathic pharmacopoeias as “production methods”. These homoeopathic pharmacopoeial production methods can be seen as examples of the general anthroposophic pharmaceutical principle described in the general APC monographs of part IIa.
In anthroposophic pharmacy the treatment of the raw or starting materials can already be part of the pharmaceutical processing, e.g. a plant can be cultivated under treatment with a metal or mineral preparation.
Metals can either be used as a concentrated starting material or undergo a pharmaceutical process depending on the rationale of the anthroposophic therapeutics.
Preparations can be differentiated according to the thermal condition or treatment in the pharmaceutical process. Hereby follows a scheme concerning the related pharmaceutical processes applied to plant material and the main sphere of action.
Preparations may be the final dosage form, be incor-porated into the final dosage form or be processed further, e.g. by potentisation.
Pharmaceutical process
Heat/cold degree
Starting material Main sphere of therapeutic action 1, 2
Cold maceration 2 – 8 °C fresh or dried plants, all parts System of nerves and senses throughout the whole organism
Maceration 15 – 25 °C fresh plants, all parts system of nerves and senses throughout the whole organism
Rhythmic processing
4/37 °C fresh plants, all parts rhythmic system
Digestion 37 °C fresh plants, leaves, flowers rhythmic system, circulation
Infusion 60 – 90 °C dried leaves, flowers metabolic system, any type of gland
Decoction ca 100 °C dried roots, barks, seeds metabolic system, digestive tract(stomach, intestine)
Distillation steam,ca 100 °C
fresh or dried plants, all parts metabolic system, digestion
Treatments in liquid phase
Pharmaceutical process
Heat degree Starting material Main sphere of therapeutic action 1, 2
Toasting 170 – 250 °C dried plants, all parts, dried zoological starting material
metabolic system, digestion (liver)
Carbonisation above 200 °C dried plants, all parts, zoological starting material
metabolic system, kidney organisation
Ash process above 500 °C dried plants, all parts, zoological starting material
region of the lungs (respiration)
Treatments in dry phase
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
A crucially important pharmaceutical process is potentisation:• Potentised preparations are gradually diluted sub-
stances, whereby at each diluting step a rhythmic succussion (liquid potencies) or trituration (solid potencies) has been carried out.
• During this process the surface of the vehicle and the substance to be potentised are expanded and the mixing is thorough. The potentising time differs for solid and liquid potentised preparations. Astrono-mical aspects may be considered (e.g. solar or lunar eclipse). Anthroposophic pharmacy mainly uses decimal attenuations. For co-potentised preparations the ratio between active substances to vehicle may vary, differing from 1:10 for homoeopathic co-potentising methods (see also Part IIa, 8 ”Potentised Preparations“).
• A
PC P
art I
Ia
21
1General scheme for the correlation between spheres of therapeutic action/ degree of potentisation:
Mother tincture – D10 Metabolic system
D11-D20 Rhythmic system
>D20 System of nerves and senses
See also:International Federation of Anthroposophic Medical Associations, “The System of Anthroposophic Medicine”, pp. 26-28 at http://www.ivaa.info/userfiles/file/SystemAnthroposMedicine2011_Interaktiv.pdf
2 See IAAP brochure: “Basic Information on the Working Principles of Anthroposophic Pharmacy”, 2005, http://www.iaap.org.uk/downloads/principles.pdf
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
22
General method of the APC Related specific production method
Ph.Eur. (2371)
HAB Ph.Helv. B.Hom.P. APC
1. Special treatment of raw materials
1.1. Vegetabilisation methods of substances used for mother tinctures
17.7.1.1, 17.7.1.2
Br1 1.1.1, 1.1.2
2. Metal preparations
2.1. Metal mirrors 17.7.2.1 – 17.7.2.4
2.1.1, 2.1.2, 2.1.3, 2.1.4
3. Tinctures and oil extracts
3.1. Cold treated mother tinctures and liquid preparations thereof
38 17.7.6
3.2. Tinctures made by maceration with water or ethanol/water
1.1.1 – 1.1.111.3.1
12b, c, m, n, o, p, q
17.7.7.1 3.2.1, 3.2.2
3.3. Tinctures made by maceration with glycerol 2.1.1 – 2.1.3 2.2.1 – 2.2.4
3.3.1, 3.3.2, 3.3.3
3.4. Liquid preparations made by maceration with oil
3.4.1
3.5. Tinctures made by percolation 1.1.8 – 1.1.9 17.7.7.2 3.5.1
3.6. Buffered aqueous mother tinctures under exclusion of oxidative influence
32
3.7. Fermented tinctures 53 17.7.7.3 3.7.1
3.8. Tinctures made by digestion (Digestio) 1.2.1 – 1.2.61.4.1
17.7.8.1 3.8.1, 3.8.2
3.9. Tinctures made by infusion (Infusum) 1.2.13, 1.4.4
17.7.8.3 3.9.1, 3.9.2, 3.9.3
3.10. Tinctures made by decoction (Decoction) 1.2.7 – 1.2.121.4.2 – 1.4.3
12k, l 17.7.8.4 3.10.1
3.11. Oil extracts with heat treatment 12d – g, 57
Survey of general methods for the manufacturing of anthroposophic medicinal products and related specific production methods in pharmacopoeias
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
23
General method of the APC Related specific production method
Ph.Eur. (2371)
HAB Ph.Helv. B.Hom.P. APC
3.12. Preparations made by distillation 52 17.7.8.5 3.12.1, 3.12.2
3.13. Tinctures obtained with rhythmic application of heat and cold
21 – 22, 33 – 37, 51
17.7.9 3.13.1, 3.13.2.
4. Solid starting materials obtained by heat
4.1. Toasted preparations (Tosta) 17.7.4.1 4.1
4.2. Carbons (Carbo) 17.7.4.2 Br4 4.2
4.3. Ashes (Cinis) 17.7.4.3 Br3 4.3
5. Solid preparations from plants and liquids (drying onto a vehicle)
5.1. Solid preparations from fresh plants 4.1.1 – 4.1.2 17.7.5.1 5.1.1
5.2. Solid preparations from liquids, plant juices or aqueous extracts
4.2.1 – 4.2.2 17.7.5.2 5.2.1, 5.2.2, 5.2.3
6. Liquid dilutions 3.1.1 – 3.1.3
7. Compositions 17.7.3 7.2.1 – 7.2.4
8. Potentised preparations
Potentising specifications in: 1 – 5
12j
11, 15, 18, 19, 20 – 24, 32 – 38, 39a, 39b, 45, 51, 53
Br5 – 6 8.1.1, 8.1.2, 8.2.1, 8.2.2Other APC Methods8.3
9. Mixtures 12a, 12h, 12i, 16
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Note: How to read the table: Specific production methods are published in different pharmacopoeias e.g. in the Ph.Eur. or in the HAB; it is not a correlation table. If a method (e.g. HAB 49), has been transferred into the Ph.Eur. (2371, 1.3.1), the number is no longer listed in the HAB column. Anthroposophic medicinal products may also be manufactured in accordance with individual specifications or monographs, see also Part I, chapter 1.
• A
PC Part IIa
24
monograph; the flowers or/and the leaves with petioles, possibly with stalks, but no woody parts are included. The plant material is mixed together with neutral plant-compost which activates the first composting processes. This metal plant-compost mixture is stored in terracotta pots which are buried almost completely in the soil in the same field used in that growing season. The composting process is continued during the whole winter until the next spring.In spring the compost is completed and ready to be used to treat the plants of the next growing season, the second life cycle.
2nd life cycle:Seeds of the same species are sown in cultivation substrate or soil, which was treated with the compost, made from the plant of the 1st growing season. These plants (of the second life cycle) are also grown to their specific plant development stage (i.e. flowering). Compost is made from these plants, which is prepared in a way similar to the compost of the plants of the first life cycle. This compost is stored in terracotta pots, buried in the soil, in the field of the plants of the second life cycle.
3rd life cycle:Seeds of the same species are sown in cultivation substrate or soil which was treated with compost made from the plants of the second vegetation period. The plants of the third growing season (third vegetation period) are cultivated to their specified harvest stage.
further processingThe harvested plants are processed into a mother tincture according to a manufacturing method of the Ph.Eur., HAB or the APC or are otherwise processed.
identification, tests, assayAccording to the relevant tincture monograph (See Part IIa, chapters in section 3) or dried herbal drug.
recommended designation The designation states:• the fertilised plant,• the substance used,• the designation “cultum”, “culta”,• the reference pharmacopoeia/codex.
Examples: Tabacum Cupro cultum APC, Equisetum arvense Silicea cultum APC
Specific pharmacopoeia/APC production methods to produce vegetabilised substancesAPC Method 1.1.1 Vegetabilisation of substances of metallic origin (“vegetabilised metals”)
1. SPECIAL TREATMENTS OF RAW MATERIALS
In anthroposophic pharmacy treatment of the raw materials can be part of the pharmaceutically relevant processing, e.g. a plant can be cultivated under treatment with a preparation of a mineral, normally containing a specific metal.
1.1. Vegetabilisation methods (“vegetabilised metals“)
definitionVegetabilisation of substances can be considered as a particular kind of potentising process of metals or minerals taking place through nature. The potentising process is carried out with plants and normally goes through three life cycles. The life cycle means one vegetation period (growing season) for annual, and two growing seasons for biennial plants. The substance and appropriate plant are chosen in accordance with the rationale of anthroposophic understanding of man and nature.
preparation of mineral substancesSee APC Method 1.1.1 and 1.1.2.
cultivationThe cultivation of vegetabilised metals is a three years process (for biennial plants 6 years), meaning three generations of plants are grown until the final plant can be further processed, for example to a mother tincture. This process is basically the same for each specific metal (mineral)-plant combination. Important for the cultivation process is, that each plant grows in the cultivation substrate and field soil specifically prepared for each vegetation period. The following is a cultivation description for each of the three growing seasons or life cycles.Exemptions have to be prescribed in individual monographs (e.g. Bryophyllum, Equisetum arvense and Thuja occidentalis).
1st life cycle: The seeds are sown in soil, which has been treated with a diluted preparation of the concerned inorganic substance (approximately 50 – 200 g/m²). Alternatively, jars with cultivation substrate, mixed with 5 – 20 g diluted preparation/L can be used. In this case, the young growing plants are transferred to soil, which has been treated as mentioned above.When the plants reach their full development, i.e. in the flowering stage, compost is made from these plants. For preparing that compost, the upper aerial parts of the specific plant are used as prescribed in the individual
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
25
2.1. Metal mirrors
definitionBy producing metal mirrors the metal is transformed through different states of aggregation.The metals or metal salts can be brought through a liquid state (melted or as solution), gas state or plasmatic state to be subsequently (obtained again) condensed in solid state as the pure metal.Metal mirrors are deposits of metals in reduced state onto a surface by a specific method of production.
Metal mirrors, produced according to APC methods 2.1.1, 2.1.2 and 2.1.3 can be removed from the surface and may be potentised according to Ph.Eur. method 4.1.1 and 4.1.2 and HAB method 48.
testsThe following analytical tests are always carried out for the metal which is used as starting material to produce the mirror. The metal mirror itself is only tested when it is produced by the method of reduction of metal salts (2.1.3), the method of chemical vapour decomposition (2.1.2) or the method of sputtering (2.1.4). The metal mirror produced by the method of distillation (2.1.1) is tested after further processing as the first or second produced dilution.
identificationAt least one suitable identification test is carried out.
testssee the individual monograph.
assayContent according to the individual monograph.
storageStore in a well-closed container.
recommended designation The designation states:• the metal used,• the designation ”metallicum praeparatum” or in the
case of metal mirror foil the name of the metal follo-wed of the word “foil”,
• the reference pharmacopoeia/codex,Examples: Argentum metallicum praeparatum APC Cuprum mirror foil APC.
Specific pharmacopoeial/APC production methods to prepare metal mirrors
For the vegetabilisation of substances of metallic origin plants are treated with a diluted substance, prepared from either a naturally occurring metal or a metal containing mineral (ore).
preparation of metallic substanceThe raw material for the manufacturing of the mineral substance is a naturally occurring metal or a metal containing mineral (ore). This is treated during several steps with mineral acids and other substances, containing the chemical elements C, H, N, O and S, to a complex composition containing the metal in a form whose chemical structure is not clearly defined. It is triturated with lactose monohydrate, the result being the metal substance D1: the content of the metal is 8 – 12 %. The metal substance D1 is diluted with a neutral material, e.g. cellulose or sucrose, to form the diluted metal substance that is ready for use. The calculated metal content of this diluted metal substance differs, according to the toxicity and natural abundance of the metal in the soil:Au, Ag, Pb, Sn, Hg: max. 100 ppmFe, Cu: max. 1000 ppm
APC Method 1.1.2 Vegetabilisation of silicatesFor the vegetabilisation of silicates plants are treated with appropriate mineral containing silica.
preparation of mineral substanceThe raw material for the manufacturing of the mineral substance is a pulverised mineral silicate. This is treated during several steps with mineral acids and other substances, containing the chemical elements C, H, N, O and S, to a complex composition containing silicium in a form whose chemical structure is not clearly defined. It is triturated with lactose monohydrate; the result is the silica, particularly quartz substance D1: the content of silicium is 8 – 12 %, calculated as silicium dioxide .The silica, particularly quartz substance D1 is diluted with a neutral material, e.g. cellulose or sucrose, to form the diluted silica, particularly quartz substance that is ready for use. The calculated content is max. 1 % silicium dioxide.
2. METAL PREPARATIONS
Metals can either be used as a concentrated starting material or undergo a pharmaceutical process depending on the rationale of the anthroposophic therapeutics.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
26
A magnetrom is comprised of a cathode (electron source) an anode (electron collector) and a combined electric and magnetic field. Vacuum conditions (0.5 – 5 x 10-3 mbar) are generated and an inert gas (e.g. Argon Ph.Eur.) is used as medium. The process begins as a result of a collision and momentum transfer from an incoming particle which impacts the inert gas molecules. Ions of the inert gas impact then the surface of the metal and the result is an ejection of metal atoms from the surface. The electric field leads to an ionisation of the metal which goes into a plasma aggregation state (at 30 – 45 °C) and condensates as a metal mirror on the substrate, in this case a plastic foil (e.g. PET). After this process the metal mirror foil is stitched to a special cotton tissue directly over the metal mirror.The metal mirror foils must not be further processed.
testsThickness of the mirror.
recommended designation the reference pharmacopoeia/codex,for external use only.
3. TINCTURES, MOTHER TINCTURES, GLYCEROL MACERATES AND VISCOUS EXTRACTS
Tinctures, mother tinctures, glycerol macerates and viscous extracts are obtained from starting materials from botanical or zoological origin by pharmaceutical processes under cold condition (2 – 8 °C), at ambient temperature (15 – 25 °C), with heat treatment at different temperatures, by rhythmic application of heat and cold, by fermentation as well as by distillation. If applicable, vehicles e.g. water, ethanol, water/ethanol mixtures, glycerol, oils may be used. They may be processed further.
3.1. Cold treated mother tinctures and liquid preparations thereof
definitionCold treated mother tinctures are prepared from fresh (frozen) or dried herbal drugs. The maceration is carried out at a temperature of 2 – 8 °C using purified water, water for injections or isotonic solution.
productionIf necessary, comminute the matter to be extracted. The prescribed quantity of extraction solvent according to the individual monograph is added to the starting
APC Method 2.1.1 Metal mirrors obtained by distillationMetal mirrors prepared by distillation are obtained from the pure metal.The pure metal is heated in appropriate equipment under vacuum until it evaporates. The temperature and the vacuum are to be chosen in such a way, that the metal is distilled. The metal vapour condenses onto the surface of the cooler parts of the distillation equipment, producing a metal mirror. The metal mirror is removed after cooling from the surface.The exact conditions of the distillation are described in the individual monograph.
APC Method 2.1.2. Metal mirrors obtained by Chemical Vapour Decomposition, CVDMetal mirrors prepared by chemical vapour decomposition are obtained from a volatile metal compound.A volatile metal compound is distilled under vacuum in appropriate equipment. The temperature and the vacuum are to be chosen in such a way, that the metal compound is distilled. The vapour is further heated until decomposition of the metal compound. As a result, the pure metal condenses onto the surface of the distillation equipment, producing a metal mirror. After cooling the metal mirror is removed from the surface.
APC Method 2.1.3. Metal mirrors obtained by reductionMetal mirrors prepared by reduction are obtained from an appropriate metal salt.To a solution of a metal salt an appropriate reducing agent and reagents are added. The pure metal precipitates onto the surface of the reaction vessel producing the metal mirror. The metal mirror is removed from the surface, filtered from the solution, washed with purified water and ethanol (the concentration of ethanol depending of the nature of the used reagents), until foreign matters are no longer detectable in the rinsing water and then dried.
APC Method 2.1.4. Metal mirror foilMetal mirror foils are prepared by a process which transforms the processed metal into a plasma aggre-gation and finally condenses as an approximate 55 – 65 nm thick metal mirror on to the substrate.To produce a metal mirror foil a process known as sputtering is used. In this vapour phase technique there is no melting of the metal. The sputtering process is most commonly used for thin-film deposition of many different metals. High energy ions impacting on the target can liberate sputtered atoms of the metal as well as positive ions and electrons. A metal target is put under the effect of a magnetrom.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
27
productionIf necessary, comminute the matter to be extracted; animals are processed immediately after killing. The prescribed quantity of extraction solvent according to the individual monograph is added to the starting material. Mix thoroughly and allow to stand in a closed container at the required temperature, where applicable protected from light for an appropriate time. If necessary shake or stir occasionally. Express and filter, if necessary.Adjustment of the content of constituents may be carried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another macerate of the herbal or animal starting material used. If prescribed in the individual monograph, the tincture can be adjusted to the specified content by concentration, carried out generally under vacuum.
identificationAt least one chromatographic identification test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). The pre-paration complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Ethanol content (Ph.Eur. 2.9.10). Where applicable, the ethanol content complies with that prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official Pharmacopoeia, or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designationThe designation states:• the herbal or animal matter used,• where applicable, the fresh herbal or animal matter
used,• where applicable, the ethanol content in the pre-
paration,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,the reference pharmacopoeia/codex.
material. Mix thoroughly and allow to stand in a closed container, where applicable protected from light, for an appropriate time (at least 7 days). Shake or stir occasionally. Express and filter.
identificationAt least one chromatographic identification test is carried out.testspH (Ph.Eur. 2.2.3). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). The pre-paration complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official Pharmacopoeia, or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
recommended designation The designation states:• the herbal drug used,• where applicable, the fresh herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce mother tinctures obtained under cold conditions (2 – 8 °C)HAB Method 38
3.2. Tinctures and mother tinctures made by macera-tions with water or ethanol/water
definitionTinctures and mother tinctures made by maceration with water or ethanol/water are liquids and are obtained from fresh (frozen) or dried matter of botanical or zoological origin. The maceration is carried out at a temperature not above 25 °C by using ethanol of a suitable concentration or purified water.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
28
3.3. Glycerol macerates
definitionGlycerol macerates comply with the definition in Ph.Eur. monograph 1038. They are prepared from fresh (frozen) or dried matter of botanical or zoological origin. The maceration is carried out at the required temperature (not above 25 °C) using glycerol of a suitable concentration or a glycerol solution containing sodium chloride.
productionLower animals are killed immediately before processing; the parts of warm-blooded animals are processed immediately after being killed. Killing is carried out with respect for the animal suffering.Comminute the matter to be extracted. Add the prescribed quantity of extraction solvent according to the individual monograph to the raw material. Mix thoroughly and allow to stand in a closed container at a temperature not above 25 °C, protected from light for an appropriate time. If necessary shake or stir occasionally. Express and filter, if necessary.Adjustment of the content of constituents may be carried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another macera-te of the starting material of botanical or animal origin used.
identificationAt least one chromatographic or electrophoretic (animal matter) identification test is carried out.
testsConductivity (Ph.Eur. 2.2.38). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individual monograph. Alternatively, the refractive index can be used.Refractive index (Ph.Eur. 2.2.6). Where applicable (preparations according to APC Methods 3.3.1 and 3.3.2), the refractive index of the preparation is measured in appropriate equipment, this measure indicates the water content in the glycerol1, and this value is called ηm indicating the refractive index of the macerate. This
Specific pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by macerations with water or ethanol/water
Ph.Eur. (2371) Methods1.1.1 – 11HAB Methods1 – 4Ph.Eur. 1.3.1 (prev. HAB Method 49)12b, c, m, n, o
APC Method 3.2.1 (related to Ph.Eur. (2371) Method 1.1.8)Mother tinctures according to APC Method 3.2.1 are prepared using the maceration methods given in the Ph.Eur. monograph “Extracts” (0765). Use 1 part of dried plant or parts of plants to 20 parts of ethanol in suitable concentration (see HAB H 5.3), unless otherwise prescribed in the individual monograph.If adjustment to a given concentration is necessary, calculate the amount of ethanol required to obtain the concentration specified or used for production from the equation given in Ph.Eur. (2371) Method 1.1.1. Mix the calculated amount of ethanol with the filtrate. Allow to stand for not less than 5 days at a temperature not exceeding 20 °C, then filter if necessary.
potentisationThe 2nd decimal dilution (D2) is made from2 parts of the mother tincture and8 parts of ethanol of the same concentration.
The 3rd decimal dilution (D3) is made from1 part of 2nd decimal dilution and9 parts of ethanol of the same concentration.
Unless a different ethanol concentration is specified, use ethanol 36 per cent (V/V) for D4 and then 18 per cent (V/V) for subsequent dilutions from D5 onwards and proceed accordingly.
APC Method 3.2.2 (related to HAB Method 12a)Preparations according to APC Method 3.2.2 are tinctures for external use. They are prepared as follows:Use 1 part of dried plant or parts of plants to 10 parts of ethanol in suitable concentration (see HAB H 5.3), unless otherwise prescribed in the individual monograph.Glycerol may be added up to 10 per cent.
1 Miner, Carl S.& Dalton, N.N: (ed.). Glycerol, American Chemical Society, Monograph Series, n⁰ 117. Reinhold Publishing Corp., New York 1953.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
29
APC Method 3.3.2Glycerol macerates according to APC Method 3.3.2 are prepared from 1 part of dried plants or parts of plants, 2 parts of purified water and 7 parts of glycerol by maceration.The prescribed quantity of purified water is added to the starting material. Allow standing in a closed container for 6 hours. After that, the prescribed quantity of glycerol is added to the mixture. Mix thoroughly and allow to stand in a closed container for an appropriate time according to the individual monograph. If necessary, shake or stir occasionally. Express and filter, if necessary.The content of glycerol is determined using measurement of refractive index and should be 75–85 % (m/m) of the total mass, calculated based on the equation above (refractive index). Adjustment of the final content of glycerol to 85 % is carried out using measurement of refractive index, and adding glycerol.Adjustment of the content of constituents may be carried out, if necessary by adding another macerate of the herbal or animal starting material used.
APC Method 3.3.3 Mother tinctures according to APC Method 3.3.3 are prepared from killed or freshly slaughtered animals or parts thereof by maceration with glycerol as vehicle (glycerol macerates).
To produce the first decimal dilution (D1), disperse 1 part of finely minced animal material in 9 parts of glycerol (85 per cent), allow to macerate for at least 2 h, then succuss. Where justified, the addition of 1 part of glycerol (85 per cent) to 1 part of animal material before the mincing is accepted. Filter when necessary. In the case of very small amounts of animal material, it is allowed to prepare the 2nd or the 3rd decimal dilution by dispersing 1 part of finely minced animal material in 99 resp. 999 parts (= D2 resp. D3) of glycerol (85 per cent).
potentisationWhere the mother tincture corresponds to the 1st decimal dilution (Ø = D1), the 2nd decimal dilution (D2) is produced from: 1 part of the mother tincture (D1); 9 parts of glycerol (85 per cent) or ethanol (18 per cent V/V).
The 3rd decimal dilution (D3) is produced from: 1 part of the 2nd decimal dilution; 9 parts of ethanol (18 per cent V/V).Subsequent dilutions are produced as stated for D3.
measure is used to calculate the proportion of glycerol of the macerate. This calculation is made based on the following equation:
(eq.1)1
Electrophoresis (Ph.Eur. 2.2.31). Where applicable, the preparation complies with the characteristics prescribed in the individual monograph.Microbiological examination (Ph.Eur. 2.6.12, 2.6.13). Where applicable, the macerate complies with the limits prescribed.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the dried herbal drug or animal matter used,• where applicable, the fresh herbal drug or animal
matter used,• the glycerol content of the solvent used for the prepa-
ration,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to macerate,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce glycerol maceratesPh.Eur. (2371) Methods2.1.1 – 2.1.3 (prev. HAB Methods 42)2.2.1 – 2.2.4 (prev. HAB Methods 41)
APC Method 3.3.1Glycerol macerates according to APC Method 3.3.1 are prepared from 3 parts of fresh (frozen) matter of botanical or zoological origin and 7 parts of glycerol by maceration.The prescribed quantity of glycerol is added to the starting material. Mix thoroughly and allow to stand in a closed container for an appropriate time according to the individual monograph. If necessary, shake or stir occasionally. Express and filter, if necessary.The content of glycerol is determined using measurement of refractive index and should be 70–85 % (m/m) of the total mass, calculated based on the equation above (refractive index). Adjustment of the final content of glycerol to 85 % is carried out using measurement of refractive index, and adding glycerol.Adjustment of the content of constituents may be carried out, if necessary by adding another macerate of the herbal or animal starting material used.
% Glycerol m⁄m = ηm – 1.3195
0.0016
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
30
storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the dried herbal drug or animal matter used,• where applicable, the fresh herbal drug or animal
matter used,• where applicable, the solvent used for the preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce liquid preparations made by maceration with oil
APC Method 3.4.1Preparations made according to APC Method 3.4.1 are oil extracts for external use prepared from 1 part of lower animals and 10 parts of arachis oil, refined (Ph.Eur.) as follows:
After having killed the animals with CO2, the animals are minced and mixed thoroughly with 10 parts of arachis oil, refined (Ph.Eur.). Protect the mixture from light. The extraction time should not exceed 8 hours. Then filter.
3.5. Mother tinctures made by percolation
definitionMother tinctures made by percolation are prepared from fresh (frozen) or dried herbal drugs. The percolation is carried out at room temperature using ethanol of suitable concentration or purified water.
productionIf necessary, comminute the herbal drug to be extracted to pieces of suitable size. Mix thoroughly with a potion of the prescribed extraction solvent and allow to stand for an appropriate time. Transfer to a percolator and allow the percolate to flow slowly making sure that the matter to be extracted is always covered with the remaining extraction solvent. The residue may be pressed out and the expressed liquid combined with the percolate.
Adjustment of the content of constituents may be carried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another percolate of the herbal drug used for the preparation.
Where the mother tincture corresponds to the 2nd or 3rd decimal dilution (Ø = D1), the 3rd or the 4th decimal dilution, respectively (D3 or D4) is produced from:1 part of the mother tincture (D2 or D3)9 parts of ethanol (18 per cent V/V).Subsequent dilutions are produced accordingly.
3.4. Liquid preparations made by maceration with oil
definitionLiquid preparations prepared by maceration with oil are prepared from fresh (frozen) or dried matter of botanical or zoological origin. The maceration is carried out at the required temperature (not above 25 °C) mostly by using arachis oil or olive oil.
productionIf necessary, comminute the matter to be extracted. When animal matter is used, lower animals are killed immediately before processing, the parts of warm-blooded animals being processed immediately after killing. Killing is carried out with respect for the animal suffering, e.g. according to HAB H 5.2.4.The prescribed quantity of extraction solvent according to the individual monograph is added to the starting material. Mix thoroughly and allow to stand in a closed container at the required temperature, protected from light for an appropriate time. If necessary shake or stir occasionally. Express and filter, if necessary.Adjustment of the content of constituents may be carried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another macerate of the herbal or animal starting material used.
identificationAt least one chromatographic identification test is carried out.
tests Relative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individual monograph.Refractive index (Ph.Eur. 2.2.6). The preparation complies with the limits prescribed in the individual monograph.Peroxide value (Ph.Eur. 2.5.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
31
Allow to stand for not less than 5 days at a temperature not exceeding 20 °C, then filter if necessary.
The 2nd decimal dilution (D2) is made from2 parts of the mother tincture and8 parts of ethanol of the same concentration.
The 3rd decimal dilution (D3) is made from1 part of 2nd decimal dilution and9 parts of ethanol of the same concentration.
Unless a different ethanol concentration is specified, use ethanol 50 per cent (V/V) for subsequent dilutions from D4 onwards and proceed accordingly.
3.6. Buffered aqueous mother tinctures manufactured under exclusion of oxidative influence
definitionBuffered aqueous mother tinctures manufactured under exclusion of oxidative influence are produced by exhaustive extraction of fresh (frozen) plants or parts of plants under the exclusion of atmospheric oxygen with a buffer.
If the fresh plant material is not processed immediately, it must be stored in liquid nitrogen. The loss on drying (H 2.8.1) must be determined before it is placed in liquid nitrogen.From 1 part of the plant material an amount of mother tincture, prescribed in the individual monograph, is produced according to HAB Method 32. This amount is determined in a validation and depends on the loss on drying of the harvested plant material.The mother tincture corresponds to the 2nd decimal dilution (mother tincture = D2).At first add a defined amount of ascorbate phosphate buffer solution to the plant material and then finely reduce this mixture to a slurry. Under further size reduction, add a quantity of ascorbate phosphate buffer solution, sufficient for achieving the required amount of extract. Express, filter and adjust to the required volume with ascorbate phosphate buffer solution.
According to the individual monograph the production of the mother tincture may require the addition of a second extract from material of the same plant species harvested at a different season. In this case mix the extracts in an appropriate apparatus to a composition (see Chapter 7) and then dilute in a defined proportion with ascorbate phosphate buffer solution. This composition is the mother tincture (=D2).Potentisation is generally carried out according to HAB Method 32.
identificationAt least one chromatographic identification test is carried out.
testsRelative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). The pre-paration complies with the limits prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official Pharmacopoeia, or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the fresh herbal drug used,• where applicable, the dried herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material
to extraction liquid or of starting material to preparation,
• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce mother tinctures made by percolation
Ph.Eur. (2371), Methods 1.1.8, 1.1.9HAB Methods 4
APC Method 3.5.1 (related to Ph.Eur. (2371) Method 1.1.8)
Mother tinctures according to APC Method 3.5.1 are prepared using the percolation methods given in the Ph.Eur. monograph “Extracts” (0765). Use 1 part of dried plant or parts of plants to 20 parts of ethanol in suitable concentration (see HAB H 5.3), unless otherwise prescribed in the individual monograph.If adjustment to a given concentration is necessary, calculate the amount of ethanol required to obtain the concentration specified or used for production from the equation given in Ph.Eur. (2371) Method 1.1.1. Mix the calculated amount of ethanol with the filtrate.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
32
productionIf necessary, comminute the herbal drug. Add purified water according to the individual monograph and mix thoroughly. If stated in the individual monograph, add the prescribed fermenting agent. Allow to stand at room temperature for the time prescribed in the individual monograph protected from air, from light and, if necessary, from oxidation. Hereafter express and filter, if necessary.
Adjustment of the content of constituents may be carried out with purified water or by adding purified water to the residue and expressing again.
identificationAt least one chromatographic identification test is carried out.
testspH (Ph.Eur. 2.2.3). The preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). The preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official Pharmacopoeia, or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the fresh herbal drug used,• where applicable, the dried herbal drug used,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce fermented mother tinctures
HAB Method 53APC Methods 7.2.1, 7.2.3, 7.2.4
Buffered aqueous mother tinctures and their liquid dilutions are exclusively intended for parenteral dosage forms. Before they are processed to finished products, the mother tincture (D2) and the liquid dilution D3 must be stored for between 6 weeks and 1 year. Any eventual sediment must be excluded from the further processing.
identificationAt least one chromatographic identification test is carried out.
testsLoss on drying (H 2.8.1). Loss on drying of the residue after filtration.Sterility (Ph.Eur. 2.6.1). If buffered aqueous mother tinctures and their liquid dilutions are stored before further processing, they must comply with the test. Proportion of original extracts: Where applicable, the proportion of both extracts in the composition is determined e.g. by HPLC or by other suitable methods.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed, airtight container.
recommended designation The designation states:• the herbal drug used,• the amount of herbal drug used,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce buffered aqueous mother tinctures manufactured under exclusion of oxidative influence
HAB Method 32
3.7. Fermented mother tinctures
definitionFermented mother tinctures are aqueous preparations from fresh (frozen) or dried herbal drugs prepared by fermentation at room temperature.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
33
35 – 39 °C in a covered container. Allow to stand at this temperature for the time prescribed in the individual monograph, stirring occasionally. After cooling, allow to stand at room temperature in a well-closed container, protected from light for the time described in the individual monograph. Add ethanol of appropriate concentration if prescribed. If necessary shake or stir occasionally. Express and filter, if necessary.Adjustment of the content of constituents may be carried out by diluting, either with the same liquid used for the digestion or with another digestion of the same raw material.If prescribed in the individual monograph, the tincture can be adjusted to the specified content by concentration, carried out carefully and generally under vacuum.
identificationAt least one chromatographic identification test is carried out.
testspH (Ph.Eur. 2.2.3). Where applicable the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). The preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individualmonograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official pharmacopoeia, or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the dried herbal drug used,• where applicable, the fresh herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material
to extraction liquid or of starting material to preparation,
• the designation “Digestio” or “ethanol. Digestio” if ethanol is used,
• the reference pharmacopoeia/codex.
APC Method 3.7.1 (see also Compositions 7.2.1)Mother tinctures according to APC Method 3.7.1 are prepared from fresh plants or parts of plants following the procedure given below.Finely comminute the plants or parts of plants and mix 1 part of the plant mass with 1 part of purified water. Leave to ferment at 20 to 24 °C with the exclusion of air, ending the fermentation when the pH of the fermentation liquid has fallen to between 4 and 5. Then express and weigh the expressed liquid. The weight of the expressed liquid is equal to 2 parts and is mixed with 1 part of a mixture of 0.95 parts of ethanol 96 per cent (V/V) and 0.05 parts of purified water.This tincture can together with another tincture of the same plant undergo a special pharmaceutical process leading to a composition according to method 7.2.1.
This procedure is followed for plants harvested in the summer and for plants of the same species, harvested in the winter. The mother tincture is produced by composing equal parts of the two tinctures.
potentisationThe 1st decimal dilution (D1) is made from3 parts of the mother tincture and7 parts of ethanol 36 per cent (V/V).
The 2nd decimal dilution (D2) is made from1 part of the 1st decimal dilution and9 parts of ethanol 18 per cent (V/V).
Subsequent dilutions are produced as stated for D2.
recommended designation Preparations according to APC Method 3.7.1 carry the designation „ferm APC 3.7.1“.
3.8. Tinctures and mother tinctures made by digestion (Digestio)
definitionTinctures and mother tinctures made by digestion are liquids prepared from fresh (frozen) or dried plants or parts of plants by heat treatment usually at 37 °C and additional maceration. The digestion is carried out using ethanol of a suitable concentration or purified water.
productionIf necessary, comminute the plant or parts of plants to be extracted. The quantity of extraction liquid is added according to the individual monograph. Mix thoroughly and warm to 35 – 39 °C. Then keep at
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
34
3.9. Tinctures and mother tinctures made by infusion (Infusum)
definitionTinctures and mother tinctures made by infusion are prepared from adequately prepared dried plant material by adding boiling purified water. If ethanol (of the prescribed concentration) is used, the quantities of ethanol and purified water are added separately.
productionIf necessary, comminute the plant material. Boiling purified water is used for extraction. If ethanol of suitable concentration is used, the quantity of ethanol is either used prior to extraction for moistening the dried plant material for the time prescribed or added to the mixture after cooling. Allow to stand in a well-closed container for the time prescribed. If only purified water is used as solvent, it is also used for moistening and to make up the final mass if prescribed. Express and filter, if necessary. If only purified water is used as solvent the preparation is processed further immediately.
identificationAt least one chromatographic identification test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). The preparation complies with the limits prescribed in the individual monograph. Relative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official Pharmacopoeia , or another limit is justified and authorised.Sterility (Ph.Eur. 2.6.1). Applicable only if the infusion is a stored aqueous preparation.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light, if the tincture contains ethanol.If aqueous tinctures made by infusion are stored they must meet the requirements of sterility (Ph.Eur. 2.6.1).
Specific pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by digestion
Ph.Eur. (2371) 1.2.1 – 6 (prev. HAB Methods 18)Ph.Eur. (2371) 1.4.1 (prev. HAB Method 24b)
APC Method 3.8.1Tinctures according to APC Method 3.8.1 are prepared from fresh plants with purified water as follows:Comminute the plants or parts of plants unless other-wise prescribed in the monograph. The amount of plants or parts of plants and purified water are defined by the monograph. Introduce the amount of purified water into a round-bottomed flask, place in a water bath and heat up to 48 – 52 °C. Add the plants or parts of plants whereby the flask should be a half to three quarters full, mix thoroughly. Close the flask hermetically. Keep the mixture at 48 – 52 °C for 6 hours. Allow to cool to 35 – 39 °C in the course of 20 – 24 hours and maintain this temperature for 64 – 72 hours with occasional stirring. Allow to cool. If prescribed in the individual monograph add the amount of ethanol 96 per cent (V/V) prescribed then express and filter.Tinctures according to APC Method 3.8.1 which are prepared with purified water only, are generally processed immediately to solid preparations (see method 5.2 “Solid preparations from liquids, plant juices or aqueous extracts”).
recommended designation Preparations made according to APC Method 3.8.1 carry the designation “Digestio APC 3.8.1”. The same applies to preparations made from them. Preparations made according to APC Method 3.8.1 with addition of ethanol carry the designation “ethanol. stab. digestio APC 3.8.1”.
APC Method 3.8.2 Method 3.8.2 is used for fresh plants.Mother tinctures prepared according to APC Method 3.8.2 are ethanolic digestions prepared by heat treatment with additional maceration as described below.Comminute appropriately the plant or the parts of plants. To 1 part of the comminuted plant add 3.1 parts of ethanol 24 per cent V/V. Warm the mixture in a well-closed container to 37 ˚C and maintain this temperature for 1 h. Cool, allow to stand for not less than 10 days, stirring the mixture or swirling the container from time to time, then express the mixture and filter the resulting liquid. The filtrate is the mother tincture.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
35
APC Method 3.9.2 (related to HAB Method 20) deleted
APC Method 3.9.3Mother tinctures according to APC Method 3.9.3 are prepared from fresh or dried plants or parts of plants, using 1 part of the plant material and 10 parts of water (m/m) or according to the individual monograph.Comminute the starting material and add the total amount of boiling purified water, cover and allow to stand until room temperature is reached, for not more than 12 h. Compensate any water loss. Allow to stand in a well-closed container for 24 – 36 h, stirring occasionally. Express and filter.
potentisationThe mother tincture corresponds to the 1st decimal dilution (Ø= D1).The 2nd decimal dilution (D2) is made from1 part of the mother tincture and9 parts of glycerol 85 % (m/m).
Subsequent dilutions are produced as stated for D2.
3.10. Tinctures and mother tinctures made by decoction (Decoction)
definitionTinctures and mother tinctures made by decoction are prepared from fresh or dried plants or parts of plants that have been allowed to boil with ethanol of a suitable concentration or purified water or extracted with glycerol 85 % at 100⁰C.
productionIf necessary, comminute the plants or parts of plants, add the prescribed quantity of extraction solvent according to the individual monograph and mix thoroughly. Heat the mixture to boiling (in the case of glycerol 85 % to 100⁰C), if necessary under reflux, maintaining at boiling temperature (in the case of glycerol 85 % at 100⁰C) for the time prescribed, usually 30 min. After cooling allow to stand in a well-closed container protected from light at room temperature for the time described in the individual monograph. If necessary, shake or stir occasionally. Express and filter, if necessary.
Adjustment of the content of constituents may be carried out by diluting, either with the same liquid used for the decoction or with another decoction of the same raw material.If prescribed in the individual monograph, the tincture
recommended designation The designation states:• the herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the designation “Infusum” or “ethanol. Infusum”, if
ethanol is used,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by infusionPh.Eur. (2371) 1.2.13 (prev. HAB Method 20)Ph. Eur. (2371) 1.4.4 (prev. HAB Method 24a)
APC Method 3.9.1 (related to Ph.Eur. Method 1.12.13)Mother tinctures according to APC Method 3.9.1 are prepared from dried plants or parts of plants, using 1 part of the plant material and 10 parts of ethanol of the concentration, prescribed in the individual monograph as follows:Add the amounts of ethanol and purified water required to obtain the prescribed ethanol concentration separately.Unless a degree of comminution is specified in the monograph, comminute the herbal drug appropriately, add the total amount of boiling purified water, cover and allow to stand until room temperature is reached, for not more than 12 h. Compensate any water loss by evaporation and add the required amount of ethanol. Allow to stand in a well-closed container for 24 – 36 h, stirring occasionally. Express and filter.
potentisationThe mother tincture corresponds to the 1st decimal dilution (Ø = D1).The 2nd decimal dilution (D2) is made from1 part of the mother tincture and9 parts of ethanol of the same concentration as calculated for the mother tincture.
Subsequent decimal dilutions are produced accordingly; in this process the ethanol concentration is reduced with each step in the succession – 50 – 36 – 18 per cent (V/V) until the 18 per cent level is reached.
recommended designation Preparations made according to APC Method 3.9.1 carry the designation “ethanol. stab. infusum”. The same applies to preparations made from them.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
36
ethanol of the appropriate concentration (anhydrous, 96 per cent V/V – 94 per cent m/m, 90 per cent V/V – 86 per cent m/m, 80 per cent V/V – 73 per cent m/m, 70 per cent V/V – 62 per cent m/m, 50 per cent V/V – 43 per cent m/m, 36 per cent V/V – 30 per cent m/m, 18 per cent V/V – 15 per cent m/m), unless otherwise prescribed in the individual monograph.
Unless otherwise prescribed, comminute the herbal drug, mix thoroughly with the total amount of ethanol of the appropriate concentration and heat to boiling under reflux, maintaining at boiling temperature for 30 min unless otherwise specified in the individual monograph. Cool or allow to cool and leave the mixture to stand in a closed container for 12 – 36 h. Separate the residue from the ethanol and, if necessary, press out. In the latter case, combine the 2 liquids obtained.Adjust to the concentrations required in the individual monograph in accordance with Ph.Eur. (2371) Method 1.1.8.
potentisationThe 2nd decimal dilution (D2) is made from2 parts of the mother tincture and8 parts of ethanol of the same concentration.
The 3rd decimal dilution (D3) is made from1 part of the 2nd decimal dilution and9 parts of ethanol of a reduced concentration as given below.
Subsequent decimal dilutions are produced accordingly; in this process the alcohol concentration is reduced with each step in the succession 96 – 90 – 80 – 70 – 50 – 36 – 18 per cent (V/V) until the 18 per cent level is reached.
3.11. Viscous extracts with heat treatment
definitionViscous extracts with heat treatment are prepared from fresh or dried herbal drugs using a fatty or mineral oil or glycerol 85 % as extraction liquid with heat.
productionIf necessary, comminute the herbal drug. Ethanol 96 per cent (V/V) may be added to moisten the plant material. The prescribed quantity of the extraction liquid (mostly peanut, olive, sesame or sunflower oil, liquid paraffin, or glycerol 85 %) is added and mixed thoroughly with the herbal drug. The mixture is heated at the prescribed temperature and allowed to stand in a closed container for an appropriate time. Extraction temperature and
can be adjusted to the specified content by concentration, carried out carefully and generally under vacuum.
identificationAt least one chromatographic identification test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). The pre-paration complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official pharmacopoeia, or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the herbal substance used,• where applicable, the fresh or dried herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the designation “Decoctum” or “ethanol. Decoctum”,
if ethanol is used,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by decoction
HAB Methods 12k, 12l, 12qPh.Eur. (2371) 1.2.7 – 12 (prev. HAB Methods 19)Ph.Eur. (2371) 1.4.2 – 3 (prev. HAB Methods 23)
APC Method 3.10.1 (related to Ph.Eur. Method 1.2.12)APC Method 3.10.1. is used for dried herbal drugs.Mother tinctures according to APC Method 3.10.1 are ethanolic decoction prepared by heat treatment with ethanol of an appropriate concentration as specified in the individual monograph with additional maceration as described below.1 part of dried herbal drug is macerated with 20 parts of
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
37
by steam distillation or water-and-steam distillation.The distillation can be done in the presence of other substances that will not interfere with the final composition of the distillate. This process can be repeated several times in a rhythmic sequence of evaporation/condensation. Distillated preparations can be part of a more complex formulation that is composed by several fractions. Distillated preparations can be used as starting materials or finished products and can be potentised.
productionAccording to the specific methods or the individual monograph.
identificationAt least one chromatographic identification test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). The preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official pharmacopoeia or another limit is justified and authorised.
recommended designation Distillates and derived dosage forms carry the designation „destillata“.
Specific pharmacopoeial/APC production methods to produce preparations made by distillation
APC Method 3.12.1 Preparations made by ethanolic distillation (related to HAB Method 52)
Distillates according to APC method 3.12.1 are prepared from fresh plants or parts of plants following the procedure given below.Comminute the plant material. Pour 8 parts of ethanol 90 per cent (V/V) over 100 parts of plant mass. Leave to stand in a closed container for at least 24 h, then steam distil, ending the steam distillation when 50 parts of distillate have been collected.
The mother tincture is made from1 part of distillate and1 part of ethanol 18 per cent (V/V).
time are prescribed in the individual monograph. Finally express and filter. If necessary, the empty space of the container is filled with a protecting gas.
identificationAt least one chromatographic identification test is carried out.
testsRelative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individual monograph.Refractive index (Ph.Eur. 2.2.6). The preparation complies with the limits prescribed in the individual monograph.Peroxide value (Ph.Eur. 2.5.5). Where applicable, the preparation made with a vegetable oil complies with the limits prescribed in the individual monograph.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-filled, airtight container, protected from light and heat. If necessary, the empty space in the container of oil extracts is filled with an inert gas.
recommended designation The designation states:• the fresh herbal drug used,• where applicable, the dried herbal drug used,• the extraction liquid used,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• an indication of the extraction temperature,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce viscous extracts with heat treatment
HAB Methods 12 d-gHAB Method 57
Individual Monographs:Cydonia oblonga, fruit, glycerol extract with heat treatment 1:2.1.
3.12. Preparations made by distillation (Distillates)
definitionDistillates are prepared from fresh plants or parts of plants or dried plants, organic or inorganic substances
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
38
complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Methanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol, unless otherwise authorised by a national official pharmacopoeia, or another limit is justified and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.storageStore in a well-closed container, protected from light, at 8 – 15 °C.
recommended designation The designation states:• the herbal drug used,• where applicable, the fresh herbal drug used,• where applicable, the name of the salt, metal or
mineral added,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the designation „ferm“ (with water and fermenting
agents) or „Rh“ (fermented plant sap without fermenting agents),
• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce mother tinctures obtained with rhythmic application of heat and cold
HAB Method 21HAB Method 22HAB Methods 33HAB Methods 34HAB Methods 35HAB Method 36HAB Methods 37HAB Methods 51
APC Method 3.13.1 (related to HAB Method 21)Rh mother tinctures according to APC Method 3.13.1 are prepared from fresh plants generally yielding more than 50 per cent of expressed liquid, as follows:
Comminute the plants immediately after harvesting and express. Transfer the expressed juice to containers and subject to the diurnal hot-cold rhythm (“Rh”) described below until fermentation is complete.Each morning, warm the expressed liquid to 35 – 39 °C over a period of 30 – 90 min and maintain
potentisationThe 1st decimal dilution (D1) is made from1 part of the mother tincture and9 parts of alcohol 18 per cent (V/V).Subsequent dilutions are produced as stated for D1.
APC Method 3.12.2 Preparations made by aqueous distillation
Distillates according to APC Method 3.12.2 are preparations of fresh or dried starting materials from mineral, vegetal and animal source, obtained by aqueous distillation.Comminute the material. To 1 part of material add water according to the individual monograph, then heat with flame source, ending the distillation when 50 parts of distillated have been collected or according to the individual monograph.
The aqueous distillation can be done in the presence of other substances that will not interfere with the final composition of the final distillate.
3.13. Mother tinctures obtained by rhythmic application of heat and cold
definitionMother tinctures obtained by rhythmic application of heat and cold are aqueous preparations from fresh or dried herbal drugs or saps from fresh herbal drugs, obtained by fermentation under cold and heat appli-cation.
productionComminute the herbal drug if necessary. Add purified water. If stated in the individual monograph, add the prescribed fermenting agent.It is also possible to ferment the expressed plant sap or the finely minced fresh plant without addition of purified water. Treat rhythmically with application of heat (generally 37 °C) and cold (generally 4 °C). Where required, express and filter after the time prescribed in the individual monograph. Salts, specific plant ashes, metals or minerals may be added according to the individual monograph.
identificationAt least one chromatographic identification test is carried out.
testspH (Ph.Eur. 2.2.3). The preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). The preparation
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
39
Subsequent decimal dilutions are produced as stated for D1.
Ethanolic dilutionsThe 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of ethanol 18 per cent (V/V).
Subsequent decimal dilutions are produced as stated for D1.
recommended designation Mother tinctures made according to APC Method 3.13.2 carry the designation “Rh”; the same applies to preparations made from them. If ethanol 18 per cent (V/V) is used from the 1st decimal dilution onwards, state this on the label.
4. SOLID STARTING MATERIALS OBTAINED BY HEAT
Heat treatment can be applied directly to solid starting materials from botanical or zoological origin without addition of a vehicle. The heat treatment may be performed under presence or reduced presence of oxygen. Solid starting materials obtained by heat include toasted preparations (Tosta), carbons (Carbo) and ashes (Cinis).
4.1. Toasted preparations – Tosta
definitionToasted preparations are obtained from dried plants or parts of plants or solid, dried animal matter by toasting. Toasted preparations are dry, usually brownish and have an intense and characteristic odour.
The substances to be toasted are crushed, if necessary, and are exposed to a heat source for the prescribed time. During the process water evaporates and the matter becomes brown or brownish. This is achieved through control of the heat supply, usually 170 – 250 °C and by tossing the material during this procedure. The toasted substance is powdered.Particle size of the raw material, temperature and heating time are prescribed in the individual monograph.
Toasted substances may be potentised according to Ph.Eur. 4.1.1.
at this temperature. Each evening, cool the expressed liquid to 2 – 6 °C over a period of 30 – 90 min and maintain at this temperature.Stir the liquid for 60 – 200 min during both temperature phases at the beginning, gradually decreasing to 10 min at the end of the fermentation process. Filter as soon as fermentation has ceased.
potentisationAqueous dilutions
The 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of water for injections.
Subsequent decimal dilutions are produced as stated for D1.
Ethanolic Dilutions The 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of ethanol 18 per cent (V/V).
Subsequent decimal dilutions are produced as stated for D1.
recommended designation Preparations made according to APC Method 3.13.1 carry the designation “Rh”; the same applies to prepa-rations made from them. If ethanol 18 per cent (V/V) is used from the 1st decimal dilution onwards, state this on the label.
APC Method 3.13.2 (related to HAB Method 22)Rh mother tinctures according to APC Method 3.13.2 are prepared from fresh plants, generally yielding distinctly less than 50 per cent of expressed liquid, as follows:
Comminute the plants immediately after harvesting. Subject the plant material to the diurnal hot-cold rhythm (“Rh”) for 7 – 10 days. Each morning, warm the plant material to approximately 35 – 39 °C and maintain at this temperature. Each evening, cool the plant material to 2 – 6 °C and maintain at this temperature.Then express. Transfer the expressed juice to containers and subject to the diurnal hot-cold rhythm (“Rh”) as described under method 3.13.1.
potentisationAqueous dilutionsThe 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of water for injections.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
40
• Sulfated ash (Ph.Eur. 2.4.14),• Sulfide,• Total ash (Ph.Eur. 2.4.16),• Zinc.
assayAn assay is carried out according to the individual monograph, where applicable.
storageStore in a well-closed container.recommended designation The designation states:• the name of the herbal or animal matter used,• the designation ”Carbo”, example: Carbo Gentianae,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce carbons
Ph.Helv. 17.7.4.2B.Hom.P. Method Br4
4.3. Ashes – Cinis
definitionAshes are obtained from dried plants or parts of plants or dried animal matter. They are generally fine, amorphous, white, grey, beige or brown powders.
The herbal or animal matter is incinerated generally at a temperature above 500 °C.
Ashes may be potentised according to Ph.Eur. 4.1.1.
identificationThe identification is carried out according to the individual monograph.
testsThe tests are carried out according to the individual monograph, where applicable:• Acid insoluble substances,• Arsenic (e.g. Ph.Eur. 2.4.2),• Heavy metals (e.g. Ph.Eur. 2.4.8),• Loss on drying (Ph.Eur. 2.2.32).
assayWhere applicable the Cinis complies with the individual monograph.
identificationAccording to the individual monograph.
testsThe tests are carried out according to the individual monograph, where applicable.
assayAn assay is carried out according to the individual monograph, where applicable.
storageStore in a well-closed container.
recommended designation The designation states:• the name of herbal or animal matter used,• the designation “tostus/a/um/”, example: Spongia
tosta,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce toasted preparations.
According to the individual monograph.Ph.Helv 17.7.4.1
4.2. Carbons – Carbo
definitionCarbons are obtained from dried plants or parts of plants or dried animal matter. They are dry, brittle, and generally black substances.The plant or animal matter is heated to a temperature usually above 200 °C under reduced presence of oxygen to produce the carbonised deposit. The carbonised substance is powdered.Carbons may be potentised according to Ph.Eur 4.1.1.
identificationThe identification is carried out according to the individual monograph.
testsThe tests are carried out according to the individual monograph, where applicable:• Acidity or Alkalinity,• Acid-soluble substances,• Adsorption power,• Alkali-soluble coloured matter,• Cyanide,• Ethanol-soluble substances,• Fluorescent substances,• Heavy metals (e.g. Ph.Eur. 2.4.8),• Loss on drying (Ph.Eur. 2.2.32),
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
41
recommended designation The designation states:• the name of the plant material used,• the quantity used,• the vehicle used,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce solid preparations from fresh plants
Ph.Eur. (2371) Method4.1.1
APC Method 5.1.1Preparations according to APC Method 5.1.1 are solid preparations of fresh plants prepared by drying fresh herbal drugs onto lactose monohydrate.Comminute the plants or parts of plants. To 1 part of the plant material add the required amount of lactose mono hydrate, usually 2.9 parts unless otherwise prescribed in the individual monograph. Mix thoroughly. Dry the moist mixture gently until it reaches the dryness required. Mill, if necessary, then sieve as specified in the individual monograph and remix thoroughly.
potentisationThe preparation can be potentised according to Ph.Eur. (2371) Methods 4.1.1 and 4.1.2.The 1st decimal dilution (D1) is made from 3 parts of the solid preparation and7 parts of lactose monohydrate
5.2. Solid preparations from liquids, plant juices or aqueous extracts
definitionSolid preparations of liquids are prepared by drying plant juices, tinctures, aqueous extracts or solutions or their dilutions onto suitable vehicles e.g. lactose monohydrate. The expressed juice or the tincture from the fresh plant material or the solution is mixed thoroughly with the vehicle. The mixture is dried gently and milled if necessary.The preparation can be potentised according to Ph.Eur. (2371) Methods 4.1.1 and 4.1.2.
productionAccording to the specific methods or the individual monograph.
identificationAt least one chromatographic test is carried out.
storageStore in a well-closed container with a desiccant if necessary.
recommended designation The designation states:• the name of the herbal or animal substance used,• the designation ”Cinis”, example: Cinis Tabaci,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce ashes
Ph. Helv. 17.7.4.3B.Hom.P. Method Br3
5. SOLID PREPARATIONS FROM PLANTS (DRYING ONTO A VEHICLE)
Solid preparations from plants are obtained either by drying fresh plants, plant juices or aqueous extracts onto a vehicle.
5.1. Solid preparations from fresh plants
definitionSolid preparations of fresh plants are prepared by drying fresh plant material onto suitable vehicles e.g. lactose monohydrate.
productionComminute the fresh plant material, and mix thoroughly with the vehicle in order to adsorb its liquid part. Dry the mixture gently and mill if necessary.The preparation can be potentised according to Ph.Eur. (2371) Methods 4.1.1 and 4.1.2.
identificationAt least one chromatographic test is carried out.
testsLoss on drying (Ph.Eur. 2.2.32): The solid preparation complies with the limits prescribed in the individual monograph.Microbiological quality (Ph.Eur. 5.1.4): (Non-aqueous preparations for oral use).
assayAn assay with quantitative limits is performed when raw materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
42
necessary to concentrate the plant juice under reduced pressure.
APC Method 5.2.3Preparations according to APC Method 5.2.3 are solid preparations from aqueous extracts prepared by drying aqueous extracts of fresh plants onto lactose monohydrate or another excipient.Mix 1 part of the comminuted fresh plants with 0.15 parts of purified water. Then express the mixture. The expressed aqueous extract is added to 4 parts of lactose monohydrate unless otherwise prescribed in the individual monograph to obtain a wet granulate. Dry the wet granulate gently until it reaches the dryness required. Mill, if necessary, then sieve as specified in the individual monograph and remix thoroughly. Before granulation it may be necessary to concentrate the aqueous extract under reduced pressure.
6. LIQUID DILUTIONS
definitionLiquid dilutions are prepared by dissolving one or more starting materials in an appropriate vehicle. The liquid obtained may be directly potentised.
productionThe starting material is dissolved in the appropriate vehicle. Dissolution may require heating or stirring. The separation of a residue may be necessary.
Where necessary, immediately after the dissolution the first potentisation step is carried out in accordance with the individual monograph.
identificationLiquid dilutions are identified using a suitable method.
testsAppearance (Ph.Eur. 2.2.1, 2.2.2). Where applicable, the preparation complies with the limits described in the individual monograph.pH (Ph.Eur. 2.2.3). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). Where applicable, the liquid solution complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). The preparation complies with the limits prescribed in the individual monograph.
assayWhere applicable, liquid solutions of chemically
testsLoss on drying (Ph.Eur. 2.2.32). The solid preparation complies with the limits prescribed in the individual monograph.Microbiological quality (Ph.Eur. 5.1.4). (Non-aqueous preparations for oral use)
assayAn assay with quantitative limits is performed when raw or starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the name of the plant material used,• the quantity used,• the vehicle used,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce solid preparations from liquid extracts/ plant juicesPh.Eur. (2371) Methods (refer to potentisation)4.1.14.1.2
APC Method 5.2.1Preparations according to APC Method 5.2.1 are solid preparations from fresh plant juices prepared by drying the fresh plant juice onto lactose monohydrate or another excipient.Add 1 part of the expressed plant juice or aqueous extract to 1.9 parts of lactose monohydrate unless otherwise prescribed in the individual monograph to obtain a wet granulate. Dry the wet granulate gently until it reaches the dryness required. Mill, if necessary, then sieve as specified in the individual monograph and remix thoroughly. For granulation it may be necessary to concentrate the plant juice under reduced pressure.
APC Method 5.2.2Preparations according to APC Method 5.2.2 are solid preparations from fresh plant juices prepared by drying the fresh plant juice onto lactose monohydrate or another excipient.The expressed plant juice of 1 part of the fresh plant is added to 3 parts of lactose monohydrate unless otherwise prescribed in the individual monograph to obtain a wet granulate. Dry the wet granulate gently until it reaches the dryness required. Mill, if necessary, then sieve as specified in the individual monograph and remix thoroughly. Before granulation it may be
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
43
recommended designation The designation states:• the name of the composition,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.
Specific APC production methods to produce compositions according to 7.1
Examples (see appendix 2.6): Anis-Pyrit, Ferrum-Quarz, Hepar-Magnesium, Hepar sulfuris, Kalium aceticum comp., Plumbum mellitum, Solutio Sacchari comp. (mineral compositions according to the model of a plant).
7.2. Compositions made by treating two or more extracts or mother tinctures of one plant by one or more pharmaceutical processes
definitionCompositions made by treating two or more mother tinctures of one plant by pharmaceutical processes are prepared from extracts (mother tinctures) of the same plant species harvested at different seasons, i.e. at different stages of development. According to the individual monograph the extracts are combined in a defined ratio by a specific pharmaceutical process possibly using specific equipment. Adjustment of concentration, of pH, and of osmolality may be carried out.
productionAccording to the specific methods or the individual monograph.
identification/testsAccording to the nature of the composition. The components of the composition comply with the requirements of the relevant monographs.
recommended designation The designation states:• the name of the composition,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.
Specific pharmacopoeial APC production methods to produce compositions according to 7.2
HAB Method 32HAB Method 38
defined starting materials are assayed.
storageStore in a well-closed container, protected from light.
recommended designation The designation states:• the name of the substance dissolved,• the quantity dissolved,• where applicable, the degree of potentisation,• the reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce liquid dilutions
Ph.Eur. (2371) Methods3.1.13.1.2
HAB Methods 5
7. COMPOSITIONS
Compositions are active substances which are obtained when two or more starting materials and/or preparations with or without excipients and/or vehicles are processed together in a pharmaceutical process that will lead to a new substance (unit). The rationale for composing is the anthroposophic understanding of man, nature, substance and processing. Compositions may be directly used as an active substance or can be potentised or diluted for any dosage form.
7.1. Compositions made by treating two or more starting materials by one or more pharmaceutical processes
definitionCompositions made by treating two or more starting materials or preparations by one or more pharmaceutical processes are prepared by combining starting materials in a defined ratio according to the individual monograph using a specified process (e.g. specified mixing, heat treatment, chemical process).
productionAccording to the specific methods or the individual monograph.
identification/testsAccording to the nature of the composition. The components of the composition comply with the requirements of the relevant monographs.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
44
or plant parts are separated by centrifugation. The centrifugate is filled up to 100 parts with 0.09 percent sodium chloride solution and filtered. The winter formulation produces the so called winter extract, the summer formulation the so called summer extract. If the extract is to be stored, sterile filtration must take place.The composition is produced by composing three parts of winter extract and one part of summer extract as described below.The winter extract is stirred in a specially constructed gilded mixing vessel. The summer extract is allowed to drop from the top of the vessel into the vortex of the winter extract. The osmolality is adjusted by adding sodium chloride and the pH is adjusted to 6.1 – 6.3 by adding sodium hydroxide solution. If the composition is to be stored, sterile filtration must take place. The composition (mother tincture) can be used directly or can be used for further dilutions. The addition of anti oxidants or substances for pH adjustment is allowed.
Dilutions are obtained by diluting the composition. At a temperature between 10 °C and 25 °C the necessary amount of 0.9 percent sodium chloride solution is stirred in a vessel; the composition is dropped from the top into the vortex. The dilution series is: (Composition + sodium chloride solution) e.g. 3+2 (30 mg), 2+3 (20 mg), 1+4 (10 mg), 1+9 (5 mg), 1+49 (1mg), 1+499 (0.1 mg); 1+4999 (0.01 mg). If the dilution is to be stored, sterile filtration must take place.
recommended designation The amount of herbal drug (fresh plant) which was extracted to achieve 1 mL/2 mL of the final preparation.
APC Method 7.2.3 and 7.2.4 Compositions of fermented aqueous extracts and liquid preparations thereofCompositions according to APC Method 7.2.3 and 7.2.4 are mother tinctures produced from fresh plants or parts of plants by the following procedure.Finely comminute the plants or parts of plants and mix 1 part of the plant mass with 1.318 parts of purified water, 0.03 parts of sucrose, and 0.002 parts of a Lactobacillus plantarum suspension, 109 – 1010 cfu/mL and mix thoroughly. Leave to ferment for 3 days at 20 to 27 °C with the exclusion of air. Then express and weigh the expressed liquid. If (except for the berries) gentle pressure applied to the plant residue does not achieve a final mass of extract equal to 2 parts, pour a sufficient amount of purified water over the plant residue and express gently. Use the resulting extract to make the extract up to 2 parts. If prescribed in the
See appendix 2.6, for example Viscum album compositions.
APC Method 7.2.1 (see also APC Method 3.7.1)Compositions according to APC Method 7.2.1 are produced from fresh plants or parts of plants by the following procedure:Finely comminute the plants or parts of plants and mix 1 part of the plant mass with 1 part of purified water. Leave to ferment at 20 to 24 °C with the exclusion of air, ending the fermentation when the pH of the fermentation liquid has fallen to between 4 and 5. Then express and weigh the expressed liquid. The weight of the expressed liquid is equal to 2 parts and is mixed with 1 part of a mixture of 0.95 parts of ethanol 96 per cent (V/V) and 0.05 parts of purified water. This tincture is stored until it will undergo another pharmaceutical process with a second tincture of the same plant.This procedure is followed for plants harvested in summer and for plants of the same species, harvested in winter.The mother tincture is a composition, produced by unifying equal parts of the two tinctures.
The mother tincture can be potentised as follows:
The 1st decimal dilution (D1) is made from3 parts of the mother tincture and7 parts of alcohol 36 per cent (V/V).
The 2nd decimal dilution (D2) is made from1 part of the 1st decimal dilution and9 parts of alcohol 18 per cent (V/V).Subsequent dilutions are produced as stated for D2.
recommended designation Preparations according to APC Method 7.2.1 carry the designation „ferm APC 7.2.1“.
APC Method 7.2.2 Compositions of aqueous extracts and liquid preparations thereofCompositions according to APC Method 7.2.2 are mother tinctures produced from fresh (frozen) plants or parts of plants by the following procedure.The plants or parts of plants are comminuted in a grinder, pressed in appropriate boxes and frozen at – 10 °C to – 30 °C. The plants or parts of plants are combined to a specific formulation: Plants and parts of plants from winter harvest with plants from spring harvest to give the so called winter formulation. Plants from summer harvest with plants from autumn harvest to give the so called summer formulation. 5 parts of frozen plants are extracted for 1 – 4 h at 10 – 20 °C with 95 parts of 0.09 % sodium chloride solution in a container with stirring. The coarse plants
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
45
Compositions produced according to methods 7.2.3 and 7.2.4 may be potentised according to chapter 8.
recommended designation The amount of herbal drug (fresh plant) which was extracted to achieve 1 mL of the final preparation.
storageStore the mother tincture in a well-closed container at 2 – 8 °C.
7.3. Compositions made by treating one or more starting materials with one or more mother tinctures which undergo one or more pharmaceutical processes together
definitionCompositions made by treating one or more starting materials with one or more mother tinctures are obtained by combining one or more starting materials with one or more stocks in a defined ratio according to the individual monograph.
productionAccording to the specific methods or the individual monograph.
identification/testsAccording to the nature of the composition. The components of the composition comply with the requirements of the relevant monographs.
recommended designation The designation states:• the name of the composition,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce compositions according to 7.3
Examples (see appendix 2.6): Cinis e fructibus Avenae sativae cum Magnesio phosphorico (1:1), Cissus-Ossa.
7.4. Compositions made by treating two or more extracts or mother tinctures and/or dilutions by one or more pharmaceutical processes
definitionComposition made by treating two or more extracts or mother tinctures and/or dilutions by pharmaceutical
individual monograph, adjust the pH to 5.0 – 6.5 by adding sodium hydroxide.Follow the same procedure for plant material harvested in the summer and for plant material of the same species, harvested in the winter. However, for the winter harvest, process the berries and the other plant parts separately according to the method described above and use 1.328 parts of purified water and 0.02 parts of sucrose. Also, leave the berry mixture to ferment for 4 days.If the extracts are stored for further processing, they must comply with the test for sterility (Ph.Eur. 2.6.1).
The composition is produced by composing equal parts of the summer and the combined winter extracts as described below.
Method 7.2.3Mix two parts of summer extract with 3 parts of water for injections.Mix one part of winter extract of plant material and one part of extract of berries with 3 parts of water for injections.
Method 7.2.4Mix two parts of summer extract with 3 parts of water for injections. Mix one part of winter extract of plant material and one part of extract of berries with a mixture of 0.002 parts of a metal salt trituration from the D4 potentisation step and 2.998 parts of water for injections.
Methods 7.2.3 and 7.2.4Feed the mixture of the winter extracts continuously onto the centre of a rotating disk. At the same time, feed the summer extracts continuously onto the slightly raised edge of the disk. The blended mixture flows continually off over the edge of the disk. Filter the mixture; the filtrate is the mother tincture. If the mother tincture is stored for further processing, it must comply with the test for sterility (Ph.Eur. 2.6.1).The dilution series is (composition or dilution + water for injections): 1+9 (20 mg), 1+19 (10 mg, corresponding to a 1:20 dilution); 1+39 (5 mg); 1 + 99 (2 mg); 1 part 1:20 dilution + 9 parts water for injections (1:200 or 1 mg); 1 part 1:200 dilution + 9 parts water for injections (1:2,000 or 0.1 mg); 1 part 1:2,000 dilution + 9 parts water for injections (1:20,000 or 0.01 mg); 1 part 1:20,000 dilution + 9 parts water for injections (1:200,000 or 0.001 mg); 1 part 1:200,000 dilution + 9 parts water for injections (0.0001 mg). To prepare the final preparation, add sodium chloride to the water for injections to obtain an isotonic solution.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC Part IIa
46
Specific pharmacopoeial/APC production methods to produce compositions according to 7.5Ph.Eur. (2371) Methods5.1.15.1.25.1.5
8. POTENTISED PREPARATIONS
Potentised preparations are gradually diluted substances, whereby at each diluting step a rhythmic succussion (liquid potencies) or trituration (solid or semi-solid potencies) has been carried out for a defined time. The potentising time differs for solid and liquid potentised preparations. Astronomical aspects may be considered (e.g. solar or lunar eclipse ).The preparations are defined by the number of liquid potentising or trituration steps respectively and by the ratio between the vehicle (diluting agent) and the substance to be potentised.
The potentising ratio is usually:1 part of substance9 parts of vehicle.
The potentising ratio for co-potentised preparations is usually:1 part of a mixture of equal parts of active substances9 parts of vehicle.
liquid potencies:The substance or mixture to be potentised is dissolved in the vehicle in the chosen ratio. Usual vehicles for liquid potencies are water (purified or water for injections), ethanol of various concentrations, glycerol or vegetable oils. Excipients might be necessary, for example to emulsify an aqueous substance into oil. After dissolution, rhythmic succussion is carried out. For the next poten-tising step one part of the first potency and the prescribed amount of vehicle are brought together and succussed. Further potentising is carried out in likewise manner.
solid potencies (triturations):Potencies of solid substances are prepared by trituration of the substance to be potentised usually with lactose monohydrate in the prescribed ratio in a mortar with a pestle or in an adequate trituration machine.Solid potencies can be further potentised in liquid phase, if they are soluble in a vehicle.
semi-solid potencies:Semi-solid potencies are prepared by trituration of a liquid or a solid substance to be potentised with an
processes are prepared according to an individual monograph prescribing the combination of the ingredients in a defined ratio by a specific pharmaceutical process using specific equipment.
productionAccording to the individual monograph.
identification/testsAccording to the nature of the composition. The components of the composition comply with the requirements of the relevant monographs.
recommended designation The designation states:• the name of the preparation,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.Specific pharmacopoeial/APC production methods to produce compositions according to 7.4
Examples (see appendix 2.6): Onopordum acanthium, Folium rec., ethanol. Digestio (1:3.1) with 1 – 2 % Hyoscyamus niger, Herba rec. Ø, see also Plantago lanceolata and Primula.
7.5. Compositions made by co-potentising
definitionCompositions made by co-potentising are prepared from two or more starting materials and/or preparations (e.g. mother tinctures, potencies) by co-poten tising over one or more steps.
productionAccording to APC Method 8.1 or the individual monograph.
identification/testsAccording to the nature of the composition. The components of the composition comply with the requirements of the relevant monographs.
recommended designation The designation states:• the name, quantity and potency degree of each
ingredient,• how many potentising steps were carried out on the
mixture as a whole,• reference pharmacopoeia/codex.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ia
47
identification, test, assayare carried out according to the individual monograph.
storageStore in a well-closed container.
recommended designation The designation states:• the name of the potentised substance(s),• where applicable, the ethanol content,• the potentising ratio; decimal potencies may be
designated as D or DH or X,• the potency degree, example: D3 or 3 DH or 3X,• the reference pharmacopoeia/codex.• APC Method 8.1.1 (Ph.Eur. (2371) Method 5.1.5)Co-potentised preparations according to APC Method 8.1.1 are liquid dilutions potentised with a suitable vehicle from two or more (n) preparations, each making up 1 part of the final 10 parts. Consequently the vehicle is 10 minus n parts.
potentisationFor the first co-potentisation step combine and succuss 1 part of each of the n preparations with 10 minus n parts of water or ethanol of the appropriate concentration specified under HAB H 5.3. For each further co-potentisation step the ratio is 1 part of the given composed potency and 9 parts of vehicle.
recommended designation The designation of co-potentised compositions according to APC Method 8.1.1 and derived dosage forms states how many potentising steps were carried out on the mixture as a whole adding the expressions “rhythmically diluted”.
APC Method 8.1.2 (related to Ph.Eur. (2371) Methods 5.1.1 and 5.1.2)
Co-potentised preparations according to APC Method 8.1.2. are liquid dilutions potentised with a suitable vehicle from two or more (n) preparations, each making up 1/n part of the final 10 parts. Consequently the vehicle is 9 parts.
potentisationFor the first co-potentisation step combine and succuss 1/n part of each of the n preparations with 9 parts of water or ethanol of the appropriate concentration specified under HAB H 5.3. For each further co-potentisation step the ratio is 1 part of the given composed potency and 9 parts of vehicle.
ointment base in the prescribed ratio in a mortar with a pestle or in an adequate trituration machine.
Specific pharmacopoeial/APC production methods to produce potentised preparationsPh.Eur. (2371) Methods3.2.1 – 34.1.1 – 24.2.1 – 25.1.1 – 5
HAB Method 12jHAB Method 17B.Hom.P. Method Br5B.Hom.P. Method Br6
The potentising specifications in Ph.Eur. monograph 2371 of Methods 1.1.1 – 1.1.11, 2.1.1, 2.1.2, 2.2.1 – 2.2.4 and 5.1.1 – 5.1.5.
The potentising specifications in HAB methods5, 11, 15, 18, 19, 20, 21, 22, 23, 24, 32, 33, 34, 35, 36, 37, 38, 39a, 39b, 45, 51, 53.
The potentising specifications in APC Methods.
8.1. Co-potentised preparations
definitionMethod 8.1 is used for preparing dilutions by co- potentising two or more stocks and/or dilutions thereof, where co-potentisation consists of mixing several stocks or dilutions of stocks then potentising them together in one or more potentisation steps.
productionCo-potentised compositions according to APC Method 8.1 may be prepared from starting materials and/or solutions, potentised preparations and mother tinctures whose method of production is specified by a ratio of 1 part of starting material and 10 parts of extraction solvent.When a solid potency D4 shall be potentised with liquids, it can be potentised one step according to Ph.Eur. (2371) Methods 3.2, and then be used as D5 for co-potentisation or dilution to a final concentration of 1 ppm.
Co-potentised compositions may be used to produce all types of dosage forms. Co-potentisation of mixtures according to APC Method 8.1 to produce parenteral preparations or eye drops is carried out with water for injections or an isotonic solution as diluting agent.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
48
recommended designation The designation of co-potentised compositions according to APC Method 8.1.2. and derived dosage forms states how many potentising steps were carried out on the mixture as a whole.
8.2. Potentising in an ointment base
definitionLiquid and solid starting materials can be potentised within an ointment base.
productionAccording to the specific methods or the individual monograph.identification, tests, assayare carried out according to the individual monograph.
storageStore in a well-closed container.
recommended designation The designation states:• the name of the potentised substance(s),• the potentising ratio; decimal potencies may be
designated as D or DH or X,• the potency degree in the ointment,• the reference pharmacopoeia/codex.
APC Method 8.2.1 (Ointments containing powdered solid starting materials, related to HAB Method 48)Ointments containing powdered solid starting materials are produced with 1 part of a powdered metal, powdered mineral or a composition containing minerals and 9 parts of an ointment base leading to a homogeneous ointment. This potentising step in an ointment base results in the first decimal dilution (D1). The particle size of the powdered solid starting material must be smaller than 100 mm.Ointments according to APC Method 8.2.1 must meet the requirements of the Ph.Eur. monograph "Semi-solid preparations for cutaneous application" (0132).Ointments according to APC Method 8.2.1 can be used further to produce ointments according to HAB Method 13.
recommended designation Ointments according to APC Method 8.2.1 carry the designation “APC M” and the resulting decimal dilution “D1”.
APC-Method 8.2.2 Ointments containing solid or liquid dilutionsOintments containing solid or liquid dilutions are
produced with 1 part of a decimal solid or liquid dilution (Dn) and 9 parts of an ointment base leading to a homogeneous ointment. The resulting decimal dilution degree is (Dn+1).Ointments according to APC Method 8.2.2. must meet the requirements of the Ph.Eur. monograph “Semi-solid preparations for cutaneous application” (0132).
recommended designation Ointments according to APC Method 8.2.2 carry the designation of the resulting degree of decimal dilution. Example: D3 or 3 DH or 3X APC 8.2.2.
8.3. Triturations
definitionPreparations according to APC Method 8.3 are triturations of solid substances with lactose monohydrate as potentising vehicle unless otherwise specified in a ratio of 1:10.
productionTriturate using a machine that ensures even trituration. Suitable machines include mixers with rhythmic, pul sating spatial inversion (e.g. “Turbula”), in combination with a sealable mixing vessel and appropriate grinding balls as well as other machines with rotating movements such as the ball mill.Triturate the whole amount of vehicle with the substance to be potentised.The trituration time depends on the machine and the chosen parameters. Trituration must be between 15 and 60 minutes. It has to be ensured, that the trituration is homogeneous and that particle size reduction is achieved.
testsare carried out according to the individual monograph.
recommended designation Preparations according to APC Method 8.3 carry the designation of the resulting degree of decimal dilution. Example: D3 or 3 DH or 3X APC 8.3.
9. MIXTURES
definitionMixtures are produced from usually two or more active substances.Vehicles and/or excipients may be added. Mixtures contain the sum of the active substances mixed together. Mixtures can also be produced from one active substance and a vehicle. A special manufacturing method is not needed (cf. compositions). Mixtures are used to
• A
PC Part IIa
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
49
facilitate the administration of more than one active substance in one single finished product. The mixture itself may be the final dosage form.
Mixtures can be classified into four categories:9.1. Mixtures of preparations without a vehicle9.1a. Mixtures of liquid preparations produced according to Ph.Eur., HAB or APC Methods.9.1b. Mixtures of solid preparations produced according to Ph.Eur., HAB or APC Methods.9.1c. Liquid and solid preparations, produced according to Ph.Eur., HAB or APC Methods, resulting in a liquid preparation.
9.2. Mixtures of preparations with a vehicle9.2a. Liquid preparations produced according to Ph.Eur., HAB or APC Methods in which the vehicle is added in a ratio other than 1 to 10 or 1 to 100.9.2b. Solid preparations produced according to Ph.Eur., HAB or APC Methods in which the vehicle is added in a ratio other than 1 to 10 or 1 to 100.9.2c. Liquid and solid preparations, produced according to Ph.Eur., HAB or APC Methods, resulting in a liquid preparation, in which the vehicle is added in a ratio other than 1 to 10 or 1 to 100.9.3. Mixtures of preparations with excipients and vehicles.9.3a. Liquid preparations produced according to Ph.Eur., HAB or APC Methods with an excipient(s).Vehicles may be added.9.3b. Liquid and solid preparations, produced according to Ph.Eur., HAB or APC Methods, resulting in a liquid preparation with an excipient(s). Vehicles may be added.9.4. Mixtures of starting materials used as active substances and mother tinctures or preparations with or without vehicles and/or excipients.
recommended labelling• the ingredients mixed and their quantity,• reference pharmacopoeia/codex.
Specific pharmacopoeial/APC production methods to produce mixturesHAB Method 12HAB Method 16
• A
PC P
art I
Ia
• A
PC Part IIb
50
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IIbIndividual monographs of starting materials and preparations
Table of ContentPart IIbCYDONIA OBLONGA, FRUIT ............................ 51CYDONIA OBLONGA, FRUIT, HEAT TREATED AQUEOUS TINCTURE 1:2.1 ............ 51CYDONIA OBLONGA, FRUIT, GLYCEROL EXTRACT WITH HEAT TREATMENT 1:2.1 ..................................... 52
CYDONIA OBLONGA, FRUIT, MOTHER TINCTURE OBTAINED BY RHYTHMIC APPLICATION OF HEAT AND COLD CYDONIA OBLONGA E FRUCTIBUS FERM 33B ..................................... 53LEVICO WATER ..................................................... 54
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
51
CYDONIA OBLONGATA, FRUITCydonia oblonga, FructusCydonia
definitionFresh, ripe fruit of Cydonia oblonga Mill. collected during late summer and autumn.
charactersThe odour is characterised by a typical flowery scent.
identificationThe pear-shaped variety (var. pyriformis) is yellow, fragrant, fuzzy, 7 – 15 cm in diameter. The gentle soft pulp is golden yellow.The apple-shaped variety (var. maliformis) is yellow to greenish yellow, fuzzy, 7-15 cm in diameter and less fragrant. The pulp is characterised by stone cells.Both varieties obtain five oblong-ovate sepals with serrate margins which are located in a depression. They are completely adnate with the 5 carpels. The 5 loculi of the core generally each contain 5 to 15 or sometimes more brown, cuneate seeds arranged in 2 vertical rows and stuck together with a mucilaginous coat.
testsForeign matter (Ph.Eur. 2.8.2).As low as possible. The whole batch is checked during manufacture. Foreign matter is sorted out.
Adulteration.Fruits from Japanese quince [Choenomeles japonica (Thunb.) Lindl. ex Spach, syn. Cydonia japonica Pers., Rosaceae] and Chinese quince [Choenomeles speciosa (Sweet) Nakai, Rosaceae] are 4 to 5 cm in diameter with a smooth peel and being devoid of stone cells.
preparations1. Heat treated aqueous preparation according to the individual monograph,2. Heat treated preparation with glycerol according to the individual monograph,3. Tincture obtained by rhythmic application of heat and cold according to APC method 3.13 and method HAB 33b.
CYDONIA OBLONGA, FRUIT, HEAT TREATED AQUEOUS TINCTURE 1:2.1
definitionThe heat treated aqueous tincture is prepared from the fresh cut fruit of Cydonia oblonga Mill., see Cydonia oblonga, Fruit (Cydonia oblonga, Fructus; Cydonia) APC
productionThe heat treated aqueous tincture is prepared in a ratio of fresh fruits to purified water 1:2.1 and by heat treatment at 65 – 70 °C as follows:
The whole fresh ripe fruit are cut into pieces (2 – 4 cm). To 1 part of the cut fruit add 2.1 parts of purified water and mix thoroughly. Heat to 65 – 70 °C in a closed container and keep at this temperature for one hour swirling repeatedly. After cooling to 40 – 45 °C separate by straining the mixture through gauze, filter the resulting liquid and process immediately.
charactersAppearance: light yellow, slightly turbid liquid.Odour: fruity.
identificationThin-layer chromatography (Ph.Eur. 2.2.27).
Test solution. Apply 10 mL onto a cartridge filled with octadecylsilylated silica gel RH (particle size 55 – 110 µm, 360 mg), preconditioned sequentially with 10 mL of methanol R and 10 mL of water R. Wash the cartridge with 10 mL of water R. Elute with 10 mL of methanol R. Evaporate the eluate to dryness under reduced pressure. Dissolve the residue in 1 mL of methanol R.
Reference solution. Dissolve 5 mg of rutin R, 5 mg of hyperoside R and 5 mg of scopoletin R in 10 mL of methanol R.
Plate: TLC silica gel plate R.
Mobile phase: anhydrous formic acid R, water R, ethyl acetate R (15:15:70 V/V/V).
Application: 20 µL as bands.
Development: over a path of 10 cm.
Drying: at 105 °C for 5 min.
Detection: spray the plate while still warm with a 10 g/L solution of diphenylboric acid aminoethyl ester R in methanol R. Subsequently spray with a 50 mL/L solution of macrogol 400 R. Examine in ultraviolet light at 365 nm within 30 min.
Results: see below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. Other faint zones may be present in the chromatogram obtained with the test solution.
• A
PC P
art I
Ib
• A
PC Part IIb
52
separate the mixture by straining through gauze, then filter if necessary.charactersAppearance: light yellow, slightly turbid, viscous liquid.Odour: fruity.
identificationThin-layer chromatography (Ph.Eur. 2.2.27).
Test solution. To 5 mL add 15 mL of water R. Apply the mixture onto a cartridge filled with octadecylsilylated silica gel RH (particle size 55 – 110 µm, 360 mg), preconditioned sequentially with 10 mL of methanol R and 10 mL of water R. Wash the cartridge with 10 mL of water R. Elute with 10 mL of methanol R. Evaporate the eluate to dryness under reduced pressure. Dissolve the residue in 0.5 mL of methanol R.
Reference solution. Dissolve 10 mg of rutin R, 10 mg of hyperoside R and 2 mg of scopoletin R in 10 mL of methanol R.
Plate: TLC silica gel plate R.
Mobile phase: anhydrous formic acid R, water R, ethylacetate R (15:15:70 V/V/V).
Application: 20 µL as bands.
Development: over a path of 10 cm.
Drying: at 105 °C for 5 min.
Detection: spray the plate while still warm with a 10 g/L solution of diphenylboric acid aminoethyl ester R in methanol R. Subsequently spray with a 50 mL/L solution of macrogol 400 R. Examine in ultraviolet light at 365 nm within 30 min.
Results: see below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. Other faint zones may be present in the chromatogram obtained with the test solution.
Top of the plate
Scopoletin: a blue zone A blue zone
A blue zone
__________________ __________________
Hyperoside: an orange zone
A strong light blue zone
Rutin: an orange zone An orange zone
__________________ __________________
Reference solution Test solution
testsRelative density (Ph.Eur. 2.2.5): 1.002 to 1.022.pH (Ph.Eur. 2.2.3): 3.0 to 4.0.Dry residue (Ph.Eur. 2.8.16): min. 2.5 % (3 g initial weight and dry at 105 °C for 2 hours).
storageIf stored it must meet the requirements of sterility, store in well closed containers, protected from light.
CYDONIA OBLONGATA, FRUIT, GLYCEROL EXTRACT WITH HEAT TREATMENT 1:2.1
definitionThe glycerol extract with heat treatment is prepared from the fresh cut fruit of Cydonia oblonga Mill., see Cydonia oblonga, Fruit (Cydonia oblonga, Fructus; Cydonia) APC.
productionThe glycerol extract with heat treatment is prepared in a ratio of fresh fruits to glycerol (85 per cent) 1:2.1 and by heat treatment at 65 – 70 °C as follows:
The whole fresh ripe fruit is cut into pieces (2 – 4 cm). To 1 part of the cut fruit add 2.1 parts of glycerol (85 per cent) and mix thoroughly. Heat to 60 – 70 °C in a closed container and keep at this temperature for one hour swirling repeatedly. After cooling to 40 – 45 °C
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ib
53
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
identificationThin-layer chromatography (Ph.Eur. 2.2.27)Test solution. Apply 2 mL of the tincture onto a cartridge filled with octadecylsilylated silica gel RH (sorbens mass 500 mg, 3 mL reservoir) preconditioned sequentially with 2 mL of methanol R and 2 mL of water R. Wash the cartridge with 10 mL of water R. Elute with 10 mL of ether R. The eluate is evaporated to dryness. Dissolve the residue in 0.5 mL of methanol R.
Reference solution. Dissolve 10 mg of caffeic acid R and 10 mg of hyperoside R in 10 mL of methanol R.
Plate: TLC silica gel plate R.
Mobile phase: anhydrous formic acid R, water R, ethyl acetate R (10:10:80 V/V/V).
Application: 60 µL of test solution and 10 µL of reference solution, as bands.
Development: over a path of 8 cm.
Drying: in air.
Detection: spray with a 10 g/L solution of diphenylboric acid aminoethyl ester R in methanol R. Subsequently spray with a 50 g/L solution of macrogol 400 R in methanol R. Examine in ultraviolet light at 365 nm after 30 min.
Results: See below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. Other faint zones may be present in the chromatogram obtained with the test solution.
Top of the plate
Scopoletin: a blue zone A blue zone
A blue zone
__________________ __________________
Hyperoside: an orange zone
A strong light blue zone
Rutin: an orange zone An orange zone
__________________ __________________
Reference solution Test solution
testsRelative density (Ph.Eur. 2.2.5): 1.170 to 1.185.pH (Ph.Eur. 2.2.3): 3.5 to 5.0.
storageProtected from light.
CYDONIA OBLONGATA, FRUIT, MOTHERTINCTURE OBTAIND BY RHYTHMIC APPLICATION OF HEAT AND COLD CYDONIA OBLONGATA E FRUCTIBUS FERM 33B
definitionThe tincture obtained by rhythmic application of heat and cold is prepared from the fresh minced fruit of Cydonia oblonga Mill., see Cydonia oblonga, Fruit (Cydonia oblonga, Fructus; Cydonia) APC.
productionThe tincture obtained by rhythmic application of heat and cold is prepared according to HAB method 33b (APC method 3.13).
charactersAppearance: slightly yellow liquid.Odour: sour, fruity.
• A
PC Part IIb
54
LEVICO WATERAqua LeviciLevico
definitionNaturally occurring spring water from the source Levico (Italy).Content:• Arsenic: 4 – 8 ppm• Iron: 1000 – 2500 ppm
charactersAppearance: colourless to yellowish-brown liquid, usually clear, a slight sediment may occur.Odour: almost odourless.
identificationA. Identification of arsenic by atomic absorption spectrometry (Ph.Eur. 2.2.23), see Assay.Results: the absorbance obtained with the test solution is not below the absorbance obtained with the reference solution with the lowest concentration.B. Identification of iron by atomic absorption spectrometry (Ph.Eur. 2.2.23), see Assay.Results: the absorbance obtained with the test solution is not below the absorbance obtained with the reference solution with the lowest concentration.C. Identification of copper by atomic absorption spectrometry (Ph.Eur. 2.2.23, Method I).Test solution. To 1.0 mL add 0.200 mL nitric acid R and dilute to 10.0 mL with water R.Reference solution. Prepare the reference solutions (0.5, 1.0, 2.0 and 4.0 ppm Cu) using copper standard solution R, diluted as necessary with a 5 per cent (V/V) solution of nitric acid R. Alternatively, commercially available copper standard solutions for atomic absorption spectrometry can be used.Source: copper hollow-cathode lamp using a transmission band preferably of 0.5 nm.Wavelength: 324.8 nm.Flame: air-acetylene.Results: the absorbance obtained with the test solution is not below the absorbance obtained with the reference solution with the lowest concentration.D. To 0.5 mL add 4.5 mL of water R. The solution gives reaction a on sulfates (Ph.Eur. 2.3.1).
testsRelative density (Ph.Eur. 2.2.5): 1.004 to 1.015.pH (Ph.Eur. 2.2.3): 1.5 to 2.5.
assayArsenic: 4 ppm to 8 ppm.Atomic absorption spectrometry (Ph.Eur. 2.2.23, Method I).
Top of the plate
Caffeic acid: a light blue zone A light blue zone
__________________ __________________
Hyperoside: an orange yellow zone A light blue zone
__________________ __________________
Reference solution Test solution
testsRelative density (Ph.Eur. 2.2.5): 1.001 to 1.013.Dry residue (based on Ph.Eur. 2.2.32 d): minimum 1.0 per cent, determined on 1.000 g of mother tincture by drying for 4 to 5 hours at 105 °C.Calculate the dry residue (per cent m/m) from the expression:
∙ 100(m₃ - m₁)m₂∙
m1 = mass of the crucible used, in grams;m2 = mass of the mother tincture used, in grams;m3 = mass of the crucible containing the mother tincture after drying, in grams.pH (Ph.Eur. 2.2.3): 3.0 to 4.2.
storageIn a well closed container at a temperature of max 15 °C.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
Ib
55
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
preparationsAccording to Ph.Eur., monograph 2371 Methods3.1.1, 3.1.2.
Test solution. To 0.200 mL add 2.00 mL nitric acid R and dilute to 100 mL with water R.Reference solutions. Prepare the reference solutions (5.0, 10.0, 15.0 and 20.0 ppb As) using arsenic standard solution R, diluted as necessary with a 5 per cent (V/V) solution of nitric acid R. Alternatively, commercially available arsenic standard solutions for atomic absorption spectrometry can be used.Source: arsenic hollow-cathode lamp using a trans-miss$ion band preferably of 0.5 nm.Wavelength: 193.7 nm.Atomisation device: graphite furnace.Calculate the content of arsenic in mg/kg from the expression:
X [ppm] = ( ) /1000A₁ ∙ F₁
F₂∙
A1: measured concentration of arsenic in µg/LF1: 100 mL (dilution factor) F2: 0.200 mL
Iron: 1000 ppm to 2500 ppm.Atomic absorption spectrometry (Ph.Eur. 2.2.23, Method I).Test solution. To 0.500 mL add 2.00 mL nitric acid R and dilute to 100 mL with water R.Reference solutions. Prepare the reference solutions (5.0, 10.0, 15.0 and 20.0 ppm Fe) using iron standard solution R, diluted as necessary with a 5 per cent (V/V) solution of nitric acid R. Alternatively, commercially available iron standard solutions for atomic absorption spectrometry can be used.Source: iron hollow-cathode lamp using a transmission band preferably of 0.2 nm.Wavelength: 372.0 nm. Flame: air-acetylene.Calculate the content of iron in mg/kg from the expression:
X [ppm] = A₂ ∙ F₁
F₂∙
A2: measured concentration of iron in mg/LF1: 100 mL (dilution factor) F2: 0.500 mL
storageStore in a well-closed container, protected from light.
• A
PC Part III
56
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IIIDosage forms
Table of ContentPart IIIDosage forms ............................................................ 56 Index list of terms of part I, II and III .................... 60
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
57
Dosage formsPrincipally an anthroposophic medicinal product can be administered in every dosage form, including external (topical), internal and parenteral dosage forms, with or without excipients.A dosage form of an anthroposophic medicinal product complies with any relevant dosage form monograph
Main dosage forms for oral use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Capsules Capsules Ph.Eur. (0016)
Granules Granules Ph.Eur. (0499)
Homoeopathic Pillules, coated
Globuli velati Ph.Eur. (1038, 2786), HAB Method 39
Homoeopathic Pillules, impregnated
Pillules Ph.Eur. (1038, 2079), HAB Method 10
Tablets Tablets Ph.Eur. (1038, 0478), HAB Method 9
Powders, oral Trituration Ph.Eur. (1165)
Oral drops Oral drops Ph.Eur. (0672)
Syrups Syrups Ph.Eur. (0672)
Oral solution Mother tincture, Dilution
Ph.Eur. (0672)
Main dosage forms for cutaneous use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Creams Creams Ph.Eur. (0132)
Ointments Ointments Ph.Eur. (0132), HAB Methods 13 and 48
Gels Gels Ph.Eur. (0132), HAB Method 13
Lotions Lotions B.P., Ph.Eur. (0927)
Oils Oils HAB Methods 12, Ph.Eur. (0927)
and any relevant test for that dosage form as described in the European Pharmacopoeia or in pharmacopoeias currently used officially in the EU Member States.
Main dosage forms for anthroposophic medicinal products and concerning references to official pharmacopoeias:
• A
PC P
art I
II
• A
PC Part III
58
Main dosage forms for cutaneous use Relevant monograph(s) in (Monograph number):
Liquid preparations (other)
Tinctures for external use, external emulsions, suspensions
Ph.Eur. (0927), HAB Methods 12
Powders Powders Ph.Eur. (1166)
Main dosage forms for auricular use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Ear drops Ear drops Ph.Eur. (0652)
Main dosage forms for ophthalmic use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Eye drops Eye drops Ph.Eur. (1163), HAB Method 15
Semi-solid eye preparations
Eye ointments Ph.Eur. (1163)
Main dosage forms for nasal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Nasal drops, solution Nasal drops Ph.Eur. (0676), HAB Method 45
Nasal spray, solution Nasal spray Ph.Eur. (0676)
Main dosage forms for oromucosal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Gels Gels Ph.Eur. (1807)
Solutions Solutions Ph.Eur. (1807)
Sprays Sprays Ph.Eur. (1807)
Pillules Pillules Ph.Eur. (1038, 2079, 2786), HAB Methods 10 and 39
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• A
PC P
art I
II
59
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Main dosage forms for vaginal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Gels Gels Ph.Eur. (1164)
Semi-solid vaginal preparations
Globules Ph.Eur. (1164)
Vaginal tablets Vagitories Ph.Eur. (1164)
Main dosage forms for rectal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Suppositories Suppositories Ph.Eur. (1145), HAB Method 14
Main dosage forms for parenteral use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Injections Liquid dilutions for injection, ampoules, Solutions for injection
Ph.Eur. (0520), HAB Method 11
APC Pillules containing lactose (related to HAB Method 10)APC Pillules containing lactose are pillules made by applying one or more potentised liquid preparations to saccharose pillules, which may contain up to 5 per cent of lactose. The potentising ratio usually is 1:100 (v/m or m/m). The ethanol concentration of the potentised liquid preparation(s) is at least 70 per cent (V/V). If this is not the case and interactions are excluded, the last potentisation step for decimal potentised prepa rations must be carried out with ethanol of at least 70 per cent (V/V). In case incompatibilities are expected, use ethanol of lower concentration.Preformed pillule sizes Ph.Eur. 3 and 6:Ph.Eur. size 3: 110 to 130 pillules weigh 1 gPh.Eur. size 6: 20 to 28 pillules weigh 1 g.Dry the pillules after impregnation in air.
recommended designation the designation states:the amount of potentised preparation(s),the potency degree,the potentising ratio in case other than 1:100.
60
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Creams 57Crystal 17Cuprum mirror foil 25Cutaneous application 48Cydonia oblonga 37, 51, 52, 53
D
DAB 13DAC 13Demeter 17, 18Digestion 19, 20, 22, 33, 34Directive 2001/83/EEC 7Distillate 37, 38Distillation products 16, 17Dornach 7, 16, 18Dosage forms 12, 14, 16, 18, 32, 37, 47, 48, 57, 58, 59
E
Ear drops 58Equisetum arvense Silicea cultum 24Essential oils 16, 17European Pharmacopoeia 7, 8, 9, 13, 16, 18, 57Excipient 14, 18Extracts 16, 17, 19, 22, 23, 30, 31, 32, 34, 36, 37, 41,
42, 43, 44, 45Eye drops 47, 58
F
Ferm 33, 38, 44, 53Fermentation 26, 32, 33, 38, 39, 44fermented tinctures 22Ferrum-Quartz 14Ferrum-Quarz 43Flowers 17French Pharmacopoeia 8, 13Fungi 16, 17
G
Gels 57, 58, 59German Homoeopathic Pharmacopoeia 7, 8, 13German Pharmacopoeia 8, 13GHP 13Glycerol macerates 26, 29Granules 57Growing season 24
H
Heat treatment 19, 22, 26, 33, 36, 37, 39, 43, 51, 52Hepar-Magnesium 43Hepar sulfuris 43Herbal Medicinal Products 7Homoeopathic manufacturing method 7Homoeopathic manufacturing procedure 7, 8Homoeopathic preparations 8
INDEX LIST OF TERMS OF PART I, II AND III
A
Active substances 16, 18Agate water 17Algae 16, 17Animal matter 27, 28, 29, 30, 39, 40Animal origin 18, 28Anis-Pyrit 43Anode 26Anthroposophic medicinal products 7, 8, 12, 16, 18,
57Anthroposophic Pharmaceutical Codex 7, 8, 12, 13Anthroposophic pharmacy 7, 8, 12, 14, 16, 20, 24Anthroposophic preparations 8, 12APC 13Aqua maris 17Argentum metallicum praeparatum 25Argon 26Ascorbate phosphate buffer solution 31Ash process 20Astronomical aspects 21, 46
B
Bark 17Biennial 17, 24Biodoron 18Biodynamic cultivation 17Blood products 16, 17Botanical origin 16, 17Brazilian Pharmacopoeia 9British Homoeopathic Pharmacopoeia 8, 9, 13
C
Calcareous products 16, 17Capsules 57Carbo 19, 23, 39, 40Carbo Gentianae 40Carbonisation 20Carbons 19, 23, 39, 40Cathode 26, 54, 55Cinis 23, 39, 40, 41, 45Cinis e fructibus Avenae sativae cum Magnesio
phosphorico 45Cinis Tabaci 41Cissus-Ossa 45Cold maceration 20Compositions 14, 45Composting process 24Contaminants 17Co-potentisation 47Co-potentising 19, 21, 46, 47Council Directive (EEC) 17, 18
• Index
• In
dex
61
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Homoeopathic stocks 7HPUS 12, 13
I
IAAP 5, 8, 9, 13, 16, 21Infusion 19, 20, 22, 34, 35Infusum 19, 22, 34, 35Injections 59Isotonic solution 18, 26, 45, 47
J
Juices 16, 17, 19, 23, 34, 41, 42
K
Kalium aceticum comp. 43KC Monograph 13Kommission C 13
L
Lactobacillus plantarum suspension 44Leaves and shoots 17Levico 17, 54Lichens 16, 17Life cycle 24Liquid dilutions 42, 59Liquid potencies 21, 46Liquid preparations 19, 22, 30, 49, 58Liquid solutions 23, 42Lotions 57Lunar eclipse 21, 46
M
Maceration 19, 20, 22, 26, 27, 28, 29, 30Magnetrom 26Medicinal Products Act 8Metabolic system 20Metallicum praeparatum 25Metal mirrors 25, 26Metal plant-compost 24Metal preparations 22Metal salts 25Metal vapour 26Minerals 15, 16, 17Miner, Carl S. 28Mixtures 23, 48, 49Mother tinctures 13, 17, 18, 19, 22, 26, 27, 28, 31, 32,
33, 34, 35, 36, 38, 39, 43, 44, 45, 46, 47, 49
N
Nasal drops 58Nasal spray 58Nitrogen 31
O
Oils 57Ointments 48, 57Oleoresins 16, 17Oral drops 57Oral solution 57Organs 16, 17
P
Parenteral preparations 18, 47Percolate 30Percolation 19, 30, 31Perennial plants 17Petioles 24Pharmaceutical processes 18, 19, 20, 26, 43, 45, 46Pharmaceutical quality 8Pharmacopoea Helvetica 13Pharmacopoeia 7, 8, 14, 24, 25, 26, 27, 29, 30, 31, 32,
33, 35, 36, 37, 38, 40, 41, 42, 43, 45, 46, 47, 48, 49Ph.Helv. 22, 23Pillules 57, 58, 59Plant secretions 16, 17Plumbum mellitum 43Potentised preparations 21, 46Powders 57, 58Preparations 20
Q
Quartz 25
R
Rh 13, 38, 39Rhythmically diluted 47Rhythmic application 19, 23, 26, 38, 51, 53Rhythmic processing 20Rhythmic succussion 21, 46Rhythmic system 20Rocks 15, 16, 17Rotating disk 45
S
Semi-solid vaginal preparations 59Silica 25, 51, 52, 53Silicium 25Silicium dioxide 25Solar or lunar eclipse 21, 46Solid or semi-solid potencies 46Solid preparations from plants 23, 41Solid starting materials obtained by heat 23, 39Solutions 58, 59Solutio Sacchari comp. 43Sprays 58Sputtering 25, 26
• Index
62
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Starting material of botanical origin 15Summer extract 44, 45Suppositories 59Swiss Pharmacopoeia 13, 14Syrups 57
T
Tabacum Cupro cultum 24Tablets 57Thuja 24Tincture 13, 21, 24, 27, 31, 33, 34, 35, 41, 44, 45, 51,
53, 57Toasted preparations 39, 40Toasting 20Tosta 19, 23, 39Triturations 46, 48
V
Vaginal tablets 59Vapour decomposition 25, 26Vegetabilisation 18, 24Vegetabilised metals 24Vegetation period 24Viscous extracts 26, 37
W
Waters, natural 16, 17
Z
Zoological origin 15, 16, 17, 18, 26, 27, 28, 29, 39
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IVAppendices
• Appendix
64
Table of ContentPart IVNote concerning appendix 2.3. .................................65Note concerning appendices 2.1., 2.4. and 2.6. .......65References concerning nomenclature in appendices 2.1. to 2.7.............................................65Note concerning the references for use in anthro-posophic medicine in appendices 2.1. to 2.7. .........65References concerning use in anthroposophic medicine in appendices 2.1. to 2.7. .........................66IVAA statement concerning starting materials of animal origin not yet mentioned in published anthroposophic medical literature or in published official regulatory documents concerning anthroposophic medicinal products ........................69Appendix 2.1. List of minerals, rocks and natural waters...............73 Appendix 2.2. List of starting materials of botanical origin ...........83
Appendix 2.3. List of starting materials of zoological origin .......135Appendix 2.4. List of starting materials that can be described chemically ................................................167Appendix 2.5. List of starting materials that have undergone special treatment.......................................................185Appendix 2.6. List of compositions .................................................189Appendix 2.7. Stocks with special manufacturing methods ........201
Appendix II ...............................................................205Correlation table: Ph.Eur. / HAB manufacturing methods used in anthroposophic pharmacy and corresponding manufacturing methods in the HPUS ..............................................205
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• Ap
pend
ix
65
Note concerning the references for use in anthroposophic medicine in appendices 2.1. to 2.7.The references given in the columns to the right in the appendices 2.1 to 2.6 aim to provide evidence, that the particular starting material is known and has been part of the medicinal tradition in anthroposophic medicine.
Where available, the monographs of the Commission C for medicinal products for human use dealing with the anthroposophic therapeutic direction (according to §25 of the German Drug Law) published in the German Federal Gazette (Bundesanzeiger) have been referred to. Some starting materials are mentioned in monographs of combined products only (e.g. Amethyst in Tropaeolum comp.)Not all starting materials are mentioned in the Commission C monographs, because on the one hand its work stopped in 1994 after the 5th amendment of the German Drug law prior to completion work. On the other hand a number of starting materials in the lists are only known in the anthroposophic medicine tradition in countries other than Germany. The Commission C monographs also refer to specific and composed active substances as well as existing pharmaceutical products. A number of references from other sources may refer generically to particular raw or starting materials, sometimes without linking to specific active substances. The latter references show that the raw or starting material has been considered in therapeutic and pharmaceutical grounds in anthroposophic medicine. They may however also refer to specific active substances.
Where there is no reference, the particular starting material has not yet been presented or discussed in publications. However anthroposophic pharmaceutical manufacturers place medicinal products on the market obtained from those starting materials. The IAAP sees it as its task to promote the writing of publications, to support the relevance of the starting material in anthroposophic medicine. Much work still needs to be done.
Note concerning appendix 2.3.Animal substances marked with “*” belong to category A materials according to “Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products” if sourced e.g. from cattle Bos taurus L. Though sourcing from animals below 6 months of age from herds not fed with meat bone meal has been practice up to now in the field of concerning anthroposophic quality management, pharmaceutical manufacturers must continuously adapt their sourcing to the requirements of the Note for guidance, such as changing the donor animal. The APC Committee needs to reflect the existing practice and will adapt to implemented changes.
Note concerning appendices 2.1., 2.4. and 2.6.Unfortunately chemical formulae and concentrations have not always been written in the conventional format (e.g. H2O and 10-5). This will be corrected in the next APC edition 4.1.
References concerning nomenclature in appendices 2.1. to 2.7.
Erhardt W, Götz E, Bödeker N, Seybold S. Zander: Handwörterbuch der Pflanzennamen. Stuttgart: Eugen Ulmer; 2008.
Roberts WL, Rapp GR Jr, Weber J. Encyclopedia of Minerals. New York: Van Nostrand; 1974.
Schindler H, Helma F. Tiere in der Pharmazie und Medizin. Stuttgart: Hippokrates-Verlag; 1961.
Teuscher E. Biogene Arzneimittel.Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 1997.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• Appendix
66
International Federation of Anthroposophic Medical Associations, IVAA. Statement concerning starting materials of animal origin not yet mentioned in published anthroposophic medical literature or in published official regulatory documents concerning anthroposophic medicinal products. Brussels: printed in APC Appendix I; 2013.
Monographs of the Commission C for medicinal products for human use dealing with the anthroposophic therapeutic direction (according to §25 of the German Drug Law) published in the German Federal Gazette (Bundesanzeiger). Publication as compilation: Anthroposophische Arzneimittel, Aufbereitungsmonographien der Kommission C, published by Gesellschaft Anthroposophischer Ärzte in Deutschland e.V. (Society of anthroposophic doctors in Germany registered association) on behalf of the Medical Section at the Goetheanum, Dornach/ Switzerland; 1999.
Gesellschaft Anthroposophischer Ärzte in Deutschland e.V. and Medizinische Sektion der Freien Hochschule für Geisteswissenschaft Dornach. Vademecum Anthroposophische Arzneimittel. Munich (Germany); 2013; 3rd edition 2013. Abbr. Vademecum
Les Associations francaises de médecine anthroposophique: Répertoire de médecine d’orientation anthroposophique. Edition Juin 2016. (abbr. Répertoire de med. anthr.)
References concerning the use in anthroposophic medicine in appendices 2.1. to 2.7.Der Merkurstab (Zeitschrift für anthroposophische Medizin – Journal of Anthroposophic Medicine). Munich: Gesellschaft Anthroposophischer Ärzte in Deutschland (Society of anthroposophic doctors in Germany).
Gardin N, Schleier R. Vademecum, medicamentos antroposoficos. São Paulo-SP: João de Barra Editora Ltda; 2009. Portugese. Abbr. ABMA Vademecum
Glöckler M. Anthroposophische Arzneitherapie (Anthroposophic Therapy with Medicinal Products). Stuttgart: Publisher Wissenschaftliche Verlagsgesellschaft; 2010.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• Ap
pend
ix
67
Statement concerning starting materials of animal origin not yet mentioned in published anthroposophic medical literature or in published official regulatory documents concerning anthroposophic medicinal products
Anthroposophic medicinal products containing preparations from starting materials of animal origin belong to the range of anthroposophic therapeutics.1
Most of these starting materials and/or the anthroposophic medicinal products concerned are mentioned in anthroposophic medical literature or in official regulatory documents. A certain number of these however are not mentioned in such references, although belonging to the range of anthroposophically used starting materials of animal origin. The anthroposophic medicinal products concerned are available to doctors.2
This statement confirms the anthroposophic therapeutic usage and relevance of these starting materials.3
The starting materials of animal origin are listed on the following papers.4
For the IVAA
Dr. Peter ZimmermannDr. Andreas Arendt
15.02.2013
1 Girke M. Innere Medizin. 2. edition. Berlin: Salumed Verlag; 2012.2 Jütte R. Organpräparate in der Geschichte der „Schulmedizin“, der Homöopathie und der Anthroposophischen Medizin. Der Merkurstab 2009; 1: 49–60.3 Roemer F. Sommer M. Zur Bedeutung der potenzierten Organpräparate in der anthroposophischen Therapierichtung. Der Merkurstab 1998; Sonderheft Organpräparate.4 Gesellschaft Anthroposophischer Ärzte in Deutschland e.V. and Medizinische Sektion der Freien Hochschule für Geisteswissenschaft Dornach. Vademecum Anthroposophische Arzneimittel. 2. edition. Filderstadt (Germany); 2011.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• Appendix
68
Scientific name Scientific name of the animal
Abbreviated definition
Aorta Oryctolagus cuniculus L.
Aorta from the rabbit
Aranea avicularis Avicularia avicularia L Whole bird spiderArteria basilaris Bos taurus L. Arteria basilaris from the calfArteria brachialis Bos taurus L. Arteria brachialis from the calfArteria coeliaca see Truncus coeliacusArteria pulmonalis Bos taurus L. Arteria pulmonalis from the calfArteria renalis Bos taurus L. Arteria renalis from the calfArticulatio cubiti Bos taurus L. Elbow joint with parts from the bones that form the joint, joint
cartilage, parts of joint capsule, synovia and parts of the ligaments from the calf
Articulatio radiocarpea
Bos taurus L. Radiocarpal joint with parts of the bones, cartilage, ligaments and joint capsule that form the proximal carpal joint from the calf
Articulatio tem-poromandibularis
Bos taurus L. Parts of the os mandibulare and of the os temporale in the joint area, of the joint capsule, of the ligaments, of cartilage, as well as synovia from the calf
Articulationes intercarpeae
Bos taurus L. Parts of the bones forming the joint, of the cartilage like surface of the articulation, as well as synovia from the calf
Articulationes intervertebrales cervicales
Bos taurus L. Region of the cervix: Parts of the bone process that participate to the intervertebral joints, cartilage and joint capsules, as well as synovia from the calf
Articulationes intervertebrales lumbales
Bos taurus L. Region of the loin: Parts of the bone process that participate to the intervertebral joints, cartilage and joint capsules, as well as synovia from the calf
Asterias rubens Asterias rubens L. The whole starfish Atlas Bos taurus L. Parts of the Atlas (1. cervical) from the calfAxis Bos taurus L. Parts of the Axis (2. cervical) from the calfBlatta orientalis Blatta orientalis L The whole fresh or dried animalCartilago articularis coxae
Bos taurus L. Cartilage of the hip joint from the calf
Cervix uteri Bos taurus L. Parts of the neck of the womb from the cowCirculus arteriosus cerebri
Bos taurus L. Circulus arteriosus cerebri of the pituitary shaft from the calf
Coccus cacti Dactylopius coccus Costa
The dried, fertilized, female of Dactylopius coccus Costa
Columna anterior Bos taurus L. Parts of the columna anterior of the spinal chord from the calf
Columna posterior Bos taurus L. Parts of the columna posterior of different parts of the spinal chord from the calf
Cornu Caprae ibecis Capra ibex L. Horn from the ibex
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
Scientific name Scientific name of the animal
Abbreviated definition
Dactylopius coccus see Coccus cactiDens Bos taurus L. Teeth from the calfDiencephalon Bos taurus L. Diencephalon from the calfDuctus deferens Bos taurus L. Ductus deferens from the calfDura mater encephali
Bos taurus L. Dura mater encephali from the calf
Elaps Micrurus corallinus Merrem
Poison from Micrurus corallinus Merrem
Endocardium Bos taurus L. Endocardium from the calfEpididymis Bos taurus L. Left epididymis from the bullErytrocytes Equus przewalskii f.
caballus PoliakovErythrocytes from the blood of the horse
Favus Apis mellifera L. Honey combs with pollenFolliculi lymphatici aggregati
Sus scrofa domestica L. Parts of Peyers’s patch of the small intestine from the pig
Galea aponeurotica Bos taurus L. Parts of the superficial fascia of the forehead from the calf Glandula parotis Bos taurus L. Glandular tissue of the body of the parotid gland
from the calfGlandula suprarenalis (Cortex)
Bos taurus L. Glandula suprarenalis (cortex) from the calf
Glandula suprarenalis (Medulla)
Bos taurus L. Medulla glandulae suprarenalis of both adrenal glands from the calf
Glucogenum Oryctolagus cuniculus L.
Glycogen from the rabbit liver
Gyrus cinguli Bos taurus L. Gyrus cinguli from the calfHepar Oryctolagus cuniculus
L.Liver from the rabbit
Jejunum Sus scrofa domestica L. Jejunum from the pigKeratinum Equi Equus przewalskii f.
caballus PoliakovHoof from the horse
Lac vaccae Bos taurus L. Fresh cow’s milkLigamentum longitudinale anterius
Bos taurus L. Parts of the ligamentum longitudinale anterius of thoracic and lumbar regions of the spine from the calf
Lingua Bos taurus L. Parts of the tongue muscles, mucous membrane and papillae from the calf
Liquor cerebrospinalis
Bos taurus L. Liquor cerebrospinalis from the calf
Mephitis putorius Mephitis mephitis Schreb.
Liquid secretion of anal glands from Mephitis mephitis Schreb.
• Ap
pend
ix
69
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
70
Moschus Moschus moschiferus L. Secretion of bursa from male Moschus moschiferus L.
Scientific name Scientific name of the animal
Abbreviated definition
Musculi glutaei Bos taurus L. Gluteal muscles from the calf Musculus soleus-Komplex
Bos taurus L. Parts of the musculus soleus-complex, musculus soleus, musculus fibularis (peronaeus) longus, musculus gastrocnemius from the calf
Mygale avicularis see Aranea avicularisNaja tripudians Naja naja L. Carefully dried poison from Naja naja L.Nervus abducens Bos taurus L. Nervus abducens from the calfNervus accessorius Bos taurus L. Nervus accessorius from the calfNervus femoralis Bos taurus L. Nervus femoralis from the calfNervus hypoglossus Bos taurus L. Nervus hypoglossus from the calfNervus pudendus Bos taurus L. Nervus pudendus from the calfNervus radialis Bos taurus L. Nervus radialis from the calfNervus tibialis Bos taurus L. Nervus tibialis from the calfNervus ulnaris Bos taurus L. Nervus ulnaris from the calfOesophagus Sus scrofa domestica L. Oesophagus from the pigOssa longa Bos taurus L. Ossa longa from the calfOssicula auditus Bos taurus L. Auditory bones from the calfPapillae duodeni Sus scrofa domestica L. Papilla duodeni region of the small intestine
from the pigPars pallida Bos taurus L. Parts of the base of the brain from the calfPatella Bos taurus L. Patella from the calfPelvis renalis (et Ureter)
Bos taurus L. Parts of the pelvis renalis and ureter from the calf
Penis Bos taurus L. Penis from the bullPia mater encephali Bos taurus L. Pia mater encephali from the calfPlexus lumbalis Bos taurus L. Plexus lumbalis from the calfPlexus rectalis see Plexus haemorr
hoidalisPortio vaginalis Bos taurus L. Portio vaginalis from the cowRenes, regio pyelorenalis
Bos taurus L. Parts of tissue from the pelvis renalis and medulla renalis from the calf
Sclera Bos taurus L. Sclera from the calfSinus cavernosus-Komplex
Bos taurus L. Parts of the sinus cavernosus-complex; sinus cavernosus, nervus opticus, nervus oculomotorius, nervus trochlearis, nervus trigeminus and nervus abducens from the calf
Tarantula hispanica Lycosa hispanica The whole spider Lycosa tarantula L., Allocosa fasciiventris Duf., or Hogna hispanica Walck.
Thrombocytes Equus przewalskii f. caballus Poliakov
Thrombocytes from the blood of the horse
Tonsilla pharyngea Bos taurus L. Tonsilla pharyngea from the calf
• Appendix
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
• Ap
pend
ix
71
Scientific name Scientific name of the animal
Abbreviated definition
Trachea Bos taurus L. Trachea from the calfTruncus coeliacus Bos taurus L. Arteria coeliaca (Truncus coeliacus) from the calfTruncus encephali Bos taurus L. Brain stem from the calfTruncus encephali Bos taurus L. Hypothalamus, thalamus, corpora quadrigemina, pons,
medulla oblongata from the calfTunica mucosa intestini tenuis
Sus scrofa domestica L. Mucosa from the different regions of the small intestine from the pig
Tunica mucosa recti Sus scrofa domestica L. Tunica mucosa recti from the pigTunica mucosa ventriculi
Sus scrofa domestica L. Mucosa from the different regions of the stomach from the pig
Ureter Bos taurus L. Ureter from the calfVagina Bos taurus L. Vagina from the cowValva trunci pulmonalis
Bos taurus L. Valva trunci pulmonalis from the calf
Valvula aortae Bos taurus L. Valva aortae from the calfValvula mitralis Bos taurus L. Valva mitralis from the calfVena cava Bos taurus L. Parts of the vena cava cranialis and vena cava caudalis
from the calfVena portae Bos taurus L. Vena portae from the calfVena tibialis Bos taurus L. Vena tibialis from the calfVertebra cervicalis Bos taurus L. Vertebra cervicalis from the calfVertebra coccygea Bos taurus L. Vertebra coccygea from the calfVertebra lumbalis Bos taurus L. Vertebra lumbalis from the calf
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
73
APPENDIX 2.1
List of minerals, rocks and natural waters Additional Information, see p. 17
•
Ap
pend
ix 2
.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
74
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
Agat
e wat
er(A
chat
wass
er)
Wat
er ex
istin
g in
side a
n un
dam
aged
Ag
ate g
eode
Ph.E
ur. 3
.1.2
Der
Mer
kurs
tab
2009
; 62(
6): 6
05-6
19
Ambe
rSu
ccin
um (B
erns
tein
)Fo
ssili
zed
tree r
esin
HAB
Ph.E
ur. 4
.1.1
(and
3.
1.1
or 3
.1.2
), 4.
1.2
Corp
us vi
treum
/Suc
cinu
m;
Olib
anum
com
p./S
ucci
num
; Ro
smar
inus
com
p.; S
tann
um/
Succ
inum
; Suc
cinu
m
Amet
hyst
(Am
ethy
st)A
viol
et va
riety
of q
uart
z (Si
O2)
API,
Ph.E
ur. 4
.1.1
, 4.
1.2
Trop
aeol
um co
mp.
Antim
onite
See S
tibni
te
Apat
iteAp
atit
Apat
iteTh
e nat
ural
min
eral
(cal
cium
fluo
r-ph
osph
ate c
hem
.: Ca5
[(PO
4)3,
(OH
,F,Cl
)])
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Ap
atit;
Apa
tit/C
onch
ae; A
patit
/Ph
osph
orus
com
p.; A
patit
/Sta
nnum
; Ce
rebe
llum
com
p.; C
onch
ae/
Ferr
um u
stum
com
p.; F
erru
m
prae
para
tum
com
p.; S
tann
um co
mp.
Aqua
mar
is(M
eerw
asse
r)Se
e Sea
wate
r
Arag
onite
(Ara
goni
t9Ar
agon
iteTh
e nat
ural
min
eral
(cal
cium
ca
rbon
ate;
chem
.: CaC
O3)
Ph.E
ur. 4
.1.1
, 4.1
.2Ré
perto
ire d
e méd
. an
thr.
Aran
disit
e(A
rand
isit)
Aran
disit
eTh
e nat
ural
min
eral
(com
plex
tin
silic
ate)
Ph.E
ur. 4
.1.1
, 4.1
.2Ar
andi
sitVa
dem
ecum
Arge
ntite
Arge
ntit
Arge
ntite
The n
atur
al m
iner
alH
ABPh
.Eur
. 4.1
.1, 4
.1.2
Arge
ntit
Vade
mec
um
Arse
nopy
rite
Arse
nopy
ritAr
seno
pyrit
eTh
e nat
ural
min
eral
(ars
enic
-iron
su
lfide
; che
m.: F
eAsS
)Ph
.Eur
. 4.1
.1, 4
.1.2
Vade
mec
um:
Arse
nopy
rit
Auru
m m
etal
licum
na
tura
le(G
old,
gedi
egen
)O
r nat
ifTh
e nat
ural
min
eral
(nat
ural
ly
occu
rrin
g go
ld w
ith tr
aces
of o
ther
ele
men
ts)
Ph.E
ur. 4
.1.1
(and
3.
2.2)
, 4.1
.2Au
rum
met
allic
um; A
urum
/Pru
nus
Bary
silite
Bary
silit
The n
atur
al m
iner
al (L
ead
man
gane
se
silic
ate;c
hem
.: Pb8
Mn(
Si2O
7)3)
Ph.E
ur. 4
.1.1
, 4.1
.2Ba
rysil
itVa
dem
ecum
Bert
hier
iteBe
rthi
erit
Bert
hier
iteTh
e nat
ural
min
eral
(ant
imon
y-iro
n su
lfide
; che
m.: F
eSb2
S4)
Ph.E
ur. 4
.1.1
, 4.1
.2Va
dem
ecum
Bolu
s alb
a(B
olus
)Se
e Kao
linite
Cass
iterit
e(K
assit
erit,
Zin
nste
in)
Cass
itérit
eTh
e nat
ural
min
eral
(tin
oxi
de; c
hem
.: Sn
O2)
Ph.E
ur. 4
.1.1
, 4.1
.2Ka
ssite
ritVa
dem
ecum
: Ka
ssite
rit
•
Appendix 2.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
75
Cerit
e(C
erit)
The n
atur
al m
iner
al (c
ompl
ex si
licat
e of
rare
eart
h ele
men
ts (c
eriu
m,
lant
hanu
m an
d ot
hers
) and
calci
um,
mag
nesiu
m an
d iro
n)
Ph.E
ur. 4
.1.1
, 4.1
.2Co
r/Cr
atae
gus c
omp.
Vade
mec
um
Ceru
ssite
Ceru
ssit
Céru
ssite
The n
atur
al m
iner
al (l
ead
carb
onat
e; ch
em.: P
bCO
3)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
; ra
w m
ater
ial f
or
prod
uctio
n of
Pl
umbu
m si
licic
um
Ceru
ssit;
Plu
mbu
m si
licic
umVa
dem
ecum
Chal
cedo
ny(C
halce
don)
The n
atur
al m
iner
al (s
ilicic
acid
; ch
em.: S
iO2)
Ph.E
ur. 4
.1.1
(and
th
en 3
.1.1
), 4.
1.2
Chal
cocit
e(C
halk
osin
)Ch
alco
sine
The n
atur
al m
iner
al (c
oppe
r sul
fide;
chem
.: Cu2
S)H
ABPh
.Eur
. 4.1
.1 (a
nd
then
3.2
.2),
4.1.
2Ch
alko
sin; Th
yreo
idea
com
p.
Chal
copy
rite
(Cha
lkop
yrit)
Chal
copy
rite
The n
atur
al m
iner
al (c
oppe
r-iro
n su
lfide
; che
m.: C
uFeS
2)Ph
.Eur
. 4.1
.1, 4
.1.2
Chlo
rarg
yrite
(Chl
orar
gyrit
, Hor
nerz
, Si
lber
horn
erz)
The n
atur
al m
iner
al (s
ilver
chlo
ride;
chem
.: AgC
l)Ph
.Eur
. 4.1
.1, 4
.1.2
Cart
ilago
/Hor
nerz
com
p.; C
orpu
s vi
treum
/Hor
nerz
com
p.
Chry
solit
e(C
hrys
olith
)Ch
ryso
lithe
The n
atur
al m
iner
al (m
agne
sium
-iron
sil
icat
e; ch
em.: (
Mg,
Fe)2
SiO
4)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Chry
solit
h; C
hrys
olith
com
p.Va
dem
ecum
Chry
sopr
ase
(Chr
ysop
ras)
The n
atur
al m
iner
al (s
ilicic
acid
with
sm
all a
mou
nts o
f nick
el)Ph
.Eur
. 4.1
.1 (a
nd
then
3.2
.2),
4.1.
2
Cinn
abar
(Zin
nobe
r)Ci
nnab
aris
natu
rale
The n
atur
al m
iner
al (m
ercu
ry su
lfide
; ch
em.: H
gS)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Ag
ropy
ron
com
p.; B
ariu
m co
mp.
; Py
rit/Z
inno
ber;
Zinn
ober
; Zin
nobe
r co
mp.
Vade
mec
um
Cupr
iteCu
prit
Cupr
iteTh
e nat
ural
min
eral
(cop
per o
xide
; ch
em.: C
u2O
)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Cupr
it
Dia
spor
e(D
iasp
or)
The n
atur
al m
iner
al (a
lum
iniu
m
oxid
e hyd
roxi
de; c
hem
.: AlO
OH
)Ph
.Eur
. 4.1
.1, 4
.1.2
Dio
ptas
eD
iopt
asD
iopt
ase
The n
atur
al m
iner
al (c
oppe
r sili
cate
; ch
em.: C
u6Si
6O18
·6H
2O)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2D
iopt
as
Dys
cras
iteD
yskr
asit
Dys
cras
iteTh
e nat
ural
min
eral
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2D
yskr
asit
Emer
ald
(Sm
arag
d)A
gree
n va
riety
of b
eryl
(alu
min
ium
-be
rylli
um si
licat
e; ch
em.:
Al2B
e3(S
i6O
18),
colo
ured
by t
race
am
ount
s of c
hrom
ium
and
som
etim
es
vana
dium
Ph.E
ur. 4
.1.1
, 4.1
.2
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
76
Ferr
um si
dere
um(M
eteo
reise
n)Fe
rrum
sid
ereu
mSe
e Iro
n m
eteo
rite =
met
eoric
iron
Ferr
um si
licic
um
natu
rale
See N
ontro
nite
Flin
t(F
lint,
Feue
rste
in)
Silex
The n
atur
al m
iner
al (c
hem
.: sili
cic
acid
SiO
2)Ph
.Eur
. 4.1
.1, 4
.1.2
(in
Lap
is ca
ncri/
Flin
tstei
n to
geth
er
with
Lap
is ca
ncri)
, Ra
w m
ater
ial f
or
prep
arin
g Si
lex -
Lapi
s can
cri s
olut
us
(see
app.
2.6
)
Lapi
s Can
cri/F
lintst
ein
Fluo
rite
Flus
sspa
tFl
uorit
eTh
e nat
ural
min
eral
(cal
cium
fluo
ride;
chem
.: CaF
2)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Cera
tum
Rat
anhi
ae co
mp.
; Flu
orit;
Ra
tanh
ia co
mp.
; Sal
Mar
is co
mp.
; Sa
lvia
com
p.
Gal
ena
Blei
glan
zG
alèn
eTh
e nat
ural
min
eral
(lea
d su
lfide
; ch
em.: P
bS)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Be
tula
/Man
drag
ora c
omp.
; Bl
eigl
anz/
Seca
le co
mp.
; Gal
enit/
Retin
a com
p.; R
etin
a com
p.; R
etin
a/Se
cale
com
p.
Gar
net
(Gra
nat)
The n
atur
al m
iner
al: A
lman
dine
(ir
on-a
lum
iniu
m si
licat
e; ch
em.:
Fe3A
l2(S
iO4)
3 ) o
r oth
er va
rietie
s
Ph.E
ur. 4
.1.1
, 4.1
.2D
er M
erku
rsta
b 20
04; 5
7(1)
: 57-
58
(Gla
cies
Mar
iae)
See s
eleni
te
Gne
iss(G
neis)
The n
atur
al p
ale r
ock
(Gne
iss fr
om
Gas
tein
(A);
cons
istin
g of
qua
rtz,
feld
spar
, mic
a and
oth
ers)
; syn
. Lap
is al
bus
Ph.E
ur. 4
.1.1
, 4.1
.2
Gra
nite
(Gra
nit)
Gra
nit
The n
atur
al ro
ck (c
onsis
ting
of q
uart
z, fe
ldsp
ar an
d m
ica a
nd o
ther
s)Ph
.Eur
. 4.1
.1, 4
.1.2
Berb
eris/
Pros
tata
com
p.; B
erbe
ris/
Ute
rus c
omp.
; Disc
i/Rhu
s to
xico
dend
ron
com
p.; R
hus
toxi
code
ndro
n co
mp.
Gra
phite
Gra
phite
s (G
raph
it)G
raph
ites
The n
atur
al m
iner
al (h
exag
onal
Ca
rbon
; che
m.: C
, with
trac
es o
f iro
n an
d ot
her e
lemen
ts)
HAB
; Ph.
fr.Ph
.Eur
. 4.1
.1, 4
.1.2
Ferr
um ro
satu
m/G
raph
ites;
Gra
phite
s; Pu
lvis
stom
achi
cus c
um
Bism
uto
prae
para
to; T
ropa
eolu
m
com
p.
Hal
iteH
alit
The n
atur
al m
iner
al (s
odiu
m ch
lorid
e; ch
em.: N
aCl)
HAB
Ph.E
ur. 3
.1.1
, API
Hal
it
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
77
Hek
la L
ava
See L
ava
Hem
atite
Häm
atit
Hém
atite
The n
atur
al m
iner
al (i
rone
oxi
de;
chem
.: Fe2
O3)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2
raw
mat
eria
l for
pr
epar
atio
ns ac
c. to
H
AB 3
7a
Hya
cinth
See Z
ircon
Hyd
rarg
yrum
m
etal
licum
nat
ural
e(Q
ueck
silbe
r)Se
e Mer
curiu
s viv
us n
atur
alis
Iron
met
eorit
eFe
rrum
side
reum
(M
eteo
reise
n)Fe
rrum
sid
ereu
mTh
e nat
ural
met
eoric
iron
(a k
ind
of
allo
y with
iron
, nick
el an
d co
balt)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Ap
atit/
Phos
phor
us co
mp.
; Aur
um/
Ferr
um si
dere
um; C
rata
egus
/Fe
rrum
side
reum
/Sac
char
um
tostu
m; F
erru
m si
dere
um; F
erru
m
sider
eum
com
p.; F
erru
m si
dere
um/
Pank
reas
; Met
eore
isen/
Phos
phor
/Q
uarz
Vade
mec
um
Jasp
er(Ja
spis)
A re
d va
riety
of c
halce
dony
(sili
cic
acid
; che
m.: S
iO2
with
iron
oxi
de)
Ph.E
ur. 4
.1.1
, 4.1
.2
Kaol
inite
(Kao
lin, w
eiße
r Ton
)Ka
olin
lour
dTh
e nat
ural
min
eral
(alu
min
ium
sil
icat
e; ch
em.: A
l4[(O
H)8
/Si4
O10
]; sy
n.: C
hina
clay
Ph.E
ur.
API,
Excip
ient
Bolu
s alb
a com
p.; B
olus
Euc
alyp
ti co
mp.
Kass
iterit
eSe
e Cas
siter
ite
Kato
ptrit
e(K
atop
trit)
The n
atur
al m
iner
al (c
ompl
ex
man
gane
se-a
ntim
ony-
iron
silic
ate)
Ph.E
ur. 4
.1.1
, 4.1
.2
Kies
erite
(Kie
serit
)Ki
esér
iteTh
e nat
ural
min
eral
(mag
nesiu
m
sulfa
te; c
hem
.: MgS
O4
·H2O
)H
ABPh
.Eur
. 3.1
.1 (s
ee
mon
ogra
ph: D
1 wi
th w
ater
)
Cera
tum
Rat
anhi
ae co
mp.
; Kie
serit
; Ra
tanh
ia co
mp.
; Sal
via c
omp.
Lapi
s alb
us(G
neiss
)Se
e Gne
iss
Lapi
s sec
tilis
(Ton
schi
fer)
See A
rgill
aceo
us S
hale
Lava
Hek
la L
ava (
Lava
)H
ekla
lava
The n
atur
al ro
ck fr
om vo
lcano
Hek
la
(Icela
nd) w
ith a
cont
ent o
f at l
east
50%
silic
on d
ioxi
de, S
iO2
(Mr 6
0.1)
an
d at
leas
t 18%
iron
(III)
oxid
e
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2
Levi
co w
ater
Levi
coM
iner
al w
ater
from
the s
ourc
e Lev
ico,
Italy
APC
Ph.E
ur. 3
.1.1
, 3.1
.2Aq
ua M
aris
com
p.; L
evico
; Lev
ico
com
p.Va
dem
ecum
Mag
nesit
eM
agne
sitM
agné
site
The n
atur
al m
iner
al (m
agne
sium
ca
rbon
ate;
chem
.: MgC
O3)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2M
agne
sit; M
agne
sit/M
amm
a com
p.;
Saba
l/Sol
idag
o co
mp.
Vade
mec
um
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
78
Mal
achi
teM
alac
hit
Mal
achi
teTh
e nat
ural
min
eral
(bas
ic co
pper
ca
rbon
ate;
chem
.: Cu2
(CO
3)(O
H)2
)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
, ra
w m
ater
ial f
or th
e pr
oduc
tion
of A
PI
(for e
.g.V
iscum
Mal
i c.
Cupr
o, ap
p. 2
.6)
Anag
allis
/Mal
achi
t com
p.;
Cham
omill
a/M
alac
hit c
omp.
; M
alac
hit
Vade
mec
um
Mar
ble
(Mar
mor
)M
arbr
eTh
e nat
ural
gra
ined
, whi
te ro
ck
(mai
nly c
onsis
ting
of ca
lcite
)Ph
.Eur
. 4.1
.1, 4
.1.2
, ra
w m
ater
ial f
or th
e pr
oduc
tion
of
Solu
tio S
ilice
a co
mp.
(app
. 2.6
)
Disc
us in
terv
erte
bral
is em
bryo
nalis
/So
lutio
Sili
ceae
com
p.; M
arm
or/
Stib
ium
; Sol
utio
Sili
cea c
omp.
Vade
mec
um:
Mar
mor
/Stib
ium
Mer
curiu
s viv
us
natu
ralis
Mer
curiu
s viv
us;
(Que
cksil
ber,
gedi
egen
)M
ercu
re
mét
alliq
ue P
PHN
atur
ally
occ
urrin
g m
ercu
ry w
ith
99,5
-100
,5%
Hg
HAB
; Ph.
fr.Ph
.Eur
. 4.1
.1, 4
.1.2
Gla
ndul
a sup
rare
nalis
/Mer
curiu
s; M
ercu
rius v
ivus
; Mer
curiu
s viv
us
com
p.; M
ercu
rius v
ivus
/ Euc
aply
ti ae
ther
oleu
m; Th
uja c
omp.
Vade
mec
um
Met
eore
isen
See F
erru
m si
dere
um
Non
troni
teN
ontro
nit
Non
troni
teTh
e nat
ural
min
eral
(com
plex
iron
sil
icat
e)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Conc
hae/
Ferr
um u
stum
com
p.;
Ferr
um si
licic
um co
mp.
; Fer
rum
us
tum
com
p.; N
ontro
nit
Vade
mec
um
Oliv
enite
Oliv
enit
Oliv
énite
The n
atur
al m
iner
al (b
asic
copp
er
arse
nate
; che
m.: C
u2As
O4(
OH
))H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Oliv
enit;
Sen
ecio
com
p.Va
dem
ecum
Oliv
ine
See C
hrys
olite
Ony
xO
nyx
Ony
xA
blac
k-wh
ite st
riped
varie
ty o
f ch
alce
dony
(sili
cic a
cid;
chem
.: SiO
2 )
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2G
naph
aliu
m co
mp.
; Ony
x
Opa
l(O
pal)
The n
atur
al m
iner
al (s
ilici
c aci
d,
cont
aini
ng w
ater
)Ph
.Eur
. 4.1
.1 (a
nd
then
3.2
.2),
4.1.
2D
er M
erku
rsta
b 20
09; 6
2(6)
: 605
-619
Ort
hocla
se(O
rtho
klas
)Th
e nat
ural
min
eral
(pot
assiu
m-
alum
iniu
m si
licat
e; ch
em.: K
AlSi
3O8)
Ph.E
ur. 4
.1.1
, 4.1
.2,
API
Ort
hokl
as
Palla
site
(Pal
lasit
)St
one-
Iron
-Met
eorit
e (ol
ivin
e cry
stals
in an
iron
-nick
el m
atrix
)Ph
.Eur
. 4.1
.1, 4
.1.2
Vade
mec
um
Phar
mac
olite
Phar
mak
olith
Phar
mac
olith
eTh
e nat
ural
min
eral
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Ph
arm
akol
ith co
mp.
Vade
mec
um
Phos
phor
ocal
cite
(Pho
spho
roch
alcit
, Ps
eudo
mal
achi
t)Ph
osph
oroc
halc
iteTh
e nat
ural
min
eral
(alk
alin
e cop
per
phos
phat
e; ch
em.: C
u5[(O
H)4
/(P
O4)
2])
Ph.E
ur. 4
.1.1
, 4.1
.2Va
dem
ecum
Plat
inum
(Plat
in, g
edie
gen)
Plat
ina
The n
atur
al m
iner
al (n
atur
ally
oc
curr
ing
plat
inum
with
trac
es o
f ot
her e
lemen
ts)
Ph.E
ur. 4
.1.1
, 4.1
.2Ba
silic
um co
mp.
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
79
Pyra
rgyr
ite(P
yrar
gyrit
)Py
rarg
yrite
The n
atur
al m
iner
al (s
ilver
-ant
imon
y su
lfide
; che
m.: A
g3Sb
S3)
Ph.E
ur. 4
.1.1
, 4.1
.2
Pyrit
ePy
ritPy
rite d
e fer
The n
atur
al m
iner
al (i
ron
sulfi
de;
chem
.: FeS
2)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Anis-
Pyrit
; Arc
hang
elica
/Pyr
it co
mp.
; Ber
beris
/Pyr
it co
mp.
; Br
onch
i/Pla
ntag
o co
mp.
; Br
onch
ialp
astil
len; P
yrit;
Pyr
it/Zi
nnob
er
Vade
mec
um
Pyro
lusit
ePy
rolu
sitPy
rolu
site
The n
atur
al m
iner
al (m
anga
nese
di
oxyd
e; ch
em.: M
nO2)
Ph.E
ur. 4
.1.1
; 4.1
.2
Pyro
mor
phite
Pyro
mor
phit
Pyro
mor
phite
The n
atur
al m
iner
al (l
ead
phos
phat
e; ch
em.: P
b5(P
O4)
3Cl)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Py
rom
orph
it
Qua
rtz
Qua
rzSi
licea
nat
ural
eTh
e nat
ural
min
eral
(sili
cic ac
id;
chem
.: SiO
2)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
, AP
I, ra
w m
ater
ial
for t
he p
rodu
ctio
n of
oth
er ch
emic
al
entit
ies (
app.
2.6
)
Acon
itum
/Cam
phor
a com
p.;
Antim
onit/
Rosa
e aet
hero
leum
co
mp.
; Arg
entu
m/B
erbe
ris co
mp.
; Ar
gent
um/Q
uarz
; Arn
ica/
Echi
nace
a co
mp.
; Bell
adon
na/Q
uarz
; Ber
beris
/Q
uarz
; Car
tilag
o/Ec
hina
cea c
omp.
; Co
njun
ctiv
a com
p.; C
upru
m/Q
uarz
co
mp.
; Disc
us in
terv
erte
bral
is em
bryo
nalis
/Sol
utio
Sili
ceae
com
p.;
Echi
nace
a/Q
uarz
com
p.;
Endo
met
rium
com
p.; F
erru
m
sider
eum
com
p.; F
erru
m/Q
uarz
; Fe
rrum
/Sul
fur c
omp.
; Flo
res
Sam
buci
com
p./Q
uarz
; Kal
ium
ph
osph
oric
um co
mp.
; Met
eore
isen/
Phos
phor
/Qua
rz; N
icotia
na/Q
uarz
; O
variu
m co
mp.
; Oxa
lis/Q
uarz
co
mp.
; Per
iodo
ntiu
m/S
ilice
a com
p.;
Prim
ula c
omp.
; Qua
rz; Q
uarz
/Re
sina L
arici
s; Q
uarz
/Sec
ale;
Sang
uina
ria co
mp.
; Sili
cea c
omp.
; So
lutio
Sac
char
i com
p.; S
olut
io
Silic
ea co
mp.
; Tar
taru
s stib
iatu
s co
mp.
Vade
mec
um
Real
gar
(Rea
lgar
)Ré
alga
rTh
e nat
ural
min
eral
(ars
enic
sulfi
de;
chem
.: As4
S4)
Ph.E
ur. 4
.1.1
, 4.1
.2Re
alga
rVa
dem
ecum
Rose
qua
rtz
(Ros
enqu
arz)
The n
atur
al m
iner
al (s
ilicic
acid
; ch
em.: S
iO2)
; syn
.: Qua
rz ro
sae
Ph.E
ur. 4
.1.1
, 4.1
.2
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
80
Rube
llite
(Rub
ellit)
Pink
to re
d to
urm
alin
e (co
mpl
ex
silic
ate w
ith al
umin
ium
, bor
on,
fluor
ine,
lithi
um, i
ron,
sodi
um an
d ot
her e
lemen
ts)
Ph.E
ur. 4
.1.1
, 4.1
.2Va
dem
ecum
: Rub
ellit
Ruby
(Rub
in)
The n
atur
al re
d co
rund
um
(alu
min
ium
oxi
de; c
hem
.: Al2
O3
with
tra
ces o
f Chr
omiu
m)
Ph.E
ur. 4
.1.1
, 4.1
.2
Sal M
aris
See S
ea sa
lt
Sapp
hire
(Sap
hir)
The n
atur
al b
lue m
iner
al co
rund
um
(alu
min
ium
oxi
de; c
hem
.: Al2
O3
with
tra
ces o
f iro
n an
d/or
tita
nium
)
Ph.E
ur. 4
.1.1
, 4.1
.2
Scor
odite
Skor
odit
Scor
odite
The n
atur
al m
iner
al (b
asic
iron
ar
sena
te; c
hem
.: FeA
sO4·
2H2O
)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Bora
go co
mp.
; Cer
ebell
um co
mp.
; Pa
rath
yreo
idea
com
p.; S
koro
dit;
Skor
odit
com
p.
Vade
mec
um
Sea s
alt
(Mee
rsal
z)So
dium
(c
hlor
ure d
e)
natu
rel p
ph, S
el m
arin
non
ra
ffiné
de
lAtla
ntiq
ue
Sea s
alt (
chem
.: com
plex
mix
ture
with
ch
lorid
es an
d su
lfate
s of m
ainl
y so
dium
, mag
nesiu
m, c
alciu
m an
d po
tass
ium
bes
ide m
inor
com
pone
nts)
; sy
n.: S
al M
aris
Ph.fr
.Ph
.Eur
. 3.1
.1 (D
1 wi
th w
ater
), AP
I (in
Sa
l Mar
is co
mp.
)
Sal M
aris
com
p.
Seaw
ater
Aqua
mar
isAq
ua m
arin
aO
cean
ic w
ater
(che
m.: d
issol
ved
mix
ture
of c
hlor
ides
and
sulfa
tes o
f m
ainl
y sod
ium
, mag
nesiu
m, c
alciu
m
and
pota
ssiu
m b
esid
e min
or
com
pone
nts)
Ph.E
ur. 3
.1.1
(D1
with
etha
nol 1
8%),
3.1.
2
Aqua
Mar
is co
mp.
; Aqu
a Mar
is/Pr
unus
spin
osa,
Sum
mita
tes
Der
Mer
kurs
tab
2009
; 62(
6): 6
05-6
19
Selen
ite(G
laci
es m
aria
s, G
ips,
Mar
ieng
las)
The n
atur
al m
iner
al: T
rans
pare
nt,
colo
urles
s, va
riety
of G
ypsu
m
(cal
cium
sulfa
te; c
hem
.: Ca
SO4·
2H2O
)
Ph.E
ur. 4
.1.1
, 4.1
.2;
raw
mat
eria
l for
the
prod
uctio
n of
Ka
lium
chlo
ratu
m
com
p.
Side
rite
Side
ritSi
dérit
eTh
e nat
ural
min
eral
(iro
n ca
rbon
ate;
chem
.: FeC
O3)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Av
ena/
Conc
hae c
omp.
; Sid
erit
Vade
mec
um
Silex
Silex
See F
lint
Silic
ea n
atur
ale
Silic
ea n
atur
ale
See Q
uart
z
Smar
agd
See E
mer
ald
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
81
Stib
nite
Antim
onit,
(G
raus
pieß
glan
z)St
ibin
eTh
e nat
ural
min
eral
(ant
imon
y su
lfide
; che
m.: S
b2S3
)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Achi
llea c
omp.
; Ana
galli
s/M
alac
hit
com
p.; A
ntim
onit;
Ant
imon
it co
mp.
; Ant
imon
it/An
isum
; An
timon
it/Ro
sae a
ethe
roleu
m
com
p.; B
irken
kohl
e com
p.;
Cart
ilago
/Man
drag
ora c
omp.
; Ch
amom
illa/
Mal
achi
t com
p.;
Echi
nace
a/Pa
ram
etriu
m co
mp.
; Ka
lium
acet
icum
com
p.; P
ulvi
s St
omac
hicu
s cum
Bell
adon
na; V
itis
com
p.
Vade
mec
um:
Antim
onit
Succ
inum
See A
mbe
r
Sulfu
r(S
chwe
fel)
Sulfu
rse
e Sul
fur a
ph (A
pp. 2
.4)
Sulfu
r
Sylv
ite(S
ylvi
n)Th
e nat
ural
min
eral
(pot
assiu
m
chlo
ride;
chem
.: KCl
)Ph
.Eur
. 3.1
.1Va
dem
ecum
: Syl
vin
(Ter
ra m
edici
nalis
)(H
eiler
de)
Drie
d, fi
nely
-div
ided
, nat
ural
ly
occu
rrin
g cla
y and
silt
with
a va
ried
com
posit
ion
of al
umin
ium
oxi
de,
silic
a, iro
n ox
ide a
nd li
mes
tone
; Ter
ra
med
icina
lis
Excip
ient
Plac
enta
/Tro
paeo
lum
Then
ardi
te(Th
enar
dit)
Thén
ardi
teTh
e nat
ural
min
eral
(sod
ium
sulfa
te;
chem
.: Na2
SO4)
Ph.E
ur. 3
.1.1
(D1
with
wat
er),
4.1.
1,
4.1.
2
Répe
rtoire
de m
éd.
anth
r.
Topa
z(T
opas
)Th
e nat
ural
min
eral
(alu
min
ium
-flu
orin
silic
ate;
chem
.: sili
cate
of
alum
iniu
m an
d flu
orin
e, Al
2[(F
,OH
)2/S
iO4.
)]
Ph.E
ur. 4
.1.1
, 4.1
.2
Tron
a(T
rona
)Th
e nat
ural
min
eral
(sod
ium
ca
rbon
ate-
hydr
ogen
carb
onat
e; ch
em.: N
a3(C
O3)
(HCO
3)·2
H2O
raw
mat
eria
l for
the
prod
uctio
n of
co
mpo
sitio
ns, e
.g.
Solu
tio S
ilice
a co
mp.
(app
. 2.6
)
Aqua
Mar
is co
mp.
; Cin
is Ar
nica
e co
mp.
; Disc
us in
terv
erte
bral
is em
bryo
nalis
/Sol
utio
Sili
ceae
com
p.;
Gla
ndul
a sup
rare
nalis
/Sol
utio
Fer
ri co
mp.
; Sol
utio
Fer
ri co
mp.
; Sol
utio
Sa
ccha
ri co
mp.
; Sol
utio
Sili
cea
com
p.
Vivi
anite
Vivi
anit
Vivi
anite
The n
atur
al m
iner
al (i
ron
phos
phat
e; ch
em.: F
e2(P
O4)
2·8H
2O)
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2D
isci c
omp.
cum
Pul
satil
la;
Frag
aria
/Urt
ica c
omp.
; Gels
emiu
m
com
p.; L
evist
icum
com
p.; P
ulm
o/Vi
vian
it co
mp.
; Viv
iani
t
Vade
mec
um
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
82
With
erite
With
erit
With
érite
The n
atur
al m
iner
al (B
ariu
m
carb
onat
e; ch
em.: B
aCO
3)H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Carb
ones
/Pan
krea
s/W
ither
itVa
dem
ecum
Zinn
ober
See C
inna
bar
Engl
ish n
ame:
Ph.E
ur. o
r sci
entifi
cG
erm
an n
ame:
HA
B (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
defin
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
83
APPENDIX 2.2
List of starting materials of botanical origin Additional Information, see p. 17
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
84
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
Abie
s alb
a Mill
.Fr
esh
tops
of A
bies
alba
Mill
.H
AB 3
3dPe
tasit
es co
mp.
; Pet
asite
s com
p. cu
m
Que
rcu;
Pet
asite
s com
p. cu
m V
eron
ica
Abie
s pec
tinat
a (La
m.)
DC
Youn
g, fr
esh,
leaf
y bra
nche
s of A
bies
alba
Mill
. (Ab
ies p
ectin
ata
(Lam
.) D
C)Ph
.fr.
Ph.E
ur. 1
.1.1
0 (s
ee
mon
ogra
ph: e
than
ol
65%
)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Abro
tanu
mse
e Arte
misi
a abr
otan
um L
.
Absin
thiu
mse
e Arte
misi
a abs
inth
ium
L.
Acet
um V
ini
see V
itis v
inife
ra L
.
Acet
um V
ini d
estil
latum
see V
itis v
inife
ra L
.
Achi
llea m
illef
oliu
m L
.Fr
esh,
who
le flo
werin
g pl
ant o
f Ach
illea
mill
efol
ium
L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(see
m
onog
raph
: eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Achi
llea m
illef
oliu
m L
.Fr
esh,
leav
es o
f Ach
illea
mill
efol
ium
L., c
ollec
ted
in Sp
ring
Ph.E
ur. 1
.1.3
Mill
efol
ium
/ H
yper
icum
Achi
llea m
illef
oliu
m L
.Fr
esh
aeria
l par
ts of
Ach
illea
mill
efol
ium
L., c
ollec
ted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.5
, HAB
33d
Achi
llea c
omp.
; Can
thar
is co
mp.
Achi
llea m
illef
oliu
m L
.W
hole
or cu
t, dr
ied
flowe
ring
tops
of A
chill
ea m
illef
oliu
m L
.Ph
.Eur
.Ph
.Eur
. 1.2
.13
(eth
anol
36
%),
API
Cent
auriu
m co
mp.
; Cich
oriu
m/
Tara
xacu
m co
mp.
; Mal
va/M
illef
oliu
m/
Oxa
lis
Achi
llea m
illef
oliu
m L
.D
ried
flowe
rs o
f Ach
illea
mill
efol
ium
L.
Ph. H
elv.
Ph.E
ur. 1
.2.1
3 (e
than
ol
50%
), aq
ueou
s ext
ract
ion
toge
ther
with
oth
er d
ried
herb
al d
rugs
Caps
ella/
Majo
rana
com
p.; V
erba
scum
co
mp.
Acon
itum
nap
ellus
L.
Who
le, fr
esh,
flow
erin
g pl
ants
of A
coni
tum
nap
ellus
L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(see
m
onog
raph
: eth
anol
45
%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Acon
itum
nap
ellus
L.
Fres
h wh
ole p
lant
s of A
coni
tum
nap
ellus
L., c
ollec
ted
at th
e sta
rt
of fl
ower
ing
HAB
Ph.E
ur. 1
.1.3
, HAB
21
Acon
itum
nap
ellus
; Aco
nitu
m n
apell
us
Plum
bo cu
ltum
; Aco
nitu
m/A
rnic
a co
mp.
/Api
s; Ac
onitu
m/A
rnic
a com
p./
Form
ica;
Acon
itum
/Arn
ica/
Betu
la
com
p.; A
coni
tum
/Arn
ica/
Bryo
nia;
Acon
itum
/Bry
onia
; Arn
ica/
Sym
phyt
um
com
p.; B
ryon
ia/E
upat
oriu
m co
mp.
; Fe
rrum
pho
spho
ricum
com
p.
Acon
itum
nap
ellus
L.
Drie
d tu
bers
of A
coni
tum
nap
ellus
L.
HAB
12d
, 12e
, 12g
Acon
itum
nap
ellus
; Aco
nitu
m/
Nic
otia
na co
mp.
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
85
Acon
itum
nap
ellus
L.
Fres
h un
derg
roun
d pa
rts o
f Aco
nitu
m n
apell
us L
.H
AB 3
3cAc
onitu
m co
mp.
; Aco
nitu
m n
apell
us;
Acon
itum
/Cam
phor
a com
p.;
Acon
itum
/Chi
na co
mp.
; Bry
onia
co
mp.
; Disc
i/Rhu
s tox
icode
ndro
n co
mp.
; Meli
ssa/
Sepi
a com
p.; R
hus
toxi
code
ndro
n co
mp.
; Rhu
s/Sa
lix co
mp.
Acor
us ca
lam
us L
Peele
d, d
ried
rhiz
ome o
f Aco
rus c
alam
us L
., with
root
s and
leaf
re
sidue
s rem
oved
.H
ABPh
.Eur
. 1.1
.8, 1
.2.1
2,
aque
ous e
xtra
ctio
n to
geth
er w
ith o
ther
pl
ants
Cala
mus
, Rhi
zom
a; G
entia
na/Z
ingi
ber
com
p.; Th
ymus
serp
yllu
m co
mp.
Acor
us ca
lam
us L
.Fr
esh
unde
rgro
und
part
s of A
coru
s cal
amus
L.
HAB
33d
Berb
eris/
Juni
peru
s com
p.; B
olus
alba
co
mp.
Acta
ea ra
cem
osa
see C
imici
fuga
race
mos
a (L.
) Nut
t.
Acta
ea sp
icat
a L.
Fres
h, u
nder
grou
nd p
arts
of A
ctae
a spi
cata
L. c
ollec
ted
after
shot
s ha
ve em
erge
d, b
ut b
efor
e flow
erin
gH
ABPh
.Eur
. 1.1
.3
Adon
is ve
rnal
is L.
Fres
h ae
rial p
arts
of A
doni
s ver
nalis
L. c
ollec
ted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.3
, 1.2
.4Ad
onis
com
p.; A
doni
s/Sc
illa c
omp.
; O
nopo
rdon
com
p./A
doni
s
Aesc
ulus
hip
poca
stanu
m L
.Fr
esh
bark
from
youn
ger b
ranc
hes o
f Aes
culu
s hip
poca
stanu
m L
.H
AB 1
2k (D
ecoc
tum
LA
10%
)Ae
scul
us, C
orte
x; C
alen
dula
/Tr
opae
olum
com
p.
Aesc
ulus
hip
poca
stanu
m L
.Fr
esh
buds
of A
escu
lus h
ippo
casta
num
L.
For S
al m
aris
com
p. 1
pa
rt o
f bud
s is e
xtra
cted
wi
th 2
par
ts of
oil.
Sal M
aris
com
p.
Aesc
ulus
hip
poca
stanu
m L
.Fr
eshl
y pee
led se
eds o
f Aes
culu
s hip
poca
stanu
m L
.H
ABPh
.Eur
. 1.1
.5, H
AB 1
2g,
34c
Aesc
ulus
, Sem
en; A
escu
lus/
Cera
com
p.;
Aesc
ulus
/Que
rcus
com
p.; B
orag
o co
mp.
; Disc
i com
p. cu
m A
escu
lo;
Hiru
do co
mp.
; Sol
um u
ligin
osum
co
mp.
Aesc
ulus
hip
poca
stanu
m L
.Fr
esh
unpe
eled
seed
s of A
escu
lus h
ippo
casta
num
L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(see
m
onog
raph
: eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Aesc
ulus
hip
poca
stanu
m L
.D
ried
bark
from
bra
nche
s of A
escu
lus h
ippo
casta
num
L.
HAB
Ph.E
ur. 1
.2.1
2 (e
than
ol
36%
)Ac
hille
a com
p.; A
escu
lus,
Corte
x;
Aesc
ulus
, Cor
tex/
Bor
ago/
Ham
ameli
s, Fo
lium
; Aes
culu
s, Co
rtex/
Rosm
arin
i ae
ther
oleu
m; A
escu
lus/
Lava
ndul
a sic
cata
; Cer
atum
Rat
anhi
ae co
mp.
; Ra
tanh
ia co
mp.
; Sal
via c
omp.
; Stib
ium
co
mp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
86
Aesc
ulus
hip
poca
stanu
m L
.D
ried
seed
s of A
escu
lus h
ippo
casta
num
L.
DAB
HAB
12g
, 12m
Aesc
ulus
, Sem
en; A
escu
lus/
Prun
us
com
p.; S
olum
ulig
inos
um co
mp.
Agar
icus
bul
bosu
sse
e Am
anita
pha
lloid
es (V
aill.
ex F
r.) L
ink.
Ph.E
ur.
Agar
icus
mus
cariu
sse
e Am
anita
mus
caria
(L.)
Pers
.
Aman
ita m
usca
ria (L
. ex
Fr.)
Hoo
k.Th
e red
skin
(cut
is ru
bra)
of t
he fr
uitin
g bo
dy o
f Am
anita
m
usca
ria (L
. ex
Fr.)
Hoo
k.Ph
.Eur
. 1.1
.11
(eth
anol
45
%)
Agnu
s cas
tus
see V
itex
agnu
s-ca
stus L
.
Agro
pyro
n re
pens
(L.)
P. Be
auv.
Who
le or
cut,
wash
ed an
d dr
ied
rhiz
ome o
f Agr
opyr
on re
pens
(L
.) P.
Beau
v. (E
lym
us re
pens
[L.]
Gou
ld);
the a
dven
titio
us ro
ots
are r
emov
ed
Ph.E
ur.
Ph.E
ur. 1
.2.1
2 (e
than
ol
36%
)Fl
ores
Sam
buci
com
p./Q
uarz
Agro
pyro
n re
pens
see E
lym
us re
pens
(L.)
Gou
ld
Alce
a ros
ea L
. (Al
thae
a ros
ea (L
.) Ca
v.D
ried,
fully
dev
elope
d flo
wers
with
calic
es o
f Alce
a ros
ea L
.H
AB 1
2gM
alva
com
p.
Alfa
lfase
e Med
icag
o sa
tiva L
.
Alliu
m ce
pa L
.Fr
esh
bulb
s of A
llium
cepa
L.
HAB
; Ph.
fr.H
AB A
llium
cepa
(and
Ph
.Eur
. 1.1
.3),
HAB
34a
, Ph
.Eur
. 1.1
.10
(see
m
onog
raph
: Eth
anol
45
%) (
Ph.fr
.)
Alliu
m ce
pa/ M
ercu
rialis
com
p.; A
llium
ce
pa/T
endo
com
p.; A
rcha
ngeli
ca co
mp.
; Ar
ticul
atio
talo
crur
alis
com
p.;
Cart
ilago
com
p.; C
epa;
Kasta
nien
-H
aarto
niku
m; M
ercu
rialis
/Stib
ium
co
mp.
; Sta
nnum
/Sym
phyt
um co
mp.
; Sy
mph
ytum
com
p.; V
espa
crab
ro co
mp.
Alliu
m sa
tivum
L.
Fres
h bu
lbs o
f Alli
um sa
tivum
L.
(HAB
); Ph
.Eur
.; USP
acc.
to m
onog
raph
Ph
.Eur
. or H
AB (a
nd
Ph.E
ur. 1
.1.5
)
Arch
ange
lica c
omp.
Alliu
m u
rsin
um L
.Fr
esh
whol
e pla
nts o
f Alli
um u
rsin
um L
. at t
he st
art o
f flow
erin
gH
ABPh
.Eur
. 1.1
.3, 1
.1.1
0 (e
than
ol 4
5%)
Aloe
fero
x M
ill. a
nd o
ther
Alo
e sp
ecie
sCo
ncen
trate
d an
d dr
ied
juic
e of t
he le
aves
of v
ario
us sp
ecie
s of
Aloe
, mai
nly A
loe f
erox
Mill
er an
d its
hyb
rids
(HAB
); Ph
.Eur
.Ph
.Eur
. 1.1
.8 (E
than
ol
70%
), 4.
1.1
Alth
aea o
ffici
nalis
L.
Peele
d or
unp
eeled
, who
le or
cut,
drie
d ro
ot o
f Al
thae
a offi
cina
lis L
.Ph
.Eur
.aq
uous
extra
ct D
ER
1:8-
12Si
rupu
s Thym
i com
p.
Aman
ita m
usca
ria (L
.) La
m.
Fres
h fr
uitin
g bo
dies
of A
man
ita m
usca
ria (L
.) La
m. C
ham
pign
on
(car
poph
ore)
entie
r, fra
is fro
m A
man
ita m
usca
ria (L
. ex
Frie
s)
Hoo
ker
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
1 (s
ee
mon
ogra
ph: e
than
ol
45%
), H
AB 3
3b
Agar
icus
com
p./P
hosp
horu
s; Ag
aric
us
mus
cariu
s; Co
ncha
e com
p.; M
ygal
e co
mp.
Aman
ita p
hallo
ides
(Vai
ll. ex
Fr.)
Li
nkW
hole,
fres
h m
ushr
oom
(fru
iting
bod
y) A
man
ita p
hallo
ides
(V
aill.
ex F
r.) L
ink)
Ph.E
ur.
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
45%
)
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
87
Amm
i visn
aga (
L.) L
am.
Drie
d rip
e fru
its o
f Am
mi v
isnag
a (L.
) Lam
.H
ABPh
.Eur
. 1.1
.8 (e
than
ol
70%
), H
AB 3
5bAm
mi v
isnag
a com
p.
Amyg
dala
e am
arae
see P
runu
s dul
cis va
r. am
ara (
DC.
) Buc
hhei
m
Anac
ardi
umse
e Sem
ecar
pus a
naca
rdiu
m L
.
Anag
allis
arve
nsis
L.Fr
esh
aeria
l par
ts of
Ana
galli
s arv
ensis
L., c
ollec
ted
at fl
ower
ing
(HAB
)Ph
.Eur
. 1.1
.3, H
AB 2
1An
agal
lis/M
alac
hit c
omp.
Anag
allis
arve
nsis
L.D
ried
aeria
l par
ts of
Ana
galli
s arv
ensis
L., h
avin
g be
en co
llect
ed
at fl
ower
ing
Ph.E
ur. 1
.2.1
3 (e
than
ol
50%
)An
agal
lis/M
alac
hit c
omp.
Répe
rtoire
de m
éd.
anth
r.
Anam
irta c
occu
lus W
ight
et A
rn.
Drie
d, ri
pe fr
uits
of A
nam
irta c
occu
lus (
L.) W
ight
et A
rn.
Ph.E
ur.
Ph.E
ur. 1
.1.8
(Eth
anol
90
%)
Cocc
ulus
/Oleu
m P
etra
e com
p.
Anan
as co
mos
us (L
.) M
err.
Fres
hly p
ress
ed ju
ice o
f fru
it of
Ana
nas c
omos
us (L
.) M
err.
Ph.E
ur. 3
.1.1
Resin
a Lar
icis c
omp.
Anan
as co
mos
us (L
.) M
err.
Fres
h fr
uit o
f Ana
nas c
omos
us (L
.) M
err.
Mac
erat
ion
with
etha
nol
96%
(Fru
it: et
hano
l 96%
: 4:
1)
Anan
assa
com
p.; R
esin
a Lar
icis c
omp.
Ange
lica a
rcha
ngeli
ca L
.Fr
esh
root
s and
rhiz
omes
of A
ngeli
ca ar
chan
gelic
a L.
HAB
Ph.E
ur. 1
.2.1
1, H
AB 3
3cAr
chan
gelic
a; Ar
chan
gelic
a com
p.;
Arch
ange
lica/
Pyrit
com
p.
Ange
lica a
rcha
ngeli
ca L
.W
hole
or cu
t, ca
refu
lly d
ried
rhiz
ome a
nd ro
ot o
f Ang
elica
ar
chan
gelic
a L. (
syn.
A. o
fficin
alis
Hoff
m.)
Ph.E
ur.
Etha
nolic
dist
illat
ion
toge
ther
with
oth
er
drug
s
Spiri
tus c
ontra
tuss
im; S
pirit
us M
eliss
ae
com
p.
Anha
loni
umse
e Lop
hoph
ora w
illia
msii
Cou
lt.
Anisu
mse
e Pim
pine
lla an
isum
L.
Anth
yllis
vuln
erar
ia L
.Fr
esh
aeria
l par
ts of
Ant
hylli
s vul
nera
ria L
. at fl
ower
ing
HAB
12c
Calen
dula
/Tro
paeo
lum
com
p.
Apoc
ynum
cann
abin
um L
.Fr
esh
unde
rgro
und
part
s of A
pocy
num
cann
abin
um L
.H
ABPh
.Eur
. 1.1
.5, 1
.2.9
Scill
a com
p.
Aral
ia ra
cem
osa L
.Fr
esh
unde
rgro
und
part
s of A
ralia
race
mos
a L.
HAB
Ph.E
ur. 1
.1.5
Arct
ium
lapp
a L.
Drie
d wh
ole o
r cut
root
s of A
rctiu
m la
ppa L
. (A.
majo
r Gae
rtn.
), A.
min
us (H
ill) B
ernh
. and
A. t
omen
tosu
m M
ill. a
lso re
lated
sp
ecie
s or h
ybrid
s (As
tera
ceae
), co
llect
ed in
autu
mn
of th
e firs
t ye
ar o
r spr
ing
of th
e sec
ond
year
DAC
HAB
12g
Arni
ca/L
appa
com
p.; B
etul
a/La
ppa
com
p.
Arct
osta
phyl
os u
va-u
rsi (
L.)
Spre
ng.
Drie
d lea
ves o
f Arc
tosta
phyl
os u
va-u
rsi (
L.) S
pren
g.Ph
.Eur
. 1.2
.12
(eth
anol
36
%)
Uva
urs
i com
p.
Arisa
ema t
riphy
llum
(L.)
Torr.
Fres
h un
derg
roun
d pa
rts o
f Aris
aem
ia tr
iphy
llum
(L.)
Torr.
, co
llect
ed b
efor
e the
leav
es d
evelo
p.H
ABPh
.Eur
. 1.1
.5
Arni
ca m
onta
na L
.Vo
latile
oil
from
the u
nder
grou
nd p
arts
of A
rnic
a mon
tana
L.
see A
pp. 2
.6 (C
alciu
m
silici
cum
com
p.)
Vade
mec
um: C
alciu
m
silici
cum
com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
88
Arni
ca m
onta
na L
.Fr
esh
flowe
r-he
ads o
f Arn
ica m
onta
na L
.H
AB 1
2cAr
gent
um/U
rtic
a com
p.; A
rnic
a, Fl
os;
Calen
dula
/Urt
ica c
omp.
Arni
ca m
onta
na L
.W
hole
fresh
flow
erin
g pl
ants
of A
rnic
a mon
tana
L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.4, 1
.1.5
, 1.1
.7,
1.1.
10 (e
than
ol 4
5%
Ph.fr
.), H
AB 1
2a, 2
1, 3
3c.
See a
lso A
pp. 2
.7: A
rnic
a m
onta
na 1
:1,1
Acon
itum
/Arn
ica c
omp.
/Api
s; Ac
onitu
m/A
rnic
a com
p./F
orm
ica;
Acon
itum
/Arn
ica/
Betu
la co
mp.
; Ac
onitu
m/A
rnic
a/Br
yoni
a; Al
lium
ce
pa/T
endo
com
p.; A
pis/
Arni
ca; A
rnic
a co
mp.
; Arn
ica,
Plan
ta to
ta; A
rnic
a, Pl
anta
tota
/Aur
um; A
rnic
a, Pl
anta
tota
/Co
r; Ar
nica
, Pla
nta t
ota/
Equi
setu
m
arve
nse;
Arni
ca, P
lant
a tot
a/Fo
rmic
a; Ar
nica
, Pla
nta t
ota/
Vesp
a Cra
bro;
Ar
nica
-Cer
ebru
m; A
rnic
a/Be
tula
co
mp.
; Arn
ica/
Cact
us co
mp.
; Arn
ica/
Echi
nace
a com
p.; A
rnic
a/Ep
iphy
sis/
Plum
bum
mell
itum
com
p.; A
rnic
a/Fo
rmic
a com
p.; A
rnic
a/H
ypop
hysis
/Pl
umbu
m m
ellitu
m co
mp.
; Arn
ica/
Levi
sticu
m co
mp.
; Arn
ica/
Plum
bum
m
ellitu
m; A
rnic
a/Sy
mph
ytum
com
p.;
Arni
ca/U
rtic
a ure
ns; A
rtic
ulat
io
talo
crur
alis
com
p.; A
urum
/Ono
pord
on
com
p.; B
etul
a/Ar
nica
com
p.; C
actu
s/M
agne
sium
pho
spho
ricum
; Cer
ebell
um
com
p.; C
rata
egus
/Pru
nus c
omp.
; Disc
i co
mp.
cum
Aes
culo
; Disc
i com
p. cu
m
Arge
nto;
Disc
i com
p. cu
m A
uro;
Disc
i co
mp.
cum
Stib
io; D
isci/R
hus
toxi
code
ndro
n co
mp.
; Disc
i/Visc
um
com
p. cu
m A
rgen
to; M
agne
sium
ph
osph
oric
um co
mp.
; Mag
nesiu
m
sulfu
ricum
/Ova
ria co
mp.
; Man
drag
ora
com
p.; M
edul
la sp
inal
is co
mp.
; Ner
vus
optic
us co
mp.
; Ono
pord
on co
mp.
/O
leand
er/ A
rnic
a; St
annu
m/
Sym
phyt
um co
mp.
; Sym
phyt
um co
mp.
Arni
ca m
onta
na L
.Fr
esh
unde
rgro
und
part
s of A
rnic
a mon
tana
L.
HAB
21,
33c
Apis
com
p.; A
rnic
a
Arni
ca m
onta
na L
.W
hole
or p
artia
lly b
roke
n, d
ried
flowe
r-he
ads o
f Ar
nica
mon
tana
L.
HAB
; Ph
.Eur
.H
AB 1
2d (o
live o
il), 1
2gAp
is/Ar
nica
com
p.; A
rnic
a com
p./
Cupr
um; A
rnic
a com
p./F
orm
ica;
Arni
ca, F
los;
Arni
ca/L
appa
com
p.;
Lotio
Pru
ni co
mp.
; Oleu
m la
ctag
ogum
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
89
Arni
ca m
onta
na L
.D
ried
unde
rgro
und
part
s of A
rnic
a mon
tana
L.
HAB
Ph.E
ur. 1
.1.8
(Eth
anol
90
%);
Ph.H
elv. 1
7.7.
4.3/
APC
4.3
Arni
ca; C
inis
Arni
cae c
omp.
Arte
misi
a abr
otan
um L
.Fr
esh
youn
g sh
oots
and
leave
s of A
rtem
isia a
brot
anum
L. H
AB
Fres
h, n
on-w
oody
aeria
l par
t of A
rtem
isia a
brot
anum
L. P
h.fr.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (E
than
ol 6
5%) H
AB 3
3cAb
rota
num
; Bol
us al
ba co
mp.
Arte
misi
a abs
inth
ium
L.
Fres
h up
per s
hoot
s with
atta
ched
leav
es an
d flo
wers
and
basa
l lea
ves o
f Arte
misi
a abs
inth
ium
L. s
epar
ately
or a
s a m
ixtu
re.
HAB
Ph.E
ur. 1
.1.5
, Ext
ract
ion
with
etha
nol 3
6% (1
:2,3
)Ci
chor
ium
/Tar
axac
um co
mp.
Arte
misi
a abs
inth
ium
L.
Basa
l lea
ves o
r slig
htly
leaf
y, flo
werin
g to
ps, o
r mix
ture
of t
hese
dr
ied,
who
le or
cut o
rgan
s of A
rtem
isia a
bsin
thiu
m L
.(H
AB);
Ph.E
ur.
Ph.E
ur. 1
.2.1
3 (e
than
ol
50%
), 1.
4.4,
Ext
ract
ion
with
wat
er (t
oget
her
with
oth
er h
erba
l dru
gs)
Absin
thiu
m/C
aryo
phyl
li co
mp.
; Ab
sinth
ium
/Res
ina L
arici
s; Ar
tem
isia
com
p.; C
inis
Caps
ellae
com
p.;
Cocc
ulus
/Oleu
m P
etra
e com
p.;
Gen
tiana
com
p.; G
entia
na/Z
ingi
ber
com
p.; U
va u
rsi c
omp.
Arum
mac
ulat
um L
.Fr
esh
unde
rgro
und
part
s of A
rum
mac
ulat
um L
., col
lecte
d be
fore
th
e lea
ves d
evelo
p.H
ABPh
.Eur
. 1.1
.5, 1
.2.4
Arum
mac
ulat
um/P
terid
ium
aqui
linum
Arum
trip
hyllu
mse
e Aris
aem
a trip
hyllu
m (L
.) To
rr.
Arun
do d
onax
L.
Fres
h un
derg
roun
d pa
rts o
f Aru
ndo
dona
x L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Asa f
oetid
ase
e Fer
ula a
ssa-
foet
ida L
.
Asar
um eu
ropa
eum
L.
Fres
h un
derg
roun
d pa
rts o
f phe
nylp
ropa
ne-c
onta
inin
g su
bspe
cies
of A
saru
m eu
ropa
eum
L.
HAB
Ph.E
ur. 1
.1.5
Aspe
rula
odo
rata
see G
aliu
m o
dora
tum
Aspi
dium
filix
-mas
see D
ryop
teris
filix
-mas
(L.)
Scho
tt.
Aspl
eniu
m sc
olop
endr
ium
see P
hylit
is sc
olop
endr
ium
Astra
galu
s exs
capu
s L.
Fres
h flo
werin
g an
d in
frui
t ros
ette
s of A
strag
alus e
xsca
pus L
.Ph
.Eur
. 1.1
.5Va
dem
ecum
: As
traga
lus e
xsca
pus
Atro
pa b
ella-
donn
a L.
Fres
h fr
uits
of A
tropa
bell
a-do
nna L
.Ph
.Eur
. 1.1
.6, H
AB 3
3aAp
is/Be
llado
nna;
Apis/
Bella
donn
a/M
ercu
rius;
Bella
donn
a; Be
llado
nna /
Rosa
e aet
hero
leum
; Ech
inac
ea/
Mer
curiu
s com
p.; R
hus/
Salix
com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
90
Atro
pa b
ellad
onna
L.
Who
le, fr
esh,
flow
erin
g pl
ant o
f Atro
pa b
ellad
onna
L., h
arve
sted
at th
e end
of fl
ower
ing,
with
the l
igne
ous b
ase o
f the
stem
s re
mov
ed
(HAB
); Ph
.Eur
.; Ph
.fr.
Ph.E
ur. 1
.1.3
, 1.1
.10
(eth
anol
45%
), H
AB 2
1Ac
idum
hyd
roch
loric
um co
mp.
; Api
s/Be
llado
nna;
Arge
ntum
com
p.; A
urum
/Be
llado
nna c
omp.
; Bell
adon
na;
Bella
donn
a/Be
tula
/For
mic
a; Be
llado
nna/
Lens
crist
allin
a Col
umba
e/
Resin
a Lar
icis;
Bell
adon
na/O
xalis
; Be
llado
nna/
Papa
ver c
omp.
; Be
llado
nna/
Qua
rz; B
olus
Euc
alyp
ti co
mp.
; Bry
onia
/Gels
emiu
m co
mp.
; Br
yoni
a/Sp
ongi
a com
p.; C
actu
s/M
agne
sium
pho
spho
ricum
; Ch
amom
illa c
omp.
; Dro
sera
/Ip
ecac
uanh
a com
p.; E
ucal
yptu
s com
p.;
Oxa
lis co
mp.
; Pul
vis S
tom
achi
cus c
um
Bella
donn
a; Zi
nnob
er co
mp.
Atro
pa b
ella-
donn
a L.
Fres
h ae
rial p
arts
of A
tropa
bell
a-do
nna L
. with
out w
oody
lowe
r ste
m se
ctio
ns, c
ollec
ted
at th
e beg
inni
ng o
f flow
erin
gH
AB 3
3aAm
mi v
isnag
a com
p.; A
ntim
onit/
Rosa
e ae
ther
oleu
m co
mp.
; Api
s/Be
rber
is co
mp.
; Aur
um/P
lum
bum
mell
itum
co
mp.
; Bell
adon
na; B
ellad
onna
/Ros
ae
aeth
erol
eum
; Bell
adon
na co
mp.
; Car
um
carv
i com
p.; C
onju
nctiv
a com
p.;
Echi
nace
a/Q
uarz
com
p.; L
ache
sis
com
p.; P
erio
dont
ium
/Sili
cea c
omp.
; Si
licea
com
p.; Th
yreo
idea
com
p.;
Vera
trum
com
p.
Atro
pa b
ella-
donn
a L.
Fres
h un
derg
roun
d pa
rts o
f Atro
pa b
ella-
donn
a L.
HAB
21,
33b
Acon
itum
com
p.; B
ellad
onna
; Be
llado
nna/
Cham
omill
a; Br
yoni
a/Pu
lsatil
la co
mp.
; Visc
um co
mp.
Aven
a sat
iva L
.W
hole
fresh
pla
nts o
f Ave
na sa
tiva L
., col
lecte
d wh
en th
e gra
in
has r
ipen
ed to
the m
ilky s
tage
HAB
HAB
33c
Apis
regi
na/A
urum
com
p.; A
vena
co
mp.
; Ave
na/P
assifl
ora c
omp.
Aven
a sat
iva L
.Fr
esh
aeria
l par
ts of
Ave
na sa
tiva L
., col
lecte
d wh
en th
e gra
in h
as
ripen
ed to
the m
ilky s
tage
Aque
ous e
xtra
ct (w
ith
sucr
ose)
1:5
(see
mon
. KC
)
Hyp
eric
um/P
assifl
ora c
omp.
Aven
a sat
iva L
.Fr
esh
aeria
l par
ts of
Ave
na sa
tiva L
., col
lecte
d at
flow
erin
g tim
eH
AB; P
h.fr.
Ph.E
ur. 1
.1.1
, 1.1
.4,
1.1.
10 (e
than
ol 4
5%)
Aven
a sat
iva;
Aven
a sat
iva c
omp.
Aven
a sat
iva L
.G
erm
inat
ed fr
uits
of A
vena
sativ
a L.
APC
4.3
Cor/
Crat
aegu
s com
p.; F
raga
ria/U
rtic
a co
mp.
; Mag
nesiu
m p
hosp
horic
um
com
p.; M
agne
sium
pho
spho
ricum
cum
ci
nere
Ave
nae;
Vera
trum
com
p.
Aven
a sat
iva L
.D
ried
mill
ed fr
uits
of A
vena
sativ
a L.
API
Aven
a/Co
ncha
e com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
91
Balsa
mum
per
uvia
num
see M
yrox
ylon
bal
sam
um (L
.) H
arm
s
Bam
busa
see P
hyllo
stach
ys vi
ridig
lauce
scen
s (Ca
rr.) A
. et C
. Riv.
Bella
donn
ase
e Atro
pa b
ella-
donn
a L.
Belli
s per
enni
s L.
Who
le fre
sh fl
ower
ing
plan
ts of
Bell
is pe
renn
is L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.3, 1
.1.1
0 (e
than
ol 4
5%)
Sym
phyt
um co
mp.
Belli
s per
enni
s L.
Fres
h ae
rial p
arts
of B
ellis
pere
nnis
L. at
flow
erin
gH
AB 1
2cBe
llis/
Trop
aeol
um; C
alen
dula
/Tr
opae
olum
com
p.
Styr
ax to
nkin
ensis
(Pie
rre)
Cra
ib
ex H
artw
ichRe
sin o
btai
ned
by in
cisin
g th
e tru
nk o
f Sty
rax
tonk
inen
sis (P
ierr
e)
Crai
b ex
Har
twich
Ph.E
ur.
Ph.E
ur. 1
.1.1
0 (e
than
ol
90%
)Ce
ratu
m b
enzo
inat
um
Berb
eris
aqui
foliu
mse
e Mah
onia
aqui
foliu
m (P
ursh
) Nut
t.
Berb
eris
vulg
aris
L.Fr
esh
aeria
l par
ts of
Ber
beris
vulg
aris
L. at
flow
erin
gH
AB 3
3cBe
rber
is/Pr
osta
ta co
mp.
; Ber
beris
/U
teru
s com
p.
Berb
eris
vulg
aris
L.Fr
esh
unde
rgro
und
part
s of B
erbe
ris vu
lgar
is L.
Ph.E
ur. 1
.4.3
, HAB
33d
Apis/
Berb
eris
com
p.; B
erbe
ris/
Hyp
eric
um co
mp.
; Ber
beris
/Pro
stata
co
mp.
; Ber
beris
/Sab
al co
mp.
; Ber
beris
/Se
pia c
omp.
; Ber
beris
/Urt
ica u
rens
, H
erba
; Ber
beris
/Ute
rus c
omp.
; Ly
copo
dium
com
p.; S
abal
/Sol
idag
o co
mp.
Berb
eris
vulg
aris
L.W
hole,
fully
ripe
ned
berr
ies o
f Ber
beris
vulg
aris
L. st
rippe
d off
th
e fru
it sta
lks
HAB
Ph.E
ur. 1
.1.4
, HAB
21,
33
cAl
umen
/Hell
ebor
us co
mp.
; Arg
entu
m/
Berb
eris
com
p.; B
erbe
ris e
fruc
tibus
co
mp.
; Ber
beris
, Fru
ctus
; Ber
beris
/Eu
caly
ptus
/ Sili
cea c
omp.
; Ber
beris
/M
ercu
rialis
per
enni
s; Be
rber
is/N
icotia
na co
mp.
; Ber
beris
/Pru
nus;
Berb
eris/
Pyrit
com
p.; B
erbe
ris/Q
uarz
; Be
rber
is/Si
licea
com
p.; E
chin
acea
co
mp.
; Ech
inac
ea/P
runu
s com
p.;
Sam
bucu
s/Te
ucriu
m co
mp.
; Uva
urs
i co
mp.
Berb
eris
vulg
aris
L.Fr
esh
whol
e pla
nt in
cludi
ng b
errie
s of B
erbe
ris vu
lgar
is L.
HAB
21
Berb
eris,
Pla
nta t
ota/
Urtic
a ure
ns
Berb
eris
vulg
aris
L.D
ried
bark
of a
eria
l and
und
ergr
ound
par
ts of
Ber
beris
vulg
aris
L.H
ABPh
.Eur
. 1.1
.8, 1
.2.1
2 (e
than
ol 7
0%),
1.4.
2Ap
is co
mp.
; Bar
ium
com
p.; B
erbe
ris,
Corte
x; B
erbe
ris/U
rtic
a ure
ns, H
erba
Berb
eris
vulg
aris
L.D
ried
bark
of u
nder
grou
nd p
arts
of B
erbe
ris vu
lgar
is L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
55
%)
Répe
rtoire
de m
éd.
anth
r. (2
010)
Berb
eris
vulg
aris
L.D
ried
unde
rgro
und
part
s of B
erbe
ris vu
lgar
is L.
HAB
12f
Berb
eris/
Cheli
doni
um co
mp.
; Ber
beris
/Ju
nipe
rus c
omp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
92
Beto
nica
see S
tach
ys o
ffici
nalis
(L.)
Trev
.
Betu
la p
endu
la R
oth
Fres
h yo
ung
leave
s of B
etul
a pen
dula
Rot
h.H
AB1.
1.7,
HAB
22,
34e
Bella
donn
a/Be
tula
/For
mic
a; Be
tula
, Fo
lium
; Bet
ula/
Arni
ca co
mp.
; Bet
ula/
Juni
peru
s; Ca
rtila
go co
mp.
; Car
tilag
o/M
andr
agor
a com
p.; M
andr
agor
a com
p.;
Trop
aeol
um co
mp.
Betu
la p
endu
la R
oth
Drie
d ba
rk fr
om w
hite
par
ts on
ly o
f tru
nk an
d br
anch
es o
f Bet
ula
pend
ula R
oth
HAB
Ph.E
ur. 1
.2.1
2 (e
than
ol
50%
)Ar
nica
/Bet
ula c
omp.
; Arn
ica/
Epip
hysis
/Pl
umbu
m m
ellitu
m co
mp.
; Arn
ica/
Form
ica c
omp.
; Arn
ica/
Hyp
ophy
sis/
Plum
bum
mell
itum
com
p.; B
etul
a co
mp.
; Bet
ula,
Corte
x; B
etul
a/M
andr
agor
a com
p.; R
etin
a/Se
cale
com
p.
Betu
la p
endu
la R
oth,
Bet
ula
pube
scen
s Ehr
h.W
hole
or fr
agm
ente
d dr
ied
leave
s of B
etul
a pen
dula
Rot
h an
d /o
r Be
tula
pub
esce
ns E
hrh.
, as w
ell as
hyb
rids o
f bot
h sp
ecie
s.Ph
.Eur
.Ph
.Eur
. 1.2
.12
(eth
anol
36
%),
HAB
12g
Acon
itum
/Arn
ica c
omp.
/Api
s; Ac
onitu
m/A
rnic
a com
p./F
orm
ica;
Acon
itum
/Arn
ica/
Betu
la co
mp.
; Api
s/Ar
nica
com
p.; A
rnic
a com
p./C
upru
m;
Arni
ca co
mp.
/For
mic
a; Ar
nica
/Lap
pa
com
p.; A
rnic
a/Sy
mph
ytum
com
p.;
Betu
la, F
oliu
m; B
etul
a/La
ppa c
omp.
; Bl
eigl
anz/
Seca
le co
mp.
; Man
drag
ora
com
p.; M
edul
la sp
inal
is co
mp.
; Oleu
m
lact
agog
um
Betu
la p
endu
la R
oth,
Bet
ula
pube
scen
s Ehr
h.Ca
rbon
obt
aine
d fro
m w
ood
of B
etul
a pen
dula
Rot
h or
B.
pube
scen
s Ehr
h.H
ABPh
.Eur
. 4.1
.1 se
e app
. 2.7
Bariu
m/P
ancr
eas c
omp.
; Bas
ilicu
m
com
p.; B
irken
kohl
e com
p.; B
olus
alba
co
mp.
; Car
bo B
etul
ae; C
arbo
Bet
ulae
cu
m M
etha
no; C
arbo
Bet
ulae
/Car
vi
aeth
erol
eum
; Car
bo B
etul
ae/C
rata
egus
; Ca
rbo
Betu
lae/
Sulfu
r; N
icot
iana
com
p.;
Nic
otia
na/N
ux vo
mic
a com
p.;
Panc
reas
/Plat
inum
chlo
ratu
m co
mp.
; So
lutio
Sac
char
i com
p.; T
ropa
eolu
m
com
p.
Bold
ose
e Peu
mus
bol
dus M
ol.
Bora
go o
ffici
nalis
L.
Fres
h lea
ves o
f Bor
ago
offici
nalis
L.
(HAB
192
4)Ph
.Eur
. 1.1
.4, H
AB 3
4bAe
scul
us, C
orte
x/ B
orag
o/H
amam
elis,
Foliu
m; A
escu
lus/
Prun
us co
mp.
; Ae
scul
us/Q
uerc
us co
mp.
; Bor
ago;
Bo
rago
com
p.; B
orag
o/Re
nes c
omp.
; Q
uerc
us co
mp.
Bora
go o
ffici
nalis
L.
Fres
h ae
rial p
arts
of B
orag
o offi
cina
lis L
. at fl
ower
ing
HAB
12a
, 12c
Bora
go
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
93
Bosw
ellia
carte
ri Bi
rdwo
od
(Bos
welli
a sac
ra F
luec
kige
r)
Boss
welli
a fre
rean
a Bird
wood
Solid
ified
gum
-res
in o
btai
ned
from
incis
ions
in th
e shr
ubs o
r tre
es o
f mem
bers
of t
he ge
nus B
oswe
llia,
part
icul
arly
Bos
welli
a ca
rteri
Bird
wood
(Syn
. Bos
welli
a sac
ra F
luec
kige
r) an
d/or
Bo
sswe
llia f
rere
ana B
irdwo
od
Ph.E
ur. 1
.1.8
(eth
anol
90
%),
4.1.
1Au
rum
com
p.; A
urum
/Epi
phys
is co
mp.
; Au
rum
/Hyp
ophy
sis co
mp.
; Olib
anum
co
mp.
/Suc
cinum
Bras
sica n
igra
(L.)
W.D
.J. K
och
Ripe
drie
d se
eds o
f Bra
ssic
a nig
ra (L
.) Ko
chD
ACH
AB 1
2fAe
scul
us/C
era c
omp.
Bryo
nia c
retic
a L. s
sp. d
ioic
a (Ja
cq.)
Tutin
Bry
onia
alba
L.
Fres
h ro
ot o
f Bry
onia
cret
ica L
. ssp
. dio
ica (
Jacq
.) Tu
tin o
r Bry
onia
al
ba L
., har
veste
d be
fore
the p
lant
com
es in
to fl
ower
HAB
Ph.E
ur. 1
.1.3
Acon
itum
/Arn
ica/
Bryo
nia;
Acon
itum
/Br
yoni
a; Ap
is/Br
yoni
a; Ap
is/Rh
us
toxi
code
ndro
n co
mp.
; Bry
onia
; Br
yoni
a/Eu
pato
rium
com
p.; B
ryon
ia/
Form
ica c
omp.
; Bry
onia
/Gels
emiu
m
com
p.; B
ryon
ia/S
pong
ia co
mp.
; Ec
hina
cea/
Prun
us co
mp.
; Fer
rum
ph
osph
oric
um co
mp.
Bryo
nia c
retic
a L. s
sp. d
ioic
a (Ja
cq.)
Tutin
Fres
h ro
ot o
f Bry
onia
cret
ica L
. ssp
. dio
ica (
Jacq
.) Tu
tin, h
arve
sted
befo
re sh
oots
are p
rodu
ced
HAB
HAB
33b
Acon
itum
/Chi
na co
mp.
; Aes
culu
s/Ce
ra
com
p.; A
pis/
Bryo
nia;
Apis/
Lary
nx
com
p.; B
ronc
hi/P
lant
ago
com
p.;
Bryo
nia;
Bryo
nia c
omp.
; Bry
onia
/Pu
lsatil
la co
mp.
; Bry
onia
/Sta
nnum
; Br
yoni
a/Vi
scum
com
p.; G
elsem
ium
co
mp.
; Mag
nesiu
m su
lfuric
um/O
varia
co
mp.
; Pul
mo/
Vivi
anit
com
p.; R
hus/
Salix
com
p.
Bryo
nia a
lba L
. or B
ryon
ia cr
etic
a L.
ssp.
dio
ica (
Jacq
.) Tu
tinFr
esh
unde
rgro
und
part
s of B
ryon
ia cr
etic
a L. s
sp. d
ioic
a (Ja
cq.)
Tutin
or B
ryon
ia al
ba L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (E
than
ol
45%
)Ré
perto
ire d
e méd
. an
thr.
(201
6)
Bryo
phyl
lum
dai
grem
ontia
num
(R
aym
.-Ham
et et
H. P
errie
r) A
. Be
rger
Bry
ophy
llum
pin
natu
m
(Lam
.) O
ken
Fres
h lea
ves o
f Bry
ophy
llum
dai
grem
ontia
num
(Ray
m.-H
amet
et
H. P
errie
r) A
. Ber
ger a
nd K
alan
choe
pin
nata
(Lam
.) Pe
rs.,
harv
este
d in
the fi
rst y
ear o
f gro
wth
HAB
Ph.E
ur. 1
.1.7
, 1.1
.10
(eth
anol
30%
), 33
bBr
yoph
yllu
m; B
ryop
hyllu
m co
mp.
; Ci
mici
fuga
com
p.; I
gnat
ia co
mp.
Bryo
phyl
lum
pin
natu
m (L
am.)
Oke
nFr
esh
pres
sed
juice
from
leav
es o
f Bry
ophy
llum
pin
natu
m (L
am.)
Oke
n(H
AB)
APC
5.2.
1Br
yoph
yllu
m
Bryo
phyl
lum
pin
natu
m (L
am.)
Oke
nFr
esh
leave
s of B
ryop
hyllu
m p
inna
tum
(Lam
.) O
ken,
har
veste
d in
th
e firs
t yea
r of g
rowt
hH
ABPh
.Eur
. 1.1
.7, H
AB 2
1,
see a
lso A
pp. 2
.7:
Bryo
phyl
lum
pin
nata
1:
1,1
Bryo
phyl
lum
; Bry
ophy
llum
/Con
chae
Buxu
s sem
perv
irens
L.
Fres
h, yo
ung
leafy
bra
nche
s of B
uxus
sem
perv
irens
L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Cact
us g
rand
iflor
usse
e Sele
nice
reus
gra
ndifl
orus
(L.)
Britt
. et R
ose
Cajep
uti a
ethe
roleu
mse
e Mela
leuca
leuc
aden
dra (
L.) L
.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
94
Cala
mus
see A
coru
s cal
amus
L.
Calen
dula
offi
cina
lis L
.Fr
esh
flowe
r hea
ds o
f Cal
endu
la o
ffici
nalis
L.
HAB
12c
Arge
ntum
/Urt
ica c
omp.
; Cal
endu
la;
Calen
dula
/Ech
inac
ea co
mp.
; Ca
lendu
la/T
ropa
eolu
m co
mp.
; Ca
lendu
la/U
rtic
a com
p.; E
chin
acea
/Vi
scum
com
p.; Th
ymus
serp
yllu
m
com
p.
Calen
dula
offi
cina
lis L
.Fr
esh
aeria
l par
ts of
Cal
endu
la o
ffici
nalis
L., c
ollec
ted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.3
, 1.1
.5; H
AB
33c,
expr
essin
g th
e jui
ceAl
lium
cepa
/ Mer
curia
lis co
mp.
; Ar
gent
um/Q
uerc
us co
mp.
; Arn
ica/
Echi
nace
a com
p.; C
alen
dula
; Cal
endu
la
com
p.; C
alen
dula
Pre
sssa
ft/Ec
hina
cea;
Calen
dula
/Ech
inac
ea p
urpu
rea;
Calen
dula
/Mer
curia
lis co
mp.
; Ca
lendu
la/S
tibiu
m; M
ajora
na/Th
uja
com
p.; M
ercu
rialis
com
p.; M
ercu
rialis
/St
ibiu
m co
mp.
; Sym
phyt
um co
mp.
Calen
dula
offi
cina
lis L
.D
ried
flowe
r hea
ds o
f Cal
endu
la o
ffici
nalis
L.
HAB
12f
, 57
Calen
dula
; Eup
hras
ia co
mp.
; Oleu
m
rhin
ale
Calen
dula
offi
cina
lis L
.D
ried
aeria
l par
ts of
Cal
endu
la o
ffici
nalis
L., c
ollec
ted
at fl
ower
ing
time
HAB
12
d, ex
tract
ion
with
oil
toge
ther
with
ot
her s
tart
ing
mat
eria
ls (1
.2:1
0)
Apis/
Arni
ca co
mp.
; Arn
ica c
omp.
/Cu
prum
; Arn
ica c
omp.
/For
mic
a; Ca
lendu
la/M
ercu
rialis
com
p.; O
leum
la
ctag
ogum
Cam
panu
la ro
tund
ifolia
L.
Fres
h, fl
ower
ing
aeria
l par
ts of
Cam
panu
la ro
tund
ifolia
L.
Ph.E
ur. 1
.1.1
0 (e
than
ol
45%
)
Caps
ella b
ursa
-pas
toris
(L.)
Med
ik.
Drie
d ae
rial p
arts
of C
apse
lla b
ursa
-pas
toris
(L.)
Med
ik, c
ollec
ted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.3
, 1.2
.13
(eth
anol
36%
)Ca
psell
a bur
sa-p
asto
ris; C
apse
lla/
Majo
rana
com
p.; C
inis
Caps
ellae
co
mp.
; Hyd
rasti
s com
p.
Caps
icum
annu
um L
.D
ried
ripe f
ruits
of C
apsic
um an
nuum
L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.8 (e
than
ol
90%
), 1.
1.10
(eth
anol
90
%)
Caps
icum
annu
um; K
asta
nien
-H
aarto
niku
m
Cara
mel
see S
acch
arum
offi
cina
rum
L.
Card
uus b
ened
ictu
sse
e Cni
cus b
ened
ictu
s L.
Card
uus m
aria
nus
see S
ilybu
m m
aria
num
(L.)
Gae
rtn.
Care
x ar
enar
ia L
.D
ried
rhiz
ome o
f Car
ex ar
enar
ia L
., col
lecte
d in
sprin
gAp
p. 2
.7: C
arex
aren
aria
, et
hano
l. D
ecoc
tum
1:4
Sold
ner /
Stell
man
n (2
011)
, Ind
ivid
uelle
Pä
diat
rie, p
. 190
-198
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
95
Caru
m ca
rvi L
.O
il ob
tain
ed b
y ste
am d
istill
atio
n fro
m th
e dry
frui
ts of
Car
um
carv
i L.
Ph.E
ur.
API
Berb
eris/
Cheli
doni
um co
mp.
; Bol
us
alba
com
p.; C
arbo
Bet
ulae
/Car
vi
aeth
erol
eum
; Meli
ssa c
omp.
; Oleu
m
lact
agog
um; T
ropa
eolu
m co
mp.
Caru
m ca
rvi L
.W
hole,
dry
mer
icar
p of
Car
um ca
rvi L
.(H
AB);
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
90
%),
1.2.
12 (e
than
ol
70%
), aq
ueou
s ext
ract
1.
8:1,
extra
ct w
ith
etha
nol 3
6%, A
PI, A
PC
4.2
Arte
misi
a com
p.; B
asili
cum
com
p.;
Caru
m ca
rvi;
Caru
m ca
rvi c
omp.
; Ce
ntau
rium
com
p.
Cary
ophy
llus
see S
yzyg
ium
arom
atic
um (L
.) M
err.
et L
. M. P
erry
Cass
ia an
gusti
folia
Vah
l., C
assia
se
nna L
.D
ried
leafle
ts of
Cas
sia se
nna L
. (C.
acut
ifolia
Deli
le), k
nown
as
Alex
andr
ian
or K
harto
um se
nna,
or C
assia
angu
stifo
lia V
ahl.,
kn
own
as T
inne
velly
senn
a, or
a m
ixtu
re o
f the
2 sp
ecie
s.
Ph.E
ur.
API
Cent
auriu
m co
mp.
Cass
ia se
nna L
. (Ca
ssia
acut
ifolia
D
elile)
Drie
d fr
uit o
f Cas
sia se
nna L
. (C.
acut
ifolia
Deli
le)Ph
.Eur
.Ph
.Eur
. 1.2
.12
(eth
anol
50
%)
Arte
misi
a com
p.
Caul
ophy
llum
thal
ictro
ides
(L.)
Mich
x.Fr
esh
unde
rgro
und
part
s of C
aulo
phyl
lum
thal
ictro
ides
(L.)
Mich
x., h
arve
sted
in la
te su
mm
erH
ABPh
.Eur
. 1.1
.5
Caul
ophy
llum
thal
ictro
ides
(L.)
Mich
x.D
ried
unde
rgro
und
part
s of C
aulo
phyl
lum
thal
ictro
ides
(L.)
Mich
aux.
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Cean
othu
s am
eric
anus
L.
Drie
d lea
ves o
f Cea
noth
us am
eric
anus
L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
), 1.
1.10
(eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Cent
auriu
m er
ythr
aea R
afn.
Fres
h ae
rial p
arts
of C
enta
uriu
m er
ythr
aea R
afn.
Ph. E
ur. 1
.1.4
, eth
anol
ic ex
tract
1:2
.3 (e
than
ol
36%
)
Cich
oriu
m/T
arax
acum
com
p.
Cent
auriu
m er
ythr
aea R
afn.
Who
le or
frag
men
ted
drie
d flo
werin
g ae
rial p
arts
of C
enta
uriu
m
eryt
hrae
a Raf
n s.
l. in
cludi
ng C
. maju
s (H
. et L
.) Ze
ltner
and
C.
suffr
utico
sum
(Gris
eb.)
Ronn
. (sy
n.: E
ryth
raea
cent
auriu
m
Pers
oon;
C. u
mbe
llatu
m G
ilibe
rt; C
. min
us G
ars.)
Ph.E
ur.
API
Cent
auriu
m co
mp.
Cent
ella a
siatic
a (L.
) Urb
anD
ried,
who
le pl
ant o
f Cen
tella
asia
tica (
L.) U
rban
(Hyd
roco
tyle
asia
tica L
.)Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
45%
)
Cepa
see A
llium
cepa
L.
Ceph
aelis
ipec
acua
nha
see P
sych
otria
ipec
acua
nha (
Brot
.) St
okes
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
96
Ceph
aelis
ipec
acua
nha (
Brot
.) A.
Ri
ch, C
epha
elis a
cum
inat
a H.
Kars
t.)
Frag
men
ted
and
drie
d un
derg
roun
d or
gans
of C
arap
ichea
ip
ecac
uanh
a (Br
ot.)
L. A
nder
sson
(syn
. Cep
haëli
s ipe
cacu
anha
(B
rot.)
A. R
ich.; C
epha
ëlis a
cum
inat
a H. K
arst.
) fro
m M
ato
Gro
sso
or C
osta
Ric
a.
Ph.E
ur.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Ré
perto
ire d
e méd
. an
thr.
(201
6)
Cetra
ria is
land
ica (
L.) A
char
ius
s.l.
Who
le or
cut,
drie
d th
allu
s of C
etra
ria is
land
ica (
L.) A
char
ius s
.l.(H
AB);
Ph.E
ur.
Ph.E
ur. 1
.2.1
2 (e
than
ol
70%
), aq
ueou
s ext
ract
Cetra
ria is
land
ica;
Lich
enes
com
p.;
Verb
ascu
m co
mp.
Cham
omill
a rec
utita
see M
atric
aria
recu
tita L
.
Cheli
doni
um m
ajus L
.Fr
esh
rhiz
ome a
nd ad
here
nt ro
ots o
f Che
lidon
ium
maju
s L.,
colle
cted
dur
ing
late a
utum
n or
on
the a
ppea
ranc
e of t
he fi
rst
shoo
ts
HAB
Ph.E
ur. 1
.1.5
, HAB
21,
34
bBe
llado
nna/
Papa
ver c
omp.
; Ber
beris
/Ch
elido
nium
com
p.; C
helid
oniu
m;
Cheli
doni
um co
mp.
; Che
lidon
ium
/Co
locy
nthi
s; Ch
elido
nium
/Cur
cum
a; Ch
elido
nium
/Ter
ebin
thin
a lar
icin
a co
mp.
; Col
chic
um co
mp.
Cheli
doni
um m
ajus L
.Fr
esh
flowe
rs o
f Che
lidon
ium
maju
s L.
HAB
Ph.E
ur. 1
.2.3
Aqui
linum
com
p.; C
helid
oniu
m;
Cheli
doni
um/O
xalis
com
p.;
Colch
icum
/Che
lidon
ium
; Col
chic
um/
Spon
gia c
omp.
Cheli
doni
um m
ajus L
.Fr
esh
aeria
l par
ts of
Che
lidon
ium
maju
s L., c
ollec
ted
at fl
ower
ing
time
HAB
34b
Berb
eris/
Cheli
doni
um co
mp.
; Ch
elido
nium
; Che
lidon
ium
/Co
locy
nthi
s; Ch
elido
nium
/Te
rebi
nthi
na la
ricin
a com
p.
Cheli
doni
um m
ajus L
.Fr
esh
whol
e flow
erin
g pl
ants
of C
helid
oniu
m m
ajus L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
45%
)
Chim
aphi
la u
mbe
llata
(L.)
Barto
nD
ried
aeria
l par
ts of
Chi
map
hila
um
bella
ta (L
.) Ba
rton
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Chin
ase
e Cin
chon
a pub
esce
ns V
ahl
Chlo
roph
ycea
e (cla
ss),
Clad
opho
ra o
r Oed
ogon
ium
(g
ener
a)
Fres
h th
alli
of al
gae f
rom
the g
enus
Cla
doph
ora o
r Oed
ogon
ium
or
oth
er ge
nera
of fi
lam
ento
us o
rgan
ised
gree
n al
gae f
rom
the
class
Chl
orop
hyce
ae.
HAB
33e
Arge
ntum
nitr
icum
com
p.
Chry
sosp
leniu
m al
tern
ifoliu
m L
.W
hole
fresh
pla
nts o
f Chr
ysos
plen
ium
alte
rnifo
lium
L.
HAB
33b
Chry
sosp
leniu
m co
mp.
Cich
oriu
m in
tybu
s L.
Who
le fre
sh fl
ower
ing
plan
ts of
Cich
oriu
m in
tybu
s L.
HAB
Ph.E
ur. 1
.1.7
, HAB
21,
33
c; ex
tract
with
etha
nol
(36%
) 1:2
.3
Anag
allis
com
p.; B
ariu
m/P
ancr
eas
com
p.; B
erbe
ris/C
helid
oniu
m co
mp.
; Ch
ryso
splen
ium
com
p.; C
ichor
ium
; Ci
chor
ium
Plu
mbo
cultu
m; C
ichor
ium
St
anno
cultu
m; C
ichor
ium
/Pan
crea
s co
mp.
; Cich
oriu
m/T
arax
acum
com
p.;
Frag
aria
/Urt
ica c
omp.
; Lie
n co
mp.
; Pa
ncre
as/P
latin
um ch
lora
tum
com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
97
Cich
oriu
m in
tybu
s L. v
ar. i
ntyb
us
& C
ichor
ium
inty
bus L
. var
. sa
tivum
DC
Drie
d wh
ole p
lant
s of C
ichor
ium
inty
bus L
. var
. int
ybus
and
Cich
oriu
m in
tybu
s L. v
ar. s
ativ
um D
C, co
llect
ed at
flow
erin
g tim
e. Th
e tou
gh m
iddl
e ste
m se
ctio
ns ar
e not
use
d.
HAB
Ph.E
ur. 1
.2.1
2 (e
than
ol
70%
), AP
C 4.
2, 4
.3Ac
idum
hyd
roch
loric
um co
mp.
; Ba
silic
um co
mp.
; Cich
oriu
m;
Cich
oriu
m co
mp.
Cim
icifu
ga ra
cem
osa (
L.) N
utt.
Fres
h rh
izom
e and
adhe
rent
root
s of C
imifu
ga ra
cem
osa (
L.)
Nut
t.H
ABPh
.Eur
. 1.1
.5, 1
.2.9
, HAB
33
cCi
mici
fuga
com
p.; C
imici
fuga
ra
cem
osa
Cinc
hona
pub
esce
ns V
ahl
Who
le or
cut,
drie
d ba
rk o
f Cin
chon
a pub
esce
ns V
ahl (
Cinc
hona
su
cciru
bra P
av.),
of C
inch
ona c
alisa
ya W
edd.
, of C
inch
ona
ledge
riana
Moe
ns ex
Trim
en o
r of t
heir
varie
ties o
r hyb
rids.
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
70
%),
HAB
35b
Acon
itum
/Chi
na co
mp.
; Dro
sera
/Ip
ecac
uanh
a com
p.
Cine
raria
mar
itim
ase
e Sen
ecio
bico
lor (
Will
d.) T
od.
Cinn
amom
um ve
rum
J. S
. Pre
slD
ried
bark
, fre
ed fr
om th
e out
er co
rk an
d th
e und
erly
ing
pare
nchy
ma,
of th
e sho
ots g
rown
on
cut s
tock
of C
inna
mom
um
veru
m J.
S. P
resl.
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
70
%);
disti
llatio
nSp
iritu
s con
tra tu
ssim
; Spi
ritus
Meli
ssae
co
mp.
Ciss
us go
ngyl
odes
(Bak
.) Bu
rch.
Fres
h ae
rial r
oots
of C
issus
gong
ylod
es (B
ak.)
Burc
h.Ph
.Eur
. 1.1
.7Ci
ssus
-Oss
a
Citr
ullu
s col
ocyn
this
(L.)
Schr
ad.
Drie
d pu
lp o
f Citr
ullu
s col
ocyn
this
(L.)
Schr
ad. w
ithou
t see
dsPh
.fr.
Ph..E
ur. 1
.1.1
0 (e
than
ol
65%
)Ré
perto
ire d
e méd
. an
thr.
(201
6)
Citr
ullu
s col
ocyn
this
(L.)
Schr
ad.
Fres
h pe
eled
unrip
e fru
it of
Citr
ullu
s col
ocyn
this
(L.)
Schr
ad.
with
out s
eeds
HAB
33a
Berb
eris/
Cheli
doni
um co
mp.
; Ch
elido
nium
/Col
ocyn
this;
Col
ocyn
this
Citr
ullu
s col
ocyn
this
(L.)
Schr
ad.
Drie
d pe
eled
frui
t of C
itrul
lus c
oloc
ynth
is (L
.) Sc
hrad
. with
out
seed
sH
ABPh
.Eur
. 1.1
.8 (e
than
ol
90%
)Co
locy
nthi
s
Citr
us li
mon
(L.)
Burm
an fi
l.Es
sent
ial o
il ob
tain
ed b
y sui
tabl
e mec
hani
cal m
eans
, with
out t
he
aid
of h
eat,
from
the f
resh
pee
l of C
itrus
lim
on (L
.) Bu
rman
fil.
Ph.E
ur.
API
Citri
aeth
erol
eum
; Sili
cea c
ollo
idal
is co
mp.
; Spi
ritus
cont
ra tu
ssim
; Spi
ritus
M
eliss
ae co
mp.
Citr
us li
mon
(L.)
Burm
an fi
l.Fr
esh
pres
sed
juice
from
the f
ruit
of C
itrus
lim
on (L
.) Bu
rman
fil.
API
Arge
ntum
/Que
rcus
com
p.; C
itrus
/Cy
doni
a; Fl
ores
Sam
buci
com
p./Q
uarz
; Lo
tio P
runi
com
p.
Citr
us li
mon
(L.)
Burm
an fi
l.Fr
esh
frui
t of C
itrus
lim
on (L
.) Bu
rman
fil.
HAB
33c
, API
, see
also
Ap
p. 2
.7: C
itrus
lim
on,
Fruc
t. re
c. 1:
0.41
Citr
us/C
ydon
ia
Citr
us m
edic
a var
. lim
onum
see C
itrus
lim
on (L
.) Bu
rman
fil.
Clad
ina r
angi
ferin
a (L.
) Nyl
. (C
lado
nia r
angi
ferin
a (L.
) Web
.)D
ried
thal
lus o
f Cla
dina
rang
iferin
a (L.
) Nyl
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%);
extra
ctio
n wi
th
wate
r (to
geth
er w
ith
othe
r ing
redi
ents)
Lich
enes
com
p.
Clad
onia
rang
iferin
ase
e Cla
dina
rang
iferin
a
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
98
Clav
icep
s pur
pure
a (Fr
.) Tu
l.D
ried
scler
otum
of C
lavic
eps p
urpu
rea (
Frie
s) T
ulas
ne, g
rown
on
rye p
lant
s (Se
cale
cere
ale L
.) an
d dr
ied
at a
tem
pera
ture
not
ex
ceed
ing
40°C
HAB
Ph.E
ur. 1
.1.8
(Eth
anol
70
%),
HAB
35b
Arge
ntum
/Sec
ale;
Blei
glan
z/Se
cale
com
p.; G
alen
it/Re
tina c
omp.
; Hyd
rasti
s co
mp.
; Qua
rz/S
ecal
e; Re
tina/
Seca
le co
mp.
Clem
atis
rect
a L.
Fres
h, yo
ung
leafy
bra
nche
s of C
lemat
is re
cta L
., col
lecte
d at
flo
werin
g tim
ePh
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)
Clem
atis
rect
a L.
Fres
h ae
rial p
arts
of o
f Clem
atis
rect
a L., c
ollec
ted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.5
Vade
mec
um:
Clem
atis
rect
a
Cnic
us b
ened
ictu
s L.
Fres
h ae
rial p
arts
of C
nicu
s ben
edic
tus L
., col
lecte
d at
flow
erin
g tim
eH
ABPh
.Eur
. 1.1
.3, 1
.2.1
1,
HAB
33d
Bora
go co
mp.
; Car
duus
ben
edic
tus/
Paeo
nia o
ffici
nalis
Cocc
ulus
see A
nam
irta c
occu
lus W
ight
et A
rn.
Coch
learia
arm
orac
iase
e Arm
orac
ia ru
stica
na P
h. G
ärtn
., B. M
ey. e
t Sch
erb.
Coch
learia
offi
cina
lis L
.Fr
esh
aeria
l par
ts of
Coc
hlea
ria o
ffici
nalis
L., c
ollec
ted
at th
e sta
rt
of fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
45%
), H
AB 2
1,
33b
Basil
icum
com
p.; C
ochl
earia
offi
cina
lis;
Torm
entil
la co
mp.
; Tro
paeo
lum
com
p.
Coch
learia
offi
cina
lis L
.D
ried
aeria
l par
ts of
Coc
hlea
ria o
ffici
nalis
L., c
ollec
ted
at th
e be
ginn
ing
of th
e flow
erin
g tim
eAP
ICo
chlea
ria o
ffici
nalis
; Lev
istic
um
com
p.
Coffe
a ara
bica
L.
Drie
d, ro
aste
d se
eds o
f Coff
ea ar
abic
a L.
Ph.E
ur. 1
.2.1
2 (e
than
ol
18%
)Av
ena s
ativ
a com
p.; C
upru
m
sulfu
ricum
com
p.; Z
incu
m
valer
iani
cum
com
p.
Coffe
a ara
bica
L.
Ripe
, drie
d, u
nroa
sted
seed
s of C
offea
arab
ica L
. with
the s
eed
coat
(silv
er sk
in) l
arge
ly re
mov
edH
ABPh
.Eur
. 1.1
.8 (e
than
ol
70%
), Ph
.Helv
.17.
7.4.
2/AP
C 4.
2
Colch
icum
autu
mna
le L.
Fres
h co
rms o
f Col
chic
um au
tum
nale
L., c
ollec
ted
at fl
ower
ing
time a
nd fr
ee fr
om fi
brou
s roo
tsH
ABPh
.Eur
. 1.1
.3, 1
.2.4
, HAB
21
Apis
com
p.; C
olch
icum
; Col
chic
um
com
p.; C
olch
icum
/Sab
ina;
Colch
icum
/Sp
ongi
a com
p.
Colch
icum
autu
mna
le L.
Fres
h wh
ole,
flowe
ring
plan
t of C
olch
icum
autu
mna
le L.
HAB
34c
Colch
icum
; Col
chic
um/C
helid
oniu
m
Colo
cynt
his
see C
itrul
lus c
oloc
ynth
is (L
.) Sc
hrad
.
Com
mip
hora
mol
mol
Eng
ler
and/
or o
ther
spec
ies
Gum
-res
in, h
arde
ned
in ai
r, ob
tain
ed b
y inc
ision
or p
rodu
ced
by
spon
tane
ous e
xuda
tion
from
the s
tem
and
bran
ches
of
Com
mip
hora
mol
mol
Eng
ler an
d/or
oth
er sp
ecie
s of
Com
mip
hora
.
Ph.E
ur.
Myr
rhae
tinc
tura
Ph.
Eur.
Auru
m co
mp.
; Aur
um/E
piph
ysis
com
p.;
Auru
m/H
ypop
hysis
com
p.; C
erat
um
Rata
nhia
e com
p.; R
atan
hia c
omp.
; Re
sina L
aric
is/So
lutio
Myr
rhae
ba
lsam
ica;
Salv
ia co
mp.
; Sol
utio
M
yrrh
ae b
alsa
mic
a
Coni
um m
acul
atum
L.
Fres
h flo
werh
eads
of C
oniu
m m
acul
atum
L., c
ollec
ted
at th
e end
of
flow
erin
g tim
ePh
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Ré
perto
ire d
e méd
. an
thr.
(201
0)
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
99
Coni
um m
acul
atum
L.
Fres
h, ae
rial p
arts
of th
e flow
erin
g, b
ut n
ot ye
t fru
iting
spec
imen
s of
Con
ium
mac
ulat
um L
.H
ABPh
.Eur
. 1.1
.3Co
nium
mac
ulat
um
Conv
alla
ria m
ajalis
L.
Fres
h ae
rial p
arts
of C
onva
llaria
maja
lis L
., col
lecte
d at
flow
erin
g tim
eH
ABPh
.Eur
. 1.1
.5, 1
.2.3
Conv
alla
ria; O
nopo
rdon
com
p./
Olea
nder
/ Con
valla
ria; S
cilla
com
p.
Conv
alla
ria m
ajalis
L.
Fres
h wh
ole,
flowe
ring
plan
ts of
Con
valla
ria m
ajalis
L.
HAB
33c
Adon
is/Sc
illa c
omp.
; Con
valla
ria/
Prim
ula c
omp.
Conv
alla
ria m
ajalis
L.
Fres
h flo
wers
with
ped
icels
of C
onva
llaria
maja
lis L
.Ph
.Eur
. 1.1
.7 w
ith
exte
nsio
n: d
urin
g th
e pr
escr
ibed
mac
erat
ion
time t
he m
ixtu
re is
ex
pose
d fo
r 3 d
ays t
o su
nlig
ht fi
ltere
d th
roug
h a s
atur
ated
solu
tion
of
alum
.
Conv
alla
ria
Coria
ndru
m sa
tivum
L.
Drie
d cr
emoc
arp
of C
oria
ndriu
m sa
tivum
L.
Ph.E
ur.
Dist
illat
ion
(toge
ther
wi
th o
ther
ingr
edie
nts)
Spiri
tus c
ontra
tuss
im; S
pirit
us M
eliss
ae
com
p.
Crat
aegu
s lae
viga
ta (P
oir.)
DC.
, Cr
atae
gus m
onog
yna J
acq.
em
end.
Lin
dm.
Fres
h lea
ves a
nd ri
pe fr
uit o
f Cra
taeg
us la
evig
ata (
Poir.
) DC.
and
Crat
aegu
s mon
ogyn
a Jac
q. em
end.
Lin
dman
HAB
33d
Adon
is co
mp.
; Ado
nis/
Scill
a com
p.;
Arni
ca/C
actu
s com
p.; A
urum
/Val
eria
na
com
p.; C
actu
s/M
eliss
a com
p.; C
or/
Crat
aegu
s com
p.; C
rata
egus
; Cra
taeg
us/
Visc
um; P
assifl
ora c
omp.
Crat
aegu
s lae
viga
ta (P
oir.)
DC.
, Cr
atae
gus m
onog
yna J
acq.
em
end.
Lin
dm.
Fres
h rip
e fru
its o
f Cra
taeg
us la
evig
ata (
Poir)
DC.
, Cra
taeg
us
mon
ogyn
a Jac
q. em
end.
Lin
dm., t
heir
hybr
ids a
nd m
ixtu
res
ther
eof
HAB
See M
onog
raph
HAB
(P
h.Eu
r. 1.
1.3)
, Ph.
Eur.
1.2.
4, 1
.2.5
; aqu
eous
ex
tract
with
sucr
ose a
nd
citric
acid
(3:4
.95:
2:0.
05)
Auru
m/C
rata
egus
; Cac
tus/
Crat
aegu
s; Ca
ctus
/Cra
taeg
us co
mp.
; Cac
tus/
Mag
nesiu
m p
hosp
horic
um; C
arbo
Be
tula
e/Cr
atae
gus;
Crat
aegu
s; Cr
atae
gus c
omp.
; Cra
taeg
us/F
erru
m
sider
eum
/Sac
char
um to
stum
; Cr
atae
gus/
Kalm
ia; C
rata
egus
/Pru
nus
com
p.; H
yper
icum
/Pas
siflor
a com
p.;
Ono
pord
on co
mp.
/Olea
nder
/ Arn
ica;
Ono
pord
on co
mp.
/Olea
nder
/ Co
nval
laria
Crat
aegu
s lae
viga
ta (P
oir.)
DC.
, Cr
atae
gus m
onog
yna J
acq.
em
end.
Lin
dm.
Drie
d lea
ves o
f Cra
taeg
us m
onog
yna J
acq.
(Lin
dm.),
C. l
aevi
gata
(P
oir.)
DC.
(syn
. C. o
xyac
anth
oide
s Thui
ll.; C
. oxy
acan
tha a
uct.)
or
thei
r hyb
rids o
r, m
ore r
arely
, oth
er E
urop
ean
Crat
aegu
s spe
cies
inclu
ding
C. p
enta
gyna
Wal
dst.
et K
it. ex
Will
d., C
. nig
ra W
alds
t. et
Kit.
and
C. az
arol
us L
Extra
ctio
n wi
th et
hano
l 36
% (D
ER 1
:1.5
-2.5
)Cr
atae
gus
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
100
Crat
aegu
s lae
viga
ta (P
oir.)
DC.
, Cr
atae
gus m
onog
yna J
acq.
em
end.
Lin
dm. a
nd o
ther
Who
le or
cut,
drie
d flo
wer-
bear
ing
bran
ches
of C
rata
egus
m
onog
yna J
acq.
(Lin
dm.),
C. l
aevi
gata
(Poi
r.) D
C. (s
yn.
C.ox
yaca
ntho
ides
Thui
ll.; C
. oxy
acan
tha a
uct.)
or t
heir
hybr
ids o
r, m
ore r
arely
, oth
er E
urop
ean
Crat
aegu
s spe
cies
inclu
ding
C.
pent
agyn
a Wal
dst.
et K
it. ex
Will
d., C
. nig
ra W
alds
t. et
Kit.
and
C.
azar
olus
L.
Ph.E
ur.
Ph.E
ur. 1
.2.1
3Cr
atae
gus
Croc
us sa
tivus
L.
Drie
d sti
gmas
of C
rocu
s sat
iva L
., usu
ally
join
ed b
y the
bas
e to
a sh
ort s
tyle.
(HAB
); Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
90%
acc.
to H
AB),
1.1.
10
(eth
anol
80%
); et
hano
lic
extra
ct 1
:20
(see
App
. 2.
6: K
aliu
m ac
etic
um
com
p.)
Anag
allis
/Mal
achi
t com
p.;
Cham
omill
a/M
alac
hit c
omp.
; Kal
ium
ac
etic
um co
mp.
Cucu
rbita
pep
o L.
Fres
h flo
wers
of C
ucur
bita
pep
o L.
Ph.E
ur. 1
.1.7
, 4.2
.1Ap
atit/
Conc
hae;
Apat
it/Ph
osph
orus
co
mp.
; Con
chae
/Fer
rum
ustu
m co
mp.
Cucu
rbita
max
ima D
uch.
Drie
d pu
lp o
f pum
pkin
s of C
ucur
bita
max
ima D
uch.
API
Vade
mec
um:
Cheli
doni
um/
Curc
uma c
omp.
Curc
uma z
anth
orrh
iza R
oxb.
(s
yn. C
. zan
thor
rhiz
a D.
Die
trich
).
Drie
d rh
izom
e, cu
t in
slice
s, of
Cuc
urm
a zan
thor
rhiz
a Rox
b. (s
yn.
C. za
ntho
rrhi
za D
. Die
trich
).Ph
.Eur
.Ph
.Eur
. 1.2
.12
(eth
anol
70
%),
also
API
Cheli
doni
um/C
urcu
ma
Cydo
nia o
blon
ga M
ill.
Fres
h rip
e fru
its o
f Cyd
onia
obl
onga
Mill
.AP
Cex
tract
acco
rdin
g to
m
onog
raph
s APC
, HAB
33
b
Citr
us/C
ydon
ia; C
ydon
ia, F
ruct
us;
Flor
es S
ambu
ci co
mp.
/Qua
rz
Cym
bopo
gon
wint
eria
nus J
owitt
Oil
obta
ined
by s
team
dist
illat
ion
from
the f
resh
or p
artia
lly d
ried
aeria
l par
ts of
Cym
bopo
gon
wint
eria
nus J
owitt
.Ph
.Eur
.H
AB 1
2hCi
trone
llae a
ethe
roleu
m; Th
ymus
se
rpyl
lum
com
p.
Cyna
ra sc
olym
us L
.Fr
esh
leave
s of C
ynar
a sco
lym
us L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
55%
)Ré
perto
ire d
e méd
. an
thr.
(201
6)
Cytis
us sc
opar
ius (
L.) L
ink.
Fres
h yo
ung
tips o
f sho
ots o
f Cyt
isus s
copa
rius (
L.) L
ink.
with
flo
wers
and
leave
sPh
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Ré
perto
ire d
e méd
. an
thr.
(201
0)
Cytis
us sc
opar
ius (
L.) L
ink.
Fres
h ae
rial p
arts
of C
ytisu
s sco
pariu
s (L.
) Lin
k at
flow
erin
g tim
eH
AB 3
3cSa
roth
amnu
s com
p.; S
cilla
com
p.
Dap
hne m
ezer
eum
L.
Fres
h ba
rk fr
om th
e bra
nche
s of D
aphn
e mez
ereu
m L
., col
lecte
d pr
ior t
o flo
werin
gH
ABPh
.Eur
. 1.1
.5M
ezer
eum
Dat
ura s
tram
oniu
m L
.Fr
esh
aeria
l par
ts of
Dat
ura s
tram
oniu
m L
., col
lecte
d at
flow
erin
g tim
eH
AB; P
h.fr.
Ph.E
ur. 1
.1.3
, 1.1
.10
(see
m
onog
raph
: eth
anol
45
%),
HAB
21
Myg
ale c
omp.
; Stra
mon
ium
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
101
Delp
hini
um st
aphi
sagr
ia L
.D
ried
ripe s
eeds
of D
elphi
nium
stap
hisa
gria
L.
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
90
%),
1.1.
10 (e
than
ol
65%
)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Dig
italis
pur
pure
a L.
Fres
h lea
ves f
rom
two-
year
-old
spec
imen
s of D
igita
lis p
urpu
rea
L., c
ollec
ted
befo
re fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.3
, 1.2
.4D
igita
lis p
urpu
rea
Dol
ichos
pru
riens
see M
ucun
a pru
riens
(L.)
DC.
Dro
sera
rotu
ndifo
lia L
., Dro
sera
in
term
edia
Hay
ne, D
rose
ra
angl
ica H
uds
Who
le dr
ied
plan
ts of
diff
eren
t Dro
sera
spec
ies,
mai
nly D
rose
ra
rotu
ndifo
lia L
., Dro
sera
angl
ica H
uds.
(D. l
ongi
folia
L.),
Dro
sera
m
adag
asca
riens
is D
C, D
rose
ra p
eltat
a Sm
, Dro
sera
ram
enta
cea
Burc
h. ex
har
v. et
Son
d., s
ingl
e spe
cies o
r mix
ed
Ph.fr
.Ph
.Eur
. 1.1
.3, 1
.1.1
0 (e
than
ol 4
5%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Dro
sera
rotu
ndifo
lia L
., Dro
sera
in
term
edia
Hay
ne, D
rose
ra
angl
ica H
uds.
Who
le fre
sh p
lant
s of D
rose
ra ro
tund
ifolia
L., D
rose
ra in
term
edia
H
ayne
and
Dro
sera
angl
ica H
uds.,
sing
le sp
ecie
s or m
ixed
, co
llect
ed at
the s
tart
of fl
ower
ing
HAB
Ph.E
ur. 1
.1.3
, HAB
33c
Dro
sera
/Ipec
acua
nha c
omp.
; Pla
ntag
o co
mp.
; Siru
pus Th
ymi c
omp.
Dry
opte
ris fi
lix-m
as (L
.) Sc
hott.
Fres
h rh
izom
e of D
ryop
teris
filix
-mas
(L.)
Scho
tt, w
ith ro
ots
HAB
33c
Aqui
linum
com
p.; C
helid
oniu
m co
mp.
; Co
ncha
e com
p.; R
hus/
Salix
com
p.
Dry
opte
ris fi
lix-m
as (L
.) Sc
hott.
Fres
h ae
rial p
arts
of D
ryop
teris
filix
-mas
(L.)
Scho
tt.AP
C 3.
8.1
(toge
ther
with
ot
her f
resh
her
bal d
rugs
1:
4.1
part
s eth
anol
25%
), 3.
8.2
Aspi
dium
/Sal
ix co
mp.
; Che
lidon
ium
co
mp.
Dry
opte
ris fi
lix-m
as (L
.) Sc
hott.
Ripe
spor
es o
f Dry
opte
ris fi
lix-m
as (L
.) Sc
hott.
Ph.E
ur. 1
.1.8
(eth
anol
70
%)
Agar
icus
com
p./P
hosp
horu
s
Dul
cam
ara
see S
olan
um d
ulca
mar
a L.
Echi
nace
a ang
ustif
olia
DC.
(R
udbe
ckia
angu
stifo
lia L
.)W
hole
fresh
flow
erin
g pl
ants
of E
chin
acea
angu
stifo
lia D
C.H
ABPh
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 5
5%),
HAB
21,
33
c
Arge
ntum
/Ech
inac
ea; A
rgen
tum
/Q
uerc
us co
mp.
; Arn
ica/
Echi
nace
a co
mp.
; Cha
mom
illa c
omp.
; Ech
inac
ea;
Echi
nace
a com
p.
Echi
nace
a ang
ustif
olia
DC.
, Ec
hina
cea p
allid
a (N
utt.)
Nut
t.W
hole
fresh
flow
erin
g pl
ants
of E
chin
acea
angu
stifo
lia D
C. an
d Ec
hina
cea p
allid
a (N
utt.)
Nut
t., si
ngle
spec
ies o
r mix
edH
ABPh
.Eur
. 1.1
.5, H
AB 3
3cAr
gent
um/E
chin
acea
; Cal
endu
la
Pres
ssaft
/Ech
inac
ea; E
uphr
asia
com
p.
Echi
nace
a pal
lida (
Nut
t.) N
utt.
Fres
h flo
werin
g pl
ants
of E
chin
acea
pal
lida (
Nut
t.) N
utt.
HAB
HAB
33c
Antim
onit/
Rosa
e aet
hero
leum
com
p.;
Arge
ntum
nitr
icum
com
p.; C
artil
ago/
Echi
nace
a com
p.; C
onju
nctiv
a com
p.;
Echi
nace
a; Ec
hina
cea/
Para
met
rium
co
mp.
; Ech
inac
ea/Q
uarz
com
p.;
Echi
nace
a/Ro
sae a
ethe
roleu
m;
Echi
nace
a/Vi
scum
; End
omet
rium
co
mp.
; Majo
rana
/Thuj
a com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
102
Echi
nace
a pal
lida (
Nut
t.) N
utt.
Fres
h ae
rial p
arts
of E
chin
acea
pal
lida (
Nut
t.) N
utt.,
colle
cted
at
flowe
ring
time
HAB
12c
Calen
dula
/Ech
inac
ea co
mp.
; Ca
lendu
la/T
ropa
eolu
m co
mp.
; Ec
hina
cea;
Echi
nace
a/Vi
scum
com
p.
Echi
nace
a pal
lida (
Nut
t.) N
utt.
Fres
h un
derg
roun
d pa
rts o
f Ech
inac
ea p
allid
a (N
utt.)
Nut
t.H
AB 3
3dAr
gent
um/E
chin
acea
; Ech
inac
ea/
Mer
curiu
s com
p.
Echi
nace
a pur
pure
a (L.
) Moe
nch
Who
le fre
sh fl
ower
ing
plan
ts of
Ech
inac
ea p
urpu
rea (
L.) M
oenc
hH
ABPh
.Eur
. 1.1
.6Ar
nica
/Ech
inac
ea co
mp.
; Cal
endu
la/
Echi
nace
a pur
pure
a; Ch
amom
illa
com
p.; E
chin
acea
; Ech
inac
ea/P
runu
s co
mp.
Echi
nace
a pur
pure
a (L.
) Moe
nch
Fres
h flo
wers
of E
chin
acea
pur
pure
a (L.
) Moe
nch
Ph.E
ur. 1
.1.5
Echi
nace
a
Elym
us re
pens
(L.)
Gou
ldFr
esh
unde
rgro
und
part
s of E
lym
us re
pens
(L.)
Gou
ldH
ABPh
.Eur
. 1.1
.5Ag
ropy
ron
com
p.
Equi
setu
m ar
vens
e L.
Fres
h, g
reen
, ste
rile s
hoot
s of E
quise
tum
arve
nse L
.H
ABH
AB 1
2c, 2
1 (s
ee
mon
ogra
ph),
35b
Arni
ca, P
lant
a tot
a/Eq
uise
tum
arve
nse;
Auru
m/E
quise
tum
; Can
thar
is co
mp.
; D
isci c
omp.
cum
Nic
otia
na; D
isci
com
p. cu
m P
ulsa
tilla
; Disc
i com
p. cu
m
Stan
no; D
isci/P
ulsa
tilla
com
p. cu
m
Stan
no; D
isci/V
iscum
com
p. cu
m
Stan
no; E
quise
tum
arve
nse;
Equi
setu
m
arve
nse S
ilice
a cul
tum
; Equ
isetu
m
arve
nse/
Form
ica;
Equi
setu
m/S
tann
um;
Man
drag
ora c
omp.
; Sol
um u
ligin
osum
co
mp.
Equi
setu
m ar
vens
e L.
Who
le or
cut,
drie
d ste
rile a
eria
l par
ts of
Equ
isetu
m ar
vens
e L.
HAB
; Ph
.Eur
.Ph
.Eur
. 1.2
.12,
HAB
12d
, 12
g, ex
tract
ion
with
gl
ycer
ol, A
PC 4
.2, 4
.3
Aesc
ulus
/Cer
a com
p.; C
arbo
Equ
iseti
arve
nsis;
Car
bone
s/Pa
nkre
as/W
ither
it;
Equi
setu
m ar
vens
e; Eq
uise
tum
arve
nse/
Form
ica;
Equi
setu
m ar
vens
e/Ta
bacu
m;
Equi
setu
m co
mp.
; Equ
isetu
m cu
m
Sulfu
re to
stum
; Equ
isetu
m/P
ancr
eas;
Equi
setu
m/R
enes
com
p.; E
quise
tum
/St
annu
m; E
quise
tum
/Visc
um; L
ens
crist
allin
a/Vi
scum
com
p. cu
m St
anno
; Li
en co
mp.
; Man
drag
ora c
omp.
; Sol
um
ulig
inos
um co
mp.
Equi
setu
m fl
uvia
tile
see E
quise
tum
lim
osum
Equi
setu
m li
mos
um L
.Fr
esh
aeria
l par
ts of
Equ
isetu
m li
mos
um L
.St
artin
g m
ater
ial f
or th
e pr
epar
atio
n of
Eq
uise
tum
lim
osum
-Ru
belli
t (ap
p. 2
.6)
Sold
ner/
Stell
man
n (2
011)
Indi
vidu
elle
Pädi
atrie
Eryt
hrae
a cen
taur
ium
see C
enta
uriu
m er
ythr
aea R
afn.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
103
Esch
scho
lzia c
alifo
rnic
a Cha
m.
Who
le fre
sh fl
ower
ing
plan
ts of
Esc
hsch
olzi
a cal
iforn
ica C
ham
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
45%
)
Euca
lypt
us g
lobu
lus L
abill
.Es
sent
ial o
il ob
tain
ed b
y ste
am d
istill
atio
n an
d re
ctifi
catio
n fro
m
the f
resh
leav
es o
r the
fres
h te
rmin
al b
ranc
hlet
s of v
ario
us sp
ecie
s of
Euc
alyp
tus r
ich in
1,8
-cin
eole.
The s
pecie
s mai
nly u
sed
are
Euca
lypt
us g
lobu
lus L
abill
., Euc
alyp
tus p
olyb
ract
ea R
.T.B
aker
and
Euca
lypt
us sm
ithii
R.T.
Bake
r.
Ph.E
ur.
API
Arge
ntum
/Que
rcus
com
p.; B
erbe
ris/
Euca
lypt
us/ S
ilice
a com
p.; B
erbe
ris/
Juni
peru
s com
p.; C
erat
um R
atan
hiae
co
mp.
; Ech
inac
ea/P
runu
s com
p.;
Euca
lypt
i aet
hero
leum
; Euc
alyp
ti ae
ther
oleu
m co
mp.
; Euc
alyp
tus c
omp.
; M
ajora
na/Th
uja c
omp.
; Mer
curiu
s vi
vus/
Euc
aply
ti ae
ther
oleu
m; O
leum
ca
mph
orat
um co
mp.
; Oleu
m rh
inal
e; Pl
anta
go co
mp.
; Rat
anhi
a com
p.;
Salv
iae a
ethe
roleu
m co
mp.
Euca
lypt
us g
lobu
lus L
abill
.Fr
esh
leave
s of E
ucal
yptu
s glo
bulu
s Lab
ill.
HAB
33d
Acon
itum
/Chi
na co
mp.
; Arg
entu
m
nitri
cum
com
p.; C
alen
dula
/Ech
inac
ea
com
p.; C
upru
m su
lfuric
um/E
ucal
yptu
s
Euca
lypt
us g
lobu
lus L
abill
.W
hole
or cu
t, dr
ied
leave
s of o
lder
bra
nche
s of E
ucal
yptu
s gl
obul
us L
abill
.(H
AB);
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
90
%)
Bolu
s Euc
alyp
ti co
mp.
; Bry
onia
/Eu
pato
rium
com
p.; F
erru
m
phos
phor
icum
com
p.
Euge
nia c
aryo
phyl
lata
see S
yzyg
ium
arom
atic
um (L
.) M
err.
et L
. M. P
erry
Eupa
toriu
m ca
nnab
inum
L.
Fres
h flo
werin
g ae
rial p
arts
of E
upat
oriu
m ca
nnab
inum
L.
HAB
33c
Acon
itum
/Chi
na co
mp.
; Bro
nchi
/Pl
anta
go co
mp.
Eupa
toriu
m p
erfo
liatu
m L
.Fr
esh
aeria
l par
ts of
Eup
ator
ium
per
folia
tum
L., c
ollec
ted
at st
art
of fl
ower
ing
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 6
5%)
Bryo
nia/
Eupa
toriu
m co
mp.
; Fer
rum
ph
osph
oric
um co
mp.
Euph
rasia
stric
ta D
. Wol
ff ex
F.J.
Lehm
. and
/or E
uphr
asia
ro
stkov
iana
Hay
ne
Who
le, fr
esh,
flow
erin
g pl
ants
of E
uphr
asia
stric
ta D
. Wol
ff ex
F.J.
Lehm
. and
/or E
uphr
asia
rostk
ovia
na H
ayne
and/
or th
eir h
ybrid
s an
d/or
thei
r mix
ture
s
Ph.fr
.Ph
.Eur
. 1.1
.10
(Eth
anol
55
%)
Répe
rtoire
de m
éd.
anth
r. (2
016)
Euph
rasia
stric
ta W
olff
ex F.
J. Le
hm. a
nd E
uphr
asia
offi
cinal
is L.
su
bsp.
rostk
ovia
na (H
ayne
) To
wns
Who
le fre
sh p
lant
s of E
uphr
asia
stric
ta W
olff
ex F.
J. Le
hm. a
nd
Euph
rasia
offi
cinal
is L.
subs
p. ro
stkov
iana
(Hay
ne) T
owns
, the
ir hy
brid
s and
mix
ture
s the
reof
, col
lecte
d at
flow
erin
g tim
e
HAB
Ph.E
ur. 1
.1.5
, 1.1
.7 (H
AB
3c),
33c
Euph
rasia
; Eup
hras
ia co
mp.
; Eup
hras
ia/
Rosa
e aet
hero
leum
Fagu
s syl
vatic
a L.
Bran
ch an
d tr
unk
wood
of F
agus
silv
atic
a L.
Ph.H
elv. 1
7.7.
4.3
(APC
4.
3); r
aw m
ater
ial f
or th
e pr
epar
atio
n of
Kal
ium
ca
rbon
icum
e Fa
gi (a
pp.
2.4)
Agro
pyro
n co
mp.
; Ana
galli
s com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
104
Fagu
s syl
vatic
aW
ood
of F
agus
sylv
atic
aRa
w m
ater
ial f
or th
e pr
epar
atio
n of
Kal
ium
ca
rbon
icum
e ci
nere
Fag
i (a
pp. 2
.4)
Feru
la as
sa-fo
etid
a L.
Drie
d gu
m re
sin fr
om F
erul
a spe
cies
such
as F
erul
a ass
a-fo
etid
a L.
and
Feru
la fo
etid
a (Bu
nge)
Reg
el. (A
sa fo
etid
a)H
ABPh
.Eur
. 1.1
.8 (e
than
ol
90%
)
Filip
endu
la u
lmar
ia (L
.) M
axim
.Fr
esh
aeria
l par
ts of
Fili
pend
ula u
lmar
ia (L
.) M
axim
. col
lecte
d at
flo
wein
g tim
e.H
ABPh
.Eur
. 1.1
.5, H
AB 3
4cBe
tula
/Man
drag
ora c
omp.
Filix
-mas
see D
ryop
teris
filix
-mas
(L.)
Scho
tt.
Foen
icul
um vu
lgar
e Mill
.Es
sent
ial o
il ob
tain
ed b
y ste
am d
istill
atio
n fro
m th
e rip
e fru
its o
f Fo
enic
ulum
vulg
are M
iller
ssp.
vulg
are v
ar. v
ulga
re.
Ph.E
ur.
API
Berb
eris/
Juni
peru
s com
p.; M
eliss
a co
mp.
; Sal
viae
aeth
erol
eum
com
p.;
Trop
aeol
um co
mp.
Foen
icul
um vu
lgar
eD
ried
crem
ocar
ps an
d m
eric
arps
of F
oeni
culu
m vu
lgar
e Mill
. sp.
vu
lgar
e var
. vul
gare
HAB
; Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
90%
), 1.
2.12
(eth
anol
70
%),
API
Spec
ies C
arvi
com
p.
Frag
aria
vesc
a L.
Fres
h, ri
pe fa
lse-fr
uits
of F
raga
ria ve
sca L
HAB
21,
extra
ct w
ith
etha
nol (
66%
m/m
) and
su
cros
e 3:2
(DER
1:0
,9)
Aqua
Mar
is co
mp.
; Fra
garia
/Urt
ica;
Frag
aria
/Urt
ica c
omp.
; Fra
garia
/Urt
ica/
Gen
tiana
; Lev
istic
um co
mp.
Frag
aria
vesc
a L.
Drie
d, w
hole
or cu
t lea
ves,
colle
cted
at fl
ower
ing
time o
f Fra
garia
ve
sca L
., Fra
garia
mos
chat
a Wes
t., F
raga
ria vi
ridis
Wes
t., F
raga
ria
x an
anas
sa (D
uch.
) Gue
des (
Rosa
ceae
), th
eir h
ybrid
s as w
ell as
hy
brid
s with
oth
er F
raga
ria sp
ecie
s or m
ixtu
res o
f the
m
DAC
API
Conc
hae/
Ferr
um u
stum
com
p.;
Frag
aria
/Urt
ica c
omp.
; Fra
garia
/Viti
s; Vi
tis co
mp.
Fran
gula
alnu
sse
e Rha
mnu
s fra
ngul
a L.
Fucu
s ves
icul
osus
L.
Fres
h th
allu
s of F
ucus
vesic
ulos
us L
.H
AB 5
1Tr
opae
olum
com
p.
Fum
aria
offi
cina
lis L
.Fr
esh
aeria
l par
ts of
Fum
aria
offi
cina
lis L
., col
lecte
d at
flow
erin
g tim
eH
ABH
AB 1
.1.3
, 33c
Trop
aeol
um co
mp.
Vade
mec
um
(com
bina
tion
see
Hip
poca
mpu
s)
Gal
anth
us n
ival
is L.
Fres
h wh
ole fl
ower
ing
plan
t of G
alan
thus
niv
alis
L.Ph
.Eur
. 1.1
.6Va
dem
ecum
(see
H
ippo
cam
pus)
Que
rcus
infe
ctor
ia O
livie
rO
ak ap
ples
pro
duce
d on
youn
g sh
oots
of Q
uerc
us in
fect
oria
O
livie
r by t
he st
ing
of th
e dye
rs g
all w
asp
Andr
icus
gal
lae
tinct
oria
e Oliv
ier
HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%)
Gels
emiu
m se
mpe
rvire
ns (L
.) Ja
ume S
t.-H
il.Fr
esh
unde
rgro
und
part
s of G
elsem
ium
sem
perv
irens
(L.)
Jaum
e St
.-Hil.
HAB
Ph.E
ur. 1
.1.5
, 1.2
.9, H
AB
35b
Apis
com
p.; B
ryon
ia/G
elsem
ium
com
p.;
Gels
emiu
m; O
xalis
com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
105
Gels
emiu
m se
mpe
rvire
ns (L
.) Ja
ume S
t.-H
il.D
ried
unde
rgro
und
part
s of G
elsem
ium
sem
perv
irens
(L.)
Jaum
e St
.-Hil.
Ph.E
ur. 2
.1.1
2 (e
than
ol
70%
), H
AB 3
5bD
isci/R
hus t
oxico
dend
ron
com
p.;
Gels
emiu
m; G
elsem
ium
com
p.; R
hus
toxi
code
ndro
n co
mp.
Gen
ista s
copa
riase
e Cyt
isus s
copa
rius (
L.) L
ink.
Gen
tiana
lute
a L.
Fres
h un
derg
roun
d pa
rts o
f Gen
tiana
lute
a L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 5
5%),
1.2.
10,
HAB
21,
33c
Achi
llea c
omp.
; Bol
us al
ba co
mp.
; Ci
chor
ium
/Tar
axac
um co
mp.
; Gen
tiana
lu
tea;
Nux
vom
ica c
omp.
Gen
tiana
lute
a L.
Drie
d, fr
agm
ente
d un
derg
roun
d or
gans
of G
entia
na lu
tea L
.Ph
.Eur
.Ph
.Eur
. 1.4
.3, a
queo
us
extra
ct (W
ALA)
, APC
4.
2
Aqua
Mar
is co
mp.
; Fra
garia
/Urt
ica/
Gen
tiana
; Gen
tiana
com
p.; G
entia
na/
Zing
iber
com
p.
Ger
ania
ceae
see P
elarg
oniu
m sp
ecie
s
Geu
m u
rban
um L
.Fr
esh
unde
rgro
und
part
s of G
eum
urb
anum
L.
HAB
Ph.E
ur. 1
.2.1
1, H
AB 2
1,
33c
Arte
misi
a com
p.; B
olus
alba
com
p.;
Geu
m u
rban
um
Gin
kgo
bilo
ba L
.Fr
esh
leave
s of G
inkg
o bi
loba
L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (E
than
ol 6
5%)
Gin
seng
see P
anax
gin
seng
C.A
. Mey
.
Glec
hom
a hed
erac
ea L
.D
ried
flowe
ring
plan
t of G
lecho
ma h
eder
acea
L.
Ph.H
elv. 1
7.7.
4.3
(APC
4.
3)Ci
nis G
lecho
mat
is
Gna
phal
ium
see L
eont
opod
ium
alpi
num
Cas
s.
Gos
sypi
um L
., G. h
irsut
um L
.D
ried
seed
s, de
void
of fi
bres
, of G
ossy
pium
her
bace
um L
. or G
. hi
rsut
um L
.M
acer
atio
n 1:
3 wi
th
etha
nol 7
3% m
/m (8
0%
V/V
)
ABM
A-Va
dem
ecum
Ham
ameli
s virg
inia
na L
.Fr
esh
bark
and
leave
s of H
amam
elis v
irgin
iana
L.
HAB
12c
(bar
k:lea
ves
1:9)
Ham
ameli
s
Ham
ameli
s virg
inia
na L
.Fr
esh
bark
from
root
s and
bra
nche
s of H
amam
elis v
irgin
iana
L.
HAB
Ph.E
ur. 1
.1.5
, HAB
33e
Ham
ameli
s
Ham
ameli
s virg
inia
na L
.Fr
esh
leave
s of H
amam
elis v
irgin
iana
L.
HAB
Ph.E
ur. 1
.1.7
, HAB
33d
Aesc
ulus
/Que
rcus
com
p.; B
orag
o co
mp.
; Ham
ameli
s; Q
uerc
us co
mp.
Ham
ameli
s virg
inia
na L
.Fr
esh
flowe
ring
bran
ches
of H
amam
elis v
irgin
iana
L., c
ollec
ted
in
late a
utum
nH
AB 3
4H
AB 5
2H
amam
elis c
omp.
; Ham
ameli
s de
stilla
ta
Ham
ameli
s virg
inia
na L
.D
ried
bark
from
the s
tem
s and
bra
nche
s of
Ham
ameli
s virg
inia
na L
.H
ABPh
.Eur
. 1.2
.12
(eth
anol
36
%)
Achi
llea c
omp.
; Ham
ameli
s; H
ydra
stis
com
p.; S
ymph
ytum
com
p.
Ham
ameli
s virg
inia
na L
.W
hole
or cu
t, dr
ied
leaf o
f Ham
ameli
s virg
inia
na L
.Ph
.Eur
.Ex
tract
with
etha
nol 3
6%
(DER
1:1
)Ae
scul
us, C
orte
x/ B
orag
o/H
amam
elis,
Foliu
m; C
alen
dula
com
p.; S
tibiu
m
com
p.
Ham
ameli
s virg
inia
na L
.Fr
esh
bark
from
bra
nche
s of H
amam
elis v
irgin
iana
L.
HAB
33e
Hiru
do co
mp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
106
Ham
ameli
s virg
inia
na L
.D
ried
leave
s and
drie
d ba
rk fr
om th
e ste
ms a
nd b
ranc
hes o
f H
amam
elis v
irgin
iana
L.
Dist
illat
e with
etha
nol
12%
(1 p
art e
than
ol 9
6%,
8.7
part
s wat
er)(D
ER
1:15
)
Lotio
Pru
ni co
mp.
Har
pago
phyt
um p
rocu
mbe
ns
(Bur
ch.)
DC
Cut a
nd d
ried,
tube
rous
seco
ndar
y roo
ts of
Har
pago
phyt
um
proc
umbe
ns D
C. an
d/or
Har
pago
phyt
um ze
yher
i Dec
ne.
Ph.E
ur.;
Ph.fr
.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
), 1.
1.10
(eth
anol
45
%),
HAB
35b
Har
pago
phyt
um, R
adix
Répe
rtoire
de m
éd.
anth
r. (2
010)
Heli
anth
us tu
bero
sus L
.Fr
esh
tube
rs o
f Heli
anth
us tu
bero
sus L
., col
lecte
d in
late
autu
mn
HAB
Ph.E
ur. 1
.1.3
Hell
ebor
us fo
etid
us L
.W
hole
fresh
pla
nt co
llect
ed in
sum
mer
and
fresh
flow
erin
g sh
oots
colle
cted
in w
inte
r of H
elleb
orus
foet
idus
L.
Ph.E
ur. 1
.3.1
, see
also
ap
p. 2
.6 (
Hell
ebor
us
foet
idus
)
Der
Mer
kurs
tab
6/20
10 p
. 565
Hell
ebor
us n
iger
L.
Fres
h wh
ole fl
ower
ing
plan
ts of
Hell
ebor
us n
iger
L.
Ph.E
ur. 1
.1.5
, HAB
21,
34
c; fe
rmen
tate
d,
aque
ous e
xtra
ct
Alum
en/H
elleb
orus
com
p.; H
elleb
orus
ni
ger
Hell
ebor
us n
iger
L.
Fres
h wh
ole p
lant
s of H
elleb
orus
nig
er L
.Ph
.Eur
. 1.1
.10
(eth
anol
45
%)
Hell
ebor
us n
iger
Hell
ebor
us n
iger
L.
Who
le fre
sh p
lant
colle
cted
in su
mm
er an
d fre
sh fl
ower
ing
shoo
ts co
llect
ed in
win
ter o
f Hell
ebor
us n
iger
L.
Ph.E
ur. 1
.3.1
; see
also
ap
p. 2
.6 (H
elleb
orus
ni
ger)
Der
Mer
kurs
tab
6/20
10 p
. 500
-566
Helo
nias
dio
ica
see C
ham
aelir
ium
lute
um (L
.) A.
Gra
y
Hip
poph
aë rh
amno
ides
L.
Fres
h fr
uits
of H
ippo
phaë
rham
noid
es L
.pr
essin
g to
obt
ain
the
juic
e (=A
PI)
Hip
poph
aë rh
amno
ides
L.
Fatty
oil
obta
ined
from
the s
eeds
and/
or fr
uit o
f Hip
poph
aë
rham
noid
es L
.AP
I
Hor
deum
vulg
are L
.Ex
tract
obt
aine
d fro
m d
ried
germ
inat
ed fr
uits
of H
orde
um
vulg
are L
. (m
alt)
conv
entio
nal m
etho
d fo
r m
akin
g m
alt
Aven
a/Co
ncha
e com
p.;
Bron
chia
lpas
tillen
; Siru
pus Th
ymi
com
p.
Hum
ulus
lupu
lus L
.Fr
esh
bine
s with
leav
es an
d ho
p co
nes o
f Hum
ulus
lupu
lus L
.H
ABH
AB 3
4d; e
xtra
ct w
ith
wate
r and
sucr
ose (
2:4:
4)Av
ena/
Pass
iflor
a com
p.; H
yper
icum
/Pa
ssifl
ora c
omp.
Hum
ulus
lupu
lus L
Fres
h, ri
pe fe
mal
e infl
ores
cenc
es o
f Hum
ulus
lupu
lus L
., col
lecte
d be
fore
the s
eeds
hav
e rip
ened
and
cont
aini
ng as
few
seed
s as
poss
ible
HAB
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
55%
)Av
ena s
ativ
a com
p.
Hyd
rasti
s can
aden
sis L
.W
hole
or cu
t, dr
ied
rhiz
ome a
nd ro
ot o
f Hyd
rasti
s can
aden
sis L
.Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
), 1.
1.10
(eth
anol
65
% fo
r 3-5
wee
ks)
Calen
dula
com
p.; E
chin
acea
com
p.;
Hyd
rasti
s can
aden
sis; H
ydra
stis c
omp.
; Li
lium
tigr
inum
com
p.
Hyd
roco
tyle
asia
tica
see C
ente
lla as
iatic
a (L.
) Urb
.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
107
Hyo
scya
mus
nig
er L
.Fr
esh
flowe
ring
aeria
l par
ts of
Hyo
scya
mus
nig
er L
.Ph
.Eur
. 1.1
.3, H
AB 2
1,
33d
Arch
ange
lica/
Pyrit
com
p.; A
urum
/O
nopo
rdon
com
p.; C
imici
fuga
com
p.;
Conv
alla
ria/P
rimul
a com
p.; C
rata
egus
co
mp.
; Hyo
scya
mus
; Ono
pord
on
com
p.; O
nopo
rdon
com
p./A
doni
s; O
nopo
rdon
com
p./M
agne
sium
ph
osph
oric
um ac
idum
; Ono
pord
on
com
p./O
leand
er; O
nopo
rdon
com
p./
Olea
nder
/ Arn
ica;
Ono
pord
on co
mp.
/O
leand
er/ C
onva
llaria
; Ono
pord
on
com
p./P
lum
bum
; Ono
pord
um/P
rimul
a co
mp.
; Pla
ntag
o-Pr
imul
a cum
H
yosc
yam
o; P
rimul
a com
p.
Hyo
scya
mus
nig
er L
.W
hole,
fres
h flo
werin
g pl
ants
of H
yosc
yam
us n
iger
L.
Ph.E
ur.
acc.
to m
onog
raph
Ph
.Eur
. or H
AB: P
h.Eu
r. 1.
1.3
Arge
ntum
/Hyo
scya
mus
; Aur
um/
Bella
donn
a com
p.; A
urum
/H
yosc
yam
us co
mp.
; Hyo
scya
mus
; H
yosc
yam
us/V
aler
iana
Hyp
eric
um p
erfo
ratu
m L
.Fr
esh
flowe
rs o
f Hyp
eric
um p
erfo
ratu
m L
.se
e App
. 2.7
: Hyp
eric
um
perfo
ratu
m; F
los;
Extr.
ol
eos 1
:2
Hyp
eric
um; M
illef
oliu
m /
Hyp
eric
um
Hyp
eric
um p
erfo
ratu
m L
.Fr
esh
aeria
l par
ts of
Hyp
eric
um p
erfo
ratu
m L
., col
lecte
d at
flo
werin
g tim
eH
ABPh
.Eur
. 1.1
.5, H
AB 2
1Ap
is re
gina
/Aur
um co
mp.
; Ber
beris
/H
yper
icum
com
p.; C
amph
ora/
Hyp
eric
um; H
yper
icum
; Hyp
eric
um
com
p.; H
yper
icum
/Pas
siflor
a com
p.;
Levi
co co
mp.
; Mal
va co
mp.
; Prim
ula
com
p.
Hyp
ogym
nia p
hyso
des (
L.) N
yl.
Drie
d th
allu
s of H
ypog
ymni
a phy
sode
s (L.
) Nyl
. (Pa
rmeli
a ph
ysod
es (L
.) Ac
h.)
Ph.E
ur. 1
.2.1
2 (e
than
ol
36%
)
Igna
tiase
e Str
ychn
os ig
natii
Ber
gius
Illici
um ve
rum
Hoo
k.f.
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
from
the d
ry ri
pe fr
uits
of Il
liciu
m ve
rum
Hoo
k.f.
Ph.E
ur.
API
Lich
enes
com
p.
Impe
rato
ria o
strut
hium
see P
euce
danu
m o
strut
hium
(L.)
W. D
. J. K
och
Ipec
acua
nha
see P
sych
otria
ipec
acua
nha (
Brot
.) St
okes
Ipec
acua
nha
see C
epha
elis i
peca
cuan
ha (B
rot.)
A. R
ich., C
epha
elis a
cum
inat
a Ka
rste
n
Iris
germ
anic
a L.
Fres
h rh
izom
e of I
ris ge
rman
ica L
.Ph
.Eur
. 1.2
.11,
HAB
21
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
108
Iris
germ
anic
a L., I
ris ge
rman
ica
var.
flore
ntin
a L. a
nd Ir
is pa
llida
La
mar
ck
Drie
d pe
eled
rhiz
ome o
f Iris
germ
anic
a L., I
ris ge
rman
ica v
ar.
flore
ntin
a L. a
nd Ir
is pa
llida
Lam
arck
HAB
12q
(eth
anol
25%
)Lo
tio P
runi
com
p.
Iris
vers
icol
or L
.Fr
esh
unde
rgro
und
part
s (rh
izom
e inc
ludi
ng ro
ots)
of I
ris
vers
icol
or L
. col
lecte
d at
flow
erin
g tim
ePh
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)
Iris
vers
icol
or L
.Fr
esh
unde
rgro
und
part
s of I
ris ve
rsic
olor
L.
HAB
Ph.E
ur. 1
.1.5
Jugl
ans r
egia
L.
Drie
d ou
ter m
embr
ane f
rom
the s
eed
of Ju
glan
s reg
ia L
.Ph
.Eur
. 4.1
.1Ca
rpell
um M
ali c
omp.
Jugl
ans r
egia
L.
Fres
h lea
ves a
nd u
nrip
e fru
it of
Jugl
ans r
egia
L.
HAB
33c
Jugl
ans r
egia
com
p.
Jugl
ans r
egia
L.
Drie
d lea
ves o
f Jug
lans
regi
a L.
DAC
Ph.E
ur. 1
.2.1
3 (e
than
ol
36%
)
Juni
peru
s com
mun
is L.
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
from
the r
ipe,
non-
ferm
ente
d be
rry c
ones
of J
unip
erus
com
mun
is L.
Ph.E
ur.
API
Berb
eris/
Juni
peru
s com
p.; E
ucal
ypti
aeth
erol
eum
com
p.; J
unip
erus
de
stilla
ta; S
alvi
ae ae
ther
oleu
m co
mp.
Juni
peru
s com
mun
is L.
Fres
h rip
e con
e ber
ry o
f Jun
iper
us co
mm
unis
L.H
ABPh
.Eur
. 1.1
.5, H
AB 3
5aTr
opae
olum
com
p.
Juni
peru
s com
mun
is L.
Drie
d tip
s of s
hoot
s of J
unip
erus
com
mun
is L.
Ph.E
ur. 1
.2.1
3 (e
than
ol
36%
)Ci
chor
ium
/Tar
axac
um co
mp.
Juni
peru
s com
mun
is L.
Drie
d rip
e con
e ber
ry o
f Jun
iper
us co
mm
unis
L.Ph
.Eur
.Ph
.Eur
. 1.1
.8; E
xtra
ctio
n wi
th w
ater
and
sucr
ose
Betu
la/Ju
nipe
rus;
Olib
anum
com
p./
Succ
inum
Juni
peru
s sab
ina L
.Fr
esh,
still
unl
igni
fied,
gro
wing
tips
of t
wigs
of J
unip
erus
sabi
na
L., w
ith ad
here
nt le
aves
HAB
Ph.E
ur. 1
.1.5
Colch
icum
/Sab
ina;
Prim
ula A
uro
culta
co
mp.
; Sab
ina
Kala
ncho
e dai
grem
ontia
nase
e Bry
ophy
llum
dai
grem
ontia
num
(Ray
m.-H
amet
et H
. Per
rier)
A.
Ber
ger
Kala
ncho
e pin
nata
see B
ryop
hyllu
m p
inna
tum
(Lam
.) O
ken
Kalm
ia la
tifol
ia L
.Fr
esh
leave
s of K
alm
ia la
tifol
ia L
.H
AB; P
h.fr.
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
65%
)Cr
atae
gus/
Kalm
ia
Kram
eria
tria
ndra
Rui
z et P
av.
Drie
d, u
sual
ly fr
agm
ente
d, u
nder
grou
nd o
rgan
s of K
ram
eria
tr
iand
ra R
uiz e
t Pav
., kno
wn as
Per
uvia
n rh
atan
y.(H
AB);
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
70
%);
extra
ct w
ith
etha
nol 5
0% (D
ER 1
:1)
Cera
tum
Rat
anhi
ae co
mp.
; Rat
anhi
a co
mp.
; Sal
via c
omp.
Lam
ium
albu
m L
.Fr
esh
leave
s, flo
wers
and
youn
g tip
s sho
ots o
f Lam
ium
albu
m L
., co
llect
ed at
flow
erin
g tim
e H
ABPh
.Eur
. 1.1
.3Ar
gent
um/Q
uerc
us co
mp.
Lam
ium
albu
m L
.D
ried
flowe
rs o
f Lam
ium
albu
m L
.H
ABPh
.Eur
. 1.2
.13
(eth
anol
36
%)
Lapp
a majo
rse
e Arc
tium
lapp
a L.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
109
Larix
dec
idua
Mill
.Ba
lsam
obt
aine
d fro
m h
oles
dril
led in
the t
runk
s of
Larix
dec
idua
Mill
.H
ABPh
.Eur
. 1.1
.8 (e
than
ol
96%
), 3.
2.1,
4.1
.1,
(Ph.
Eur.
1.1.
8, et
hano
l 50
%),
API
Absin
thiu
m/R
esin
a Lar
icis;
Anan
assa
co
mp.
; Api
s/Be
rber
is co
mp.
; Arn
ica/
Sym
phyt
um co
mp.
; Bell
adon
na/L
ens
crist
allin
a Col
umba
e/ R
esin
a Lar
icis;
Berb
eris/
Juni
peru
s com
p.; B
erbe
ris/
Saba
l com
p.; C
alen
dula
/Mer
curia
lis
com
p.; C
erat
um R
atan
hiae
com
p.;
Cheli
doni
um/T
ereb
inth
ina l
arici
na
com
p.; C
hrys
olith
com
p.; E
chin
acea
/Vi
scum
com
p.; F
lore
s Sam
buci
com
p./
Qua
rz; G
alen
it/Re
tina c
omp.
; M
ercu
rialis
com
p.; P
lant
ago
com
p.;
Qua
rz/R
esin
a Lar
icis;
Resin
a Lar
icis;
Resin
a Lar
icis c
omp.
; Res
ina L
arici
s/O
leum
Ter
ebin
thin
ae; R
esin
a Lar
icis/
Retin
a; Re
sina L
arici
s/So
lutio
Myr
rhae
ba
lsam
ica;
Retin
a com
p.; S
al M
aris
com
p.; S
ambu
cus c
omp.
; Uva
urs
i co
mp.
Lava
ndul
a ang
ustif
olia
Mill
. (L
avan
dula
offi
cinal
is Ch
aix)
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
from
the fl
ower
ing
tops
of
Lav
andu
la an
gusti
folia
Mill
. (La
vand
ula o
fficin
alis
Chai
x)Ph
.Eur
.H
AB 1
2h, A
PIAc
onitu
m/C
amph
ora c
omp.
; Api
s/Ar
nica
com
p.; A
rcha
ngeli
ca co
mp.
; Ar
nica
com
p./C
upru
m; A
rnic
a com
p./
Form
ica;
Auru
m/L
avan
dula
e ae
ther
oleu
m/R
osa;
Cera
tum
be
nzoi
natu
m; C
erat
um R
atan
hiae
co
mp.
; Lav
ende
löl;
Oleu
m la
ctag
ogum
; Pr
unus
/Ros
mar
inus
com
p.; R
atan
hia
com
p.; R
esin
a Lar
icis c
omp.
; Res
ina
Laric
is/So
lutio
Myr
rhae
bal
sam
ica;
Solu
m u
ligin
osum
com
p.; S
olut
io
Myr
rhae
bal
sam
ica;
Thym
us se
rpyl
lum
co
mp.
Lava
ndul
a ang
ustif
olia
Mill
. (L.
offi
cinal
is Ch
aix)
Drie
d flo
wer o
f Lav
andu
la an
gusti
folia
Mill
. (L.
offi
cinal
is Ch
aix)
.Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
)Ae
scul
us/L
avan
dula
sicc
ata;
Lava
ndul
a sic
cata
Ledu
m p
alustr
e L.
Drie
d tip
s of t
wigs
of L
edum
palu
stre L
.H
ABPh
.Eur
. 1.1
.8 (e
than
ol
70%
)Pr
imul
a Aur
o cu
lta co
mp.
Ledu
m p
alustr
e L.
Fres
h, le
afy t
wig
of L
edum
palu
stre L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)
Leon
topo
dium
niv
ale s
ubsp
. alp
inum
(Cas
s) G
reut
er)
Who
le fre
sh p
lant
s of L
eont
opod
ium
alpi
num
Cas
s.Ph
.Eur
. 1.1
.7, 1
.1.1
0 (E
than
ol 6
5%),
App.
2.7
Apis
com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
110
Leon
topo
dium
alpi
num
Cas
s. ( L
. ni
vale
subs
p. al
pinu
m (C
ass)
G
reut
er)
Who
le dr
ied
flowe
ring
plan
ts of
Leo
ntop
odiu
m al
pinu
m C
ass.
HAB
36
Disc
i/Rhu
s tox
icod
endr
on co
mp.
; G
naph
aliu
m co
mp.
; Rhu
s to
xico
dend
ron
com
p.
Leon
urus
card
iaca
L.
Fres
h ae
rial p
arts
of L
eonu
rus c
ardi
aca L
., col
lecte
d at
flow
erin
g tim
eH
ABPh
.Eur
. 1.1
.5, 1
.1.6
, 1.
1.10
(eth
anol
65%
),Ci
mic
ifuga
com
p.
Levi
sticu
m o
ffici
nale
W.D
.J. K
och
Who
le or
cut,
drie
d rh
izom
e and
root
of L
evist
icum
offi
cina
le Ko
ch.
HAB
; Ph
.Eur
.Ph
.Eur
. 1.2
.12
(eth
anol
70
%),
HAB
12d
, 12g
; see
al
so A
pp. 2
.7.: M
ucila
go
Levi
stici
D1
Apis
cum
Lev
istic
o; L
evist
icum
; Le
visti
cum
com
p.; M
eliss
a/Ph
osph
orus
co
mp.
Levi
sticu
m o
ffici
nale
W. D
. J.
Koch
Fres
h un
derg
roun
d pa
rts o
f Lev
istic
um o
ffici
nale
W. D
. J. K
och
HAB
HAB
21,
33c
Apis/
Lary
nx co
mp.
; Api
s/Le
visti
cum
; Ar
nica
/Lev
istic
um co
mp.
; Ave
na/
Conc
hae c
omp.
; Cer
ebell
um co
mp.
; Co
rnea
/Lev
istic
um co
mp.
; Lar
ynx
com
p.; L
evist
icum
Liliu
m la
ncifo
lium
Thun
b.Fr
esh
plan
ts of
Lili
um la
ncifo
lium
Thun
b., w
ithou
t bul
bs,
colle
cted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.3
Arge
ntum
/Que
rcus
com
p.
Liliu
m la
ncifo
lium
Thun
b.Fr
esh
aeria
l par
ts of
Lili
um la
ncifo
lium
Thun
b., c
ollec
ted
at
flowe
ring
time a
nd in
cludi
ng b
ulbi
lsH
AB 3
3cLi
lium
tigr
inum
com
p.; M
ajora
na/
Thuj
a com
p.
Liliu
m ti
grin
umse
e Lili
um la
ncifo
lium
Thun
b.
Linu
m u
sitat
issim
um L
.Fa
tty o
il ob
tain
ed b
y col
d ex
pres
sion
from
ripe
seed
s of L
inum
us
itatis
simum
L.
Ph.E
ur.
API
Berb
eris/
Cheli
doni
um co
mp.
Litse
a cub
eba P
ers.
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
from
the f
ruit
of L
itsea
cu
beba
Per
s.Ex
cipie
nt
Loba
ria p
ulm
onar
ia (L
.) H
offm
./ St
icta
pul
mon
aria
Ach
.D
ried
thal
lus o
f Lob
aria
pul
mon
aria
(L.)
Hoff
m.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.8 (e
than
ol
90%
), 1.
1.10
(eth
anol
65
%)
Lich
enes
com
p.
Lobe
lia in
flata
L.
Fres
h flo
werin
g ae
rial p
arts
of L
obeli
a infl
ata L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Lo
belia
com
p.Ré
perto
ire d
e méd
. an
thr.
(201
6)
Lobe
lia in
flata
L.
Who
le fre
sh fl
ower
ing
plan
ts of
Lob
elia i
nflat
a L.
HAB
Ph.E
ur. 1
.1.5
Lobe
lia co
mp.
; Lob
elia i
nflat
a
Lyco
pers
icon
lyco
pers
icum
(L.)
Kars
t. ex
Far
w.Fr
esh
aeria
l par
ts of
Lyc
oper
sicon
lyco
pers
icum
(L.)
Kars
t. ex
Fa
rw., c
ollec
ted
at fl
ower
ing
time.
HAB
34
Ph.E
ur. 1
.1.3
and
4.2.
1D
er M
erku
rsta
b 19
99
Hep
atiti
s, 4/
2002
: p.
271-
7
Lyco
podi
um cl
avat
um L
.W
hole
spor
e-be
arin
g pl
ant o
f Lyc
opod
ium
clav
atum
L.
HAB
33e
Lyco
podi
um; L
ycop
odiu
m co
mp.
Lyco
podi
um cl
avat
um L
.D
ried
ripe s
pore
s of L
ycop
odiu
m cl
avat
um L
.H
AB; P
h.fr.
Ph.E
ur. 1
.1.8
(eth
anol
90
%),
Ph.E
ur. 1
.1.1
0 (e
than
ol 9
0%)
Lyco
podi
um
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
111
Lyco
pus v
irgin
icus
L.
Fres
h ae
rial p
arts
of L
ycop
us vi
rgin
icus
L., c
ollec
ted
at fl
ower
ing
time
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 6
5%)
Lyco
pus v
irgin
icus
L.
Who
le fre
sh p
lant
of L
ycop
us vi
rgin
icus
L., c
ollec
ted
at fl
ower
ing
time.
HAB
33d
Der
Mer
kurs
tab
5/20
04: p
. 359
Lysim
achi
a num
mul
aria
L.
Fres
h flo
werin
g ae
rial p
arts
of L
ysim
achi
a num
mul
aria
L.
Ph.E
ur. 1
.2.1
1;
Dec
octio
n wi
th
wate
r:eth
anol
96%
(1
2:9.
5) (D
ER 1
:2.1
5)
Dul
cam
ara/
Lysim
achi
a
Mah
onia
aqui
foliu
m (P
ursh
) N
utt.
Drie
d ba
rk fr
om b
ranc
hes a
nd tw
igs a
nd d
ried
tips o
f twi
gs o
f M
ahon
ia aq
uifo
lium
(Pur
sh) N
utt.
HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%)
Majo
rana
see O
rigan
um m
ajora
na L
.
Malt
umse
e Hor
deum
vulg
are L
.
Malu
s dom
estic
a Bor
kh.
Core
from
fres
h fr
uit o
f Malu
s dom
estic
a Bor
kh. w
ithou
t ker
nel
Ph.E
ur. 4
.1.1
Carp
ellum
Mal
i com
p.
Malu
s dom
estic
a Bor
kh.
sour
appl
es o
f Malu
s dom
estic
a Bor
kh.
see F
erru
m p
omat
um
(App
. 2.6
)M
erku
rsta
b 67
(201
4)(4
)270
-282
Mal
va sy
lves
tris L
.W
hole
or fr
agm
ente
d dr
ied
flowe
r of M
alva
sylv
estri
s L. o
r its
culti
vate
d va
rietie
s.H
AB;
Ph.E
ur.
Ph.E
ur. 1
.2.1
3 (e
than
ol
50%
), H
AB 1
2gM
alva
/Mill
efol
ium
/ Oxa
lis;
Phos
phor
us/M
alva
Mal
va sy
lves
tris L
., Mal
va
negl
ecta
Wal
lr.D
ried
leave
s of M
alva
sylv
estri
s L., M
alva
neg
lecta
Wal
lr. o
r a
mix
ture
of b
oth
spec
ies
Ph.E
ur.
Extra
ctio
n to
geth
er w
ith
leave
s acc
. to
Ph.E
ur.
1.2.
13 (E
than
ol 5
0%)
Mal
va/M
illef
oliu
m/ O
xalis
Man
drag
ora a
utum
nalis
see M
andr
agor
a offi
cinar
umH
ABPh
.Eur
. 1.1
.8 o
r 1.2
.12
Man
drag
ora o
fficin
arum
L.
Fres
h ro
ot o
f Man
drag
ora o
fficin
arum
L.
HAB
34d
Betu
la/M
andr
agor
a com
p.; C
artil
ago/
Man
drag
ora c
omp.
; Disc
i/Rhu
s to
xico
dend
ron
com
p.; M
andr
agor
a; Rh
us to
xico
dend
ron
com
p.
Man
drag
ora o
fficin
arum
L.
Man
drag
ora a
utum
nalis
Ber
tol.
Drie
d ro
ots o
f Man
drag
ora o
fficin
arum
L. a
nd M
andr
agor
a au
tum
nalis
Ber
tol.
HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%) o
r 1.2
.12
(eth
anol
50
%)
Acon
itum
/Arn
ica c
omp.
/Api
s; Ac
onitu
m/A
rnic
a com
p./F
orm
ica;
Acon
itum
/Arn
ica/
Betu
la co
mp.
; Ar
nica
/Sym
phyt
um co
mp.
; Bet
ula
com
p.; M
andr
agor
a; M
andr
agor
a co
mp.
; Man
drag
ora/
Men
iscus
Gen
us
Mar
acuj
a doc
ese
e Pas
siflor
a alat
a Cur
tis
Mar
rubi
um vu
lgar
e L.
Who
le or
frag
men
ted
drie
d flo
werin
g ae
rial p
arts
of M
arru
bium
vu
lgar
e L.
Ph.E
ur.
aque
ous e
xtra
ct to
geth
er
with
oth
er d
rugs
Siru
pus Th
ymi c
omp.
Mar
um ve
rum
see T
eucr
ium
mar
um L
.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
112
Mat
ricar
ia re
cutit
a L.
(Cha
mom
illa r
ecut
ita (L
.) Ra
usch
ert)
Fres
h flo
wer h
eads
of M
atric
aria
recu
tita L
. (Ch
amom
illa r
ecut
ita
(L.)
Raus
cher
t)Ph
.Eur
. 1.1
.3, H
AB 2
1An
agal
lis/M
alac
hit c
omp.
Mat
ricar
ia re
cutit
a L.
(Cha
mom
illa r
ecut
ita (L
.) Ra
usch
ert
Who
le fre
sh fl
ower
ing
plan
ts of
Mat
ricar
ia re
cutit
a L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 4
5%),
HAB
21,
33
c
Bolu
s alb
a com
p.; C
ham
omill
a; Pu
lvis
Stom
achi
cus c
um B
ellad
onna
Mat
ricar
ia re
cutit
a L.
(Cha
mom
illa r
ecut
ita (L
.) Ra
usch
ert)
Fres
h un
derg
roun
d pa
rts o
f Mat
ricar
ia re
cutit
a L. (
Cham
omill
a re
cutit
a (L.
) Rau
sche
rt) b
efor
e flow
erin
g tim
ePh
.Eur
. 1.2
.11,
1.4
.2,
HAB
21,
33c
Amm
i visn
aga c
omp.
; Bell
adon
na
com
p.; B
ellad
onna
/Cha
mom
illa;
Caru
m ca
rvi c
omp.
; Cha
mom
illa,
Radi
x; C
ham
omill
a/M
alac
hit c
omp.
; Ch
amom
illa/
Nic
otia
na;
Chry
sosp
leniu
m co
mp.
; Meli
ssa/
Sepi
a co
mp.
; Nic
otia
na co
mp.
; Nic
otia
na/N
ux
vom
ica c
omp.
; Ver
atru
m co
mp.
Mat
ricar
ia re
cutit
a L.
(Cha
mom
illa r
ecut
ita (L
.) Ra
usch
ert).
Drie
d ca
pitu
la o
f Mat
ricar
ia re
cutit
a L. (
Cham
omill
a rec
utita
(L.)
Raus
cher
t).Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
50%
), H
AB 1
2fAr
gent
um/Q
uerc
us co
mp.
; Birk
enko
hle
com
p.; O
leum
rhin
ale
Mat
ricar
ia re
cutit
a L.
(Cha
mom
illa r
ecut
ita (L
.) Ra
usch
ert)
Drie
d ro
ot o
f Mat
ricar
ia re
cutit
a L. (
Cham
omill
a rec
utita
(L.)
Raus
cher
t)Ph
.Eur
. 1.2
.12
(eth
anol
36
%)
Acid
um h
ydro
chlo
ricum
com
p.;
Birk
enko
hle c
omp.
; Cha
mom
illa c
omp.
; Ch
amom
illa,
Radi
x; C
ham
omill
a/M
alac
hit c
omp.
; Kal
ium
acet
icum
co
mp.
; Oxa
lis co
mp.
Mela
leuca
caju
puti
Powe
ll,
Mela
leuca
leuc
aden
dra (
L.) L
.Re
ctifi
ed es
sent
ial o
il ob
tain
ed fr
om fr
esh
leave
s and
bra
nche
s of
Mela
leuca
caju
puti
Powe
ll or
Mela
leuca
leuc
aden
dra (
L.) L
.AP
IBe
rber
is/Eu
caly
ptus
/ Sili
cea c
omp.
; Re
sina L
aric
is/So
lutio
Myr
rhae
ba
lsam
ica;
Solu
tio M
yrrh
ae b
alsa
mic
a
Meli
ssa i
ndic
umse
e Cym
bopo
gon
wint
eria
nus J
owitt
and
othe
r Cym
bopo
gon
sp.
Meli
ssa o
ffici
nalis
L.
Fres
h lea
ves a
nd yo
ung
tips o
f Meli
ssa o
ffici
nalis
L.
(HAB
)Ph
.Eur
. 1.1
.5, H
AB 2
1,
steam
dist
illat
ion
Arge
ntum
/Que
rcus
com
p.; M
eliss
a Cu
pro
culta
; Meli
ssa/
Phos
phor
us co
mp.
Meli
ssa o
ffici
nalis
L.
Fres
h ae
rial p
arts
of M
eliss
a offi
cina
lis L
., bef
ore fl
ower
ing
time
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r.
Meli
ssa o
ffici
nalis
L.
Fres
h ae
rial p
arts
of M
eliss
a offi
cina
lis L
.H
AB 3
3cCa
ctus
/Meli
ssa c
omp.
; Meli
ssa/
Sepi
a co
mp.
Meli
ssa o
ffici
nalis
L.
Drie
d lea
f of M
eliss
a offi
cina
lis L
.Ph
.Eur
.Ex
tract
s with
etha
nol
(DER
1:1
), to
geth
er w
ith
Majo
rana
with
Oleu
m
Caca
o (D
ER 1
:1:1
0),
steam
dist
illat
ion
Cera
et M
el co
mp.
; Majo
rana
/Meli
ssa;
Spiri
tus c
ontra
tuss
im; S
pirit
us M
eliss
ae
com
p.
Meli
ssa o
ffici
nalis
L.
Drie
d ae
rial p
arts
of M
eliss
a offi
cina
lis L
.H
AB 1
2gM
eliss
a com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
113
Men
tha p
iper
ita L
.Es
sent
ial o
il ob
tain
ed b
y ste
am d
istill
atio
n fro
m th
e fre
sh ae
rial
part
s of t
he fl
ower
ing
plan
t of M
enth
a x p
iper
ita L
.Ph
.Eur
.AP
IBe
rber
is/Ch
elido
nium
com
p.; C
arbo
Sa
ngui
nis c
omp.
; Cer
atum
Rat
anhi
ae
com
p.; E
chin
acea
/Pru
nus c
omp.
; O
leum
rhin
ale;
Rata
nhia
com
p.; S
alvi
ae
aeth
erol
eum
com
p.
Men
tha p
iper
ita L
.W
hole
or cu
t drie
d lea
ves o
f Men
tha x
pip
erita
L.
Ph.E
ur.
API
Cent
auriu
m co
mp.
; Majo
rana
/Men
tha/
Ruta
Men
tha p
iper
ita L
.W
hole
fresh
flow
erin
g pl
ant o
f Men
tha x
pip
erita
L.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
) Ré
perto
ire d
e méd
. an
thr.
Mer
curia
lis p
eren
nis L
.Fr
esh
aeria
l par
ts of
Mer
curia
lis p
eren
nis L
., col
lecte
d at
flow
erin
g tim
eH
ABH
AB 3
4cAl
lium
cepa
/ Mer
curia
lis co
mp.
; La
ches
is co
mp.
; Mer
curia
lis /
Rosa
e ae
ther
oleu
m; M
ercu
rialis
/Stib
ium
co
mp.
Mer
curia
lis p
eren
nis L
.W
hole
fresh
flow
erin
g pl
ant o
f Mer
curia
lis p
eren
nis L
.H
ABPh
.Eur
. 1.1
.4, 1
.1.1
0 (e
than
ol 4
5%)
Berb
eris/
Mer
curia
lis p
eren
nis;
Calen
dula
/Mer
curia
lis co
mp.
; M
ercu
rialis
com
p.; M
ercu
rialis
pe
renn
is; M
ercu
rialis
/Mel
Mer
curia
lis p
eren
nis L
.W
hole
drie
d flo
werin
g pl
ant o
f Mer
curia
lis p
eren
nis L
.Ex
tract
ion
with
ve
geta
ble o
ilCa
lendu
la/M
ercu
rialis
com
p.
Mez
ereu
mse
e Dap
hne m
ezer
eum
L.
Mill
efol
ium
see A
chill
ea m
illef
oliu
m L
.
Muc
una p
rurie
ns (L
.) D
CD
ried
hairs
from
the f
ruits
of M
ucun
a pru
riens
(L.)
DC
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.8 (e
than
ol
90%
)
Myr
istic
a fra
gran
s Hou
tt.D
ried
seed
ker
nel o
f Myr
istic
a fra
gran
s Hou
tt.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Ré
perto
ire d
e méd
. an
thr.
(201
6)
Myr
istic
a fra
gran
s Hou
tt.D
ried,
usu
ally
lim
e-tre
ated
seed
s of M
yrist
ica f
ragr
ans H
outt.
, wi
th ar
il an
d te
sta re
mov
edH
ABPh
.Eur
. 1.1
.8 (e
than
ol
90%
); et
hano
lic d
istill
ate
(toge
ther
with
oth
er
drug
s)
Nux
vom
ica c
omp.
; Spi
ritus
cont
ra
tuss
im; S
pirit
us M
eliss
ae co
mp.
Myr
istic
a seb
ifera
see V
irola
sebi
fera
Aub
l.
Myr
oxyl
on b
alsa
mum
(L.)
Har
ms
var.
pere
irae (
Royl
e) H
arm
s.Ba
lsam
obt
aine
d fro
m th
e sco
rche
d an
d wo
unde
d tr
unk
of
Myr
oxyl
on b
alsa
mum
(L.)
Har
ms v
ar. p
erei
rae (
Royl
e) H
arm
s.Ph
.Eur
.AP
IBe
rber
is/Eu
caly
ptus
/ Sili
cea c
omp.
; Be
rber
is/Si
licea
com
p.; C
alen
dula
/M
ercu
rialis
com
p.; M
ercu
rialis
com
p.
Myr
rha
see C
omm
ipho
ra Ja
cq. s
pecie
s
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
114
Nas
turt
ium
offi
cina
le R.
Br.
Who
le fre
sh p
lant
of N
astu
rtiu
m o
ffici
nale
R. B
r.Ph
.Eur
. 1.1
.11
(Eth
anol
45
%)
Nas
turt
ium
offi
cina
le R.
Br.
Fres
h ae
rial p
arts
of N
astu
rtiu
m o
ffici
nale
R. B
r., co
llect
ed at
flo
werin
g tim
eH
ABPh
.Eur
. 1.1
.5, H
AB 2
1,
(Ph.
Eur.
1.1.
3)N
astu
rtiu
m M
ercu
rio cu
ltum
Nas
turt
ium
offi
cina
le R.
Br.
Drie
d ae
rial p
arts
of N
astu
rtiu
m o
ffici
nale
R. B
r.AP
IM
ercu
rius v
ivus
com
p.
Nic
otia
na ta
bacu
m L
.Fr
esh
leave
s of N
icot
iana
taba
cum
L.
HAB
HAB
21,
33b
Amm
i visn
aga c
omp.
; Bell
adon
na
com
p.; B
erbe
ris/N
icot
iana
com
p.;
Blei
glan
z/Se
cale
com
p.; B
orag
o co
mp.
; Ca
rum
carv
i com
p.; C
ham
omill
a/N
icot
iana
; Cor
/Cra
taeg
us co
mp.
; Cu
prum
acet
icum
com
p.; C
upru
m/
Nic
otia
na; D
isci c
omp.
cum
Nic
otia
na;
Nic
otia
na co
mp.
; Nic
otia
na/N
ux
vom
ica c
omp.
; Nic
otia
na/Q
uarz
; N
icot
iana
/Stro
phan
tus c
omp.
; Oxa
lis/
Qua
rz co
mp.
; Ret
ina/
Seca
le co
mp.
; Ro
bini
a com
p.; T
abac
um; T
abac
um
Cupr
o cu
ltum
Nic
otia
na ta
bacu
m L
.D
ried
ferm
ente
d lea
ves o
f Nic
otia
na ta
bacu
m L
.Ph
.Eur
. 1.2
.13
(eth
anol
18
%)
Taba
cum
Nic
otia
na ta
bacu
m L
.D
ried
unfe
rmen
ted
leave
s of N
icot
iana
taba
cum
L.
HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%),
HAB
12d
, 12f
, AP
C 4.
2, 4
.3
Acon
itum
/Nic
otia
na co
mp.
; Car
bone
s/Pa
nkre
as/W
ither
it; C
ham
omill
a/M
alac
hit c
omp.
; Cup
rum
/Nic
otia
na;
Equi
setu
m ar
vens
e/Ta
bacu
m;
Equi
setu
m co
mp.
; Mag
nesiu
m
phos
phor
icum
acid
um/T
abac
um;
Rosm
arin
i aet
hero
leum
/Tab
acum
; Ta
bacu
m
Nux
mos
chat
ase
e Myr
istic
a fra
gran
s Hou
tt.
Nux
vom
ica
see S
tryc
hnos
nux
-vom
ica L
.
Oci
mum
bas
ilicu
m L
.Fr
esh
aeria
l par
ts of
Oci
mum
bas
ilicu
m L
., col
lecte
d pr
ior t
o flo
werin
gH
ABPh
.Eur
. 1.1
.5, 1
.1.1
1 (e
than
ol 6
5%)
Basil
icum
com
p.
Olib
anum
see B
oswe
llia s
peci
es
Ono
nis s
pino
saW
hole
or cu
t, dr
ied
root
of O
noni
s spi
nosa
L.
HAB
; Ph
.Eur
.Ph
.Eur
. 1.2
.12
(eth
anol
70
%)
Ono
pord
um ac
anth
ium
L.
Fres
h lea
ves o
f Ono
pord
um ac
anth
ium
L.
Ph.E
ur. 1
.1.7
, 1.1
.10
(eth
anol
45%
)Ch
elido
nium
com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
115
Ono
pord
um ac
anth
ium
L.
Fres
h flo
werh
ead
of O
nopo
rdum
acan
thiu
m L
.H
AB 3
3c; s
ee A
pp. 2
.6:
Ono
pord
um ac
anth
ium
, Fl
os re
c., et
hano
l. D
iges
tio (1
:3.1
) with
0.
1-1%
Hyo
scya
mus
ni
ger,
Her
ba re
c. Ø
, also
ex
tract
s with
Eth
anol
24
,5%
or W
FI
Auru
m/O
nopo
rdon
com
p.; C
imici
fuga
co
mp.
; Con
valla
ria/P
rimul
a com
p.;
Crat
aegu
s com
p.; O
nopo
rdon
com
p.;
Ono
pord
on co
mp.
/Ado
nis;
Ono
pord
on
com
p./M
agne
sium
pho
spho
ricum
ac
idum
; Ono
pord
on co
mp.
/Olea
nder
; O
nopo
rdon
com
p./O
leand
er/ A
rnic
a; O
nopo
rdon
com
p./O
leand
er/
Conv
alla
ria; O
nopo
rdon
com
p./
Plum
bum
; Ono
pord
um/P
rimul
a com
p.
Orc
his L
. or O
phry
deae
trib
e (O
rchi
dace
ae)
Filia
l tub
ers o
f diff
eren
t spe
cies o
f the
genu
s Orc
his L
. (O
rchi
dace
ae) o
r oth
er su
itabl
e int
ra- a
nd in
terg
ener
ic O
rchi
s-H
ybrid
s of t
he tr
ibe O
phry
deae
, whi
ch h
ave b
een
blan
ched
in
boili
ng w
ater
and
drie
d
Ph.E
ur. 1
.4.3
Cere
bellu
m co
mp.
Orig
anum
majo
rana
L.
Fres
h ae
rial p
arts
of O
rigan
um m
ajora
na L
., col
lecte
d at
flow
erin
g tim
eH
ABPh
.Eur
. 1.1
.5, 2
1, 3
3cM
ajora
na; M
ajora
na/Th
uja c
omp.
; M
eliss
a/Ph
osph
orus
com
p.
Orig
anum
majo
rana
L.
Drie
d ae
rial p
arts
of O
rigan
um m
ajora
na L
.Ph
.Eur
. 1.2
.13
(eth
anol
36
%),
HAB
12g
, ex
tract
ion
with
Eth
anol
(D
ER 1
:1);
toge
ther
with
M
eliss
a with
Oleu
m
Caca
o (D
ER 1
:1:1
0)
Caps
ella/
Majo
rana
com
p.; M
ajora
na;
Majo
rana
/Meli
ssa;
Majo
rana
/Men
tha/
Ruta
; Meli
ssa c
omp.
Orig
anum
majo
rana
L.
Ripe
frui
t of O
rigan
um m
ajora
na L
.Et
hano
lic d
ecoc
tion
(DER
1:3
), pe
rcol
atio
n wi
th et
hano
l 96%
and
aque
ous d
ecoc
tion
of th
e re
sidue
Caps
ella/
Majo
rana
com
p.
Oxa
lis ac
etos
ella L
.Fr
esh
leave
s of O
xalis
acet
osell
a L.
HAB
Ph.E
ur. 1
.1.3
, 1.1
.7,
1.1.
11 (e
than
ol 4
5%),
HAB
12a
(afte
r Ph.
Eur.
1.1.
3), 2
1; m
acer
atio
n wi
th et
hano
l 36%
(DER
1:
1.3)
.
Bella
donn
a/O
xalis
; Bell
adon
na/P
apav
er
com
p.; C
helid
oniu
m/O
xalis
com
p.;
Form
ica/
Oxa
lis; M
alva
/Mill
efol
ium
/ O
xalis
; Oxa
lis; O
xalis
com
p.
Oxa
lis ac
etos
ella L
.W
hole
fresh
flow
erin
g pl
ant o
f Oxa
lis ac
etos
ella L
.H
AB 1
2c, 3
4bBa
rium
/Pan
crea
s com
p.; B
erbe
ris/
Pros
tata
com
p.; B
erbe
ris/U
teru
s com
p.;
Card
uus m
aria
nus/
Oxa
lis; F
orm
ica/
Oxa
lis; O
xalis
; Oxa
lis/Q
uarz
com
p.;
Panc
reas
/Plat
inum
chlo
ratu
m co
mp.
; Tr
opae
olum
com
p.
Oxa
lis ac
etos
ella L
.D
ried
flowe
ring
plan
t of O
xalis
acet
osell
a LH
AB 1
2fO
xalis
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
116
Paeo
nia o
ffici
nalis
L. e
men
d.
Will
d.Fr
esh
unde
rgro
und
part
s of P
aeon
ia o
ffici
nalis
L. e
men
d. W
illd.
, co
llect
ed d
urin
g sp
ring
HAB
Ph.E
ur. 1
.1.5
, 1.2
.11,
H
AB 3
3cCa
rduu
s ben
edic
tus/
Paeo
nia o
ffici
nalis
; H
irudo
com
p.
Pana
x gi
nsen
g C.
A. M
ey.
Who
le or
cut d
ried
root
, des
igna
ted
white
gin
seng
; tre
ated
with
ste
am an
d th
en d
ried,
des
igna
ted
red
gins
eng,
of P
anax
gin
seng
C.
A. M
ey.
(HAB
); Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
90%
), 1.
2.12
(eth
anol
36
%)
Vade
mec
um: G
inse
ng
Papa
ver r
hoea
s L.
Fres
h flo
wers
of P
apav
er rh
oeas
L.
HAB
Ph.E
ur. 1
.1.3
, HAB
12a
(P
h.Eu
r. 1.
1.3)
, 33c
Papa
ver r
hoea
s
Papa
ver s
omni
feru
m L
.Fr
esh
latex
obt
aine
d fro
m in
cisio
ns in
unr
ipe f
ruit
of P
apav
er
som
nife
rum
L.
Extra
ctio
n wi
th et
hano
l 36
% (D
ER 1
:100
)Pa
pave
r som
nife
rum
Papa
ver s
omni
feru
m L
.Fr
esh
unrip
e fru
it of
Pap
aver
som
nife
rum
L.
Ph.E
ur. 1
.1.7
, 1.1
.10
(eth
anol
45%
), H
AB 3
3cBe
llado
nna/
Papa
ver c
omp.
; Ch
amom
illa c
omp.
; Pap
aver
so
mni
feru
m
Paris
qua
drifo
lia L
.W
hole
fresh
pla
nts o
f Par
is qu
adrif
olia
L., c
ollec
ted
when
the
frui
ts ha
ve ri
pene
dH
ABPh
.Eur
. 1.1
.3
Parm
elia
see H
ypog
ymni
a phy
sode
s (L.
) Nyl
.
Pass
iflor
a alat
a Cur
tisdr
ied
leave
s of P
assifl
ora a
lata C
urtis
cont
aini
ng at
leas
t 1.0
% o
f to
tal fl
avon
oids
, exp
ress
ed in
apig
enin
Farm
acop
éia
Bras
ileira
Pass
iflor
a alat
a Cur
tisFr
esh
aeria
l par
ts of
Pas
siflor
a alat
a Cur
tisPh
.Eur
. 1.1
.5AB
MA-
Vade
mec
um
Pass
iflor
a cae
rulea
L.
Fres
h ae
rial p
arts
of P
assifl
ora c
aeru
lea L
. col
lecte
d at
flow
erin
g tim
eH
AB 3
3c, e
xtra
ctio
n wi
th w
ater
and
sucr
ose
(2:4
:4)
Aven
a/Pa
ssifl
ora c
omp.
; Hyp
eric
um/
Pass
iflor
a com
p.; P
assifl
ora c
omp.
Pass
iflor
a inc
arna
ta L
.Fr
esh
aeria
l par
ts of
Pas
siflor
a inc
arna
ta L
.H
AB; P
h.fr.
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
65%
)Av
ena s
ativ
a com
p.; P
assifl
ora i
ncar
nata
Peat
see S
olum
ulig
inos
um
Pela
rgon
ium
gra
veol
ens A
it. an
d ot
her P
elarg
oniu
m sp
ecie
sEs
sent
ial o
il ob
tain
ed b
y ste
am d
estil
latio
n fro
m th
e aer
ial p
arts
of
suita
ble s
peci
es o
f Pela
rgon
ium
e.g.
Pela
rgon
ium
gra
veol
ens A
it.AP
IM
alva
com
p.; R
osae
aeth
erol
eum
/Si
licea
collo
idal
is co
mp.
Peta
sites
hyb
ridus
(L.)
Ph.
Gae
rtn.
B. M
ey. e
t Sch
erb
Fres
h rh
izom
e of P
etas
ites h
ybrid
us (L
.) Ph
. Gae
rtn.
B. M
ey. e
t Sc
herb
. with
atta
ched
root
sH
AB 3
3cPe
tasit
es co
mp.
; Pet
asite
s com
p. cu
m
Que
rcu;
Pet
asite
s com
p. cu
m V
eron
ica;
Peta
sites
, Rad
ix; P
etas
ites/
Plan
tago
co
mp.
; Pla
ntag
o co
mp.
Peta
sites
hyb
ridus
(L.)
Ph.
Gae
rtn.
B. M
ey. e
t Sch
erb.
Who
le fre
sh fl
ower
ing
plan
t of P
etas
ites h
ybrid
us (L
.) Ph
. Gae
rtn.
B.
Mey
. et S
cher
b.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 4
5%)
Peta
sites
, Pla
nta t
ota
Petro
selin
um cr
ispum
(Mill
.) N
ym. e
x A.
W. H
illW
hole
fresh
flow
erin
g pl
ants
of P
etro
selin
um cr
ispum
(Mill
.) N
ym. e
x A.
W. H
ill co
nvar
. cris
pum
, col
lecte
d at
the s
tart
of
flowe
ring
HAB
Ph.E
ur. 1
.1.5
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
117
Peuc
edan
um o
strut
hium
(L.)
W.
D. J
. Koc
hFr
esh
rhiz
ome o
f Peu
ceda
num
ostr
uthi
um (L
.) W
.D.J.
Koc
hPh
. Eur
. 1.2
.10,
etha
nolic
de
coct
ion
(1:2
.15)
(e
than
ol 5
0%)
Cich
oriu
m/T
arax
acum
com
p.
Peum
us b
oldu
s Mol
ina
Who
le or
frag
men
ted
drie
d lea
f of P
eum
us b
oldu
s Mol
ina.
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
70
%),
1.1.
10 (e
than
ol
55%
)
Répe
rtoire
de m
éd.
anth
r.: B
oldo
Phyl
litis
scol
open
driu
m L
. (A
splen
ium
scol
open
driu
m L
.)Fr
esh
spor
e-be
arin
g lea
ves o
f Phy
llitis
scol
open
driu
m L
.H
AB 3
4h, A
PC 3
.8.1
(to
geth
er w
ith o
ther
fre
sh h
erba
l dru
gs, 1
:4.1
pa
rts e
than
ol 2
5%),
3.8.
2
Aqui
linum
com
p.; A
spid
ium
/Sal
ix
com
p.; C
helid
oniu
m co
mp.
; Con
chae
co
mp.
; Rhu
s/Sa
lix co
mp.
Phyl
losta
chys
virid
iglau
cesc
ens
(Car
r.) A
. et C
. Riv.
Nod
es fr
om th
e ste
m o
f Phy
llosta
chys
spec
ies,
espe
cial
ly
Phyl
losta
chys
virid
iglau
cesc
ens (
Carr.
) A. e
t C. R
iv., c
ollec
ted
in
sum
mer
Ph.E
ur. 1
.1.1
0 (e
than
ol
45%
), H
AB 3
5cBa
mbu
sa; D
isci c
omp.
cum
Aes
culo
; D
isci c
omp.
cum
Arg
ento
; Disc
i com
p.
cum
Aur
o; D
isci c
omp.
cum
Nico
tiana
; D
isci c
omp.
cum
Pul
satil
la; D
isci c
omp.
cu
m St
anno
; Disc
i com
p. cu
m St
ibio
; D
isci/P
ulsa
tilla
com
p. cu
m St
anno
; D
isci/R
hus t
oxico
dend
ron
com
p.;
Disc
i/Visc
um co
mp.
cum
Arg
ento
; D
isci/V
iscum
com
p. cu
m St
anno
; Len
s cr
istal
lina/
Visc
um co
mp.
cum
Stan
no
Phyt
olac
ca am
eric
ana L
. (Ph
. de
cand
ra)
Fres
h ro
ots o
f Phy
tola
cca a
mer
ican
a L., c
ollec
ted
durin
g au
tum
nH
ABPh
.Eur
. 1.1
.5, H
AB 3
3cPh
ytol
acca
; Phy
tola
cca c
omp.
Phyt
olac
ca am
eric
ana L
.Fr
esh
ripe f
ruits
of P
hyto
lacc
a am
eric
ana L
.H
ABPh
.Eur
. 1.1
.5
Pice
a abi
es (L
.) Ka
rst.,
Abi
es
sibiri
ca L
edeb
our &
oth
er sp
ecie
sEs
sent
ial o
il ob
tain
ed b
y ste
am d
istill
atio
n of
nee
dles
and
tips o
f br
anch
es o
r bra
nche
s of P
icea a
bies
(L.)
Kars
t. an
d of
Abi
es
sibiri
ca L
edeb
our o
r oth
er sp
ecie
s of t
he ge
nera
Abi
es an
d Pi
cea
DAB
API
Salv
iae a
ethe
roleu
m co
mp.
Pice
a abi
es (L
.) Ka
rst.
Fres
h yo
ung
tips o
f sho
ots o
f Pice
a abi
es (L
.) Ka
rst.
Extra
ctio
n wi
th
Wat
er:S
ucro
se (1
:1)
(DER
1:5
)
Peta
sites
/Pla
ntag
o co
mp.
Pim
pine
lla an
isum
L.
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
of th
e dry
ripe
frui
ts of
Pi
mpi
nella
anisu
m L
.Ph
.Eur
.AP
IAr
nica
/Lap
pa co
mp.
; Ber
beris
/Ch
elido
nium
com
p.; B
erbe
ris/
Juni
peru
s com
p.; B
etul
a/La
ppa c
omp.
; Bo
lus a
lba c
omp.
; Car
bo S
angu
inis
com
p.; L
ichen
es co
mp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
118
Pim
pine
lla an
isum
L.
Who
le dr
y cre
moc
arp
of P
impi
nella
anisu
m L
.H
AB;
Ph.E
ur.
Ph.E
ur. 1
.2.1
2 (e
than
ol
70%
), 1.
4.4
Absin
thiu
m/C
aryo
phyl
li co
mp.
; Ani
s-Py
rit; A
ntim
onit/
Anisu
m; C
enta
uriu
m
com
p.; C
onch
ae/F
erru
m u
stum
com
p.;
Ferr
um si
licic
um co
mp.
; Fer
rum
ustu
m
com
p.; F
erru
m/A
nisu
m; L
evist
icum
co
mp.
; Siru
pus Th
ymi c
omp.
; Ve
rbas
cum
com
p.
Pinu
s mug
o Tu
rra
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
of th
e fre
sh le
aves
and
twig
s of P
inus
mug
o Tu
rra.
Ph.E
ur.
API
Arch
ange
lica c
omp.
; Ber
beris
/Juni
peru
s co
mp.
Pinu
s pin
aste
r Aito
n an
d/or
Pin
us
mas
soni
ana D
.Don
.Es
sent
ial o
il ob
tain
ed b
y ste
am d
istill
atio
n, fo
llowe
d by
re
ctifi
catio
n at
a te
mpe
ratu
re b
elow
180
°C, f
rom
the o
leore
sin
obta
ined
by t
appi
ng P
inus
pin
aste
r Aito
n an
d/or
Pin
us
mas
soni
ana D
.Don
.
Ph.E
ur.
API
Berb
eris/
Juni
peru
s com
p.
Pinu
s syl
vestr
is L.
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
of th
e fre
sh le
aves
and
bran
ches
of P
inus
sylv
estr
is L.
Ph.E
ur.
API
Arch
ange
lica c
omp.
; Oleu
m
cam
phor
atum
com
p.
Pinu
s syl
vestr
is L.
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
of fr
esh
need
les an
d tip
s or f
resh
bra
nche
s with
nee
dles
and
tips o
f the
twig
s of P
inus
sy
lves
tris
L. o
r oth
er sp
ecie
s of t
he ge
nus P
inus
.
DAB
API
Pipe
r nig
rum
L.
Drie
d, ri
pe o
r nea
rly ri
pe fr
uit o
f Pip
er n
igru
m L
. with
an
unbr
oken
per
icar
p (b
lack
pep
per)
or w
ith th
e out
er la
yers
of t
he
peric
arp
rem
oved
(whi
te p
eppe
r)
Ph.E
ur.
aque
ous e
xtra
ctio
n to
geth
er w
ith o
ther
dr
ugs,
aque
ous
extra
ctio
n wi
th su
cros
e
Gen
tiana
/Zin
gibe
r com
p.
Pix
betu
lina
Birc
h ta
r see
Bet
ula p
endu
la R
oth,
Bet
ula p
ubes
cens
Ehr
hart
Plan
tago
lanc
eolat
a L.
Fres
h lea
ves o
f Pla
ntag
o la
nceo
lata L
.Ph
.Eur
. 1.1
.11
(eth
anol
45
%),
HAB
34c
, App
. 2.6
: Pl
anta
go la
nceo
lata,
Foliu
m re
c.,
etha
nol.D
iges
tio (1
:3.1
) wi
th 1
-2%
Hyo
scya
mus
ni
ger,
Her
ba re
c. Ø
; aq
ueou
s ext
ract
ion
with
su
cros
e (1:
1) (D
ER 1
:5)
Bron
chi/P
lant
ago
com
p.; P
etas
ites
com
p.; P
etas
ites c
omp.
cum
Que
rcu;
Pe
tasit
es co
mp.
cum
Ver
onic
a; Pe
tasit
es/P
lant
ago
com
p.; P
hyto
lacc
a co
mp.
; Pla
ntag
o co
mp.
; Pla
ntag
o la
nceo
lata;
Plan
tago
-Prim
ula c
um
Hyo
scya
mo
Poly
gala
sene
ga L
.D
ried
and
usua
lly fr
agm
ente
d ro
ot an
d ro
ot cr
own
of P
olyg
ala
sene
ga L
. or o
f cer
tain
oth
er cl
osely
relat
ed sp
ecie
s or o
f a m
ixtu
re
of th
ese P
olyg
ala s
peci
es.
(HAB
); Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
90%
), 1.
2.12
(eth
anol
50
%)
Répe
rtoire
de m
éd.
anth
r.: S
eneg
a
Poly
gona
tum
odo
ratu
m (M
ill.)
Dru
ceFr
esh,
und
ergr
ound
par
ts of
Pol
ygon
atum
odo
ratu
m (M
ill.)
Dru
cePh
. Eur
. 1.1
.7, H
AB 3
3dVe
spa c
rabr
o co
mp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
119
Poly
podi
um vu
lgar
e L.
Fres
h lea
ves o
f Pol
ypod
ium
vulg
are L
.Ph
.Eur
. 1.2
.5, A
PC 3
.8.1
(to
geth
er w
ith o
ther
fre
sh h
erba
l dru
gs 1
:4.1
pa
rts e
than
ol 2
5%),
3.8.
2.
Aspi
dium
/Sal
ix co
mp.
; Che
lidon
ium
co
mp.
Popu
lus t
rem
ula L
.Fr
esh
leave
s of P
opul
us tr
emul
a L.
Ph. E
ur. 1
.1.5
, 1.1
.10
(eth
anol
65%
) tog
ethe
r wi
th fr
esh
bark
1:1
(see
Po
pulu
s tre
mul
a, fre
sh
bark
), H
AB 3
3d
Berb
eris/
Saba
l com
p.; S
abal
/Sol
idag
o co
mp.
Popu
lus t
rem
ula L
.fre
sh b
ark
of P
opul
us tr
emul
a L.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
) tog
ethe
r with
lea
ves 1
:1 (s
ee P
opul
us
trem
ula,
fresh
leav
es)
Pote
ntill
a ere
cta (
L.) R
aeus
ch.
Who
le or
cut,
drie
d rh
izom
e, fre
ed fr
om th
e roo
ts, o
f Pot
entil
la
erec
ta (L
.) Ra
eusc
h. (P
. tor
men
tilla
Stok
es)
HAB
; Ph
.Eur
.Ph
.Eur
. 1.2
.12
(eth
anol
50
%)
Cora
llium
com
p.; H
ydra
stis c
omp.
; To
rmen
tilla
Pote
ntill
a ere
cta (
L.) R
aeus
ch.
Fres
h un
derg
roun
d pa
rts o
f Pot
entil
la er
ecta
(L.)
Raeu
sch.
, co
llect
ed d
urin
g sp
ring
HAB
Ph.E
ur. 1
.1.5
, HAB
21,
34
dTo
rmen
tilla
; Tor
men
tilla
com
p.
Pote
rium
see S
arco
pote
rium
spin
osum
(L.)
Spac
h.
Prim
ula f
arin
osa L
.Fr
esh
root
s of P
rimul
a far
inos
a L.
Ph.E
ur. 1
.4.2
Prim
ula v
eris
L.Fr
esh
flowe
rs o
f Prim
ula v
eris
L.Ph
.Eur
. 1.2
.5, H
AB 2
1,
33c.
See A
pp.2
.6:
Prim
ula v
eris,
Flo
s rec
., et
hano
l. D
iges
tio (1
:3.1
) wi
th 0
.1-1
% H
yosc
yam
us
nige
r, H
erba
rec.
Ø;
Prim
ula v
eris,
Flo
s rec
., et
hano
l. D
iges
tio (1
: 12
.35)
with
0.6
%
Hyo
scya
mus
nig
er,
Her
ba re
c. Ø
;
Auru
m/O
nopo
rdon
com
p.; C
imici
fuga
co
mp.
; Con
valla
ria/P
rimul
a com
p.;
Crat
aegu
s com
p.; O
nopo
rdon
com
p.;
Ono
pord
on co
mp.
/Ado
nis;
Ono
pord
on
com
p./M
agne
sium
pho
spho
ricum
ac
idum
; Ono
pord
on co
mp.
/Olea
nder
; O
nopo
rdon
com
p./O
leand
er/ A
rnic
a; O
nopo
rdon
com
p./O
leand
er/
Conv
alla
ria; O
nopo
rdon
com
p./
Plum
bum
; Ono
pord
um/P
rimul
a com
p.;
Plan
tago
-Prim
ula c
um H
yosc
yam
o;
Prim
ula A
uro
culta
; Prim
ula A
uro
culta
co
mp.
Prim
ula v
eris
L.D
ried
flowe
rs o
f Prim
ula v
eris
L.D
ACH
AB 1
2gPr
imul
a com
p.
Prun
us d
ulcis
(Mill
er) D
. A.
Web
b va
r. du
lcis a
nd/o
r am
ara
(D. C
.) Bu
chhe
im
Fatty
oil
otai
ned
by co
ld ex
pres
sion
from
the r
ipe s
eeds
of P
runu
s du
lcis (
Mill
.) D
.A. W
ebb
var.
dulci
s or P
runu
s dul
cis (M
ill.)
D.A
. W
ebb
var.
amar
a (D
C.) B
uchh
eim
or a
mix
ture
of b
oth
varie
ties
Ph.E
ur.
API (
and
excip
ient
)O
leum
Pet
rae c
omp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
120
Prun
us d
ulcis
(Mill
.) D
.A.W
ebb
var.
amar
a (D
C.) B
uchh
eim
Drie
d, ri
pe se
eds o
f Pru
nus d
ulcis
(Mill
.) D
.A.W
ebb,
var.
amar
a (D
C.) B
uchh
eim
HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%)
Prun
us la
uroc
eras
us L
.Fr
esh
leave
s of P
runu
s lau
roce
rasu
s L.
HAB
Ph.E
ur. 1
.1.3
, see
also
Ap
p. 2
.7: L
auro
cera
sus
100%
Prun
us sp
inos
a L.
Juic
e fro
m th
e fru
it of
Pru
nus s
pino
sa L
.AP
ILo
tio P
runi
com
p.; P
runu
s spi
nosa
; Th
ymus
serp
yllu
m co
mp.
Prun
us sp
inos
a L.
Fres
h flo
wers
and
youn
g tip
s of s
hoot
s of P
runu
s spi
nosa
L.,
harv
este
d at
the b
egin
ning
of t
he b
loom
ing
seas
onPh
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Au
rum
/Pru
nus;
Levi
co co
mp.
; Pru
nus
spin
osa;
Prun
us sp
inos
a cum
Fer
ro;
Skor
odit
com
p.
Répe
rtoire
de m
éd.
anth
r.
Prun
us sp
inos
a L.
Fres
h flo
wers
of P
runu
s spi
nosa
L., c
ollec
ted
befo
re th
e pet
als
drop
off
HAB
Ph.E
ur. 1
.1.5
Prun
us sp
inos
a L.
Fres
h fr
uit o
f Pru
nus s
pino
sa L
.Ph
.Eur
. 1.1
.10
(eth
anol
45
%) H
AB 1
2o;
extra
ctio
n wi
th et
hano
l 24
,5%
(DER
1:4
)
Aesc
ulus
/Pru
nus c
omp.
; Ber
beris
/Eu
caly
ptus
/ Sili
cea c
omp.
; Ber
beris
/Pr
unus
; Ber
beris
/Sili
cea c
omp.
; Cac
tus/
Crat
aegu
s com
p.; E
chin
acea
/Pru
nus
com
p.; P
runu
s spi
nosa
; Pru
nus/
Rosm
arin
us co
mp.
Répe
rtoire
de m
éd.
anth
r.
Prun
us sp
inos
a L.
Fres
h yo
ung
tips o
f sho
ots o
f Pru
nus s
pino
sa L
., col
lecte
d so
me
week
s afte
r flow
erin
gH
ABPh
.Eur
. 1.1
.7, H
AB 2
2Aq
ua M
aris
com
p.; A
qua M
aris/
Prun
us
spin
osa,
Sum
mita
tes;
Auru
m/P
runu
s; Cr
atae
gus/
Prun
us co
mp.
; For
mic
a/Pr
unus
spin
osa;
Prun
us sp
inos
a
Prun
us sp
inos
a L.
Fully
ope
ned
drie
d flo
wers
of P
runu
s spi
nosa
L.
DAC
HAB
12g
Mal
va co
mp.
; Pru
nus s
pino
sa
Psyc
hotr
ia ip
ecac
uanh
a (Br
ot.)
Stok
esD
ried
unde
rgro
und
orga
ns o
f Psy
chot
ria ip
ecac
uanh
a (Br
ot.)
Stok
es.
HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%),
1.2.
12 (e
than
ol
(70%
)
Acid
um h
ydro
chlo
ricum
com
p.;
Cocc
ulus
/Oleu
m P
etra
e com
p.;
Dro
sera
/Ipec
acua
nha c
omp.
; Ip
ecac
uanh
a; Si
rupu
s Thym
i com
p.
Répe
rtoire
de m
éd.
anth
r.: Ip
eca
Pter
idiu
m aq
uilin
um (L
.) Ku
hnFr
esh
leave
s of P
terid
ium
aqui
linum
(L.)
Kuhn
Ph.E
ur. 1
.2.5
, HAB
34c
, AP
C 3.
8.1
(toge
ther
with
ot
her f
resh
her
bal d
rugs
1:
4.1
part
s eth
anol
25%
), 3.
8.2
Aqui
linum
com
p.; A
rum
mac
ulat
um/
Pter
idiu
m aq
uilin
um; C
onch
ae co
mp.
; Rh
us/S
alix
com
p.
Pulm
onar
ia o
ffici
nalis
L.
Fres
h ae
rial p
arts
of P
ulm
onar
ia o
ffici
nalis
L., c
ollec
ted
at
flowe
ring
time
HAB
Ph.E
ur. 1
.1.3
Pulsa
tilla
vulg
aris
Mill
.W
hole
fresh
flow
erin
g pl
ants
of P
ulsa
tilla
vulg
aris
Mill
.H
AB; P
h.fr.
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
55%
)Ec
hina
cea c
omp.
; Meli
ssa/
Phos
phor
us
com
p.; P
ulsa
tilla
; Siru
pus Th
ymi c
omp.
Répe
rtoire
de m
éd.
anth
r.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
121
Pulsa
tilla
vulg
aris
Mill
.Fr
esh
flowe
rs o
f Pul
satil
la vu
lgar
is M
ill. w
ith ap
ical
leaf
hus
k.H
AB 3
3cAu
rum
/Pul
satil
la/S
pong
ia co
mp.
; Be
rber
is/N
icotia
na co
mp.
; Bry
onia
/Pu
lsatil
la co
mp.
; Disc
i com
p. cu
m
Pulsa
tilla
; Disc
i/Pul
satil
la co
mp.
cum
St
anno
; Disc
i/Visc
um co
mp.
cum
Ar
gent
o; H
irudo
com
p.; P
ulsa
tilla
Pyru
s malu
sse
e Malu
s syl
vestr
is M
ill.
Que
brac
hose
e Asp
idos
perm
a que
brac
ho-b
lanc
o Sc
hlec
hten
d.
Que
rcus
robu
r L. a
nd Q
uerc
us
petra
ea (M
att.)
Lie
bl.
Fres
h ba
rk fr
om yo
ung
twig
s, br
anch
es an
d sh
oots
of Q
uerc
us
robu
r L. a
nd Q
uerc
us p
etra
ea (M
att.)
Lie
bl.
HAB
12k
Aesc
ulus
/Pru
nus c
omp.
; Que
rcus
, Co
rtex
Que
rcus
robu
r L., Q
uerc
us
petra
ea (M
att.)
Lie
bl., Q
uerc
us
pube
scen
s Will
d.
Cut a
nd d
ried
bark
from
the f
resh
youn
g br
anch
es o
f Que
rcus
ro
bur L
., Q. p
etra
ea (M
att.)
Lie
bl. o
r Que
rcus
pub
esce
ns W
illd.
HAB
; Ph
.Eur
.Ph
.Eur
. 1.2
.12
(eth
anol
36
%),
1.4.
3, H
AB 1
2q,
APC
4.3
Aesc
ulus
/Que
rcus
com
p.; A
patit
/Co
ncha
e; Ar
gent
um/Q
uerc
us co
mp.
; Ca
lcium
carb
onic
um cu
m Q
uerc
u;
Caps
ella/
Majo
rana
com
p.; C
onch
ae/
Que
rcus
com
p.; C
orne
a/Le
visti
cum
co
mp.
; Lob
elia c
omp.
; Pet
asite
s com
p.
cum
Que
rcu;
Pha
rmak
olith
com
p.;
Que
rcus
com
p.; Q
uerc
us, C
orte
x
.
Ranu
ncul
us b
ulbo
sus L
.W
hole
fresh
flow
erin
g pl
ants
of R
anun
culu
s bul
bosu
s L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 4
5%)
Prim
ula A
uro
culta
com
p.
Raph
anus
sativ
us L
. var
nig
er
(Mill
.) J.
Kern
Fres
h un
derg
roun
d pa
rts o
f Rap
hanu
s sat
ivus
L. v
ar. n
iger
(Mill
.) J.
Kern
.H
ABPh
.Eur
. 1.1
.5
Raph
anus
sativ
us L
. var
. nig
er
(Mill
er) K
erne
rD
ried
root
of R
apha
nus s
ativ
us L
. var
. nig
er (M
iller
) Ker
ner
Ph.fr
.Ph
.Eur
. 1.1
.11
(eth
anol
55
%)
Rata
nhia
see K
ram
eria
tria
ndra
Rui
z. et
Pav
.
Rauv
olfia
serp
entin
a (L.
) Be
ntha
m ex
Kur
zW
hole
or cu
t, dr
ied
root
s of R
auvo
lfia s
erpe
ntin
a (L.
) Ben
tham
ex
Kurz
DAB
; HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%),
1.2.
12 (e
than
ol
70%
)
Rauw
olfia
serp
entin
a
Resin
a Lar
icis
see L
arix
dec
idua
Mill
.
Fran
gula
alnu
s Mill
.Fr
esh
bark
of t
he st
ems a
nd b
ranc
hes o
f Fra
ngul
a aln
us M
ill.
HAB
Ph.E
ur. 1
.1.5
, HAB
33c
, 33
eTr
opae
olum
com
p.
Rheu
m o
fficin
ale B
aillo
n, R
heum
pa
lmat
um L
.Rh
ubar
b co
nsist
s of t
he w
hole
or cu
t, dr
ied
unde
rgro
und
part
s of
Rheu
m p
alm
atum
L. o
r of R
heum
offi
cinal
e Bai
llon
or o
f hyb
rids
of th
ese t
wo sp
ecie
s or o
f a m
ixtu
re. Th
e und
ergr
ound
par
ts ar
e oft
en d
ivid
ed; t
he st
em an
d m
ost o
f the
bar
k wi
th th
e roo
tlets
are
rem
oved
.
Ph.E
ur.
Ph. E
ur. 1
.1.8
(eth
anol
70
%)
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
122
Rheu
m rh
apon
ticum
L.
Who
le or
cut,
drie
d un
derg
roun
d pa
rts o
f Rhe
um rh
apon
ticum
L.
Ph.E
ur. 1
.1.8
(eth
anol
90
%)
Vade
mec
um: R
heum
rh
apon
ticum
(ext
.)
Rhod
oden
dron
chry
sant
hum
Pa
ll., R
hodo
dend
ron
aure
um
Geo
rgi
Drie
d lea
fy tw
igs o
f Rho
dode
ndro
n ca
mpy
loca
rpum
Hoo
k. f.
and
Rhod
oden
dron
aure
um G
eorg
i or t
heir
hybr
ids,
allo
ne o
r m
ixtu
res t
here
of
HAB
Ph.E
ur. 1
.1.8
(eth
anol
90
%)
Rhod
oden
dron
ferr
ugin
eum
L.
Fres
h, fl
ower
ing,
leaf
y, tw
igs o
f Rho
dode
ndro
n fe
rrug
ineu
m L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Ré
perto
ire d
e méd
. an
thr
Rhus
toxi
code
ndro
n L.
Fres
h, yo
ung
leafy
twig
s of R
hus t
oxic
oden
dron
L., h
arve
sted
in
sum
mer
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r.
Rhus
toxi
code
ndro
n L.
(T
oxic
oden
dron
que
rcifo
lium
(M
ichx.
) Gre
ene
Fres
h, yo
ung,
not
yet l
igni
fied
shoo
ts of
Rhu
s tox
icod
endr
on L
. wi
th le
aves
BP; H
ABPh
.Eur
. 1.1
.3, 1
.1.1
0 (e
than
ol 6
5%),
HAB
33d
Rhus
toxi
code
ndro
n L.
(T
oxic
oden
dron
que
rcifo
lium
(M
ichx.
) Gre
ene
Fres
h lea
ves o
f Tox
icod
endr
on q
uerc
ifoliu
m (M
ichx.
) Gre
ene
Ph.E
ur. 1
.1.3
, 1.1
.10
(eth
anol
65%
), H
AB 3
3dAc
onitu
m co
mp.
; Api
s/Rh
us
toxi
code
ndro
n co
mp.
; Bry
onia
/For
mic
a co
mp.
; Disc
i/Rhu
s tox
icod
endr
on
com
p.; R
hus t
oxic
oden
dron
; Rhu
s to
xico
dend
ron
com
p.; R
hus/
Salix
com
p.
Ribe
s nig
rum
L.
Fres
h lea
ves o
f Rib
es n
igru
m L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
55%
)
Rici
nus c
omm
unis
L.Fa
tty o
il ob
tain
ed b
y col
d ex
pres
sion
from
the s
eeds
of R
icin
us
com
mun
is L.
Ph.E
ur.
API
Berb
eris/
Cheli
doni
um co
mp.
; Ber
beris
/Ju
nipe
rus c
omp.
Rici
nus c
omm
unis
L.D
ried
seed
s of R
icin
us co
mm
unis
L.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
90%
)
Robi
nia p
seud
oaca
cia L
.Fr
esh
bark
from
youn
g br
anch
es o
f Rob
inia
pse
udoa
caci
a L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 6
5%),
1.2.
9,
HAB
33e
Robi
nia c
omp.
Rosa
gal
lica L
., Ros
a dam
asce
na
Mill
. and
Ros
a cen
tifol
ia L
.Es
sent
ial o
il ob
tain
ed b
y ste
am d
estil
latio
n fro
m fr
esh
flowe
rs o
f su
itabl
e spe
cies
of t
he ge
nus R
osa,
part
icul
arly
Ros
a gal
lica L
., Ro
sa d
amas
cena
Mill
. and
Ros
a cen
tifol
ia L
.
Ph.E
ur. 3
.1.1
(eth
anol
96
%),
API (
HAB
16.
2)An
timon
it/Ro
sae a
ethe
roleu
m co
mp.
; Be
llado
nna /
Rosa
e aet
hero
leum
; Ci
nera
ria/R
osae
aeth
erol
eum
; Cor
nea/
Levi
sticu
m co
mp.
; Cor
pus v
itreu
m/
Hor
nerz
com
p.; E
chin
acea
/Qua
rz
com
p.; E
chin
acea
/Ros
ae ae
ther
oleu
m;
Euph
rasia
/Ros
ae ae
ther
oleu
m; I
ris
bovi
s com
p.; M
ercu
rialis
/ Ro
sae
aeth
erol
eum
; Ner
vus o
ptic
us co
mp.
; Ro
sa, F
los;
Rosa
e aet
hero
leum
/Sili
cea
collo
idal
is co
mp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
123
Rosa
dam
asce
na L
. and
Ros
a ce
ntifo
lia L
.Su
bsta
nce o
btai
ned
by st
epwi
se ex
tract
ion
with
pet
rolet
her a
nd
alco
hol f
rom
fres
h flo
wers
of R
osa d
amas
cena
L. a
nd R
osa
cent
ifolia
L. (
DER
ca. 5
00:1
)
API
Auru
m/L
avan
dula
e aet
hero
leum
/Ros
a
Rosa
L.
Fres
h flo
wers
of s
uita
ble s
pecie
s of t
he ge
nus R
osa L
., par
ticul
arly
da
rk re
d te
a hyb
rids
HAB
37a
Ferr
um ro
satu
m/G
raph
ites;
Rosa
, Flo
s
Rosa
gal
lica L
., Ros
a cen
tifol
ia L
., Ro
sa d
amas
cena
Mill
.D
ried
buds
and
peta
ls of
suita
ble s
pecie
s of t
he ge
nus R
osa L
., pa
rtic
ular
ly R
osa g
allic
a L., R
osa c
entif
olia
L., R
osa d
amas
cena
M
ill. a
s well
as d
ark
red
tea h
ybrid
s
HAB
12f
Rosa
, Flo
s
Rosa
cent
ifolia
L.
Fres
h pe
tals
of R
osa c
entif
olia
L.
see A
pp.2
.6: F
erru
m
rosa
tum
Cheli
doni
um/T
ereb
inth
ina l
arici
na
com
p.; R
osa,
Flos
Rosm
arin
us o
fficin
alis
L.Es
sent
ial o
il ob
tain
ed b
y ste
am d
istill
atio
n fro
m th
e flow
erin
g ae
rial p
arts
of R
osm
arin
us o
fficin
alis
L.Ph
.Eur
.AP
IAc
onitu
m/A
rnic
a com
p./A
pis;
Acon
itum
/Arn
ica c
omp.
/For
mic
a; Ac
onitu
m/N
icotia
na co
mp.
; Aes
culu
s, Co
rtex/
Rosm
arin
i aet
hero
leum
; Api
s/Ar
nica
com
p.; A
rcha
ngeli
ca co
mp.
; Ar
nica
com
p./C
upru
m; A
rnic
a com
p./
Form
ica;
Arni
ca/S
ymph
ytum
com
p.;
Cera
tum
ben
zoin
atum
; Cup
rum
/Qua
rz
com
p.; E
chin
acea
/Visc
um co
mp.
; M
ajora
na/Th
uja c
omp.
; Oleu
m
lact
agog
um; P
rimul
a com
p.; P
runu
s/Ro
smar
inus
com
p.; R
esin
a Lar
icis/
Solu
tio M
yrrh
ae b
alsa
mic
a; Ro
smar
ini
aeth
erol
eum
/Tab
acum
; Ros
mar
inus
co
mp.
; Ros
mar
inöl
; Sal
Mar
is co
mp.
; Sa
lvia
e aet
hero
leum
com
p.; S
olut
io
Myr
rhae
bal
sam
ica;
Vesp
a cra
bro
com
p.
Rosm
arin
us o
fficin
alis
L.Fr
esh
leave
s of R
osm
arin
us o
fficin
alis
L.H
ABPh
.Eur
. 1.1
.5Be
toni
ca/R
osm
arin
us; R
osm
arin
us
Rosm
arin
us o
fficin
alis
L.Fr
esh
flowe
ring
twig
s of R
osm
arin
us o
fficin
alis
L.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
)Ro
smar
inus
; Ros
mar
inus
com
p.
Rosm
arin
us o
fficin
alis
L.W
hole
drie
d lea
f of R
osm
arin
us o
fficin
alis
L.(H
AB);
Ph.E
ur.
Ph.E
ur. 1
.1.8
(eth
anol
90
%),
1.4.
4Be
toni
ca/R
osm
arin
us; R
osm
arin
us
Rum
ex cr
ispus
L.
Fres
h un
derg
roun
d pa
rts o
f Rum
ex cr
ispus
L., h
arve
sted
at th
e en
d of
the v
eget
atio
n pe
riod
HAB
Ph.E
ur. 1
.1.3
, 1.1
.10
(eth
anol
45%
)Ru
mex
crisp
us
Ruta
gra
veol
ens L
.Fr
esh
aeria
l par
ts of
Rut
a gra
veol
ens L
., col
lecte
d at
the s
tart
of
flowe
ring
HAB
Ph.E
ur. 1
.1.5
, HAB
33c
Cheli
doni
um/T
ereb
inth
ina l
arici
na
com
p.; R
uta g
rave
olen
s; Sy
mph
ytum
co
mp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
124
Ruta
gra
veol
ens L
.Fr
esh,
aeria
l, un
ligni
fied
part
s of R
uta g
rave
olen
s L. h
arve
sted
befo
re fl
ower
ing
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Répe
rtoire
de m
éd.
anth
r.
Saba
dilla
see S
choe
noca
ulon
offi
cina
le (C
ham
. et S
chlec
hten
d.) A
. Gra
y
Saba
l ser
rulat
umse
e Ser
enoa
repe
ns (W
. Bar
tram
) Sm
all.
Sabi
nase
e Jun
iper
us sa
bina
L.
Sacc
haru
m o
ffici
naru
m L
.Ca
ram
el ob
tain
ed th
roug
h th
e roa
sting
of s
ucro
se fr
om
Sacc
haru
m o
ffici
naru
m L
.Ph
.Eur
. 3.1
.1 (D
1 wi
th
purifi
ed w
ater
), 3.
1.2,
3.
1.3,
4.1
.1 (t
oget
her
with
Ani
si fr
uctu
s)
Anis-
Pyrit
; Bas
ilicu
m co
mp.
; Cr
atae
gus/
Ferr
um si
dere
um/
Sacc
haru
m to
stum
Sacc
haru
m to
stum
see S
acch
arum
offi
cina
rum
L.
Salix
alba
ssp.
vite
llina
(L.)
Arch
ang.
Fres
h ba
rk an
d lea
ves o
f Sal
ix al
ba ss
p. vi
telli
na (L
.) Ar
chan
g.H
AB 3
3dH
yper
icum
/Pas
siflor
a com
p.; P
assifl
ora
com
p.; R
hus/
Salix
com
p.
Salix
pur
pure
a L.
Fres
h ba
rk an
d lea
ves o
f Sal
ix p
urpu
rea L
.H
AB 3
3dH
yper
icum
/Pas
siflor
a com
p.; R
hus/
Salix
com
p.
Salix
spec
ies
Fres
h lea
ves o
f Sal
ix al
ba, s
sp. a
lba L
. and
/or s
sp. v
itelli
na (L
.) Ar
chan
g. an
d/or
Sal
ix p
urpu
rea L
. and
/or S
alix
vim
inal
is L.
Ph.E
ur. 1
.2.5
, APC
3.8
.2,
etha
nolic
mac
erat
ion
(eth
anol
25%
)
Aspi
dium
/Sal
ix co
mp.
; Che
lidon
ium
co
mp.
Salix
spec
ies
Who
le or
frag
men
ted
drie
d ba
rk o
f you
ng b
ranc
hes o
r who
le dr
ied
piec
es o
f cur
rent
-yea
r twi
gs o
f var
ious
spec
ies o
f gen
us S
alix
in
cludi
ng S
. pur
pure
a L., S
. dap
hnoi
des V
ill. a
nd S
. fra
gilis
L.
Ph.E
ur.
Ph.E
ur. 1
.2.1
2 (e
than
ol
36%
)
Salix
vim
inal
is L.
Fres
h ba
rk an
d lea
ves o
f Sal
ix vi
min
alis
L.H
AB 3
3dH
yper
icum
/Pas
siflor
a com
p.; R
hus/
Salix
com
p.
Salv
ia o
ffici
nalis
L.
Thuj
one-
rich
esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
from
the
aeria
l par
ts of
Sal
via o
ffici
nalis
L.
DAC
API
Cera
tum
Rat
anhi
ae co
mp.
; Majo
rana
/Th
uja c
omp.
; Pru
nus/
Rosm
arin
us
com
p.; R
atan
hia c
omp.
; Sal
viae
ae
ther
oleu
m co
mp.
; Thym
us se
rpyl
lum
co
mp.
Salv
ia o
ffici
nalis
L.
Fres
h lea
ves o
f Sal
via o
ffici
nalis
L.
HAB
Ph.E
ur. 1
.1.5
, HAB
33d
, 12
cAr
chan
gelic
a/Py
rit co
mp.
; Cal
endu
la/
Echi
nace
a com
p.
Salv
ia o
ffici
nalis
L.
Who
le or
cut,
drie
d lea
ves o
f Sal
via o
ffici
nalis
L.
Ph.E
ur.
Ph.E
ur. 1
.2.1
3 (e
than
ol
70%
), AP
ICi
chor
ium
/Tar
axac
um co
mp.
; Fra
garia
/Ur
tica c
omp.
; Lev
istic
um co
mp.
; Sal
via
com
p.
Sam
bucu
s nig
ra L
.Fr
esh
pith
from
bra
nche
s of S
ambu
cus n
igra
L.
HAB
35a
Flor
es S
ambu
ci co
mp.
/Qua
rz;
Sam
bucu
s com
p.
Sam
bucu
s nig
ra L
.D
ried
pith
from
bra
nche
s of S
ambu
cus n
igra
L.
Ph.E
ur. 1
.2.1
2 (e
than
ol
36%
)Fl
ores
Sam
buci
com
p./Q
uarz
; Sa
mbu
cus c
omp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
125
Sam
bucu
s nig
ra L
.Fr
esh,
blo
omin
g flo
wer h
eads
of S
ambu
cus n
igra
L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
45
%)
Répe
rtoire
de m
éd.
anth
r.: S
ambu
cus
nigr
a, flo
s
Sam
bucu
s nig
ra L
.Fr
esh
inflo
resc
ence
s of S
ambu
cus n
igra
L.
HAB
33c
Phyt
olac
ca co
mp.
; Sam
bucu
s com
p.
Sam
bucu
s nig
ra L
.D
ried
flowe
rs o
f Sam
bucu
s nig
ra L
.Ph
.Eur
.H
AB 1
2gFl
ores
Sam
buci
com
p./Q
uarz
; Mal
va
com
p.; S
ambu
cus c
omp.
Sam
bucu
s nig
ra L
.Eq
ual p
arts
of fr
esh
leave
s and
inflo
resc
ence
s of S
ambu
cus n
igra
L.
HAB
Ph.E
ur. 1
.1.5
Sam
bucu
s/Te
ucriu
m co
mp.
Sang
uina
ria ca
nade
nsis
L.D
ried
unde
rgro
und
part
s of S
angu
inar
ia ca
nade
nsis
L., c
ollec
ted
in au
tum
nH
ABPh
.Eur
. 1.1
.8 (e
than
ol
70%
), 1.
2.12
(eth
anol
70
%)
Calen
dula
com
p.; O
xalis
com
p.;
Sang
uina
ria; S
angu
inar
ia co
mp.
Sani
cula
euro
paea
L.
Fres
h wh
ole fl
ower
ing
plan
t of S
anic
ula e
urop
aea L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
45%
)Ci
chor
ium
com
p.
Saro
tham
nus s
copa
rius
see C
ytisu
s sco
pariu
s (L.
) Lin
k.
Sars
apar
illa
see S
mila
x sp
ecie
s
Scho
enoc
aulo
n offi
cinal
e (Ch
am.
et S
chlec
hten
d.) A
. Gra
y (Sy
n.:
Saba
dilla
offi
cinar
um B
rand
t &
Ratz
eb.)
Drie
d rip
e see
ds o
f Sch
oeno
caul
on o
fficin
ale (
Cham
. et
Schl
echt
end.
) A. G
ray.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
), 1.
1.10
(eth
anol
65
%)
Bryo
nia/
Eupa
toriu
m co
mp.
; Fer
rum
ph
osph
oric
um co
mp.
Scill
ase
e Urg
inea
mar
itim
a (L.
) Bak
.
Scol
open
driu
mse
e Phy
llitis
scol
open
driu
m (L
.) N
ewm
.
Seca
le co
rnut
umse
e Clav
iceps
pur
pure
a (Fr
.) Tu
l.
Sedu
m ac
re L
.Fr
esh
aeria
l par
ts of
Sed
um ac
re L
., col
lecte
d at
flow
erin
g tim
eH
ABPh
.Eur
. 1.1
.3
Selen
icere
us g
rand
iflor
us (L
.) Br
itt. e
t Ros
eFr
esh
youn
g ste
m an
d flo
wers
of S
eleni
cere
us g
rand
iflor
us (L
.) Br
itt. e
t Ros
e.H
ABPh
.Eur
. 1.1
.5, 1
.2.3
, HAB
33
dAr
nica
/Cac
tus c
omp.
; Aur
um/V
aler
iana
co
mp.
; Cac
tus g
rand
iflor
us; C
actu
s/Cr
atae
gus;
Cact
us/C
rata
egus
com
p.;
Cact
us/M
agne
sium
pho
spho
ricum
; Ca
ctus
/Meli
ssa c
omp.
; Cac
tus/
Stro
phan
tus k
ombe
; Cra
taeg
us co
mp.
; Sa
roth
amnu
s com
p.
Sem
ecar
pus a
naca
rdiu
m L
.D
ried
frui
t of S
emec
arpu
s ana
rcar
dium
L. (
Anac
ardi
um o
rient
ale
L.)
(HAB
); Ph
.Eur
.ac
c. to
mon
ogra
ph
Ph.E
ur. (
1.1.
10, e
than
ol
90%
) or H
AB
mon
ogra
ph (a
nd P
h.Eu
r. 1.
1.8)
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
126
Sene
cio
bico
lor (
Will
d.) T
od.
Fres
h ae
rial p
arts
of S
enec
io b
icol
or (W
illd.
) Tod
., col
lecte
d be
fore
flo
werin
gPh
.Eur
. 1.1
.7Ci
nera
ria m
ariti
ma;
Cine
raria
/Ros
ae
aeth
erol
eum
Sene
cio
jaco
baea
L.
Fres
h ae
rial p
arts
of S
enec
io ja
coba
ea L
., col
lecte
d at
flow
erin
g tim
eH
AB 3
3dSe
neci
o co
mp.
Sene
gase
e Pol
ygal
a sen
ega L
.
Senn
ase
e Cas
sia an
gusti
folia
Vah
l.
Sere
noa r
epen
s (W
. Bar
tram
) Sm
all (
Syn.
Sab
al se
rrul
ata
(Mich
aux)
T. N
utta
l ex
Schu
ltes &
Sc
hulte
s
Drie
d rip
e fru
it of
Ser
enoa
repe
ns (W
. Bar
tram
) Sm
all (
Syn.
Sab
al
serr
ulat
a (M
ichau
x) T
. Nut
tal e
x Sc
hulte
s & S
chul
tes
Ph.E
ur.;
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Berb
eris/
Saba
l com
p.; S
abal
/Sol
idag
o co
mp.
Sily
bum
mar
ianu
m (L
.) G
aert
n.M
atur
e fru
it, d
evoi
d of
the p
appu
s, of
Sily
bum
mar
ianu
m (L
.) G
aert
ner
HAB
; Ph
.Eur
.; Ph
.fr.
Acco
rdin
g to
the
relev
ant m
onog
raph
(H
AB o
r Ph.
fr.)
Aesc
ulus
/Que
rcus
com
p.; A
naga
llis
com
p.; C
ardu
us m
aria
nus;
Card
uus
mar
ianu
s/ V
iscum
Mal
i com
p.; C
ardu
us
mar
ianu
s/O
xalis
; Che
lidon
ium
com
p.;
Lyco
podi
um co
mp.
Smila
x ar
istol
ochi
ifolia
Mill
. (S
yn.: S
. med
ica S
chlec
hten
d. et
Ch
am)
Drie
d un
derg
roun
d pa
rts o
f Sm
ilax
arist
oloc
hiifo
lia M
ill. (
S.
med
ica S
chlec
hten
d. et
Cha
m) a
nd re
lated
spec
ies
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.10
(eth
anol
55
%),
1.2.
12 (e
than
ol
70%
)
Répe
rtoire
de m
éd.
anth
r.: S
arsa
paril
la
Sola
num
dul
cam
ara L
.Fr
esh
flowe
rs o
f Sol
anum
dul
cam
ara L
.Ph
.Eur
. 1.2
.11;
dec
octio
n wi
th w
ater
and
etha
nol
96%
(12:
9.5)
(DER
1:
2.15
)
Dul
cam
ara/
Lysim
achi
a
Sola
num
dul
cam
ara L
.D
ried,
lign
ified
stem
s of S
olan
um d
ulca
mar
a L.
DAB
6
Erg.
B.Aq
ueou
s dec
octio
n to
geth
er w
ith o
ther
dr
ugs
Siru
pus Th
ymi c
omp.
Sola
num
dul
cam
ara L
.Fr
esh,
youn
g, b
loom
ing,
leaf
y-ste
m o
f Sol
anum
dul
cam
ara L
.Ph
.fr.
Ph.E
ur. 1
.1.1
0 (e
than
ol
45%
)
Sola
num
lyco
pers
icum
see L
ycop
ersic
on ly
cope
rsic
um (L
.) Ka
rst.
ex F
arw.
Solid
ago
virg
aure
a L.
Fres
h in
flore
scen
ce o
f Sol
idag
o vi
rgau
rea L
.H
AB; P
h.fr.
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
55%
)Aq
uilin
um co
mp.
; Sab
al/S
olid
ago
com
p.
Solid
ago
virg
aure
a L.
Fres
h ae
rial p
arts
of S
olid
ago
virg
aure
a L., c
ollec
ted
at fl
ower
ing
time
HAB
12c
, 33c
Aesc
ulus
/Pru
nus c
omp.
; Ber
beris
/Ju
nipe
rus c
omp.
; Sci
lla co
mp.
; Sol
idag
o vi
rgau
rea
Solu
m u
ligin
osum
Fres
h m
oist
peat
from
moo
rland
[e.g
. upl
and
moo
r]se
e App
. 2.6
: Pea
t mos
s ex
tract
com
posit
ion
I an
d Pe
at m
oss e
xtra
ct
com
posit
ion
II
Solu
m u
ligin
osum
com
p.Va
dem
ecum
: Sol
um
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
127
Spar
tium
scop
ariu
mse
e Cyt
isus s
copa
rius (
L.) L
ink.
Spig
elia a
nthe
lmia
L.
Drie
d ae
rial p
arts
of Sp
igeli
a ant
helm
ia L
.H
ABPh
.Eur
. 1.1
.8 (e
than
ol
90%
)
Spin
acia
oler
acea
L.
Fres
h un
derg
roun
d pa
rts o
f Spi
naci
a oler
acea
L.
HAB
34f
Frag
aria
/Urt
ica c
omp.
; Sen
ecio
com
p.
Spira
ease
e Fili
pend
ula u
lmar
ia (L
.) M
axim
.
Spiri
tus e
vino
see V
itis v
inife
ra L
.
Stac
hys o
fficin
alis
(L.)
Trev
.Fr
esh
aeria
l par
ts of
Stac
hys o
fficin
alis
(L.)
Trev
., col
lecte
d at
flo
werin
g tim
eH
ABPh
.Eur
. 1.1
.5, 1
.1.1
0 (e
than
ol 6
5%)
Beto
nica
/Ros
mar
inus
Stap
hysa
gria
see D
elphi
nium
stap
hisa
gria
L.
Stic
tase
e Lob
aria
pul
mon
aria
(L.)
Hoff
m.
Stra
mon
ium
see D
atur
a stra
mon
ium
L.
Stro
phan
thus
kom
be O
liv.
Fatty
oil
from
the s
eeds
of S
troph
anth
us k
ombe
Oliv
.AP
ICi
nis A
rnic
ae co
mp.
; Oleu
m
Stro
phan
thi;
Ono
pord
on co
mp.
/Ado
nis
Stro
phan
thus
kom
be O
liv.
Drie
d rip
e see
ds o
f Stro
phan
thus
kom
bé O
liv.
Ph.E
ur. 1
.2.6
(eth
anol
70
%),
HAB
35b
Auru
m/S
troph
anth
us k
ombe
; Aur
um/
Valer
iana
com
p.; C
actu
s/St
roph
antu
s ko
mbe
; Nico
tiana
/Stro
phan
tus c
omp.
; O
leum
Stro
phan
thi;
Stro
phan
thus
co
mp.
; Stro
phan
thus
kom
be
Stry
chno
s ign
atii
P.J. B
ergi
usD
ried,
ripe
seed
s of S
tryc
hnos
igna
tii J.
P. Be
rgiu
s.Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
), 1.
1.10
(eth
anol
65
%, 3
-5 w
eeks
), H
AB
35b
Apis
regi
na/A
urum
com
p.; I
gnat
ia;
Igna
tia co
mp.
; Sep
ia co
mp.
Stry
chno
s nux
-vom
ica L
.D
ried,
ripe
seed
s of S
tryc
hnos
nux
-vom
ica L
.Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
), 1.
1.10
(eth
anol
65
%);
HAB
35b
Cocc
ulus
/Oleu
m P
etra
e com
p.;
Gen
tiana
com
p.; N
icotia
na/N
ux vo
mic
a co
mp.
; Nux
vom
ica;
Nux
vom
ica c
omp.
; Rh
us/S
alix
com
p.; R
obin
ia co
mp.
Styr
ax to
nkin
ensis
see B
enzo
e
Sym
phyt
um o
fficin
ale L
.Fr
esh
unde
rgro
und
part
s of S
ymph
ytum
offi
cinal
e L.
HAB
Ph.E
ur. 1
.1.5
, 1.2
.11,
H
AB 3
4cAl
lium
cepa
/Ten
do co
mp.
; Ant
imon
it co
mp.
; Arn
ica c
omp.
; Arn
ica/
Sym
phyt
um co
mp.
; Art
icul
atio
ta
locr
ural
is co
mp.
; Sal
via c
omp.
; St
annu
m/S
ymph
ytum
com
p.;
Sym
phyt
um; S
ymph
ytum
com
p.
Sym
phyt
um o
fficin
ale L
.Fr
esh
aeria
l par
ts of
Sym
phyt
um o
fficin
ale L
., col
lecte
d at
flo
werin
g tim
eH
AB 1
2cAr
gent
um/U
rtic
a com
p.; C
alen
dula
/Ur
tica c
omp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
128
Syzy
gium
arom
atic
um (L
.) M
err.
et L
. M. P
erry
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
from
the d
ried
flowe
r bu
ds o
f Syz
ygiu
m ar
omat
icum
(L.)
Mer
r. et
L. M
. Per
ry (s
yn.
Euge
nia c
aryo
phyl
lus [
Spre
ng.]
Bullo
ck et
S.G
. Har
rison
)
Ph.E
ur.
API
Cera
tum
Rat
anhi
ae co
mp.
; Rat
anhi
a co
mp.
; Res
ina L
aric
is/So
lutio
Myr
rhae
ba
lsam
ica;
Solu
tio M
yrrh
ae b
alsa
mic
a; Sp
iritu
s con
tra tu
ssim
; Spi
ritus
Meli
ssae
co
mp.
Syzy
gium
arom
atic
um (L
.) M
err.
et L
. M. P
erry
Who
le flo
wer b
uds o
f Syz
ygiu
m ar
omat
icum
(L.)
Mer
r. et
L.M
. Pe
rry (
syn.
Eug
enia
cary
ophy
llus [
Spre
ng.]
Bullo
ck et
S.G
. H
arris
on) d
ried
until
they
bec
ome r
eddi
sh-b
rown
Ph.E
ur.
Ph.E
ur. 1
.2.1
3; et
hano
lic
disti
llate
(tog
ethe
r with
ot
her d
rugs
)
Absin
thiu
m/C
aryo
phyl
li co
mp.
; Ce
ntau
rium
com
p.
Taba
cum
see N
icot
iana
taba
cum
L.
Tara
xacu
m o
ffici
nale
F.H. W
igg.
(fr
.: Tar
axac
um o
ffici
nale
Web
er)
Who
le fre
sh fl
ower
ing
plan
ts of
Tar
axac
um o
ffici
nale
F.H. W
igg.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.3, 1
.1.1
0 (e
than
ol 4
5%),
HAB
21,
34
c
Agro
pyro
n co
mp.
; Ana
galli
s com
p.;
Aqui
linum
com
p.; C
helid
oniu
m co
mp.
; Ch
ryso
splen
ium
com
p.; C
ichor
ium
/Ta
raxa
cum
com
p.; G
entia
na co
mp.
; Ta
raxa
cum
; Tar
axac
um St
anno
cultu
m;
Tara
xacu
m St
anno
cultu
m/H
epar
Bov
is
Tara
xacu
m o
ffici
nale
F.H. W
igg.
Fres
h un
derg
roun
d pa
rts o
f Tar
axac
um o
ffici
nale
F.H. W
igg.
co
llect
ed in
autu
mn
(aut
umna
le) o
r spr
ing
(ver
nale)
HAB
34c
; Ph.
Eur.
1.1.
2 (th
e lat
ex o
nly i
s pr
oces
sed)
Tara
xacu
m
Tart
arus
crud
usse
e Viti
s vin
ifera
L.
Teuc
rium
mar
um L
.Fr
esh
flowe
ring,
aeria
l par
ts of
Teu
criu
m m
arum
L.
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
65%
)Ré
perto
ire d
e méd
. an
thr.
Teuc
rium
scor
odon
ia L
.Fr
esh
aeria
l par
ts of
flow
erin
g pl
ants
of T
eucr
ium
scor
odon
ia L
.H
AB; P
h.fr.
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
65%
)Ka
lium
/Teu
criu
m co
mp.
; Sam
bucu
s/Te
ucriu
m co
mp.
; Teu
criu
m sc
orod
onia
Teuc
rium
scor
odon
ia L
.D
ried
aeria
l par
ts of
flow
erin
g pl
ants
of T
eucr
ium
scor
odon
ia L
.AP
I, AP
C 4.
3Sp
ecie
s pul
mon
ales
; Teu
criu
m
scor
odon
ia
Thuj
a occ
iden
talis
L.
Fres
h lea
fy b
ranc
hes o
f Thuj
a occ
iden
talis
L., c
ollec
ted
pref
erab
ly
in sp
ring
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
65
%)
Thuj
a occ
iden
talis
L.
Fres
h, le
afy,
one-
year
-old
twig
s of Th
uja o
ccid
enta
lis L
.H
ABPh
.Eur
. 1.1
.5, H
AB 1
2c,
22, 3
3eAr
gent
um n
itric
um co
mp.
; Arg
entu
m/
Urtic
a com
p.; C
alen
dula
/Urt
ica c
omp.
; M
ajora
na/Th
uja c
omp.
; Prim
ula A
uro
culta
com
p.; S
abal
/Sol
idag
o co
mp.
; Th
uja c
omp.
; Thuj
a occ
iden
talis
; Thuj
a oc
cide
ntal
is Ar
gent
o cu
lta; V
espa
cr
abro
com
p.
Thym
us se
rpyl
lum
L. e
men
d.
Mill
.W
hole
or cu
t, dr
ied,
flow
erin
g ae
rial p
arts
of Th
ymus
serp
yllu
m L
.Ph
.Eur
.D
ecoc
tion
with
wat
er,
toge
ther
with
oth
er
herb
al d
rugs
Siru
pus Th
ymi c
omp.
; Thym
us
serp
yllu
m co
mp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
129
Thym
us vu
lgar
is L.
, Th
ymus
zygi
s L.
Esse
ntia
l oil
obta
ined
by s
team
dist
illat
ion
from
the f
resh
flo
werin
g ae
rial p
arts
of Th
ymus
vulg
aris
L., T
. zyg
is L.
or a
m
ixtu
re o
f bot
h sp
ecie
s
Ph.E
ur.
HAB
12i
, API
Echi
nace
a/Pr
unus
com
p.; M
ajora
na/
Thuj
a com
p.; O
leum
rhin
ale;
Plan
tago
co
mp.
; Thym
i aet
hero
leum
; Thym
us
serp
yllu
m co
mp.
Thym
us vu
lgar
is L.
Fres
h ae
rial p
arts
of Th
ymus
vulg
aris
L., c
ollec
ted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.1.5
Thym
us vu
lgar
is L.
, Th
ymus
zygi
s L.
Who
le lea
ves a
nd fl
ower
s sep
arat
ed fr
om th
e pre
viou
sly d
ried
stem
s of Th
ymus
vulg
aris
L. o
r Thym
us zy
gis L
. or a
mix
ture
of
both
spec
ies.
Ph.E
ur.
Dec
octio
n wi
th w
ater
, to
geth
er w
ith o
ther
he
rbal
dru
gs
Siru
pus Th
ymi c
omp.
Tilia
cord
ata M
iller
, Ti
lia p
latyp
hyllo
s Sco
poli
Fres
h in
flore
scen
ce o
f Tili
a cor
data
Mill
er an
d Ti
lia p
latyp
hyllo
s Sc
opol
iH
AB 3
4Ph
.Eur
. 1.1
.5Fl
ores
Sam
buci
com
p./Q
uarz
Tilia
cord
ata M
iller
, Tili
a pl
atyp
hyllo
s Sco
poli,
Tili
a x
vulg
aris
Hey
ne
Who
le, d
ried
inflo
resc
ence
of T
ilia c
orda
ta M
iller
, of T
ilia
plat
yphy
llos S
cop.
, of T
ilia x
vulg
aris
Hey
ne o
r a m
ixtu
re o
f the
sePh
.Eur
.H
AB 1
2gM
alva
com
p.
Torm
entil
lase
e Pot
entil
la er
ecta
(L.)
Raeu
sch.
Toxi
code
ndro
nse
e Rhu
s tox
icode
ndro
n L.
Toxi
code
ndro
n qu
ercif
oliu
mse
e Rhu
s tox
icode
ndro
n L.
Triti
cum
aesti
vum
L.
Fatty
oil
obta
ined
from
the g
erm
of t
he g
rain
of T
ritic
um ae
stivu
m
L. b
y col
d ex
pres
sion
or o
ther
suita
ble m
echa
nica
l mea
ns an
d/or
by
extra
ctio
n. It
is th
en re
fined
.
Ph.E
ur.
API
Berb
eris/
Cheli
doni
um co
mp.
Triti
cum
aesti
vum
L. e
men
d.
Fior
i et P
aol.
Fres
h ge
rmin
ated
frui
t of T
ritic
um ae
stivu
m L
. em
end.
Fio
ri et
Pa
ol.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
), H
AB 3
3dH
irnsta
mm
/Trit
icum
Triti
cum
aesti
vum
L. e
men
d.
Fior
i et P
aol.
Fres
h pa
rts p
roje
ctin
g ou
t of t
he in
flore
senc
e spi
kelet
of T
ritic
um
aesti
vum
L. e
men
d. F
iori
et P
aol.
HAB
33d
Triti
cum
aesti
vum
L. e
men
d.
Fior
i et P
aol.
Drie
d ge
rm o
f the
gra
in o
f Trit
icum
aesti
vum
L. e
men
d Fi
ori e
t Pa
ol.
API
Hirn
stam
m/T
ritic
um; L
evist
icum
co
mp.
Triti
cum
aesti
vum
L. e
men
d.
Fior
i et P
aol.
Whe
at g
lute
nSt
artin
g m
ater
ial f
or th
e pr
epar
atio
n of
Cal
icum
sil
icicu
m co
mp.
(app
. 2.
6)
Triti
cum
repe
nsse
e Ely
mus
repe
ns (L
.) G
ould
Triti
cum
aesti
vum
L. e
men
d.
Fior
i et P
aol.
Drie
d in
flore
scen
ces o
f Trit
icum
aesti
vum
L. e
men
d. F
iori
et P
aol.
Ph.E
ur. 1
.1.1
0 (e
than
ol
65%
), 4.
1.1
(and
then
3.
2.1)
Flor
es T
ritici
com
p.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
130
Trop
aeol
um m
ajus L
.Fr
esh
aeria
l par
ts of
Tro
paeo
lum
maju
s L., c
ollec
ted
at fl
ower
ing
time
HAB
12c
, 33b
, 33c
Belli
s/Tr
opae
olum
; Cal
endu
la/
Trop
aeol
um co
mp.
; Pla
cent
a/Tr
opae
olum
; Tro
paeo
lum
com
p.
Tulip
a silv
estr
is L.
Fres
h wh
ole fl
ower
ing
plan
t of T
ulip
a silv
estr
is L.
HAB
33a
Vade
mec
um: T
ulip
a
Urgi
nea m
ariti
ma (
L.) B
aker
se
nsu
latio
re (e
.g. U
rgin
ea
num
idic
a [Jo
rd. e
t Fou
rr.] G
rey)
Fres
h, fl
eshy
scal
e lea
ves o
f the
red-
scal
ed su
bspe
cies
of U
rgin
ea
mar
itim
a (L.
) Bak
er se
nsu
latio
re (e
.g. U
rgin
ea n
umid
ica [
Jord
. et
Four
r.] G
rey)
with
a cle
arly
det
ecta
ble s
cilli
rosid
e con
tent
HAB
Ph.E
ur. 1
.1.5
, 1.2
.3, H
AB
33b
Adon
is/Sc
illa c
omp.
; Con
valla
ria/
Prim
ula c
omp.
; Sci
lla al
ba; S
cilla
com
p.
Urtic
a dio
ica L
.W
hole,
fres
h, fl
ower
ing
plan
ts of
Urt
ica d
ioic
a L.
HAB
; Ph
.Eur
.Ph
.Eur
. 1.1
.3, 1
.1.4
, 1.
1.10
(eth
anol
45%
), H
AB 3
3c; e
xtra
ctio
n wi
th et
hano
l 73%
and
sucr
ose (
3:2)
(D
rug:
excip
ient
1:0
.9)
Aqua
Mar
is co
mp.
; Ber
beris
e fr
uctib
us
com
p.; C
helid
oniu
m co
mp.
; Fer
rum
sil
icic
um co
mp.
; Fra
garia
/Urt
ica;
Frag
aria
/Urt
ica/
Gen
tiana
; Tro
paeo
lum
co
mp.
; Urt
ica d
ioic
a
Urtic
a dio
ica L
.Fr
esh
aeria
l par
ts of
Urt
ica d
ioic
a L.
Ph.E
ur. 1
.1.4
, 1.1
.7 an
d 4.
2.1,
HAB
21
Conc
hae/
Ferr
um u
stum
com
p.; F
erru
m
ustu
m co
mp.
; Urt
ica d
ioic
a; Ur
tica
dioi
ca F
erro
culta
Urtic
a dio
ica L
.D
ried
flowe
rs o
f Urt
ica d
ioic
a L.
Ph.E
ur. 1
.2.1
3, in
fusio
n wi
th et
hano
l 33%
(DER
1:
6) o
r with
wat
er
toge
ther
with
oth
er
herb
al d
rugs
Caps
ella/
Majo
rana
com
p.
Urtic
a dio
ica L
.D
ried,
aeria
l par
ts wi
th m
axim
um 3
mm
thick
stem
s of U
rtic
a di
oica
L., c
ollec
ted
shor
tly b
efor
e flow
erin
gH
AB 1
2gAr
nica
/Lap
pa co
mp.
; Bet
ula/
Lapp
a co
mp.
; Lev
istic
um co
mp.
; Urt
ica d
ioic
a
Urtic
a dio
ica L
.Fr
esh
unde
rgro
und
part
s of U
rtic
a dio
ica L
.H
AB 2
1 (s
ee A
pp.2
.5
Urtic
a dio
ica F
erro
culta
, Ra
dix)
Urtic
a dio
ica;
Urtic
a dio
ica F
erro
culta
Urtic
a ure
ns L
.Fr
esh,
who
le flo
werin
g pl
ant o
f Urt
ica u
rens
L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
45
%)
Berb
eris,
Pla
nta t
ota/
Urtic
a ure
ns;
Prim
ula A
uro
culta
com
p.
Urtic
a ure
ns L
.Fr
esh,
flow
erin
g ae
rial p
arts
of U
rtic
a ure
ns L
.BP
; HAB
Ph.E
ur. 1
.1.3
, 1.1
.4, H
AB
12c,
33c
Arge
ntum
/Urt
ica c
omp.
; Arn
ica/
Urtic
a ur
ens;
Berb
eris/
Pros
tata
com
p.;
Berb
eris/
Saba
l com
p.; B
erbe
ris/S
epia
co
mp.
; Ber
beris
/Urt
ica u
rens
, Her
ba;
Berb
eris/
Ute
rus c
omp.
; Cal
endu
la/
Urtic
a com
p.; P
runu
s/Ro
smar
inus
co
mp.
; Urt
ica c
omp.
Urtic
a ure
ns L
.D
ried,
aeria
l par
ts of
Urt
ica u
rens
L.
Ph.E
ur. 1
.2.1
3 (e
than
ol
36%
), 1.
4.4
Berb
eris/
Urtic
a ure
ns, H
erba
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
131
Usne
a bar
bata
(L.)
Wig
g.D
ried
thal
lus f
rom
Usn
ea P.
Br.
ex A
dans
. spe
cies,
espe
cial
ly
Usne
a bar
bata
(L.)
Wig
g.Ph
.Eur
. 1.1
.10
(eth
anol
65
%);
extra
ctio
n wi
th
wate
r tog
ethe
r with
ot
her l
ichen
s (D
ER 1
:6)
Lich
enes
com
p.
Uva
urs
ise
e Arc
tosta
phyl
os u
va-u
rsi
Valer
iana
offi
cinal
is L.
Fres
h, u
nder
grou
nd p
arts
of V
aler
iana
offi
cinal
is L.
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
55
%)
Répe
rtoire
de m
éd.
anth
r.: V
aler
iana
offi
cinal
is, ra
dix
Valer
iana
offi
cinal
is L.
sens
u lat
iore
Fres
h un
derg
roun
d pa
rts o
f Val
eria
na o
fficin
alis
L. se
nsu
latio
reH
ABPh
.Eur
. 1.2
.9, H
AB 3
3c,
extra
ct w
ith w
ater
and
sucr
ose (
2:4:
4)
Auru
m/V
aler
iana
com
p.; A
vena
com
p.;
Aven
a sat
iva c
omp.
; Ave
na/P
assifl
ora
com
p.; C
inis
Arni
cae c
omp.
; H
yosc
yam
us/V
aler
iana
; Hyp
eric
um/
Pass
iflor
a com
p.; V
aler
iana
com
p.
Valer
iana
offi
cinal
is L.
Drie
d, w
hole
or fr
agm
ente
d un
derg
roun
d pa
rts o
f Val
eria
na
officin
alis
L. s.
l., in
cludi
ng th
e rhi
zom
e sur
roun
ded
by th
e roo
ts an
d sto
lons
(HAB
); Ph
.Eur
.Ph
.Eur
. 1.1
.8 (e
than
ol
70%
)
Vauc
heria
DC
spec
ies
Fres
h, w
hole
orga
nism
of V
auch
eria
DC
spec
ies
Ph.E
ur. 1
.1.5
, 1.1
.10
(eth
anol
65%
)Va
uche
ria
Vera
trum
albu
m L
.Ca
refu
lly d
ried
rhiz
ome w
ith at
tach
ed ro
ots o
f Ver
atru
m al
bum
L.
HAB
Ph.E
ur. 1
.1.8
(eth
anol
70
%),
1.2.
12 (e
than
ol
70%
)
Dro
sera
/Ipec
acua
nha c
omp.
; Ver
atru
m
albu
m
Vera
trum
albu
m L
.Fr
esh,
und
ergr
ound
par
ts of
Ver
atru
m al
bum
L.
HAB
33c
Equi
setu
m/R
enes
com
p.; S
koro
dit
com
p.; V
erat
rum
albu
m; V
erat
rum
co
mp.
Verb
ascu
m d
ensifl
orum
Ber
tol.
Fres
h, u
nrip
e fru
its o
f Ver
basc
um d
ensifl
orum
Ber
tol.
Ph.E
ur. 1
.1.7
Verb
ascu
m co
mp.
Vero
nica
offi
cinal
is L.
Drie
d ae
rial p
arts
of V
eron
ica o
fficin
alis
L., c
ollec
ted
at fl
ower
ing
time
HAB
Ph.E
ur. 1
.2.1
2 (e
than
ol
50%
), AP
C 4.
3Lo
belia
com
p.; V
eron
ica o
fficin
alis
Vero
nica
offi
cinal
is L.
Fres
h ae
rial p
arts
of V
eron
ica o
fficin
alis
L., c
ollec
ted
at fl
ower
ing
time
Ph. E
ur. 1
.1.3
, HAB
33c
Vero
nica
offi
cinal
is
Vinu
mse
e Viti
s vin
ifera
L.
Viol
a tric
olor
L.
Fres
h ae
rial p
arts
of V
iola
trico
lor L
., col
lecte
d at
flow
erin
g tim
eH
ABPh
.Eur
. 1.1
.3, H
AB 3
3eTr
opae
olum
com
p.
Viro
la se
bife
ra A
ubl.
Fres
h ju
ice o
f Viro
la se
bife
ra A
ubl.
obta
ined
by i
ncisi
ng th
e bar
k,
and
pres
erve
d wi
th an
appr
oxim
ately
equa
l vol
ume o
f eth
anol
(9
6%) (
Ph.E
ur.)
HAB
Ph.E
ur. 3
.1.1
(see
mon
. H
AB (s
ol. w
ith et
hano
l 70
%))
Myr
istic
a seb
ifera
; Myr
istic
a seb
ifera
co
mp.
Visc
um al
bum
ssp.
abie
tis
(Wie
sb.)
Abro
m.
Fres
h pl
ant i
nclu
ding
frui
t and
hau
storiu
m o
f Visc
um al
bum
ssp.
ab
ietis
(Wie
sb.)
Abro
m. (
Hos
t tre
e: Ab
ies s
pecie
s)H
AB 3
4gBe
rber
is/Pr
osta
ta co
mp.
; Visc
um al
bum
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
132
Visc
um al
bum
ssp.
abie
tis (B
eck)
(W
iesb
.) Ab
rom
. (Ab
ies p
ectin
ata
(Lam
.) D
C)
Fres
h pl
ant e
xclu
ding
hau
storiu
m o
f Visc
um al
bum
ssp.
abie
tis
(Bec
k) (W
iesb
.) Ab
rom
. (H
ost t
ree:
Abie
s alb
a Mill
. (Ab
ies
pect
inat
a (La
m.)
DC)
; fir)
APC
7.2.
2Vi
scum
albu
m
Visc
um al
bum
ssp.
albu
m L
.Fr
esh
plan
t inc
ludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m ss
p.
albu
m L
. (H
ost t
rees
: Pop
ulus
spec
ies)
HAB
33f
Visc
um al
bum
Visc
um al
bum
L. s
sp. a
ustr
iacu
m
(Wie
sb.)
Vollm
.Fr
esh
plan
t inc
ludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m L
. ss
p. au
stria
cum
(Wie
sb.)
Vollm
. (H
ost t
ree:
Pinu
s spe
cies
)H
AB 3
4gVi
scum
albu
m
Visc
um al
bum
ssp.
albu
m L
.Fr
esh
plan
t exc
ludi
ng h
austo
rium
of V
iscum
albu
m ss
p. al
bum
L.
(Hos
t tre
e: M
alus
dom
estic
a Bor
kh.; A
pple
tree)
APC
7.2.
2Vi
scum
albu
m
Visc
um al
bum
ssp.
austr
iacu
m
(Wie
sb.)
Vollm
.Fr
esh
plan
t exc
ludi
ng h
austo
rium
of V
iscum
albu
m ss
p.
austr
iacu
m (W
iesb
.) Vo
llm. (
Hos
t tre
e: Pi
nus s
ylve
stris
L.; P
ine)
APC
7.2.
2Vi
scum
albu
m
Visc
um al
bum
ssp.
albu
m L
.Fr
esh
haus
toriu
m o
f Visc
um al
bum
L ss
p. al
bum
(Hos
t tre
e: M
alus
spec
ies)
HAB
33e
Visc
um al
bum
Visc
um al
bum
L. s
sp. a
lbum
Drie
d pl
ant i
nclu
ding
frui
t, ex
cludi
ng h
austo
rium
of V
iscum
al
bum
L. s
sp. a
lbum
(Hos
t tre
es: O
ak sp
ecie
s)H
AB 3
8Vi
scum
albu
m
Visc
um al
bum
ssp.
albu
m L
.D
ried
plan
t inc
ludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m ss
p.
albu
m L
. (H
ost t
rees
: Cra
taeg
us sp
ecie
s)H
AB 3
8Vi
scum
albu
m
Visc
um al
bum
ssp.
albu
m L
.D
ried
plan
t inc
ludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m ss
p.
albu
m L
. (H
ost t
rees
: Sal
ix sp
ecie
s)H
AB 3
8Vi
scum
albu
m
Visc
um al
bum
ssp.
albu
m L
.D
ried
bran
ches
with
leav
es, fl
ower
s, fr
uit o
f Visc
um al
bum
ssp.
al
bum
L. (
Hos
t tre
es: M
alus
spec
ies)
HAB
12g
Visc
um al
bum
Visc
um al
bum
L. s
sp. a
lbum
Fres
h pl
ant i
nclu
ding
frui
t and
hau
storiu
m o
f Visc
um al
bum
ssp.
al
bum
L. (
Hos
t tre
e: M
alus
dom
estic
a Bor
kh.; A
pple
tree)
HAB
34i
Berb
eris/
Ute
rus c
omp.
; Bry
onia
/Vi
scum
com
p.; C
ardu
us m
aria
nus/
Vi
scum
Mal
i com
p.; C
artil
ago/
Hor
nerz
co
mp.
; Cor
pus v
itreu
m/H
orne
rz co
mp.
; D
isci c
omp.
cum
Pul
satil
la; D
isci/
Pulsa
tilla
com
p. cu
m St
anno
; Disc
i/Vi
scum
com
p. cu
m A
rgen
to; D
isci/
Visc
um co
mp.
cum
Stan
no; E
chin
acea
/Vi
scum
; Ech
inac
ea/V
iscum
com
p.;
Equi
setu
m/R
enes
com
p.; E
quise
tum
/Vi
scum
; Len
s cris
talli
na/V
iscum
com
p.
cum
Stan
no; L
ilium
tigr
inum
com
p.;
Mag
nesit
/Mam
ma c
omp.
; Mag
nesiu
m
sulfu
ricum
/Ova
ria co
mp.
; Visc
um
albu
m
Visc
um al
bum
ssp.
albu
m L
.Fr
esh
plan
t inc
ludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m ss
p.
albu
m L
. (H
ost t
ree:
Tilia
e spe
cies
; lim
e tre
e)H
AB 3
3fCr
atae
gus/
Visc
um; V
iscum
albu
m
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
133
Visc
um al
bum
L. s
sp. a
biet
is (W
iesb
.) Ja
nch.
Drie
d pl
ants
inclu
ding
frui
t and
hau
storiu
m o
f Visc
um al
bum
L.
ssp.
abie
tis (W
iesb
.) Ja
nch.
(Hos
t tre
e: Ab
ies s
pecie
s)H
AB 3
8Vi
scum
albu
m
Visc
um al
bum
ssp.
albu
m L
.D
ried
plan
ts in
cludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m ss
p.
albu
m L
. (H
ost t
ree:
Malu
s dom
estic
a Bor
kh.)
HAB
38
Visc
um al
bum
Visc
um al
bum
L. s
sp. a
ustri
acum
(W
iesb
.)Vol
lm.
Drie
d pl
ant i
nclu
ding
frui
t and
hau
storiu
m o
f Visc
um al
bum
L.
ssp.
austr
iacu
m (W
iesb
.)Vol
lm. (
host
tree:
Pinu
s spe
cies)
HAB
38
Visc
um al
bum
Visc
um al
bum
L. s
sp. a
lbum
Drie
d pl
ant i
nclu
ding
frui
t and
hau
storiu
m o
f Visc
um al
bum
L.
ssp.
albu
m (h
ost t
ree:
Popu
lus s
pecie
s)H
AB 3
8Vi
scum
albu
m
Visc
um al
bum
L. s
sp. a
lbum
Drie
d pl
ant i
nclu
ding
frui
t and
hau
storiu
m o
f Visc
um al
bum
L.
ssp.
albu
m (h
ost t
ree:
Tilia
spec
ies)
HAB
38
Visc
um al
bum
Visc
um al
bum
ssp.
abie
tis (B
eck)
(W
iesb
.) Ab
rom
.Fr
esh
one-
year
shoo
ts fro
m m
ale a
nd fe
mal
e pla
nts i
ncl.
ripe
berr
ies o
f the
win
ter h
arve
st (H
ost t
ree:
Abie
s alb
a)H
AB 3
2Vi
scum
albu
m
Vite
x ag
nus-
castu
s L.
whol
e, rip
e, dr
ied
frui
ts of
Vite
x ag
nus-
castu
s L.
(HAB
); Ph
.Eur
.; Ph
.fr.
Ph.E
ur. 1
.1.8
(eth
anol
70
%),
1.1.
10 (e
than
ol
65%
)
Meli
ssa/
Phos
phor
us co
mp.
Vitis
vini
fera
L.
Dist
illed
red
wine
vine
gar (
acet
um vi
ni d
estil
latum
)se
e App
. 2.6
(Kal
ium
ac
etic
um co
mp.
)An
agal
lis/M
alac
hit c
omp.
; Ch
amom
illa/
Mal
achi
t com
p.; K
aliu
m
acet
icum
com
p.
Vitis
vini
fera
L.
Red
wine
vine
gar (
acet
um vi
ni)
Dist
illat
ion
(to ge
t di
stille
d re
d wi
ne
vine
gar)
Vitis
vini
fera
L.
Drie
d lea
ves o
f Viti
s vin
ifera
L.
Ph.E
ur. 1
.2.1
2 (e
than
ol
36%
), AP
ICo
ncha
e/Fe
rrum
ustu
m co
mp.
; Fr
agar
ia/V
itis;
Vitis
com
p.
Vitis
vini
fera
L.
Dist
illat
e of w
ine
Vehi
cle fo
r pre
parin
g a
tinct
ure o
f Cro
cus
sativ
us (s
ee A
pp. 2
.6,
Kaliu
m ac
etic
um co
mp.
)
Vitis
vini
fera
L.
Crea
m o
f tar
tar (
Tart
arus
crud
us)
raw
mat
eria
l for
the
prod
uctio
n of
Tar
taru
s sti
biat
us an
d So
lutio
al
kalin
a
Vitis
vini
fera
L.
Whi
te w
ine
Dist
illat
ion
(for
prep
arin
g di
stilla
te o
f wi
ne),
raw
mat
eria
l for
th
e pro
duct
ion
of
Ferr
um-Q
uarz
(see
app.
2.
6)
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
134
Zing
iber
offi
cina
le Ro
scoe
Drie
d, w
hole
or cu
t rhi
zom
e of Z
ingi
ber o
ffici
nale
Rosc
oe, w
ith
the c
ork
rem
oved
, eith
er co
mpl
etely
or f
rom
the w
ide,
flat s
urfa
ces
only
Ph.E
ur.
Aque
ous e
xtra
ct to
geth
er
with
oth
er h
erba
l dru
gsG
entia
na/Z
ingi
ber c
omp.
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
defin
ition
of t
he p
art u
sed
Refe
renc
e to
Sta
ndar
dPr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
135
•
Ap
pend
ix 2
.3
APPENDIX 2.3
List of starting materials of zoological originAdditional Information, see p. 17-18 and pp. 65-71 Abbreviation *: p. 65
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
136
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
Acid
um F
orm
icae
(A
cidu
m fo
rmic
icum
e fo
rmic
a; Ac
idum
Fo
rmic
ae ve
nenu
m)
Seve
ral s
peci
es o
f woo
d an
ts of
th
e Sub
genu
s For
mic
a s. s
tr. (e
.g.
Form
ica l
ugub
ris Z
ett.,
F.
poly
cten
a För
ster,
F. pa
ralu
gubr
is Se
ifert
or F
. ruf
a L.)
Aque
ous s
olut
ion
of th
e sec
retio
n of
wo
od an
ts of
the s
ubge
nus F
orm
ica s
. str.
, co
ntai
ning
not
less
than
1.2
% m
/m o
f fo
rmic
acid
Ph.E
ur. 3
.1.1
, 3.1
.2; D
2 is
stand
ardi
zed
to
1.0%
form
ic ac
id
Liste
HAS
(10.
2012
)
Ambr
a gris
eaPh
yset
er ca
todo
n L.
(Phy
sete
r m
acro
ceph
alus
L.)
Subs
tanc
e pro
duce
d in
the d
iges
tive
syste
m o
f the
sper
m w
hale
HAB
; Ph.
fr.H
AB A
mbr
a gris
ea,
Ph.E
ur. 1
.1.1
1 (P
h.fr.
Et
hano
l 90%
)
Zinc
um va
leria
nicu
m co
mp.
Amni
onBo
s tau
rus L
.Am
nion
from
the b
ovin
e foe
tus
Ph.E
ur. 2
.2.2
Vade
mec
um: A
mni
on
Anus
Bos t
auru
s L.
Anus
from
the c
alf
Ph.E
ur. 2
.2.3
Prun
us/R
osm
arin
us co
mp.
Aort
aBo
s tau
rus L
.D
iffer
ent s
ectio
ns o
f the
aort
a fro
m th
e ca
lfPh
.Eur
. 2.2
.3Va
dem
ecum
[m
entio
ned
unde
r: At
ropa
bell
adon
na e
radi
ce]
Aort
aO
ryct
olag
us cu
nicu
lus L
.Ao
rta f
rom
the r
abbi
tPh
.Eur
. 2.1
.1IV
AA st
atem
ent 2
013
Apis
mell
ifica
Apis
mell
ifera
L.
Live
wor
ker h
oney
bee
(HAB
); Ph
.Eur
.ac
c.to
mon
ogra
ph
(60-
70%
etha
nol);
H
AB m
onog
raph
; Ph
.Eur
. 2.1
.1, 2
.1.2
, 2.
2.3
Acon
itum
/Arn
ica c
omp.
/Api
s; Ap
is co
mp.
; Api
s cum
Lev
istic
o; A
pis
mell
ifica
; Api
s/Ar
nica
; Api
s/Ar
nica
co
mp.
; Api
s/Be
llado
nna;
Apis/
Bella
donn
a/M
ercu
rius;
Apis/
Berb
eris
com
p.; A
pis/
Bryo
nia;
Apis/
Lary
nx
com
p.; A
pis/
Levi
sticu
m; A
pis/
Rhus
to
xico
dend
ron
com
p.; A
rnic
a/Le
visti
cum
com
p.; B
erbe
ris/P
yrit
com
p.; B
olus
Euc
alyp
ti co
mp.
; Br
yoni
a/Pu
lsatil
la co
mp.
; Bry
onia
/Sp
ongi
a com
p.; E
chin
acea
/Mer
curiu
s co
mp.
; Equ
isetu
m/R
enes
com
p.;
Euca
lypt
us co
mp.
; Mag
nesit
/Mam
ma
com
p.; M
agne
sium
sulfu
ricum
/Ova
ria
com
p.
Apis
regi
naAp
is m
ellife
ra L
.W
hole
quee
n ce
ll wi
th la
rvae
and
nour
ishin
g sa
pPh
.Eur
. 2.2
.3Ap
is re
gina
com
p.; A
pis r
egin
a/Au
rum
co
mp.
; Fra
garia
/Urt
ica c
omp.
; Ova
ria
com
p.; T
este
s com
p.
Apisi
num
Apis
mell
ifera
L.
Drie
d po
ison
from
the h
oney
bee
HAB
Mon
ogra
phBo
lus E
ucal
ypti
com
p.; Z
inno
ber
com
p.
Appe
ndix
verm
iform
isO
ryct
olag
us cu
nicu
lus L
.Ve
rmifo
rm p
roce
ss o
f the
blin
d gu
t fro
m
the r
abbi
tPh
.Eur
. 2.2
.2D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
137
Aran
ea av
icul
aris
Avic
ular
ia av
icul
aria
L.
Who
le bi
rd sp
ider
Ph.E
ur. 1
.1.9
(eth
anol
90
%),
1.1.
11 (e
than
ol
65%
)
Myg
ale c
omp.
IVAA
stat
emen
t 201
3
Aran
ea d
iade
ma
Aran
eus d
iade
mat
us C
lerk
Who
le di
adem
spid
er(H
AB 1
924)
Ph.E
ur. 1
.1.9
(HAB
19
24: 9
0% E
than
ol),
2.1.
1, 2
.2.3
Vade
mec
um: A
rane
a
Arte
ria b
asila
ris*
Bos t
auru
s L.
Arte
ria b
asila
ris fr
om th
e cal
fPh
.Eur
. 2.2
.3IV
AA st
atem
ent 2
013
Arte
ria b
rach
ialis
Bos t
auru
s L.
Arte
ria b
rach
ialis
from
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Arte
ria ca
rotis
co
mm
unis
et si
nus
caro
ticus
Bos t
auru
s L.
Part
s fro
m th
e Arte
ria ca
rotis
com
mun
is de
xtra
and
sinist
ra fr
om th
e cal
fPh
.Eur
. 2.2
.3Va
dem
ecum
: Arte
ria
caro
tis co
mm
unis
et
sinus
caro
ticus
Arte
ria ce
rebr
i med
ia*
Bos t
auru
s L.
Arte
ria ca
rotis
cere
bral
is an
d its
ra
mifi
catio
ns fr
om th
e cal
fPh
.Eur
. 2.2
.3Va
dem
ecum
: Arte
ria
cere
bri m
edia
Arte
ria co
eliac
ase
e Tru
ncus
coeli
acus
IVAA
stat
emen
t 201
3
Arte
ria co
rona
riaBo
s tau
rus L
.Ar
teria
coro
naria
from
the c
alf
Ph.E
ur. 2
.2.3
Vade
mec
um: A
rteria
co
rona
ria
Arte
ria fe
mor
alis
Bos t
auru
s L.
Arte
ria fe
mor
alis
from
the c
alf
Ph.E
ur. 2
.2.3
Vade
mec
um
[men
tione
d un
der:
Seca
le/Bl
eigl
anz c
omp.
]
Arte
ria o
phth
alm
ica*
Bos t
auru
s L.
Arte
ria o
phth
alm
ica e
xter
na fr
om th
e cal
fPh
.Eur
. 2.2
.3Va
dem
ecum
: Arte
ria
opht
halm
ica
Arte
ria p
oplit
eaBo
s tau
rus L
.Ar
teria
pop
litea
from
the c
alf
Ph.E
ur. 2
.2.3
Blei
glan
z/Se
cale
com
p.
Arte
ria p
ulm
onal
isBo
s tau
rus L
.Ar
teria
pul
mon
alis
from
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Arte
ria re
nalis
Bos t
auru
s L.
Arte
ria re
nalis
from
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Arte
ria ve
rtebr
alis
Bos t
auru
s L.
Part
s fro
m th
e Arte
ria ve
rtebr
alis
dext
ra
and
sinist
ra fr
om th
e cal
fPh
.Eur
. 2.2
.3
Arte
riae*
Bos t
auru
s L.
Part
s of A
rteria
bas
ilaris
, Arte
ria
brac
hial
is, A
rteria
coro
naria
, Arte
ria
fem
oral
is, A
rteria
mes
ente
rica,
Arte
ria
pulm
onal
is an
d Ar
teria
rena
lis fr
om th
e ca
lf
Ph.E
ur. 2
.2.3
Vade
mec
um: A
rteria
e
Artic
ulat
ioBo
s tau
rus L
.Th
e fol
lowi
ng ar
ticul
atio
ns: c
ubits
, gen
us,
hum
eri,
radi
ocar
pa, s
acro
iliac
a, su
btal
aris,
talo
crur
alis,
te
mpo
rom
andi
bula
ris
Ph.E
ur. 2
.2.2
, APC
3.
3.1
Liste
HAS
(10.
2012
) AB
MA-
Vade
mec
um:
Artic
ulat
io-A
rgen
tum
p.
49
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
138
Artic
ulat
io co
xae
Bos t
auru
s L.
Hip
join
t with
equa
l par
ts fro
m th
e ac
etab
ulum
, Cap
ut fe
mor
is, jo
int c
artil
age
and
Liga
men
tum
capi
tis fe
mor
is fro
m th
e ca
lf
Ph.E
ur. 2
.2.2
Artic
ulat
io co
xae
Artic
ulat
io cu
biti
Bos t
auru
s L.
Elbo
w jo
int w
ith p
arts
from
the b
ones
th
at fo
rm th
e joi
nt, j
oint
cart
ilage
, par
ts of
jo
int c
apsu
le, sy
novi
a and
par
ts of
the
ligam
ents
from
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Artic
ulat
io ge
nus
Bos t
auru
s L.
Knee
join
t with
par
ts fro
m th
e bon
es th
at
form
the j
oint
, men
iscus
, joi
nt ca
psul
e, lig
amen
ts, ca
rtila
ge an
d sy
novi
a fro
m th
e ca
lf
Ph.E
ur. 2
.2.2
Artic
ulat
io ge
nus
Artic
ulat
io h
umer
iBo
s tau
rus L
.Sh
ould
er jo
int w
ith p
arts
of th
e bon
es th
at
form
the j
oint
, car
tilag
e, pa
rts o
f the
join
t ca
psul
e and
the B
ursa
inte
rtube
rcul
aris
from
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um
[men
tione
d un
der:
Acon
it Sc
hmer
zöl]
Artic
ulat
io
inte
rpha
lang
eaBo
s tau
rus L
.Pa
rts o
f the
toe j
oint
from
the f
ore
extre
miti
es fr
om th
e cal
fPh
.Eur
. 2.2
.2Ca
rtila
go/E
chin
acea
com
p.
Artic
ulat
io
radi
ocar
pea
Bos t
auru
s L.
Radi
ocar
pal j
oint
with
par
ts of
the b
ones
, ca
rtila
ge, l
igam
ents
and
join
t cap
sule
that
fo
rm th
e pro
xim
al ca
rpal
join
t fro
m th
e ca
lf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Artic
ulat
io sa
croi
liaca
Bos t
auru
s L.
Part
s of I
lium
and
sacr
um fr
om th
e joi
nt
area
, joi
nt ca
psul
e and
liga
men
ts fro
m th
e ca
lf
Ph.E
ur. 2
.2.2
Der
Mer
kurs
tab:
So
nder
heft
1999
Artic
ulat
io su
btal
aris
Bos t
auru
s L.
Part
s of t
he ca
rtila
ge, j
oint
caps
ule a
nd
syno
via o
f the
par
t dist
al to
the O
s ce
ntro
quar
tale
of th
e joi
nt li
ke u
nion
be
twee
n Ta
lus a
nd C
alca
neus
from
the
calf
Ph.E
ur. 2
.2.2
Artic
ulat
io ta
locr
ural
is co
mp.
Artic
ulat
io ta
locr
ural
isBo
s tau
rus L
.Pa
rts o
f the
bon
es fo
rmin
g th
e joi
nt, T
ibia
an
d Ta
lus,
of th
e joi
nt ca
psul
e, lig
amen
ts as
well
as sy
novi
a of t
he an
kle j
oint
from
th
e cal
f
Ph.E
ur. 2
.2.2
Artic
ulat
io ta
locr
ural
is co
mp.
Artic
ulat
io
tem
poro
man
dibu
laris
Bos t
auru
s L.
Part
s of t
he O
s man
dibu
lare
and
of th
e Os
tem
pora
le in
the j
oint
area
, of t
he jo
int
caps
ule,
of th
e lig
amen
ts, o
f car
tilag
e, as
we
ll as
syno
via f
rom
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
139
Artic
ulat
ione
s in
terc
arpe
aeBo
s tau
rus L
.Pa
rts o
f the
bon
es fo
rmin
g th
e joi
nt, o
f th
e car
tilag
e lik
e sur
face
of t
he
artic
ulat
ion,
as w
ell as
syno
via f
rom
the
calf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Artic
ulat
ione
s in
terv
erte
bral
es
cerv
ical
es
Bos t
auru
s L.
Regi
on o
f the
cerv
ix: P
arts
of th
e bon
e pr
oces
sus t
hat p
artic
ipat
e to
the
inte
rver
tebr
al jo
ints,
cart
ilage
and
join
t ca
psul
es, a
s well
as sy
novi
a fro
m th
e cal
f
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Artic
ulat
ione
s in
terv
erte
bral
es
lum
bales
Bos t
auru
s L.
Regi
on o
f the
loin
: Par
ts of
the b
one
proc
essu
s tha
t par
ticip
ate t
o th
e in
terv
erte
bral
join
ts, ca
rtila
ge an
d jo
int
caps
ules
, as w
ell as
syno
via f
rom
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Ascid
iaSe
vera
l spe
cies o
f pro
to-
Chor
date
s of A
scid
ia g
roup
The w
hole
anim
alAP
C 3.
3.1
ABM
A-Va
dem
ecum
Ar
teria
e-Ba
rium
p. 4
8
Atla
s*Bo
s tau
rus L
.Pa
rts o
f the
Atla
s (1.
cerv
ical
) fro
m th
e ca
lfPh
.Eur
. 2.2
.2IV
AA st
atem
ent 2
013
Audi
tum
Bos t
auru
s L.
The w
hole
hear
ing
orga
n (p
arts
of co
chlea
fro
m th
e ske
letou
s as w
ell as
der
mal
par
ts of
the i
nner
ear f
rom
the c
alf
APC
3.3.
1AB
MA-
Vade
mec
um
Audi
tum
-Arg
entu
m p
. 51
Audi
tum
inte
rnum
Bos t
auru
s L.
Inte
rnal
hea
ring
orga
n (p
arts
of co
chlea
fro
m th
e ske
letou
s as w
ell as
der
mal
par
ts of
the i
nner
ear a
nd la
byrin
thus
from
the
calf
).
APC
3.3.
1AB
MA-
Vade
mec
um
Laby
rinth
us-M
ercu
rius
p. 1
61
Axis*
Bos t
auru
s L.
Part
s of t
he A
xis (
2. ce
rivic
al) f
rom
the
calf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Bron
chi
Bos t
auru
s L.
Bron
chi f
rom
the c
alf
Ph.E
ur. 2
.2.2
Bron
chi/P
lant
ago
com
p.
Bron
chi
Ory
ctol
agus
cuni
culu
s L.
Bron
chi f
rom
the r
abbi
tPh
.Eur
. 2.1
.1Br
onch
i/Pla
ntag
o co
mp.
Bulb
us o
lfact
oriu
s*Bo
s tau
rus L
.Bu
lbus
olfa
ctor
ius o
f bot
h he
misp
here
s of
the c
ereb
rum
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: B
ulbu
s ol
fact
oriu
s
Burs
ae ar
ticul
atio
nis
hum
eri-K
ompl
exBo
s tau
rus L
.Pa
rts o
f Bur
sa m
uscu
li in
frasp
inam
and
Burs
a int
ertu
berc
ular
is hu
mer
i fro
m th
e ca
lf
Ph.E
ur. 2
.2.2
Vade
mec
um: B
ursa
e ar
ticul
atio
nis h
umer
i-Ko
mpl
ex
Calca
rea c
arbo
nica
os
trear
umse
e Con
chae
Ph.fr
.
Calci
um ca
rbon
icum
H
ahne
man
nise
e Con
chae
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
140
Cant
haris
Lytta
vesic
ator
ia L
.As
far a
s pos
sible
inta
ct sp
ecim
ens,
kille
d an
d dr
ied
at a
tem
pera
ture
not
exce
edin
g 40
°C
HAB
Ph.E
ur. 1
.1.9
(HAB
: Et
hano
l 90%
), 2.
2.3
Arge
ntum
/Urt
ica c
omp.
; Cal
endu
la/
Urtic
a com
p.; C
anth
aris;
Can
thar
is co
mp.
; Hyp
eric
um co
mp.
; Uva
urs
i co
mp.
Vade
mec
um: C
anth
aris
Card
iaSu
s scr
ofa d
omes
tica L
.Ca
rdia
, par
ts of
the w
all o
f the
stom
ach
in
the r
egio
n of
the e
ntra
nce i
nto
the
stom
ach
from
the p
ig
Ph.E
ur. 2
.2.3
Vade
mec
um: C
ardi
a
Cart
ilago
Ory
ctol
agus
cuni
culu
s L.
Cart
ilage
of j
oint
from
the r
abbi
tPh
.Eur
. 2.1
.1
Cart
ilago
artic
ular
isBo
s tau
rus L
.Ca
rtila
ge o
f the
hip
, kne
e and
shou
lder
jo
ints
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.2Ca
rtila
go co
mp.
; Car
tilag
o/H
orne
rz
com
p.; C
artil
ago/
Man
drag
ora c
omp.
Cart
ilago
artic
ular
is co
xae
Bos t
auru
s L.
Cart
ilage
of t
he h
ip jo
int f
rom
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Cart
ilago
artic
ular
is ge
nus
Bos t
auru
s L.
Cart
ilage
of t
he k
nee j
oint
from
the c
alf
Ph.E
ur. 2
.2.2
Der
Mer
kurs
tab:
So
nder
heft
1999
Cavu
m ty
mpa
ni*
Bos t
auru
s L.
Part
s of t
he w
all o
f the
Cav
um ty
mpa
ni,
as w
ell as
audi
tory
bon
es fr
om th
e cal
fPh
.Eur
. 2.2
.2Va
dem
ecum
: Cav
um
tym
pani
Cera
flav
aW
ax o
btai
ned
by m
eltin
g th
e wal
ls of
the
hone
ycom
b m
ade b
y the
hon
ey-b
ee, A
pis
mell
ifera
L., w
ith h
ot w
ater
and
rem
ovin
g fo
reig
n m
atte
r
Ph.E
ur.
API
Aesc
ulus
/Cer
a com
p.; O
leum
Pet
rae
com
p.; P
lant
ago
com
p.
Cere
bellu
mO
ryct
olag
us cu
nicu
lus L
.Ce
rebe
llum
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
nica
/Epi
phys
is/Pl
umbu
m m
ellitu
m
com
p.; A
rnic
a/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Epi
phys
is co
mp.
; Aur
um/H
ypop
hysis
com
p.;
Cere
bellu
m co
mp.
; Epi
phys
is co
mp.
; G
naph
aliu
m co
mp.
; Hyp
ophy
sis co
mp.
Cere
bellu
m*
Bos t
auru
s L.
Cere
bellu
m fr
om th
e cal
fPh
.Eur
. 2.2
.1Ar
nica
/Epi
phys
is/Pl
umbu
m m
ellitu
m
com
p.; A
rnic
a/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Epi
phys
is co
mp.
; Aur
um/H
ypop
hysis
com
p.;
Cere
bellu
m co
mp.
; Epi
phys
is co
mp.
; G
naph
aliu
m co
mp.
; Hyp
ophy
sis co
mp.
Cere
brum
Bos t
auru
s L.
Cere
brum
from
the c
alf
see a
pp. 2
.6: A
rnic
a-Ce
rebr
umAr
nica
-Cer
ebru
m
Cere
brum
, reg
io
mot
oric
a*Bo
s tau
rus L
.G
rey m
atte
r of t
he G
yrus
pra
ecen
tralis
be
long
ing
to th
e Lob
us fr
onta
lis o
f bot
h he
misp
here
s fro
m th
e cal
f
Ph.E
ur. 2
.2.1
Vade
mec
um:
Cere
brum
, reg
io
mot
oric
a
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
141
Cerv
ix u
teri
Bos t
auru
s L.
Part
s of t
he n
eck
of th
e ute
rus f
rom
the
cow
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Circ
ulus
arte
riosu
s ce
rebr
i*Bo
s tau
rus L
.Ci
rcul
us ar
terio
sus c
ereb
ri of
the p
ituita
ry
shaft
from
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Cocc
us ca
cti
Dac
tylo
pius
cocc
us C
osta
The d
ried,
fert
ilize
d, fe
mal
e of
Dac
tylo
pius
cocc
us C
osta
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.9 (H
AB
etha
nol 9
0%),
1.1.
11
(eth
anol
65%
)
Dro
sera
/Ipec
acua
nha c
omp.
IVAA
stat
emen
t 201
3
Coch
lea*
Bos t
auru
s L.
Part
s of t
he C
ochl
ea fr
om th
e ske
letou
s as
well
as d
erm
al p
arts
of th
e inn
er ea
r fro
m
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um: C
ochl
ea
Cod
liver
oil
see I
ecor
is as
elli o
leum
Colo
nSu
s scr
ofa d
omes
tica L
.Co
lon
from
the p
igPh
.Eur
. 2.1
.1, 2
.2.3
Colo
n
Colo
nO
ryct
olag
us cu
nicu
lus L
.Co
lon
from
the r
abbi
tPh
.Eur
. 2.1
.1
Colo
n sig
moi
deum
Sus s
crof
a dom
estic
a L.
Colo
n sig
moi
deum
, par
ts of
the fi
nal t
ract
of
the C
olon
des
cend
ens f
rom
the p
igPh
.Eur
. 2.2
.3Co
lon
Vade
mec
um
[men
tione
d un
der:
Erys
idor
on® 1
; M
ercu
rius v
ivus
na
tura
lis]
Colu
mna
Bos t
auru
s L.
Part
s of s
pina
l cor
d fro
m th
e cal
fAP
C 3.
3.1
ABM
A-Va
dem
ecum
: Co
lum
na-A
rgen
tum
p.
97
Colu
mna
ante
rior*
Bos t
auru
s L.
Part
s of t
he co
lum
na an
terio
r of t
he sp
inal
ch
ord
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Colu
mna
pos
terio
r*Bo
s tau
rus L
.Pa
rts o
f the
colu
mna
pos
terio
r of d
iffer
ent
part
s of t
he sp
inal
chor
d fro
m th
e cal
fPh
.Eur
. 2.2
.1IV
AA st
atem
ent 2
013
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
142
Conc
hae
Ostr
ea ed
ulis
L. P
h.fr.
also
: Cr
asos
trea a
ngul
ata L
amk.
, Cr
asos
trea g
igas
Lam
k.
The i
nner
par
ts of
the s
hells
of t
he o
yste
rH
AB; P
h.fr.
HAB
-Mon
ogra
ph an
d Ph
.Eur
. 4.1
.1., A
PI
(Apa
tit/C
onch
ae)
Agar
icus
com
p./P
hosp
horu
s; Ap
atit/
Conc
hae;
Aven
a com
p.; A
vena
/Co
ncha
e com
p.; B
ariu
m co
mp.
; Br
yoph
yllu
m/C
onch
ae; C
ereb
ellum
co
mp.
; Con
chae
; Con
chae
com
p.;
Conc
hae/
Ferr
um u
stum
com
p.;
Conc
hae/
Que
rcus
com
p.; C
onva
llaria
/Pr
imul
a com
p.; F
raga
ria/U
rtic
a com
p.;
Hep
ar su
lfuris
; Hep
ar su
lfuris
com
p.;
Levi
sticu
m co
mp.
; Ono
pord
um/
Prim
ula c
omp.
; Pan
krea
s com
p.;
Prun
us/R
osm
arin
us co
mp.
; Sep
ia
com
p.; Th
yreo
idea
com
p.; U
rtic
a co
mp.
; Val
eria
na co
mp.
Vade
mec
um: C
onch
ae
Conj
unct
iva
Bos t
auru
s L.
Conj
unct
iva f
rom
the c
alf
Ph.E
ur. 2
.2.2
Conj
unct
iva c
omp.
Conn
ectiv
e tiss
uese
e Tex
tus c
onne
ctiv
us
Cor
Bos t
auru
s L.
Cor f
rom
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.3Ar
nica
, Pla
nta t
ota/
Cor;
Auru
m/C
or;
Calci
um ca
rbon
icum
/Mes
ench
ym
com
p.; C
onva
llaria
/Prim
ula c
omp.
; Co
r; Co
r/Cr
atae
gus c
omp.
; Cra
taeg
us
com
p.; O
rgan
um q
uadr
uplex
Cor
Bos t
auru
s L.
Part
s of t
he ep
icar
dium
, myo
card
ium
, en
doca
rdiu
m an
d th
e arte
rial
mus
culat
ure o
f the
hea
rt fr
om th
e cal
f
Ph.E
ur. 2
.1.1
, 2.2
.3Ca
lcium
carb
onic
um/M
esen
chym
co
mp.
; Con
valla
ria/P
rimul
a com
p.;
Cor;
Cor/
Crat
aegu
s com
p.; C
rata
egus
co
mp.
; Org
anum
qua
drup
lex
Cor
Ory
ctol
agus
cuni
culu
s L.
Cor f
rom
the r
abbi
tPh
.Eur
. 2.1
.1
Cora
llium
Seve
ral s
peci
es o
f Cor
al o
f the
ge
nus M
ussid
ae o
r Cor
allii
deae
or
Tra
chyp
hylii
deae
Frag
men
ted
part
s obt
aine
d by
co
mm
unitu
ng th
e fre
sh an
imal
APC
3.3.
1AB
MA-
Vade
mec
um:
Cora
llium
-Mill
efol
ium
-St
ibiu
m S
irim
im
Cora
llium
rubr
umCo
ralli
um ru
brum
L.
Frag
men
ted
part
s of t
he ch
alk
skele
ton
from
Cor
alliu
m ru
brum
, con
tain
ing
at
least
82%
CaC
O3
(Mr 1
00,1
)
HAB
Ph.E
ur. 4
.1.1
; see
also
ap
p. 2
.6 (K
aliu
m
acet
icum
com
p.)
Anag
allis
/Mal
achi
t com
p.; C
oral
lium
co
mp.
; Kal
ium
acet
icum
com
p.
Corn
eaBo
s tau
rus L
.Co
rnea
from
the c
alf
Ph.E
ur. 2
.2.3
Corn
ea/L
evist
icum
com
p.
Corn
u Ca
prae
ibec
isCa
pra i
bex
L.H
orn
from
the i
bex
Ph.E
ur. 4
.1.1
IVAA
stat
emen
t 201
3
Corn
u Ce
rvi
Cerv
us el
aphu
s L.
Antle
rs fr
om th
e dee
rPh
.Eur
. 4.1
.1M
edul
la sp
inal
is co
mp.
Liste
HAS
(10.
2012
)
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
143
Corp
ora
quad
rigem
ina*
Bos t
auru
s L.
Part
s of t
he L
amin
a tec
ti wi
th th
e Co
rpor
a qua
drig
emin
a fro
m th
e cal
fPh
.Eur
. 2.2
.1Ar
nica
/Epi
phys
is/Pl
umbu
m m
ellitu
m
com
p.; A
rnic
a/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Epi
phys
is co
mp.
; Aur
um/H
ypop
hysis
com
p.;
Epip
hysis
com
p.; G
naph
aliu
m co
mp.
; H
ypop
hysis
com
p.; N
ervu
s opt
icus
co
mp.
Corp
us
amyg
dalo
ideu
m*
Bos t
auru
s L.
Brai
n m
atte
r of t
he re
gion
of t
he C
orpu
s am
ygda
loid
eum
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: C
orpu
s am
ygda
loid
eum
Corp
us ci
liare
Ory
ctol
agus
cuni
culu
s L.
Corp
us ci
liare
from
the r
abbi
tPh
.Eur
. 2.1
.1
Corp
us lu
teum
Bos t
auru
s L.
Corp
us lu
teum
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.2M
eliss
a/Ph
osph
orus
com
p.
Corp
us lu
teum
Sus s
crof
a dom
estic
a L.
Corp
us lu
teum
from
the s
owPh
.Eur
. 2.1
.1M
eliss
a/Ph
osph
orus
com
p.
Corp
us vi
treum
Ory
ctol
agus
cuni
culu
s L.
Corp
us vi
treum
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
gent
um-C
orpu
s vitr
eum
; Cor
nea/
Levi
sticu
m co
mp.
; Cor
pus v
itreu
m-
Stan
num
; Cor
pus v
itreu
m/H
orne
rz
com
p.; C
orpu
s vitr
eum
/Suc
cinum
Corp
us vi
treum
*Bo
s tau
rus L
.Co
rpus
vitre
um fr
om th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.1
, 2.
2.2;
star
ting
mat
eria
l fo
r the
pro
duct
ion
of
Arge
ntum
-Cor
pus
vitre
um an
d Co
rpus
vi
treum
-Sta
nnum
(see
ap
p. 2
.6)
Arge
ntum
-Cor
pus v
itreu
m; C
orne
a/Le
visti
cum
com
p.; C
orpu
s vitr
eum
-St
annu
m; C
orpu
s vitr
eum
/Hor
nerz
co
mp.
; Cor
pus v
itreu
m/S
uccin
um
Corte
x ce
rebr
iO
ryct
olag
us cu
nicu
lus L
.Co
rtex
of th
e cer
ebru
m fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Crot
alus h
orrid
usCr
otalu
s hor
ridus
L.
Free
ze d
ried
poiso
n fro
m C
rota
lus
horr
idus
L.
HAB
HAB
Mon
ogra
phD
er M
erku
rsta
b 19
93;
46(3
): 28
8-29
7
Crot
alus t
errifi
cus
Crot
alus d
uriss
us te
rrifi
cus
Laur
enti
Free
ze d
ried
poiso
n fro
m C
rota
lus
duris
sus t
errifi
cus L
aure
nti
acc.
to m
onog
raph
La
ches
is H
ABN
aja co
mp.
Der
Mer
kurs
tab
1993
; 46
(3):
288-
297
Der
M
erku
rsta
b 20
05;
58(1
)32-
39
Cutis
(fet
i fem
ini)
Bos t
auru
s L.
The e
xter
nal s
kin
of a
ca. 5
mon
ths o
ld
fem
ale b
ovin
e foe
tus
Ph.E
ur. 2
.2.2
Prun
us/R
osm
arin
us co
mp.
Cutis
(fet
i)Bo
s tau
rus L
.Th
e ext
erna
l ski
n of
a 3
to 9
mon
ths o
ld
bovi
ne fo
etus
Ph.E
ur. 2
.2.2
Calen
dula
/Tro
paeo
lum
com
p.;
Echi
nace
a/Vi
scum
com
p.; V
espa
cr
abro
com
p.
Cutis
(fet
i)Su
s scr
ofa d
omes
tica L
.Th
e ext
erna
l ski
n fro
m th
e foe
tus o
f the
pi
gPh
.Eur
. 2.1
.1
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
144
Dac
tylo
pius
cocc
usse
e Coc
cus c
acti
Den
sBo
s tau
rus L
.Te
eth
from
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Dia
phra
gma
Bos t
auru
s L.
Mus
cula
r and
tend
inou
s par
ts of
the
diap
hrag
m fr
om th
e cal
fPh
.Eur
. 2.2
.2Va
dem
ecum
[m
entio
ned
unde
r: Re
gio
subs
tant
iae
nigr
ae]
Dia
phra
gma p
elvis
Bos t
auru
s L.
Part
s of t
he m
uscle
and
fasc
ies c
losin
g th
e pe
lvis,
inclu
ding
conn
ectiv
e tiss
ue fr
om
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um:
Dia
phra
gma p
elvis
Die
ncep
halo
n*Bo
s tau
rus L
.D
ienc
epha
lon
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Disc
i int
erve
rtebr
ales
Sus s
crof
a dom
estic
a L.
Inte
rver
tebr
al d
iscs o
f cer
vica
l spi
ne fr
om
the p
igPh
.Eur
. 2.1
.1
Disc
i int
erve
rtebr
ales
(c
ervi
cales
)Bo
s tau
rus L
.Fi
broc
artil
age o
f int
erve
rtebr
al d
iscs o
f ce
rvic
al sp
ine f
rom
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um
[men
tione
d un
der:
Disc
i int
erve
rtebr
ales
(fe
ti)]
Disc
i int
erve
rtebr
ales
(c
ervi
cales
, tho
raci
ci et
lu
mba
les)
Bos t
auru
s L.
Part
s of i
nter
verte
bral
disc
s of c
ervi
cal,
thor
acic
and
lum
bar s
pine
from
the c
alf
Ph.E
ur. 2
.2.2
Disc
i com
p. cu
m A
escu
lo; D
isci c
omp.
cu
m A
rgen
to; D
isci c
omp.
cum
Aur
o;
Disc
i com
p. cu
m N
icot
iana
; Disc
i co
mp.
cum
Pul
satil
la; D
isci c
omp.
cum
St
anno
; Disc
i com
p. cu
m St
ibio
; Disc
i/Pu
lsatil
la co
mp.
cum
Stan
no; D
isci/
Rhus
toxi
code
ndro
n co
mp.
; Disc
i/Vi
scum
com
p. cu
m A
rgen
to; D
isci/
Visc
um co
mp.
cum
Stan
no
Disc
i int
erve
rtebr
ales
(fe
ti)Bo
s tau
rus L
.In
terv
erte
bral
disc
s of d
iffer
ent r
egio
ns o
f th
e spi
ne fr
om a
3 to
9 m
onth
s old
bov
ine
foet
us
Ph.E
ur. 2
.1.1
, 2.2
.2D
iscus
inte
rver
tebr
alis
embr
yona
lis/
Solu
tio S
ilice
ae co
mp.
Vade
mec
um: D
isci
inte
rver
tebr
ales
(fet
i)
Disc
i int
erve
rtebr
ales
(lu
mba
les)
Bos t
auru
s L.
Inte
rver
tebr
al d
iscs o
f lum
bar s
pine
from
th
e cal
fPh
.Eur
. 2.2
.2Va
dem
ecum
[m
entio
ned
unde
r: D
isci i
nter
verte
bral
es
(feti)
]
Duc
tus c
holed
ochu
sSu
s scr
ofa d
omes
tica L
.D
uctu
s cho
ledoc
hus f
rom
the p
igPh
.Eur
. 2.2
.3D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Duc
tus t
hora
cicu
sBo
s tau
rus L
.D
uctu
s tho
raci
cus f
rom
the c
alf
Ph.E
ur. 2
.2.3
Bora
go/R
enes
com
p.
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
145
Duo
denu
mSu
s scr
ofa d
omes
tica L
.Pa
rts o
f duo
denu
m fr
om th
e pig
Ph.E
ur. 2
.2.3
Vade
mec
um
[men
tione
d un
der:
Plex
us g
astri
cus]
Dur
a mat
er en
ceph
ali*
Bos t
auru
s L.
Dur
a mat
er en
ceph
ali f
rom
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Endo
card
ium
Bos t
auru
s L.
Endo
card
ium
from
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Endo
met
rium
Bos t
auru
s L.
Endo
met
rium
from
the c
owPh
.Eur
. 2.2
.3En
dom
etriu
m co
mp.
Epid
idym
isBo
s tau
rus L
.Le
ft ep
idid
ymis
from
the b
ull
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Epip
hysis
Ory
ctol
agus
cuni
culu
s L.
Part
s of t
he ep
iphy
sis fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Arni
ca/E
piph
ysis/
Plum
bum
mell
itum
co
mp.
; Aur
um/E
piph
ysis
com
p.;
Epip
hysis
; Epi
phys
is co
mp.
; Epi
phys
is/Pl
umbu
m; G
naph
aliu
m co
mp.
Epip
hysis
*Bo
s tau
rus L
.Pa
rts o
f the
epip
hysis
from
the c
alf
Ph.E
ur. 2
.2.1
Arni
ca/E
piph
ysis/
Plum
bum
mell
itum
co
mp.
; Aur
um/E
piph
ysis
com
p.;
Epip
hysis
; Epi
phys
is co
mp.
; Epi
phys
is/Pl
umbu
m; G
naph
aliu
m co
mp.
Eryt
rocy
tes
Equu
s prz
ewal
skii
f. ca
ballu
s PO
LIAK
OV
Eryt
hroc
ytes
from
the b
lood
of t
he h
orse
Ph.E
ur. 2
.2.4
IVAA
stat
emen
t 201
3
Fasc
icul
us
atrio
vent
ricul
aris
Bos t
auru
s L.
Part
s of t
he co
nduc
tion
syste
m o
f the
he
art,
His´
s bun
dle a
nd P
urki
nje´
s fibe
r fro
m th
e cal
f
Ph.E
ur. 2
.2.3
Vade
mec
um: F
ascic
ulus
at
riove
ntric
ular
is
Fasc
icul
us o
ptic
us*
Bos t
auru
s L.
Fasc
icul
us o
ptic
us fr
om th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.1
Lam
ina/
Retin
a com
p.Li
ste H
AS (1
0.20
12)
Fel p
iscis
Salm
o tr
utta
L.
Bile
from
pre
dato
ry fi
sh, e
.g. t
rout
Ph.E
ur. 2
.1.1
Der
Mer
kurs
tab
2004
; 57
(3):
224
Fel t
auri
Bos t
auru
s L.
Fres
h bi
le fro
m g
all b
ladd
er fr
om th
e cal
fPh
.Eur
. 2.2
.1G
land
ulae
supr
aren
ales
com
p.
Fem
urBo
s tau
rus L
.Pa
rts o
f the
dia
phys
is of
os f
emor
is fro
m
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um: F
emur
Folli
culi
lym
phat
ici
aggr
egat
iSu
s scr
ofa d
omes
tica L
.Pa
rts o
f Pey
er’s
patc
h of
the s
mal
l in
testi
ne fr
om th
e pig
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
146
Form
ica
Form
ica r
ufa L
., For
mic
a po
lyct
ena F
ÖRS
TER
Live
wor
ker a
nts
HAB
; Ph.
fr.Ph
.Eur
. 2.1
.1, 2
.2.3
H
AB m
onog
raph
; di
lutio
ns P
h.Eu
r. 1.
1.9;
Ph
.fr. m
onog
raph
(e
than
ol 6
5%)
Extra
ctio
n wi
th
glyc
erol
85%
to ge
t an
API w
ith 2
.4%
form
ic
acid
. see
also
Aci
dum
Fo
rmic
ae
Acon
itum
/Arn
ica c
omp.
/For
mic
a; Ae
scul
us/C
era c
omp.
; Api
s com
p.;
Arni
ca co
mp.
; Arn
ica c
omp.
/For
mic
a; Ar
nica
, Pla
nta t
ota/
Form
ica;
Arni
ca/
Form
ica c
omp.
; Arn
ica/
Lapp
a com
p.;
Auru
m/O
nopo
rdon
com
p.;
Bella
donn
a/Be
tula
/For
mic
a; Be
tula
/Ar
nica
com
p.; B
etul
a/La
ppa c
omp.
; Br
yoni
a/Fo
rmic
a com
p.; C
artil
ago
com
p.; D
isci c
omp.
cum
Aes
culo
; Disc
i co
mp.
cum
Arg
ento
; Disc
i com
p. cu
m
Auro
; Disc
i com
p. cu
m N
icot
iana
; D
isci c
omp.
cum
Pul
satil
la; D
isci
com
p. cu
m St
anno
; Disc
i com
p. cu
m
Stib
io; D
isci/P
ulsa
tilla
com
p. cu
m
Stan
no; D
isci/R
hus t
oxic
oden
dron
co
mp.
; Disc
i/Visc
um co
mp.
cum
Ar
gent
o; D
isci/V
iscum
com
p. cu
m
Stan
no; E
quise
tum
arve
nse/
Form
ica;
Form
ica;
Form
ica D
3/Fo
rmic
a D15
; Fo
rmic
a/O
xalis
; For
mic
a/Pr
unus
sp
inos
a; Le
ns cr
istal
lina/
Visc
um co
mp.
cu
m St
anno
; Mag
nesiu
m
phos
phor
icum
com
p.; M
andr
agor
a co
mp.
Vade
mec
um: F
orm
ica
Form
ica p
arva
Lasiu
s nig
erLi
ve w
orke
r ant
sPh
.Eur
. 2.1
.1Fl
ores
Trit
ici c
omp.
Liste
HAS
(10.
2012
)
Funi
culu
s um
bilic
alis
Bos t
auru
s L.
Funi
culu
s um
bilic
alis
from
a bo
vine
fo
etus
bet
ween
the t
hird
and
nint
h m
onth
of
pre
gnan
cy
Ph.E
ur. 2
.2.2
Bora
go/R
enes
com
p.; C
alen
dula
/Tr
opae
olum
com
p.; E
chin
acea
/Visc
um
com
p.; M
agne
sit/M
amm
a com
p.;
Mag
nesiu
m su
lfuric
um/O
varia
com
p.;
Prun
us/R
osm
arin
us co
mp.
Gal
ea ap
oneu
rotic
aBo
s tau
rus L
.Pa
rts o
f the
supe
rfici
al fa
scia
of t
he
fore
head
from
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Gin
giva
Bos t
auru
s L.
Gin
giva
from
the c
alf
Ph.E
ur. 2
.2.2
Calen
dula
/Ech
inac
ea co
mp.
; Pe
riodo
ntiu
m/S
ilice
a com
p.;
Perio
dont
ium
/Sta
nnum
com
p.
Gin
giva
Sus s
crof
a dom
estic
a L.
Gin
giva
from
the f
oetu
s of t
he p
igPh
.Eur
. 2.1
.1
Gla
ndul
a lac
rimal
isBo
s tau
rus L
.G
land
ula l
acrim
alis
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: G
land
ula
lacr
imal
is
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
147
Gla
ndul
a par
otis
Bos t
auru
s L.
Gla
ndul
ar ti
ssue
of t
he b
ody o
f the
pa
rotid
gla
nd fr
om th
e cal
fPh
.Eur
. 2.2
.1IV
AA st
atem
ent 2
013
Gla
ndul
a sup
rare
nales
Ory
ctol
agus
cuni
culu
s L.
Supr
aren
al g
land
from
the r
abbi
tPh
.Eur
. 2.1
.1
Gla
ndul
a sup
rare
nalis
Bos t
auru
s L.
Gla
ndul
a sup
rare
nalis
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1Ca
lendu
la/T
ropa
eolu
m co
mp.
; Cu
prum
-Ren
-Gla
ndul
a sup
rare
nalis
; G
land
ula s
upra
rena
lis; G
land
ula
supr
aren
alis/
Solu
tio F
erri
com
p.;
Gla
ndul
ae su
prar
enal
es co
mp.
Gla
ndul
a sup
rare
nalis
(C
orte
x)Bo
s tau
rus L
.G
land
ula s
upra
rena
lis (C
orte
x) fr
om th
e ca
lfPh
.Eur
. 2.2
.1IV
AA st
atem
ent 2
013
Gla
ndul
a sup
rare
nalis
(M
edul
la)
Bos t
auru
s L.
Med
ulla
gla
ndul
ae su
prar
enal
is of
bot
h ad
rena
l gla
nds f
rom
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Gla
ndul
a sup
rare
nalis
de
xtra
Bos t
auru
s L.
Gla
ndul
a sup
rare
nalis
dex
tra fr
om th
e ca
lfPh
.Eur
. 2.2
.1Cu
prum
/Gla
ndul
a sup
rare
nalis
dex
tra
Gla
ndul
a sup
rare
nalis
sin
istra
Bos t
auru
s L.
Gla
ndul
a sup
rare
nalis
sini
stra f
rom
the
calf
Ph.E
ur. 2
.2.1
Cupr
um/G
land
ula s
upra
rena
lis
sinist
ra; G
land
ula s
upra
rena
lis/
Mer
curiu
s
Gla
ndul
a Thym
usse
e Thym
us (G
land
ula)
Gla
ndul
a thy
reoi
dea
Bos t
auru
s L.
Gla
ndul
a thy
reoi
dea f
rom
the c
alf
Ph.E
ur. 2
.2.1
, 2.1
.1Co
lchic
um co
mp.
; Fer
rum
/Thyr
eoid
ea;
Gla
ndul
a thy
reoi
dea;
Thyr
eoid
ea
com
p.
Gla
ndul
a thy
reoi
dea
Ory
ctol
agus
cuni
culu
s L.
Gla
ndul
a thy
reoi
dea f
rom
the r
abbi
tPh
.Eur
. 2.1
.1Co
lchic
um co
mp.
; Fer
rum
/Thyr
eoid
ea;
Gla
ndul
a thy
reoi
dea;
Thyr
eoid
ea
com
p.
Gla
ndul
ae
para
thyr
eoid
eae
Bos t
auru
s L.
Gla
ndul
ae p
arat
hyre
oide
ae fr
om th
e cal
fPh
.Eur
. 2.2
.1Au
rum
/Par
athy
reoi
dea;
Para
thyr
eoid
ea co
mp.
; Pha
rmak
olith
co
mp.
Gla
ndul
ae
para
thyr
eoid
eae
Sus s
crof
a dom
estic
a L.
Gla
ndul
ae p
arat
hyre
oide
ae fr
om th
e pig
APC
3.3.
3 G
lyce
rol
mac
erat
e 1:1
000
(as
Ph.E
ur. 2
.1.1
)
Auru
m/P
arat
hyre
oide
a; Pa
rath
yreo
idea
com
p.; P
harm
akol
ith
com
p.
Gla
ndul
ae
supr
aren
ales
see G
land
ula s
upra
rena
lis
Glo
bus o
culi
Ory
ctol
agus
cuni
culu
s L.
Eyeb
all o
f the
rabb
itPh
.Eur
. 2.1
.1Ré
perto
ire d
e méd
. an
thr.:
Glo
be o
cula
ire
Gyr
us ci
ngul
i*Bo
s tau
rus L
.G
yrus
cing
uli f
rom
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
148
Hep
arBo
s tau
rus L
.Pa
rs in
term
edia
of t
he li
ver f
rom
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1Ca
lcium
carb
onic
um/M
esen
chym
co
mp.
; Car
duus
mar
ianu
s/ V
iscum
M
ali c
omp.
; Hep
ar; H
epar
-M
agne
sium
; Hep
ar/S
tann
um
met
allic
um A
; Hep
ar/S
tann
um
met
allic
um B
; Org
anum
qua
drup
lex;
Tara
xacu
m St
anno
cultu
m/H
epar
Bo
vis
Hep
arO
ryct
olag
us cu
nicu
lus L
.Li
ver f
rom
the r
abbi
tPh
.Eur
. 2.1
.1Ca
lcium
carb
onic
um/M
esen
chym
co
mp.
; Car
duus
mar
ianu
s/ V
iscum
M
ali c
omp.
; Hep
ar/S
tann
um
met
allic
um A
; Hep
ar/S
tann
um
met
allic
um B
; Org
anum
qua
drup
lex
IVAA
stat
emen
t 201
3
Hip
poca
mpu
s*Bo
s tau
rus L
.H
ippo
cam
pus f
rom
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um:
Hip
poca
mpu
s
Hiru
do ex
anim
ale
Hiru
do m
edic
inal
is L.
Leec
h im
med
iate
ly aft
er sa
crifi
cePh
.Eur
. 1.1
.11,
2.2
.3H
irudo
com
p.; V
espa
crab
ro co
mp.
Hyp
ophy
sisO
ryct
olag
us cu
nicu
lus L
.H
ypop
hysis
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
nica
/Hyp
ophy
sis/P
lum
bum
m
ellitu
m co
mp.
; Aur
um/H
ypop
hysis
co
mp.
; Disc
i com
p. cu
m N
icot
iana
; H
ypop
hysis
; Hyp
ophy
sis co
mp.
; H
ypop
hysis
/Sta
nnum
; Mag
nesit
/M
amm
a com
p.; M
agne
sium
su
lfuric
um/O
varia
com
p.;
Perio
dont
ium
/Sta
nnum
com
p.;
Skor
odit
com
p.
Hyp
ophy
sis*
Bos t
auru
s L.
Hyp
ophy
sis fr
om th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.1
Arni
ca/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Hyp
ophy
sis
com
p.; D
isci c
omp.
cum
Nic
otia
na;
Hyp
ophy
sis; H
ypop
hysis
com
p.;
Hyp
ophy
sis/S
tann
um; M
agne
sit/
Mam
ma c
omp.
; Mag
nesiu
m
sulfu
ricum
/Ova
ria co
mp.
; Pe
riodo
ntiu
m/S
tann
um co
mp.
; Sk
orod
it co
mp.
Hyp
otha
lam
usO
ryct
olag
us cu
nicu
lus L
.H
ypot
hala
mus
from
the r
abbi
tPh
.Eur
. 2.1
.1
Hyp
otha
lam
us*
Bos t
auru
s L.
Hyp
otha
lam
us fr
om th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.1
Vade
mec
um:
Hyp
otha
lam
us
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
149
Ieco
ris as
elli o
leum
Gad
us m
orhu
a L.
Purifi
ed fa
tty o
il ob
tain
ed fr
om th
e fre
sh
liver
s of w
ild co
d, G
adus
mor
hua L
. and
ot
her s
pecie
s of G
adid
ae, s
olid
subs
tanc
es
bein
g re
mov
ed b
y coo
ling
and
filte
ring
Ph.E
ur.
API
Berb
eris/
Cheli
doni
um co
mp.
; Be
rber
is/Ju
nipe
rus c
omp.
Ileum
Sus s
crof
a dom
estic
a L.
Ileum
from
the p
igPh
.Eur
. 2.2
.3Va
dem
ecum
[m
entio
ned
unde
r: N
ux
vom
ica/
Nico
tiana
co
mp.
]
Iris
Bos t
auru
s L.
Iris
from
the c
alf
Ph.E
ur. 2
.2.2
Arni
ca/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Hyp
ophy
sis
com
p.; H
ypop
hysis
com
p.; I
ris b
ovis
com
p.
Jeco
ris o
leum
see I
ecor
is as
elli o
leum
Laby
rinth
us*
Bos t
auru
s L.
Coch
lea an
d la
byrin
th fr
om th
e cal
fPh
.Eur
. 2.2
.1Ar
nica
/Epi
phys
is/Pl
umbu
m m
ellitu
m
com
p.; A
urum
/Epi
phys
is co
mp.
; Ep
iphy
sis co
mp.
; Gna
phal
ium
com
p.
Lac c
anin
umCa
nis l
upus
fam
iliar
is L.
Fres
h m
ilk fr
om fe
mal
e dog
Ph.E
ur. 3
.1.1
ABM
A-Va
dem
ecum
O
varia
-Mer
curiu
s p.
195
Lac v
acca
eBo
s tau
rus L
.Fr
esh
cow’
s milk
Ph.E
ur. 3
.1.1
(eth
anol
18
%)
Vade
mec
um IV
AA
state
men
t 201
3
Lach
esis
Lach
esis
mela
noce
phal
a So
lòrz
ano
& C
erda
s, La
ches
is ste
noph
rys C
ope,
Lach
esis
mut
a L.
Care
fully
drie
d po
ison
from
Lac
hesis
m
elano
ceph
ala S
olòr
zano
& C
erda
s, La
ches
is ste
noph
rys C
ope o
r Lac
hesis
m
uta L
.
HAB
Mon
ogra
ph H
ABIg
natia
com
p.; L
ache
sis; L
ache
sis
com
p.; M
eliss
a/Se
pia c
omp.
; Naja
co
mp.
Vade
mec
um: L
ache
sis
Répe
rtoire
de m
éd.
anth
r.
Lam
ina q
uadr
igem
ina
Ory
ctol
agus
cuni
culu
s L.
Lam
ina q
uadr
igem
ina f
rom
the r
abbi
tPh
.Eur
. 2.1
.1La
min
a/Re
tina c
omp.
Lam
ina
quad
rigem
ina*
Bos t
auru
s L.
Lam
ina q
uadr
igem
ina f
rom
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1La
min
a/Re
tina c
omp.
Lapi
s can
cri
Asta
cus a
stacu
s L.
The g
astro
lithe
s fro
m th
e bod
y cav
ity
from
Asta
cus a
stacu
s L. o
r oth
er cr
ayfis
hPh
.Eur
. 4.1
.1; A
PI, r
aw
mat
eria
l for
the
prod
uctio
n of
co
mpo
sitio
ns: S
ilex
- La
pis C
ancr
i sol
utus
(a
pp. 2
.6)
Lapi
s Can
cri/F
lintst
ein
Vade
mec
um: S
ilex
- La
pis C
ancr
i sol
utus
Li
ste H
AS (1
0.20
12)
Lary
nxBo
s tau
rus L
.Pa
rts o
f the
lary
nx fr
om th
e cal
fPh
.Eur
. 2.2
.2Ap
is/La
rynx
com
p.; B
ronc
hi/P
lant
ago
com
p.; L
aryn
x co
mp.
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
150
Lary
nxO
ryct
olag
us cu
nicu
lus L
.Pa
rts o
f the
lary
nx fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Apis/
Lary
nx co
mp.
; Bro
nchi
/Pla
ntag
o co
mp.
; Lar
ynx
com
p.
Lath
rode
ctus
Lath
rode
ctus
mac
tans
Koc
hLi
ve sp
ider
of L
athr
odec
tus m
acta
ns K
och
APC
3.3.
1AB
MA-
Vade
mec
um
Cor-
Arse
nicu
m al
bum
p.
105
Lens
crist
allin
aBo
s tau
rus L
.Le
ns cr
istal
lina f
rom
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.2Co
rnea
/Lev
istic
um co
mp.
; Cor
pus
vitre
um/H
orne
rz co
mp.
; Iris
bov
is co
mp.
; Len
s cris
talli
na/V
iscum
com
p.
cum
Stan
no
Lens
crist
allin
aO
ryct
olag
us cu
nicu
lus L
.Le
ns cr
istal
lina f
rom
the r
abbi
tPh
.Eur
. 2.1
.1Co
rnea
/Lev
istic
um co
mp.
; Iris
bov
is co
mp.
; Len
s cris
talli
na/V
iscum
com
p.
cum
Stan
no
Lien
Bos t
auru
s L.
Splee
n fro
m th
e cal
fP.E
ur. 2
.1.1
, 2.2
.1G
land
ulae
supr
aren
ales
com
p.; L
ien
com
p.; L
ien/
Plum
bum
Lien
Ory
ctol
agus
cuni
culu
s L.
Splee
n fro
m th
e rab
bbit
Ph.E
ur. 2
.1.1
Gla
ndul
ae su
prar
enal
es co
mp.
; Lie
n co
mp.
; Lie
n/Pl
umbu
m
Liga
men
tum
lo
ngitu
dina
le an
teriu
sBo
s tau
rus L
.Pa
rts o
f the
Lig
amen
tum
long
itudi
nale
ante
rius o
f tho
raci
c and
lum
bar r
egio
ns o
f th
e spi
ne fr
om th
e cal
f
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Liga
men
tum
lo
ngitu
dina
le po
steriu
s*
Bos t
auru
s L.
Liga
men
tum
long
itudi
nale
dors
ale f
rom
th
e cal
fPh
.Eur
. 2.2
.2Va
dem
ecum
: Li
gam
entu
m
long
itudi
nale
poste
rius
Liga
men
tum
voca
leBo
s tau
rus L
.Pa
rts o
f the
voca
l cor
ds in
clude
d th
e m
ucou
s mem
bran
e of t
he la
rynx
from
the
calf
Ph.E
ur. 2
.2.2
Vade
mec
um
[men
tione
d un
der:
Lary
nx co
mp.
]
Ling
uaBo
s tau
rus L
.Pa
rts o
f the
tong
ue m
uscle
s, m
ucou
s m
embr
ane a
nd p
apill
ae fr
om th
e cal
fPh
.Eur
. 2.2
.3IV
AA st
atem
ent 2
013
Liqu
or ce
rebr
ospi
nalis
Bos t
auru
s L.
Cere
bros
pina
lal fl
uid
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
151
Lobu
s fro
ntal
is*Bo
s tau
rus L
.Fr
onta
l lob
e of c
ereb
rum
from
the c
alf
Ph.E
ur. 2
.2.1
Glö
ckler
, M.:
"Ant
hrop
osop
hisc
he
Arzn
eithe
rapi
e" (A
nthr
opos
ophi
c Ther
apy w
ith
Med
icina
l Pro
duct
s)
with
Med
icina
l Pr
oduc
ts), P
ublis
her
Wiss
ensc
haftl
iche
Verla
gsge
sells
chaft
, St
uttg
art 2
010
Lobu
s occ
ipita
lis*
Bos t
auru
s L.
Occ
ipita
l lob
e of c
ereb
rum
from
the c
alf
Ph.E
ur. 2
.2.1
Glö
ckler
, M.:
"Ant
hrop
osop
hisc
he
Arzn
eithe
rapi
e" (A
nthr
opos
ophi
c Ther
apy w
ith
Med
icina
l Pro
duct
s)
with
Med
icina
l Pr
oduc
ts), P
ublis
her
Wiss
ensc
haftl
iche
Verla
gsge
sells
chaft
, St
uttg
art 2
010
Lobu
s par
ieta
lis*
Bos t
auru
s L.
Parie
tal l
obe o
f the
cere
brum
from
the
calf
Ph.E
ur. 2
.2.1
Glö
ckler
, M.:
"Ant
hrop
osop
hisc
he
Arzn
eithe
rapi
e" (A
nthr
opos
ophi
c Ther
apy w
ith
Med
icina
l Pro
duct
s)
with
Med
icina
l Pr
oduc
ts), P
ublis
her
Wiss
ensc
haftl
iche
Verla
gsge
sells
chaft
, St
uttg
art 2
010
Lobu
s tem
pora
lis*
Bos t
auru
s L.
Tem
pora
l lob
e fro
m th
e cal
fPh
.Eur
. 2.2
.1G
löck
ler, M
.: "A
nthr
opos
ophi
sche
Ar
zneit
hera
pie"
(Ant
hrop
osop
hic Th
erap
y with
M
edici
nal P
rodu
cts)
wi
th M
edici
nal
Prod
ucts)
, Pub
lishe
r W
issen
scha
ftlich
e Ve
rlags
gese
llsch
aft,
Stut
tgar
t 201
0
Mam
ma
Bos t
auru
s L.
Gla
ndul
ar ti
ssue
from
bov
ine u
dder
Ph.E
ur. 2
.1.1
, 2.2
.3M
agne
sit/M
amm
a com
p.
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
152
Mam
ma
Ory
ctol
agus
cuni
culu
s L.
Mam
mae
from
the r
abbi
tPh
.Eur
. 2.1
.1M
agne
sit/M
amm
a com
p.
Mam
ma (
dext
ra)
Bos t
auru
s L.
Gla
ndul
ar ti
ssue
from
righ
t par
t of b
ovin
e ud
der
Ph.E
ur. 2
.2.3
, APC
3.
3.1
Vade
mec
um: M
amm
a AB
MA-
Vade
mec
um:
Mam
ma-
Arge
ntum
Si
rimim
p. 1
69
Mam
ma (
sinist
ra)
Bos t
auru
s L.
Gla
ndul
ar ti
ssue
from
left
part
of b
ovin
e ud
der
Ph.E
ur. 2
.2.3
, APC
3.
3.1
Vade
mec
um: M
amm
a AB
MA-
Vade
mec
um:
Mam
ma-
Arge
ntum
p.
169
Man
dibu
la (f
eti)
Bos t
auru
s L.
Man
dibl
e fro
m a
bovi
ne fo
etus
bet
ween
3
and
9 m
onth
sPh
.Eur
. 2.1
.1, 2
.2.2
Perio
dont
ium
/Sili
cea c
omp.
; Pe
riodo
ntiu
m/S
tann
um co
mp.
Man
dibu
la (f
eti)
Sus s
crof
a dom
estic
a L.
Man
dibl
e of t
he fo
etus
from
the p
igPh
.Eur
. 2.1
.1Pe
riodo
ntiu
m/S
ilice
a com
p.;
Perio
dont
ium
/Sta
nnum
com
p.
Mar
mot
fat
see M
arm
otta
e oleu
m
Max
illa (
feti)
Bos t
auru
s L.
Max
illa f
rom
a bo
vine
foet
us b
etwe
en 3
an
d 9
mon
ths
Ph.E
ur. 2
.1.1
, 2.2
.2Pe
riodo
ntiu
m/S
ilice
a com
p.;
Perio
dont
ium
/Sta
nnum
com
p.
Max
illa (
feti)
Sus s
crof
a dom
estic
a L.
Max
illa f
rom
a fo
etus
of t
he p
igPh
.Eur
. 2.1
.1Pe
riodo
ntiu
m/S
ilice
a com
p.;
Perio
dont
ium
/Sta
nnum
com
p.
Med
ulla
obl
onga
taO
ryct
olag
us cu
nicu
lus L
.M
edul
la o
blon
gata
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
nica
/Epi
phys
is/Pl
umbu
m m
ellitu
m
com
p.; A
rnic
a/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Epi
phys
is co
mp.
; Aur
um/H
ypop
hysis
com
p.;
Epip
hysis
com
p.; G
naph
aliu
m co
mp.
; H
ypop
hysis
com
p.
Med
ulla
obl
onga
ta*
Bos t
auru
s L.
Med
ulla
obl
onga
ta fr
om th
e cal
fPh
.Eur
. 2.2
.1Ar
nica
/Epi
phys
is/Pl
umbu
m m
ellitu
m
com
p.; A
rnic
a/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Epi
phys
is co
mp.
; Aur
um/H
ypop
hysis
com
p.;
Epip
hysis
com
p.; G
naph
aliu
m co
mp.
; H
ypop
hysis
com
p.
Med
ulla
oss
ium
(r
ubra
)Bo
s tau
rus L
.Re
d bo
ne m
arro
w fro
m th
e epi
phys
is of
tu
bula
r bon
es fr
om th
e cal
fPh
.Eur
. 2.2
.1M
edul
la o
ssiu
m
Med
ulla
oss
ium
(r
ubra
)O
ryct
olag
us cu
nicu
lus L
.Re
d bo
ne m
arro
w fro
m th
e epi
phys
is of
tu
bula
r bon
es fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Med
ulla
oss
ium
Med
ulla
spin
alis
Ory
ctol
agus
cuni
culu
s L.
spin
al co
rd fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Med
ulla
spin
alis
com
p.
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
153
Med
ulla
spin
alis
tota
*Bo
s tau
rus L
.M
edul
la sp
inal
is of
diff
eren
t sec
tions
from
th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.1
Med
ulla
spin
alis
com
p.Va
dem
ecum
: Med
ulla
sp
inal
is (to
ta)
Mel
Hon
ey is
pro
duce
d by
bee
s (Ap
is m
ellife
ra
L.) f
rom
the n
ecta
r of p
lant
s or f
rom
se
cret
ions
of l
ivin
g pa
rts o
f pla
nts w
hich
th
e bee
s col
lect,
trans
form
by c
ombi
ning
wi
th sp
ecifi
c sub
stanc
es o
f the
ir ow
n,
depo
sit, d
ehyd
rate
, sto
re an
d lea
ve in
the
hone
y com
b to
ripe
n an
d m
atur
e.
Ph.E
ur.
API,
raw
mat
eria
l for
th
e pro
duct
ion
of
seve
ral c
ompo
sitio
ns
(see
app.
2.6
).
Aesc
ulus
/Cer
a com
p.; A
qua M
aris
com
p.; A
rcha
ngeli
ca co
mp.
; Ave
na/
Conc
hae c
omp.
; Bro
nchi
alpas
tillen
; Fe
rrum
/Acid
um ch
olal
icum
; Fra
garia
/Ur
tica;
Frag
aria
/Urt
ica/
Gen
tiana
; Le
visti
cum
com
p.; L
ichen
es co
mp.
; M
el; M
ercu
rialis
/Mel;
Sol
utio
Sac
char
i co
mp.
Mem
bran
a sin
us
front
alis
Bos t
auru
s L.
Muc
osa o
f Sin
us fr
onta
lis fr
om th
e cal
fPh
.Eur
. 2.2
.1Ci
na co
mp.
Liste
HAS
(10.
2012
)
Mem
bran
a sin
us
max
illar
isBo
s tau
rus L
.M
ucos
a of S
inus
max
illar
is fro
m th
e cal
fPh
.Eur
. 2.2
.1G
löck
ler, M
.: "A
nthr
opos
ophi
sche
Ar
zneit
hera
pie"
(Ant
hrop
osop
hic Th
erap
y with
M
edici
nal P
rodu
cts)
Pu
blish
er
Wiss
ensc
haftl
iche
Verla
gsge
sells
chaft
, St
uttg
art
Mem
bran
a sin
us
para
nasa
lisBo
s tau
rus L
.M
ucos
a of s
inus
par
anas
ales
from
the c
alf
Ph.E
ur. 2
.2.1
Hep
ar su
lfuris
com
p.
Mem
bran
a syn
ovia
lisBo
s tau
rus L
.In
ner l
ayer
of t
he jo
int c
apsu
le of
diff
eren
t jo
ints
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um
[men
tione
d un
der:
Salix
/Rhu
s com
p.]
Men
iscus
artic
ular
isBo
s tau
rus L
.M
enisc
us ar
ticul
aris
of th
e kne
e fro
m ca
lfPh
.Eur
. 2.2
.2D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Men
iscus
genu
sBo
s tau
rus L
.M
enisc
us o
f the
kne
e fro
m th
e cal
fPh
.Eur
. 2.1
.1M
andr
agor
a com
p.; M
andr
agor
a/M
enisc
us G
enus
Mep
hitis
put
oriu
sM
ephi
tis m
ephi
tis S
chre
b.Li
quid
secr
etio
n of
anal
gla
nds f
rom
M
ephi
tis m
ephi
tis S
chre
b.H
AB 3
4Ph
.Eur
. 3.1
.1 (D
2 wi
th
etha
nol 9
0% ac
c. to
H
AB 3
4)
Dro
sera
/Ipec
acua
nha c
omp.
Mes
ence
phal
on*
Bos t
auru
s L.
Mes
ence
phal
on fr
om th
e cal
fPh
.Eur
. 2.2
.1Va
dem
ecum
[m
entio
ned
unde
r: Re
gio
subs
tant
iae
nigr
ae]
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
154
Mes
ench
ymBo
s tau
rus L
.Em
bryo
nal c
onne
ctiv
e tiss
ue an
d tis
sue
part
s of t
he ad
ult a
nim
al. F
oeta
l tiss
ues
deve
lope
d fro
m m
esen
chym
a with
a hi
gh
mes
ench
ymal
func
tion:
ute
rus o
f the
ad
ult a
nim
al; f
oeta
l sla
ck co
nnec
tive
tissu
e (e.g
. fro
m ax
illa)
, thy
mus
, hea
rt
tissu
e (wi
thou
t val
ves)
, red
bon
e mar
row
with
retic
ular
conn
ectiv
e tiss
ue an
d sp
ongi
ous b
ones
, nuc
leus p
ulpo
sus
inte
rver
tebr
alis,
mes
ente
rium
Ph.E
ur. 2
.2.2
Bora
go/R
enes
com
p.; C
alciu
m
carb
onic
um/M
esen
chym
com
p.; L
ien
com
p.; M
esen
chym
; Ves
pa cr
abro
co
mp.
Mes
ench
ymSu
s scr
ofa d
omes
tica L
.Em
bryo
nal c
onne
ctiv
e tiss
ue an
d tis
sue
part
s of t
he ad
ult a
nim
al. F
oeta
l tiss
ues
deve
lope
d fro
m m
esen
chym
a with
a hi
gh
mes
ench
ymal
func
tion:
ute
rus o
f the
ad
ult a
nim
al; f
oeta
l sla
ck co
nnec
tive
tissu
e (e.g
. fro
m ax
illa)
, thy
mus
, hea
rt
tissu
e (wi
thou
t val
ves)
, red
bon
e mar
row
with
retic
ular
conn
ectiv
e tiss
ue an
d sp
ongi
ous b
ones
, nuc
leus p
ulpo
sus
inte
rver
tebr
alis,
mes
ente
rium
Ph.E
ur. 2
.1.1
Liste
HAS
(10.
2012
) Ré
perto
ire d
e méd
. an
thr.:
T.R
.E.
Muc
osa b
ucca
lisBo
s tau
rus L
.M
ucou
s mem
bran
es o
f the
follo
wing
in
tern
al p
arts
of th
e cal
fs m
outh
: Arc
us
glos
sopa
latin
us, A
. pha
ryng
opal
atin
us,
ging
iva,
lingi
na, p
alat
um, u
vula
and
tons
illa p
alat
inae
APC
3.3.
1AB
MA-
Vade
mec
um
Cydo
nia-
Silic
ea p
. 117
Muc
osa s
inus
alis
Ory
ctol
agus
cuni
culu
s L.
Sinu
sal m
ucos
a fro
m th
e rab
bit
Ph.E
ur. 2
.1.1
Répe
rtoire
de m
éd.
anth
r.: M
uque
use
sinus
ale
Mus
culi
Bos t
auru
s L.
The f
ollo
wing
mus
cles o
f the
ox
(age
1,5
-4
year
s): M
uscu
lus d
eltoi
deus
, M.
supr
aspi
natu
s, M
. inf
rasp
inat
us, M
. bic
eps
brac
hii,
M. t
ricep
s bra
chii,
M. s
oleu
s and
M
. glu
tei
APC
3.3.
1AB
MA-
Vade
mec
um:
Mus
culi-
Auru
m p
. 178
Mus
culi
glut
aei
Bos t
auru
s L.
Glu
teal
mus
cles f
rom
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Mus
culu
s delt
oide
us-
Kom
plex
Bos t
auru
s L.
Part
s of t
he M
uscu
lus d
eltoi
deus
-co
mpl
ex, M
uscu
lus s
upra
spin
am,
Mus
culu
s inf
ra sp
inam
, Mus
culu
s de
ltoid
eus,
Mus
culu
s bic
eps b
rach
ii an
d M
uscu
lus t
ricep
s bra
chii
from
the c
alf
Ph.E
ur. 2
.2.3
Der
Mer
kurs
tab:
So
nder
heft
1999
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
155
Mus
culu
s rec
tus
abdo
min
isBo
s tau
rus L
.M
uscu
lus r
ectu
s abd
omin
is fro
m th
e cal
fPh
.Eur
. 2.2
.3Va
dem
ecum
: Mus
culu
s re
ctus
abdo
min
is
Mus
culu
s sol
eus-
Kom
plex
Bos t
auru
s L.
Part
s of t
he M
uscu
lus s
oleu
s-Ko
mpl
ex,
Mus
culu
s sol
eus,
Mus
culu
s fibu
laris
(p
eron
aeus
) lon
gus,
Mus
culu
s ga
stroc
nem
ius f
rom
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Myg
ale
Seve
ral s
pecie
s of t
he
Ther
aphr
osid
ae fa
mily
Live
spid
erAP
C 3.
3.1
ABM
A-Va
dem
ecum
H
epar
-Plu
mbu
m p
. 148
Myg
ale a
vicu
laris
see A
rane
a avi
cula
ris
Myo
card
ium
Bos t
auru
s L.
Myo
card
ium
from
the c
alf
Ph.E
ur. 2
.2.3
Prim
ula c
omp.
Naja
trip
udia
nsN
aja n
aja L
.Ca
refu
lly d
ried
poiso
n fro
m N
aja n
aja L
.H
ABM
onog
raph
HAB
Naja
com
p.Va
dem
ecum
: Naja
co
mp.
Ner
vi in
terc
osta
lesBo
s tau
rus L
.In
terc
osta
l ner
ves f
rom
the c
alf
Ph.E
ur. 2
.2.1
Der
Mer
kurs
tab:
So
nder
heft
1999
Ner
vus a
bduc
ens*
Bos t
auru
s L.
Ner
vus a
bduc
ens f
rom
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Ner
vus a
cces
soriu
sBo
s tau
rus L
.N
ervu
s acc
esso
rius f
rom
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Ner
vus f
acia
lis*
Bos t
auru
s L.
Ner
vus f
acia
lis fr
om th
e cal
fPh
.Eur
. 2.2
.1D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Ner
vus f
emor
alis
Bos t
auru
s L.
Ner
vus f
emor
alis
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Ner
vus
glos
soph
aryn
geus
Bos t
auru
s L.
Ner
vus g
loss
opha
ryng
eus f
rom
the c
alf
Ph.E
ur. 2
.2.1
Glö
ckler
, M.:
"Ant
hrop
osop
hisc
he
Arzn
eithe
rapi
e" (A
nthr
opos
ophi
c Ther
apy w
ith
Med
icina
l Pro
duct
s)
Publ
isher
W
issen
scha
ftlich
e Ve
rlags
gese
llsch
aft,
Stut
tgar
t
Ner
vus h
ypog
loss
usBo
s tau
rus L
.N
ervu
s hyp
oglo
ssus
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Ner
vus i
schi
adic
usBo
s tau
rus L
.N
ervu
s isc
hiad
icus
from
the c
alf
Ph.E
ur. 2
.2.1
Artic
ulat
io ta
locr
ural
is co
mp.
; Ner
vus
ischi
adic
us
Ner
vus i
schi
adic
usO
ryct
olag
us cu
nicu
lus L
.N
ervu
s isc
hiad
icus
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
ticul
atio
talo
crur
alis
com
p.; N
ervu
s isc
hiad
icus
Ner
vus l
aryn
geus
re
curr
ens
Bos t
auru
s L.
Ner
vus l
aryn
geus
recu
rren
s fro
m th
e cal
fPh
.Eur
. 2.2
.1Ap
is/La
rynx
com
p.; L
aryn
x co
mp.
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
156
Ner
vus l
aryn
geus
su
perio
rBo
s tau
rus L
.N
ervu
s lar
ynge
us su
perio
r fro
m th
e cal
fPh
.Eur
. 2.2
.1Ap
is/La
rynx
com
p.; L
aryn
x co
mp.
Ner
vus m
edia
nus
Bos t
auru
s L.
Ner
vus m
edia
nus f
rom
the c
alf
Ph.E
ur. 2
.2.1
Der
Mer
kurs
tab:
So
nder
heft
1999
Ner
vus o
culo
mot
oriu
sSu
s scr
ofa d
omes
tica L
.Pa
rts o
f the
Ner
vus o
culo
mot
oriu
s fro
m
the p
igPh
.Eur
. 2.2
.1Ir
is bo
vis c
omp.
; Ner
vus o
ptic
us co
mp.
Ner
vus
ocul
omot
oriu
s*Bo
s tau
rus L
.N
ervu
s ocu
lom
otor
ius f
rom
the c
alf
Ph.E
ur. 2
.2.1
Iris
bovi
s com
p.; N
ervu
s opt
icus
com
p.
Ner
vus o
phta
lmic
usBo
s tau
rus L
.N
ervu
s oph
talm
icus
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1Ir
is bo
vis c
omp.
Ner
vus o
phta
lmic
usSu
s scr
ofa d
omes
tica L
.Pa
rts o
f the
Ner
vus o
phta
lmic
us fr
om th
e pi
gPh
.Eur
. 2.2
.1Ir
is bo
vis c
omp.
Ner
vus o
ptic
usO
ryct
olag
us cu
nicu
lus L
.N
ervu
s opt
icus
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
nica
/Hyp
ophy
sis/P
lum
bum
m
ellitu
m co
mp.
; Aur
um/H
ypop
hysis
co
mp.
; Cor
nea/
Levi
sticu
m co
mp.
; H
ypop
hysis
com
p.; N
ervu
s opt
icus
co
mp.
Ner
vus o
ptic
usSu
s scr
ofa d
omes
tica L
.Pa
rts o
f Ner
vus o
ptic
us fr
om th
e pig
Ph.E
ur. (
2371
) 2.2
.1Ar
nica
/Hyp
ophy
sis/P
lum
bum
m
ellitu
m co
mp.
; Aur
um/H
ypop
hysis
co
mp.
; Cor
nea/
Levi
sticu
m co
mp.
; H
ypop
hysis
com
p.; N
ervu
s opt
icus
co
mp.
Ner
vus o
ptic
us*
Bos t
auru
s L.
Ner
vus o
ptic
us fr
om th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.1
Arni
ca/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Hyp
ophy
sis
com
p.; C
orne
a/Le
visti
cum
com
p.;
Hyp
ophy
sis co
mp.
; Ner
vus o
ptic
us
com
p.
Ner
vus
para
sym
path
icus
Ory
ctol
agus
cuni
culu
s L.
Ner
vus p
aras
ympa
thic
us fr
om th
e rab
bit
APC
3.3.
3 (g
lyce
rol
mac
erat
e 1:1
000
(as
Ph.E
ur. 2
.1.1
))
Ner
vus p
eron
aeus
Bos t
auru
s L.
Ner
vus p
eron
aeus
(fibu
laris
) fro
m th
e cal
fPh
.Eur
. 2.2
.1D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Ner
vus p
hren
icus
Bos t
auru
s L.
Ner
vus p
hren
icus
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: N
ervu
s ph
reni
cus
Ner
vus p
uden
dus
Bos t
auru
s L.
Ner
vus p
uden
dus f
rom
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Ner
vus r
adia
lisBo
s tau
rus L
.N
ervu
s rad
ialis
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
157
Ner
vus s
tato
acus
ticus
Ory
ctol
agus
cuni
culu
s L.
Ner
vus s
tato
acus
ticus
from
the r
abbi
tAP
C 3.
3.3
(gly
cero
l m
acer
ate 1
:100
0 (a
s Ph
.Eur
. 2.1
.1))
Arni
ca/E
piph
ysis/
Plum
bum
mell
itum
co
mp.
; Aur
um/E
piph
ysis
com
p.;
Epip
hysis
com
p.; G
naph
aliu
m co
mp.
Ner
vus s
tato
acus
ticus
*Bo
s tau
rus L
.N
ervu
s sta
toac
ustic
us fr
om th
e cal
fPh
.Eur
. 2.2
.1Ar
nica
/Epi
phys
is/Pl
umbu
m m
ellitu
m
com
p.; A
urum
/Epi
phys
is co
mp.
; Ep
iphy
sis co
mp.
; Gna
phal
ium
com
p.
Ner
vus t
ibia
lisBo
s tau
rus L
.N
ervu
s tib
ialis
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Ner
vus t
rigem
inus
*Bo
s tau
rus L
.N
ervu
s trig
emin
us fr
om th
e cal
fPh
.Eur
. 2.2
.1N
ervu
s trig
emin
usVa
dem
ecum
Ner
vus t
roch
learis
*Bo
s tau
rus L
.N
ervu
s tro
chlea
ris fr
om th
e cal
fPh
.Eur
. 2.2
.1D
er M
erku
rsta
b 20
05;
58(4
): 31
0-31
5
Ner
vus u
lnar
isBo
s tau
rus L
.N
ervu
s uln
aris
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Ner
vus v
agus
Bos t
auru
s L.
Ner
vus v
agus
from
the c
alf
Ph.E
ur. 2
.2.1
Apis/
Lary
nx co
mp.
; Lar
ynx
com
p.
Ner
vus v
agus
Ory
ctol
agus
cuni
culu
s L.
Ner
vus v
agus
from
the r
abbi
tPh
.Eur
. 2.1
.1Ap
is/La
rynx
com
p.; L
aryn
x co
mp.
Nod
i lym
phat
iciBo
s tau
rus L
.Pa
rts o
f lym
ph n
ode t
issue
from
diff
eren
t pa
rts o
f the
bod
y fro
m th
e cal
fPh
.Eur
. 2.2
.1D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Nuc
leus r
uber
*Bo
s tau
rus L
.Br
ain
subs
tanc
e fro
m th
e nuc
leus r
uber
fro
m th
e cal
fPh
.Eur
. 2.2
.1D
er M
erku
rsta
b 20
05;
58(4
): 31
0-31
5
Oes
opha
gus
Sus s
crof
a dom
estic
a L.
Oes
opha
gus f
rom
the p
igPh
.Eur
. 2.2
.3IV
AA st
atem
ent 2
013
Oss
aAv
es va
riae,
e.g. P
hasia
nus
colch
icus
L.
Clea
ned
and
mill
ed b
ones
from
bird
s, e.g
. Ph
asia
nus c
olch
icus
L.
Raw
mat
eria
l for
the
prod
uctio
n of
Ciss
us-
Oss
a (se
e app
. 2.6
)
Ciss
us-O
ssa
Liste
HAS
(10.
2012
)
Oss
icul
a aud
itus*
Bos t
auru
s L.
Audi
tory
bon
es fr
om th
e cal
fPh
.Eur
. 2.2
.2IV
AA st
atem
ent 2
013
Ova
riase
e Ova
rium
Ova
rium
Bos t
auru
s L.
Ova
ry fr
om th
e cow
Ph.E
ur. 2
.1.1
, 2.2
.1Ar
gent
um/O
varia
; Ber
beris
/Ute
rus
com
p.; E
chin
acea
/Par
amet
rium
com
p.;
Mag
nesiu
m su
lfuric
um/O
varia
com
p.;
Ova
ria co
mp.
; Ova
rium
; Ova
rium
co
mp.
Ova
rium
Ory
ctol
agus
cuni
culu
s L.
Ova
ry fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Ova
rium
; Ova
rium
com
p.
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
158
Panc
reas
Bos t
auru
s L.
Panc
reas
from
the c
alf
Ph.E
ur. 2
.1.1
Arge
ntum
/Pan
crea
s; Ba
rium
/Pan
crea
s co
mp.
; Bas
ilicu
m co
mp.
; Cal
cium
ca
rbon
icum
/Mes
ench
ym co
mp.
; Ci
chor
ium
/Pan
crea
s com
p.;
Equi
setu
m/P
ancr
eas;
Ferr
um
sider
eum
/Pan
krea
s; Pa
ncre
as/P
latin
um
chlo
ratu
m co
mp.
; Pan
krea
s; Pa
nkre
as
com
p.
Panc
reas
Ory
ctol
agus
cuni
culu
s L.
Panc
reas
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
gent
um/P
ancr
eas;
Bariu
m/P
ancr
eas
com
p.; C
alciu
m ca
rbon
icum
/M
esen
chym
com
p.; C
ichor
ium
/Pa
ncre
as co
mp.
; Equ
isetu
m/P
ancr
eas;
Ferr
um si
dere
um/P
ankr
eas;
Panc
reas
/Pl
atin
um ch
lora
tum
com
p.; P
ankr
eas;
Pank
reas
com
p.
Panc
reas
Sus s
crof
a dom
estic
a L.
Panc
reas
from
the p
igPh
.Eur
. 2.2
.1Ar
gent
um/P
ancr
eas;
Bariu
m/P
ancr
eas
com
p.; B
asili
cum
com
p.; C
alciu
m
carb
onic
um/M
esen
chym
com
p.;
Cich
oriu
m/P
ancr
eas c
omp.
; Eq
uise
tum
/Pan
crea
s; Fe
rrum
sid
ereu
m/P
ankr
eas;
Panc
reas
/Plat
inum
ch
lora
tum
com
p.; P
ankr
eas;
Pank
reas
co
mp.
Papi
llae d
uode
niSu
s scr
ofa d
omes
tica L
.Pa
pilla
duo
deni
regi
on o
f the
smal
l in
testi
ne fr
om th
e pig
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Para
met
rium
Bos t
auru
s L.
Tiss
ue fr
om th
e bro
ad li
gam
ent o
f the
ut
erus
from
the c
owPh
.Eur
. 2.2
.2Ec
hina
cea/
Para
met
rium
com
p.
Para
met
rium
dex
trum
Bos t
auru
s L.
Tiss
ue fr
om th
e rig
ht b
road
liga
men
t of
the u
teru
s fro
m th
e cow
Ph.E
ur. 2
.2.2
Der
Mer
kurs
tab:
So
nder
heft
1999
Pars
feta
lis (p
lace
nta)
Bos t
auru
s L.
Alla
ntoc
horio
n fro
m th
e bov
ine f
oetu
sPh
.Eur
. 2.2
.2Pr
unus
/Ros
mar
inus
com
p.
Pars
pal
lida*
Bos t
auru
s L.
Part
s of t
he b
ase o
f the
bra
in fr
om th
e cal
fPh
.Eur
. 2.2
.1IV
AA st
atem
ent 2
013
Pate
llaBo
s tau
rus L
.Pa
tella
from
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Peni
sBo
s tau
rus L
.Pe
nis f
rom
the b
ull
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Peric
ardi
umBo
s tau
rus L
.Pe
ricar
dium
from
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um
Perio
dont
ium
Bos t
auru
s L.
Part
s of t
he al
veol
ar an
d de
ntal
s reg
ions
fro
m th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.2
Perio
dont
ium
/Sili
cea c
omp.
; Pe
riodo
ntiu
m/S
tann
um co
mp.
Vade
mec
um
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
159
Perio
dont
ium
Sus s
crof
a dom
estic
a L.
Part
s of t
he al
veol
ar an
d de
ntal
regi
ons
from
the p
igPh
.Eur
. 2.1
.1Pe
riodo
ntiu
m/S
ilice
a com
p.;
Perio
dont
ium
/Sta
nnum
com
p.
Perio
steum
Bos t
auru
s L.
Perio
steum
from
the c
alf
Ph.E
ur. 2
.2.2
Alliu
m ce
pa/T
endo
com
p.; A
rtic
ulat
io
talo
crur
alis
com
p.
Perio
steum
Ory
ctol
agus
cuni
culu
s L.
Perio
steum
from
the r
abbi
tPh
.Eur
. 2.1
.1Al
lium
cepa
/Ten
do co
mp.
; Art
icul
atio
ta
locr
ural
is co
mp.
Perit
onae
umBo
s tau
rus L
.Pe
riton
aeum
from
the c
alf
Ph.E
ur. 2
.2.2
Bryo
nia/
Visc
um co
mp.
Perit
onae
umO
ryct
olag
us cu
nicu
lus L
.Pe
riton
aeum
from
the r
abbi
tPh
.Eur
. 2.1
.1Br
yoni
a/Vi
scum
com
p.
Phar
ynx
Bos t
auru
s L.
Part
s fro
m th
e Pha
rynx
dig
esto
rium
and
Phar
ynx
resp
irato
rius f
rom
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um: P
hary
nx
Phys
eter
cato
don
see A
mbr
a gris
ea
Phys
eter
m
acro
ceph
alus
see A
mbr
a gris
ea
Pia m
ater
ence
phal
i*Bo
s tau
rus L
.Pi
a mat
er en
ceph
ali f
rom
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Plac
enta
Bos t
auru
s L.
Plac
ento
mas
from
the p
regn
ant c
owPh
.Eur
. 2.2
.2Be
rber
is/Se
pia c
omp.
; Cal
endu
la/
Trop
aeol
um co
mp.
; Ech
inac
ea/V
iscum
co
mp.
; Pla
cent
a/Tr
opae
olum
Glö
ckler
, M.:
"Ant
hrop
osop
hisc
he
Arzn
eithe
rapi
e" (A
nthr
opos
ophi
c Ther
apy w
ith
Med
icina
l Pro
duct
s)
Publ
isher
W
issen
scha
ftlich
e Ve
rlags
gese
llsch
aft,
Stut
tgar
t
Pleu
raBo
s tau
rus L
.Pl
eura
par
ieta
lis fr
om th
e cal
fPh
.Eur
. 2.2
.1D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Plex
us b
rach
ialis
Bos t
auru
s L.
Plex
us b
rach
ialis
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um
[men
tione
d un
der:
Disc
i/Rhu
s to
xico
dend
ron
com
p.]
Plex
us ca
rdia
cus
Bos t
auru
s L.
Plex
us ca
rdia
cus f
rom
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: P
lexus
ca
rdia
cus
Plex
us co
eliac
usBo
s tau
rus L
.Pl
exus
coeli
acus
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: P
lexus
co
eliac
us
Plex
us g
astri
cus
Bos t
auru
s L.
Plex
us g
astri
cus f
rom
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: P
lexus
ga
stric
us
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
160
Plex
us
haem
orrh
oida
lisBo
s tau
rus L
.Ve
nous
net
work
in th
e reg
ion
of th
e re
ctum
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: P
lexus
ha
emor
rhoi
dalis
Plex
us lu
mba
lisBo
s tau
rus L
.Pl
exus
lum
balis
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Plex
us p
elvin
usBo
s tau
rus L
.Pl
exus
pelv
inus
from
the c
alf
Ph.E
ur. 2
.2.1
Der
Mer
kurs
tab:
So
nder
heft
1999
Plex
us p
ulm
onal
is (N
ervu
s vag
us)
Bos t
auru
s L.
Plex
us p
ulm
onal
is fro
m th
e cal
fPh
.Eur
. 2.2
.1Va
dem
ecum
: Plex
us
pulm
onal
is (N
ervu
s va
gus)
Plex
us re
ctal
isse
e Plex
us h
aem
orrh
oida
lisIV
AA st
atem
ent 2
013
Plex
us sa
cral
isBo
s tau
rus L
.Pl
exus
sacr
alis
from
the c
alf
Ph.E
ur. 2
.2.1
Der
Mer
kurs
tab:
So
nder
heft
1999
Pons
*Bo
s tau
rus L
.Po
ns fr
om th
e cal
fPh
.Eur
. 2.2
.1D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Prop
olis
Apis
mell
ifera
L.
Prop
olis
Ph.fr
.Ph
.Eur
. 1.1
.10
(eth
anol
90
%)
Der
Mer
kurs
tab
2011
; 64
(4):
338
Pros
tata
Bos t
auru
s L.
Pros
tata
from
the b
ull
Ph.E
ur. 2
.2.1
Berb
eris/
Pros
tata
com
p.
Pude
ndum
fem
iniu
mBo
s tau
rus L
.La
bia v
ulva
e, cli
toris
and
glan
dula
ve
stibu
laris
majo
r fro
m th
e cow
Ph.E
ur. 2
.2.2
Prun
us/R
osm
arin
us co
mp.
Pulm
oBo
s tau
rus L
.Lu
ng ti
ssue
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1Ca
lcium
carb
onic
um/M
esen
chym
co
mp.
; Fer
rum
/Pul
mo;
Mer
curiu
s/Pu
lmo;
Org
anum
qua
drup
lex; P
ulm
o/Ta
rtar
us st
ibia
tus A
; Pul
mo/
Tart
arus
sti
biat
us B
; Pul
mo/
Vivi
anit
com
p.
Pulm
oO
ryct
olag
us cu
nicu
lus L
.Lu
ng fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Calci
um ca
rbon
icum
/Mes
ench
ym
com
p.; F
erru
m/P
ulm
o; M
ercu
rius/
Pulm
o; O
rgan
um q
uadr
uplex
; Pul
mo/
Tart
arus
stib
iatu
s A; P
ulm
o/Ta
rtar
us
stibi
atus
B; P
ulm
o/Vi
vian
it co
mp.
Pulp
a den
tisBo
s tau
rus L
.Pu
lpa d
entis
from
the c
alf
Ph.E
ur. 2
.2.1
Vade
mec
um: P
ulpa
de
ntis
Pylo
rus
Sus s
crof
a dom
estic
a L.
Pylo
rus f
rom
the p
igPh
.Eur
. 2.2
.3D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Rect
umSu
s scr
ofa d
omes
tica L
.Re
ctum
from
the p
igPh
.Eur
. 2.2
.3D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
161
Regi
o su
bsta
ntia
e ni
grae
*Bo
s tau
rus L
.Ti
ssue
from
the s
ubsta
ntia
nig
ra fr
om th
e ca
lfPh
.Eur
. 2.2
.1Va
dem
ecum
: Reg
io
subs
tant
iae n
igra
e
Rene
sBo
s tau
rus L
.Ki
dney
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1Ar
gent
um n
itric
um/R
enes
; Bor
ago/
Rene
s com
p.; C
alciu
m ca
rbon
icum
/M
esen
chym
com
p.; C
upru
m ac
etic
um
com
p.; C
upru
m-R
en-G
land
ula
supr
aren
alis;
Cup
rum
/Ren
es;
Equi
setu
m/R
enes
com
p.; L
ien
com
p.;
Nico
tiana
/Nux
vom
ica c
omp.
; O
rgan
um q
uadr
uplex
; Ren
Rene
sO
ryct
olag
us cu
nicu
lus L
.Ki
dney
from
the r
abbi
tPh
.Eur
. 2.1
.1Ar
gent
um n
itric
um/R
enes
; Bor
ago/
Rene
s com
p.; C
alciu
m ca
rbon
icum
/M
esen
chym
com
p.; C
upru
m ac
etic
um
com
p.; C
upru
m-R
en-G
land
ula
supr
aren
alis;
Cup
rum
/Ren
es;
Equi
setu
m/R
enes
com
p.; L
ien
com
p.;
Nico
tiana
/Nux
vom
ica c
omp.
; O
rgan
um q
uadr
uplex
; Ren
Rene
s, re
gio
pyelo
rena
lisBo
s tau
rus L
.Pa
rts o
f tiss
ue fr
om th
e pelv
is re
nalis
and
med
ulla
rena
lis fr
om th
e cal
fPh
.Eur
. 2.2
.1IV
AA st
atem
ent 2
013
Retic
uloe
ndot
helia
l Sy
stem
Bos t
auru
s L.
Part
s fro
m th
e thy
mus
gla
nd, l
ymh
node
s, bo
ne m
arro
w, li
ver a
nd sp
leen
from
the
calf
Ph.E
ur. 2
.2.1
Vade
mec
um
[men
tione
d un
der:
Levi
co co
mp.
]
Retin
a (et
Cho
rioid
ea)
Ory
ctol
agus
cuni
culu
s L.
Part
s of t
he re
tina a
nd th
e cho
rioid
ea
from
the r
abbi
tPh
.Eur
. 2.1
.1Re
tina;
Retin
a com
p.; R
etin
a/Se
cale
com
p.
Retin
a et C
horio
idea
*Bo
s tau
rus L
.Pa
rts o
f the
retin
a and
the c
horio
idea
fro
m th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.3
Arni
ca/H
ypop
hysis
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Hyp
ophy
sis
com
p.; C
hrys
olith
com
p.; G
alen
it/Re
tina c
omp.
; Hyp
ophy
sis co
mp.
; La
min
a/Re
tina c
omp.
; Ner
vus o
ptic
us
com
p.; R
esin
a Lar
icis/
Retin
a; Re
tina;
Retin
a com
p.; R
etin
a/Se
cale
com
p.
Scler
a*Bo
s tau
rus L
.Sc
lera f
rom
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Scol
open
dra
Seve
ral s
pecie
s of S
colo
pend
ra
fam
ilyLi
ving
cent
iped
e of S
colo
pend
ridea
e fa
mily
APC
3.3.
1AB
MA-
Vade
mec
um
Sinu
s fac
ialis
-Mer
curiu
s p.
238
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
162
Sepi
a offi
cina
lisSe
pia o
ffici
nalis
L.
Drie
d in
k ba
g fro
m S
epia
offi
cina
lis L
.Ph
.fr.
Ph.E
ur. 1
.1.1
1 (E
than
ol 6
5% V
/V);
see a
lso A
pp. 2
.7:
Sepi
a Gru
neris
Der
Mer
kurs
tab
1997
; 52
(1):
51
Sepi
a offi
cina
lis e
volu
min
e bur
sae r
ec.
Sepi
a offi
cina
lis L
.Fr
esh
secr
etio
n fro
m in
k gl
and
from
Sep
ia
offici
nalis
L.
Ph.E
ur. 2
.2.3
Auru
m/P
ulsa
tilla
/Spo
ngia
com
p.;
Berb
eris/
Sepi
a com
p.; M
eliss
a/Se
pia
com
p.
Vade
mec
um: S
epia
Der
M
erku
rsta
b 19
97; 5
2(1)
: 51
Sinu
s cav
erno
sus-
Kom
plex
*Bo
s tau
rus L
.Pa
rts o
f the
sinu
s cav
erno
sus-
Kom
plex
; sin
us ca
vern
osus
, ner
vus o
ptic
us, n
ervu
s oc
ulom
otor
ius,
nerv
us tr
ochl
earis
, ner
vus
trig
emin
us an
d ne
rvus
abdu
cens
from
the
calf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Spon
gia t
osta
Eusp
ongi
a offi
cina
lis L
.To
aste
d Eu
spon
gia o
ffici
nalis
L.
HAB
; Ph.
fr.Ph
.Eur
. 1.1
.9, (
etha
nol
70%
), 1.
1.11
(eth
anol
65
%),
4.1.
1 (a
nd th
en
3.2.
2), A
PI
Auru
m/P
ulsa
tilla
/Spo
ngia
com
p.;
Bryo
nia/
Spon
gia c
omp.
; Col
chic
um
com
p.; C
olch
icum
/Spo
ngia
com
p.;
Spon
gia;
Spon
gia c
omp.
Vade
mec
um: S
pong
ia
Stom
achu
sO
ryct
olag
us cu
nicu
lus L
.St
omac
h fro
m th
e rab
bit
Ph.E
ur. 2
.1.1
Cich
oriu
m co
mp.
Stom
achu
sse
e Ven
tric
ulus
from
the p
ig
Sym
path
icus
see T
runc
us sy
mpa
thic
us
Tend
oBo
s tau
rus L
.Te
ndo
from
the c
alf
Ph.E
ur. 2
.2.2
Alliu
m ce
pa/T
endo
com
p.; A
rtic
ulat
io
talo
crur
alis
com
p.
Tend
oO
ryct
olag
us cu
nicu
lus L
.Te
ndo
from
the r
abbi
tPh
.Eur
. 2.1
.1
Testa
ovi
Gal
lus g
allu
s dom
estic
us L
.Sh
ell o
f hen
's eg
gsPh
.Eur
. 4.1
.1Au
rum
/Pul
satil
la/S
pong
ia co
mp.
; Sp
ongi
a com
p.
Teste
sBo
s tau
rus L
.Te
stes f
rom
the b
ull
Ph.E
ur. 2
.2.1
Arge
ntum
/Tes
tes;
Teste
s com
p.
Text
us co
nnec
tivus
Bos t
auru
s L.
Subc
utan
eous
and
inte
rmus
cula
r co
nnec
tive t
issue
, fas
cia,
ligam
ents,
te
ndon
s, as
well
as m
esen
teriu
m fr
om th
e ca
lf
Ph.E
ur. 2
.2.2
Bora
go/R
enes
com
p.
Thal
amus
*Bo
s tau
rus L
.Th
alam
us fr
om th
e cal
fPh
.Eur
. 2.2
.1Ar
nica
/Hyp
ophy
sis/P
lum
bum
m
ellitu
m co
mp.
; Aur
um/H
ypop
hysis
co
mp.
; Hyp
ophy
sis co
mp.
Thro
mbo
cyte
sEq
uus p
rzew
alsk
ii f.
caba
llus
POLI
AKO
VTh
rom
bocy
tes f
rom
the b
lood
of t
he
hors
ePh
.Eur
. 2.2
.4Va
dem
ecum
: Th
rom
bocy
ten
Thym
us (G
land
ula)
Bos t
auru
s L.
Thym
us fr
om th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.1
Gla
ndul
a Thym
us
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
163
Thym
us (G
land
ula)
Ory
ctol
agus
cuni
culu
s L.
Thym
us fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Gla
ndul
a Thym
us
Tons
illa p
hary
ngea
Bos t
auru
s L.
Tons
illa p
hary
ngea
from
the c
alf
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Tons
illae
pal
atin
aeBo
s tau
rus L
.To
nsill
a pal
atin
ae fr
om th
e cal
fPh
.Eur
. 2.2
.1Ca
lendu
la/E
chin
acea
com
p.
Trab
ecul
um*
Bos t
auru
s L.
Trab
ecul
um fr
om th
e cal
fRa
w m
ater
ial f
or th
e pr
oduc
tion
of
Trab
ecul
um co
mp.
(s
ee ap
p. 2
.6)
Trab
ecul
um co
mp.
Liste
HAS
(10.
2012
)
Trac
hea
Bos t
auru
s L.
Trac
hea f
rom
the c
alf
Ph.E
ur. 2
.2.2
IVAA
stat
emen
t 201
3
Trac
tus d
iges
tivus
Bos t
auru
s L.
Equa
l par
ts of
the c
ompl
ete d
iges
tive
syste
m fr
om th
e cal
fAP
C 3.
3.1
ABM
A-Va
dem
ecum
: Tr
actu
s dig
estiv
us-
Cupr
um p
. 257
Trig
onum
vesic
ae et
M
uscu
lus s
phin
cter
Bos t
auru
s L.
Tiss
ue o
f the
vesic
a fro
m th
e reg
ion
of th
e tri
gonu
m ve
sicae
and
mus
cula
r tiss
ue
from
the s
phin
cter
of t
he ve
sica f
rom
the
calf
Ph.E
ur. 2
.2.3
Der
Mer
kurs
tab:
So
nder
heft
1999
Trun
cus c
ereb
riO
ryct
olag
us cu
nicu
lus L
.Br
ain
stem
from
the r
abbi
tPh
.Eur
. 2.1
.1Ap
is re
gina
com
p.; H
irnsta
mm
/Tr
iticu
m
Trun
cus c
ereb
ri*Bo
s tau
rus L
.Pa
rts f
rom
Hyp
otha
lam
us, Th
alam
us,
Corp
ora q
uadr
igem
ina,
Pons
, Med
ulla
ob
long
ata a
nd C
ereb
ellum
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1Ap
is re
gina
com
p.; H
irnsta
mm
/Tr
iticu
m
Trun
cus c
oelia
cus
Bos t
auru
s L.
Arte
ria co
eliac
a (tr
uncu
s coe
liacu
s) fr
om
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Trun
cus s
ympa
thic
usBo
s tau
rus L
.Tr
uncu
s sym
path
icus
from
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.1Va
dem
ecum
: Sy
mpa
thic
us
Trun
cus s
ympa
thic
usO
ryct
olag
us cu
nicu
lus L
.Tr
uncu
s sym
path
icus
from
the r
abbi
tAP
C 3.
3.3
(gly
cero
l m
acer
ate 1
:100
0 (a
s Ph
.Eur
. 2.1
.1))
Vade
mec
um:
Sym
path
icus
Tuba
audi
tiva*
Bos t
auru
s L.
Tuba
audi
tiva f
rom
the c
alf
Ph.E
ur. 2
.2.2
Vade
mec
um: T
uba
audi
tiva
Tuba
ute
rina
Bos t
auru
s L.
Tuba
ute
rina f
rom
the c
owPh
.Eur
. 2.1
.1, 2
.2.2
Echi
nace
a/Pa
ram
etriu
m co
mp.
Tuba
ute
rina
Ory
ctol
agus
cuni
culu
s L.
Tuba
ute
rina f
rom
the (
fem
ale)
rabb
itPh
.Eur
. 2.1
.1Ec
hina
cea/
Para
met
rium
com
p.
Tuni
ca m
ucos
a in
testi
ni te
nuis
Sus s
crof
a dom
estic
a L.
Muc
osa f
rom
the d
iffer
ent r
egio
ns o
f the
sm
all i
ntes
tine f
rom
the p
igPh
.Eur
. 2.2
.1IV
AA st
atem
ent 2
013
Tuni
ca m
ucos
a nas
iBo
s tau
rus L
.Tu
nica
muc
osa n
asi f
rom
the c
alf
Ph.E
ur. 2
.2.1
Bron
chi/P
lant
ago
com
p.Va
dem
ecum
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
164
Tuni
ca m
ucos
a rec
tiSu
s scr
ofa d
omes
tica L
.Tu
nica
muc
osa r
ecti
from
the p
igPh
.Eur
. 2.2
.1IV
AA st
atem
ent 2
013
Tuni
ca m
ucos
a ve
ntric
uli
Sus s
crof
a dom
estic
a L.
Muc
osa f
rom
the d
iffer
ent r
egio
ns o
f the
sto
mac
h fro
m th
e pig
Ph.E
ur. 2
.2.1
IVAA
stat
emen
t 201
3
Uret
erBo
s tau
rus L
.Ur
eter
from
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Uret
hra f
emin
ina
Bos t
auru
s L.
Uret
hra f
rom
the f
emal
e cal
fPh
.Eur
. 2.2
.3D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Uret
hra m
ascu
lina
Bos t
auru
s L.
Uret
hra f
rom
the m
ale c
alf
Ph.E
ur. 2
.2.3
Der
Mer
kurs
tab:
So
nder
heft
1999
Ute
rus
Bos t
auru
s L.
Ute
rus f
rom
the c
owPh
.Eur
. 2.2
.3Be
rber
is/U
teru
s com
p.; B
ryop
hyllu
m
com
p.
Ute
rus
Ory
ctol
agus
cuni
culu
s L.
Ute
rus f
rom
the (
fem
ale)
rabb
itPh
.Eur
. 2.1
.1Be
rber
is/U
teru
s com
p.; B
ryop
hyllu
m
com
p.
Uve
a*Bo
s tau
rus L
.U
vea f
rom
the c
alf
Raw
mat
eria
l for
the
prod
uctio
n of
Uve
a co
mp.
(see
app.
2.6
)
Liste
HAS
(10.
2010
: U
vea c
omp.
)
Vagi
naBo
s tau
rus L
.Va
gina
from
the c
owPh
.Eur
. 2.2
.3IV
AA st
atem
ent 2
013
Vagi
nae s
ynov
iales
te
ndin
umBo
s tau
rus L
.Te
ndon
shea
ths f
rom
the c
alf
Ph.E
ur. 2
.1.1
, 2.2
.3Al
lium
cepa
/Ten
do co
mp.
Vade
mec
um
Vagi
nae s
ynov
ialis
te
ndin
umSu
s scr
ofa d
omes
tica L
.Te
ndon
shea
ths f
rom
the p
igPh
.Eur
. 2.1
.1Al
lium
cepa
/Ten
do co
mp.
Valv
a tru
nci
pulm
onal
isBo
s tau
rus L
.Va
lva t
runc
i pul
mon
alis
from
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Valv
ula a
orta
eBo
s tau
rus L
.Va
lva a
orta
e fro
m th
e cal
fPh
.Eur
. 2.2
.3Va
dem
ecum
Valv
ula m
itral
isBo
s tau
rus L
.Va
lva m
itral
is fro
m th
e cal
fPh
.Eur
. 2.2
.3IV
AA st
atem
ent 2
013
Valv
ula t
ricus
pida
lisBo
s tau
rus L
.Va
lva t
ricus
pida
lis fr
om th
e cal
fPh
.Eur
. 2.2
.3D
er M
erku
rsta
b:
Sond
erhe
ft 19
99
Vena
cava
Bos t
auru
s L.
Part
s of t
he V
ena c
ava c
rani
alis
and
Vena
ca
va ca
udal
is fro
m th
e cal
fPh
.Eur
. 2.1
.1, 2
.2.3
IVAA
stat
emen
t 201
3
Vena
cava
Ory
ctol
agus
cuni
culu
s L.
Part
s of t
he ve
na ca
va fr
om th
e rab
bit
Ph.E
ur. 2
.1.1
Vena
fem
oral
isBo
s tau
rus L
.Ve
na fe
mor
alis
from
the c
alf
Ph.E
ur. 2
.2.3
Der
Mer
kurs
tab:
So
nder
heft
1999
Vena
por
tae
Bos t
auru
s L.
Vena
por
tae f
rom
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
165
Vena
saph
ena m
agna
Bos t
auru
s L.
Vena
saph
ena m
agna
from
the c
alf
Ph.E
ur. 2
.2.3
Vade
mec
um: V
ena
saph
ena m
agna
Vent
ricul
usSu
s scr
ofa d
omes
tica L
.Ve
ntric
ulus
from
the p
igPh
.Eur
. 2.1
.1, 2
.2.3
Vade
mec
um:
Vent
ricul
us
Verte
bra c
ervi
calis
*Bo
s tau
rus L
.Ve
rtebr
a cer
vica
lis fr
om th
e cal
fPh
.Eur
. 2.2
.3IV
AA st
atem
ent 2
013
Verte
bra c
occy
gea
Bos t
auru
s L.
Verte
bra c
occy
gea f
rom
the c
alf
Ph.E
ur. 2
.2.3
IVAA
stat
emen
t 201
3
Verte
bra l
umba
lis*
Bos t
auru
s L.
Verte
bra l
umba
lis fr
om th
e cal
fPh
.Eur
. 2.2
.3IV
AA st
atem
ent 2
013
Vesic
a fell
eaBo
s tau
rus L
.Ve
sica f
ellea
from
the c
alf
Ph.E
ur. 2
.2.3
Ferr
um/V
esic
a fell
ea
Vesic
a urin
aria
Bos t
auru
s L.
Vesic
a urin
aria
from
the c
alf
Ph.E
ur. 2
.2.3
Cant
haris
com
p.Va
dem
ecum
Vesic
a urin
aria
Ory
ctol
agus
cuni
culu
s L.
Vesic
a urin
aria
from
the r
abbi
tPh
.Eur
. 2.1
.1Ca
ntha
ris co
mp.
Vesp
a cra
bro
Vesp
a cra
bro
L.Li
ve h
orne
tsH
ABM
onog
raph
, Dilu
tions
ac
c. to
Ph.
Eur.
1.1.
9;
Ph.E
ur. 1
.1.1
1 (e
than
ol
65%
), 2.
1.1,
2.2
.3
Arge
ntum
com
p.; A
rnic
a, Pl
anta
tota
/Ve
spa C
rabr
o; C
olch
icum
com
p.;
Mag
nesiu
m su
lfuric
um/O
varia
com
p.;
Vesp
a cra
bro;
Ves
pa cr
abro
com
p.
Vade
mec
um: V
espa
cr
abro
Vesp
a vul
garis
Vesp
ula g
erm
anic
a Fab
riciu
s, Ve
spul
a vul
garis
L. a
nd/o
r D
olich
oves
pula
saxo
nia
Fabr
icius
Live
wor
ker w
asps
Ph.E
ur. 1
.1.1
1 (e
than
ol
65%
), 2.
1.1
Flor
es T
ritici
com
p.Li
ste H
AS (1
0.20
12)
Vipe
ra b
erus
Vipe
ra b
erus
L.
Free
ze d
ried
veno
m o
f Vip
era b
erus
L.
acc.
to H
AB
mon
ogra
ph L
ache
sisN
aja co
mp.
Scie
ntifi
c nam
eSc
ient
ific n
ame o
f the
anim
alAb
brev
iate
d de
finiti
on o
f the
par
t use
dRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
167
•
Ap
pend
ix 2
.4
APPENDIX 2.4
Starting materials that can be described chemically Additional Information, see p. 18
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
168
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
Acid
um ar
seni
cosu
mse
e Ars
enii
trio
xidu
m
Acid
um ci
tric
umAc
idum
citr
icum
Citr
ic ac
idPh
.Eur
.ex
cipie
nt
Acid
um ci
tric
um
mon
ohyd
ricum
Acid
um ci
tric
um
mon
ohyd
ricum
Citr
ic ac
id m
onoh
ydra
tePh
.Eur
.as
raw
mat
eria
l for
the
prep
arat
ion
for c
itrat
es
of F
e and
Ba
Berb
eris/
Silic
ea co
mp.
Acid
um F
orm
icae
see a
pp. 2
.3
Acid
um
hexa
chlo
ropl
atin
icum
Hex
achl
orop
latin
ic ac
idH
ABPh
.Eur
. 3.1
.2, 4
.1.1
, 4.
1.2
Panc
reas
/Plat
inum
chlo
ratu
m co
mp.
Acid
um h
ydro
chlo
ridum
di
lutu
mAc
idum
hyd
roch
loric
umH
ydro
chlo
ric ac
id, d
ilute
(10%
)Ph
.Eur
.se
e mon
ogra
ph H
AB
(D2
with
wat
er, D
3 wi
th
etha
nol 5
0%);
excip
ient
Acid
um h
ydro
chlo
ricum
com
p.
Acid
um la
ctic
umAc
idum
lact
icum
Lact
ic ac
idPh
.Eur
.AP
IM
ajora
na/Th
uja c
omp.
Acid
um n
itric
umAc
idum
nitr
icum
, N
itric
um ac
idum
pph
Nitr
ic ac
id(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(see
m
onog
raph
HAB
), 3.
1.2,
API
& ex
cipie
nt
Mix
tura
Stan
ni co
mp.
Acid
um p
hosp
horic
um
dilu
tum
Acid
um p
hosp
horic
umPh
osph
oric
acid
, dilu
te (1
0%)
Ph.E
ur.
Ph.E
ur. 3
.1.1
(eth
anol
50
%),
3.1.
2Ac
idum
pho
spho
ricum
; Api
s reg
ina/
Auru
m co
mp.
Acid
um p
hosp
horic
um
conc
entra
tum
Acid
um p
hosp
horic
um
conc
entra
tum
, Ph
osph
oric
um ac
idum
pp
h
Phos
phor
ic ac
id, c
once
ntra
ted
Ph.E
ur.
Ph.E
ur. 3
.1.1
, 3.1
.2Ap
is re
gina
/Aur
um co
mp.
Acid
um si
licic
umAc
idum
silic
icum
Prec
ipita
ted
silic
on d
ioxi
deD
ABPh
.Eur
. 4.1
.1, 4
.1.2
, AP
I, ra
w m
ater
ial f
or
prod
uctio
n
Acid
um su
lfuric
umAc
idum
sulfu
ricum
, Su
lfuric
um ac
idum
pph
Sulfu
ric ac
id (9
5-10
0.5%
H2S
O4)
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (s
ee
mon
ogra
ph H
AB),
raw
mat
eria
l for
the
prod
uctio
n of
star
ting
mat
eria
ls
Acid
um ta
rtar
icum
Acid
um ta
rtar
icum
Tart
aric
acid
Ph.E
ur.
raw
mat
eria
l for
the
prep
arat
ion
of S
olut
io
Ferr
i com
p. (a
pp. 2
.6)
Gla
ndul
a sup
rare
nalis
/Sol
utio
Fer
ri co
mp.
Aesc
ulin
umAe
scul
inD
AB; H
ABLi
quid
dilu
tion
see
Aesc
ulin
um H
AB
(Ph.
Eur.
3.1.
1 (e
than
ol
90%
), Ph
.Eur
. 4.1
.1,
4.1.
2, A
PI
Echi
nace
a/Pr
unus
com
p.
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
169
Aeth
iops
antim
onia
lisse
e Hyd
rarg
yrum
stib
iato
-sul
fura
tum
Aeth
iops
antim
onia
lis
Alum
enAl
umen
Alum
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (s
ee
mon
ogra
ph H
AB),
3.1.
1 (D
1 wi
th w
ater
, fro
m
D2
with
etha
nol 3
0%),
4.1.
1, A
PI
Alum
en/H
elleb
orus
com
p.; M
ixtu
ra
Stan
ni co
mp.
Alum
en ch
rom
icum
Pota
ssiu
m ch
rom
ium
(III)
sulfa
te
dode
cahy
drat
ePh
.Eur
. 4.1
.1, 4
.1.2
Vade
mec
um: A
lum
en
chro
mic
um
Alum
iniu
m-k
aliu
m-
sulfu
ricum
see A
lum
enPh
.Eur
.
Amm
onia
e sol
utio
co
ncen
trata
Amm
onia
solu
tion,
conc
entra
ted
(25-
30%
N
H3)
Ph.E
ur.
raw
mat
eria
l for
the
prod
uctio
n of
star
ting
mat
eria
ls
Amm
oniu
m ca
rbon
icum
Mix
ture
of a
mm
oniu
m h
ydro
gen
carb
onat
e and
amm
oniu
m ca
rbam
ate o
f va
ryin
g pr
opor
tions
HAB
Ph.E
ur. 3
.1.1
(eth
anol
18
%)
Echi
nace
a com
p.
Antim
oniu
m ta
rtar
icum
see K
aliu
m st
ibyl
tart
aric
um
Arge
nti c
arbo
nas
Arge
ntum
carb
onic
umSi
lver
carb
onat
e, 99
-100
.5%
Ag2
CO3
see A
ppen
dix
2.6,
e.g.
Vi
scum
Mal
i cum
Ar
gent
o
Visc
um al
bum
c. A
rg
Arge
nti n
itras
Arge
ntum
nitr
icum
, Ar
gent
um n
itric
um p
phSi
lver
nitr
ate
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (w
ater
) se
e Arg
entu
m n
itric
um
HAB
; raw
mat
eria
l for
pr
epar
atio
n of
Ar
gent
um-C
orpu
s vi
treum
(see
app,
2.6
) an
d an
excip
ient
(p
rese
rvat
ive)
Antim
onit/
Rosa
e aet
hero
leum
com
p.;
Arch
ange
lica/
Pyrit
com
p.; A
rgen
tum
ni
tricu
m; A
rgen
tum
nitr
icum
com
p.;
Arge
ntum
nitr
icum
/Ren
es; C
alen
dula
/Ec
hina
cea c
omp.
; Cer
atum
Rat
anhi
ae
com
p.; M
yrist
ica s
ebife
ra co
mp.
; Pe
riodo
ntiu
m/S
ilice
a com
p.;
Phyt
olac
ca co
mp.
; Rat
anhi
a com
p.;
Robi
nia c
omp.
; Sal
via c
omp.
; Sili
cea
com
p.
Arge
ntum
collo
idal
eAr
gent
um co
lloid
ale
Collo
idal
silv
er, a
silv
er p
repa
ratio
n wi
th a
prot
ectiv
e col
loid
coat
ing
of so
lubl
e pr
otei
n
HAB
see m
onog
raph
HAB
Arge
ntum
/Urt
ica c
omp.
; Majo
rana
/Th
uja c
omp.
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
170
Arge
ntum
met
allic
um,
Arge
ntum
met
allic
um
pph
Met
allic
silv
erH
AB; P
h.fr.
Ph.E
ur. 4
.1.1
, 4.1
.2,
Ph.fr
. (se
e mon
ogra
ph)
Agar
icus
com
p./P
hosp
horu
s; Ar
gent
um co
mp.
; Arg
entu
m
met
allic
um; A
rgen
tum
-Cor
pus
vitre
um; A
rgen
tum
/Ber
beris
com
p.;
Arge
ntum
/Ech
inac
ea; A
rgen
tum
/H
yosc
yam
us; A
rgen
tum
/Ova
ria;
Arge
ntum
/Pan
crea
s; Ar
gent
um/Q
uarz
; Ar
gent
um/Q
uerc
us co
mp.
; Arg
entu
m/
Rohr
zuck
er; A
rgen
tum
/Sec
ale;
Arge
ntum
/Stib
ium
; Arg
entu
m/T
este
s; Be
tula
/Arn
ica c
omp.
; Bry
ophy
llum
co
mp.
; Car
tilag
o/M
andr
agor
a com
p.;
Cham
omill
a com
p.; C
onch
ae co
mp.
; Co
njun
ctiv
a com
p.; D
isci c
omp.
cum
Ar
gent
o; D
isci/R
hus t
oxic
oden
dron
co
mp.
; Disc
i/Visc
um co
mp.
cum
Ar
gent
o; E
chin
acea
/Mer
curiu
s com
p.;
Echi
nace
a/Pr
unus
com
p.; E
chin
acea
/Vi
scum
com
p.; E
ndom
etriu
m co
mp.
; O
varia
com
p.; R
osm
arin
us co
mp.
; Te
stes c
omp.
; Thuj
a com
p.
Arse
nii t
rioxi
dum
Arse
nicu
m al
bum
aph
Arse
nicu
m al
bum
(HAB
); Ph
.Eur
.Ph
.Eur
. 4.1
.1, 4
.1.2
, so
lutio
n ac
c. to
m
onog
raph
HAB
Arse
nicu
m al
bum
; Bol
us al
ba co
mp.
; Br
yoni
a/G
elsem
ium
com
p.; C
olch
icum
co
mp.
Auru
m ch
lora
tum
Hyd
roge
n te
trach
loro
aura
te(II
I) tr
ihyd
rate
HAB
Ph.E
ur. 3
.1.1
, 3.1
.2Ap
is re
gina
/Aur
um co
mp.
Auru
m ch
lora
tum
na
trona
tum
see N
atriu
m te
trach
loro
aura
tum
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
171
Auru
m m
etal
licum
, Au
rum
met
allic
um p
phM
etal
lic go
ldH
AB; P
h.fr.
Ph.E
ur. 4
.1.1
, 4.1
.2Ar
nica
, Pla
nta t
ota/
Auru
m; A
urum
co
mp.
; Aur
um m
etal
licum
; Aur
um/
Bella
donn
a com
p.; A
urum
/Cor
; Au
rum
/Cra
taeg
us; A
urum
/Epi
phys
is co
mp.
; Aur
um/E
quise
tum
; Aur
um/
Ferr
um si
dere
um; A
urum
/H
yosc
yam
us co
mp.
; Aur
um/
Hyp
ophy
sis co
mp.
; Aur
um/L
avan
dula
e ae
ther
oleu
m/R
osa;
Auru
m/
Ono
pord
on co
mp.
; Aur
um/
Para
thyr
eoid
ea; A
urum
/Plu
mbu
m
mell
itum
com
p.; A
urum
/Pru
nus;
Auru
m/P
ulsa
tilla
/Spo
ngia
com
p.;
Auru
m/S
tibiu
m; A
urum
/Stro
phan
thus
ko
mbe
; Aur
um/V
aler
iana
com
p.;
Berb
eris/
Sepi
a com
p.; C
artil
ago
com
p.;
Crat
aegu
s com
p.; D
isci c
omp.
cum
Au
ro; K
aliu
m p
hosp
horic
um co
mp.
; M
edul
la sp
inal
is co
mp.
; Pan
krea
s co
mp.
; Sar
otha
mnu
s com
p.; S
tann
um
com
p.; S
troph
anth
us co
mp.
Auru
m m
etal
licum
fo
liatu
mG
old
leaf
Raw
mat
eria
l for
the
prep
arat
ion
of M
yrrh
a co
mp.
(see
app.
2.6
)
Auru
m m
uria
ticum
na
trona
tum
see N
atriu
m te
trach
loro
aura
tum
Auru
m n
atur
ale
see A
ppen
dix
2.1
Auru
m su
lfura
tum
Mix
ture
of g
old(
I)- an
d go
ld(II
I) su
lfide
Ph.E
ur. 4
.1.1
(the
n 3.
1.1
or 3
.1.2
), 4.
1.2
Bariu
m ci
tricu
mBa
rium
citra
te h
exah
ydra
t with
diff
eren
t am
ount
s of c
rysta
l wat
er:
Ba3(
C6H
5O7)
2*n
H2O
(n =
5-7
)
Ph.E
ur. 4
.1.1
(the
n pe
rhap
s 3.2
.2),
4.1.
2Ba
rium
citri
cum
; Bar
ium
com
p.;
Bariu
m/P
ancr
eas c
omp.
; Ves
pa cr
abro
co
mp.
Barii
iodi
dum
Bariu
m io
datu
mBa
rium
iodi
de m
onoh
ydra
teH
ABPh
.Eur
. 3.1
.1 (e
than
ol
50%
), 4.
1.1,
4.1
.2Ba
rium
joda
tum
; Ech
inac
ea co
mp.
Bism
uthu
m p
phse
e Bism
utum
subn
itras
pon
dero
sus
Bism
utum
met
allic
umM
etal
lic b
ismut
hH
ABPh
.Eur
. 4.1
.1, 4
.1.2
Bism
utum
/Stib
ium
; Pul
vis
stom
achi
cus c
um B
ismut
o pr
aepa
rato
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
172
Bism
utum
subn
itras
po
nder
osus
Bism
utum
subn
itric
um,
Bism
uthu
m p
phBi
smut
h su
bnitr
ate,
heav
yPh
.Eur
.Ph
.Eur
. 4.1
.1, 4
.1.2
, API
Arge
ntum
/Que
rcus
com
p.; C
arbo
Sa
ngui
nis c
omp.
; Pul
vis S
tom
achi
cus
cum
Bell
adon
na
Bora
xN
atriu
m te
trabo
raciu
m,
Bora
x pp
hD
isodi
um te
trabo
rate
dec
ahyd
rate
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (e
than
ol
18%
, see
mon
ogra
ph
HAB
), 4.
1.1,
4.1
.2,
excip
ient
Calca
rea f
orm
icic
aCa
lcium
form
ate,
obta
ined
from
Con
chae
an
d Ac
idum
For
mic
ae (s
ee A
ppen
dix
2.3)
Ph.E
ur. 4
.1.1
, 4.1
.2Vi
tis co
mp.
Calca
rea p
hosp
horic
ase
e Cal
cii h
ydro
geno
phos
phas
dih
ydric
usPh
.Eur
.Ph
.Eur
. 4.1
.1, 4
.1.2
Répe
rtoire
de m
éd.
anth
r.: C
alca
rea
phos
phor
ica
Calci
i hyd
roge
noph
osph
as
dihy
dric
usCa
lcium
pho
spho
ricum
, Ca
lcium
pho
spho
rica
pph
Calci
um h
ydro
gen
phos
phat
e dih
ydra
te(H
AB);
Ph.E
ur.
Ph.E
ur. 4
.1.1
, 4.1
.2
Calci
i hyd
roxi
dum
Calci
i hyd
roxi
dum
Calci
um h
ydro
xide
Ph.E
ur.
Ph.E
ur. 4
.1.1
, 4.1
.2; r
aw
mat
eria
l for
the
prep
arat
ion
of
Caus
ticum
H
ahne
man
ni
Calci
i lac
tas
Calci
i lac
tas
Calci
um la
ctat
e pen
tahy
drat
ePh
.Eur
.AP
IAr
gent
um/Q
uerc
us co
mp.
Calci
i oxi
dum
Calci
i oxi
dum
Fres
hly b
urnt
lim
e or m
arbl
era
w m
ater
ial f
or th
e pr
epar
atio
n of
Cal
cium
sil
icic
um co
mp.
(see
ap
p. 2
.6)
Calci
um st
ibia
to-
sulfu
ratu
mA
mix
ture
, pre
pare
d by
melt
ing
stibi
um
sulfu
ratu
m n
igru
m, s
ulfu
r and
conc
hae
toge
ther
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2
d-Ca
mph
ora
Cam
phor
a, Ca
mph
ora
pph
D-C
amph
orPh
.Eur
.Ph
.Eur
. 3.1
.1 (e
than
ol
70%
), 3.
1.2,
HAB
12i
, AP
I
Acon
itum
/Cam
phor
a com
p.; A
escu
lus/
Cera
com
p.; A
urum
/Val
eria
na co
mp.
; Be
rber
is/Ju
nipe
rus c
omp.
; Cam
phor
a; Ca
mph
ora/
Hyp
eric
um; O
leum
ca
mph
orat
um co
mp.
; Oleu
m P
etra
e co
mp.
; Oleu
m rh
inal
e; Pl
anta
go co
mp.
; Sa
l Mar
is co
mp.
; Sar
otha
mnu
s com
p.;
Skor
odit
com
p.
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
173
Caus
ticum
Hah
nem
anni
Caus
ticum
Hah
nem
anni
A su
bsta
nce,
prep
ared
acco
rdin
g to
the
mon
ogra
ph C
austi
cum
Hah
nem
anni
H
AB
HAB
Ph.E
ur. 3
.1.1
(see
mon
. H
AB)
Ceru
ssa
see P
lum
bum
carb
onic
um
Chlo
roph
yllu
mCh
loro
phyl
lum
The g
reen
pla
nt p
igm
ent (
gree
n of
leav
es)
API
Arge
ntum
/Que
rcus
com
p.
Cinn
abar
isse
e Hyd
rarg
yrum
sulfu
ratu
m ru
brum
or
Cinn
abar
in A
ppen
dix
2.1
Coba
ltum
met
allic
umM
etal
lic co
balt
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Co
baltu
m m
etal
licum
Copp
er te
tram
min
e su
lfate
mon
ohyd
rate
Prep
ared
from
copp
er(II
) sul
fate
pe
ntah
ydra
te an
d co
ncen
trate
d am
mon
ia
solu
tion
Raw
mat
eria
l for
the
prep
arat
ion
of
Cupr
um-R
en-G
land
ula
supr
aren
aes (
see a
pp.
2.6)
Cupr
um-R
en-G
land
ula s
upra
rena
lis
Creo
sotu
mse
e Kre
osot
um
Cupr
i ace
tas m
onoh
ydric
us
aph
Cupr
um ac
etic
umCo
pper
(II) a
ceta
te m
onoh
ydra
te fh
pPh
.Eur
.Ph
.Eur
. 3.1
.1 (s
olut
ion
acco
rdin
g to
m
onog
raph
HAB
, et
hano
l 50%
), 3.
1.2,
4.
1.1
Bora
go/R
enes
com
p.; C
upru
m
acet
icum
; Cup
rum
acet
icum
com
p.;
Cupr
um ac
etic
um/Z
incu
m
valer
iani
cum
; Ech
inac
ea/V
iscum
co
mp.
Cupr
i sul
fas p
enta
hydr
icus
Cu
prum
sulfu
ricum
Copp
er(II
) sul
fate
pen
tahy
drat
ePh
.Eur
.Ph
.Eur
. 3.1
.1 (D
1 wi
th
wate
r, se
e mon
ogra
ph
HAB
), 4.
1.1,
4.1
.2
Cina
com
p.; C
inis
Caps
ellae
com
p.;
Cupr
um su
lfuric
um; C
upru
m
sulfu
ricum
com
p.; C
upru
m
sulfu
ricum
/Euc
alyp
tus;
Trab
ecul
um
com
p.; V
erat
rum
com
p.
Cupr
o-St
ibiu
mAl
loy o
f 1 p
art o
f cop
per a
nd 1
par
t of
antim
ony
Ph.E
ur. 4
.1.1
, 4.1
.2
Cupr
um ci
tricu
mCo
pper
(II) c
itrat
e 2.5
hyd
rate
Ph.E
ur. 4
.1.1
, 4.1
.2Cu
prum
citri
cum
Cupr
um ap
hCu
prum
met
allic
um ap
hCu
prum
met
allic
um fh
p(H
AB);
Ph.E
ur.
Ph.E
ur. 4
.1.1
, 4.1
.2Ar
nica
com
p./C
upru
m; C
upru
m
met
allic
um; C
upru
m/G
land
ula
supr
aren
alis
dext
ra; C
upru
m/G
land
ula
supr
aren
alis
sinist
ra; C
upru
m/
Nico
tiana
; Cup
rum
/Qua
rz co
mp.
; Cu
prum
/Ren
es; C
upru
m/S
tibiu
m;
Euca
lypt
i aet
hero
leum
com
p.; M
ixtu
ra
Stan
ni co
mp.
Cupr
um o
xydu
latum
ru
brum
Copp
er(I)
oxi
deAP
ICu
prum
oxy
dulat
um ru
brum
; Cu
prum
/Nico
tiana
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
174
Din
atrii
pho
spha
s do
deca
hydr
icus
Nat
rium
pho
spho
ricum
D
isodi
um p
hosp
hate
dod
ecah
ydra
te(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(eth
anol
18
%),
3.1.
2, 4
.1.1
, 4.1
.2Ro
bini
a com
p.
Ferr
osi s
ulfa
s des
icca
tus
Ferr
um su
lfuric
umD
ried
ferr
ous s
ulfa
te w
ith li
mit
valu
es fo
r M
n (0
.5%
) and
Zn
(150
ppm
) diff
eren
t fro
m th
ose f
or F
erro
us su
lfate
, drie
d Ph
.Eur
.
Ph.E
ur. 4
.1.1
, 4.1
.2,
start
ing
mat
eria
l for
the
prep
arat
ion
of F
erru
m/
Qua
rz (s
ee ap
p. 2
.6),
API
Ferr
um/Q
uarz
; Kal
ium
pho
spho
ricum
co
mp.
; Ova
rium
com
p.
Ferr
osi s
ulfa
s hep
tahy
dric
usFe
rrou
s sul
fate
hep
tahy
drat
e with
lim
it va
lues
for M
n (0
.5%
) and
Zn
(150
ppm
) di
ffere
nt fr
om th
ose f
or F
erro
us su
lfate
he
ptah
ydra
te P
h.Eu
r.
API f
or th
e pre
para
tion
of F
erru
m-Q
uarz
(app
. 2.
6)
Cini
s Cap
sella
e com
p.; F
erru
m/Q
uarz
Ferr
um ap
hFe
rrum
met
allic
umIr
on fh
p (o
btai
ned
by re
duct
ion
or
subl
imat
ion)
(HAB
); Ph
.Eur
.Ph
.Eur
. 4.1
.1; 4
.1.2
, sta
rtin
g m
ater
ial f
or
prep
arat
ion
of F
erru
m
pom
atum
(see
app.
2.6
)
Cheli
doni
um/O
xalis
com
p.; F
erru
m
met
allic
um; F
erru
m p
raep
arat
um
com
p.; F
erru
m/A
nisu
m; F
erru
m/
Pulm
o; F
erru
m/S
ulfu
r com
p.; F
erru
m/
Thyr
eoid
ea; F
erru
m/V
esic
a fell
ea
Der
Mer
kurs
tab
2014
; 67
(4)2
70-2
82
Ferr
um ci
tric
umIr
on(II
I) cit
rate
, con
tain
ing
not l
ess t
han
18.0
and
not m
ore t
han
20.0
% o
f Fe (
Ar
55.8
5)
Ph.E
ur. 3
.1.1
(eth
anol
18
%)
Ferr
um h
ydro
xyda
tum
see A
ppen
dix
2.6
(Fer
rum
hyd
roxy
datu
m)
Ferr
umFe
rrum
met
allic
um
redu
ctum
Iron
obt
aine
d by
redu
ctio
n of
the m
iner
al
sider
ite(H
AB)
Ph.E
ur. 4
.1.1
, 4.1
.2; r
aw
mat
eria
l for
the
prep
arat
ion
of F
erru
m
hydr
oxyd
atum
(app
. 2.
6)
Ferr
um p
hosp
horic
um,
Ferr
um p
hosp
horic
um
pph
Ferr
i pho
spha
s aph
Hyd
rate
d iro
n(III
) pho
spha
teH
AB; P
h.fr.
Ph.E
ur. 4
.1.1
, 4.1
.2Fe
rrum
pho
spho
ricum
; Fer
rum
ph
osph
oric
um co
mp.
Ferr
um se
squi
chlo
ratu
m
solu
tum
, Fer
rum
se
squi
chlo
ratu
m
Aque
ous s
olut
ion
of ir
on(II
I) ch
lorid
e he
xahy
drat
e with
9.8
-10.
3% F
eH
ABPh
.Eur
. 3.1
.1 (D
1 an
d D
2 ac
c. to
mon
HAB
!)Fe
rrum
pra
epar
atum
com
p.
Ferr
um u
stum
Com
plex
Iron
(II, I
II) o
xide
- ob
tain
ed b
y gl
owin
g an
d fo
rgin
g m
etal
lic ir
on -
cont
aini
ng n
ot le
ss th
an 7
1.0
and
not
mor
e tha
n 75
.0%
of F
e (Ar
55.
85)
Ph.E
ur. 4
.1.1
, 4.1
.2Co
ncha
e/Fe
rrum
ustu
m co
mp.
; Fe
rrum
silic
icum
com
p.; F
erru
m
ustu
m co
mp.
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
175
Ferr
um(II
I)-ka
lium
-ta
rtar
icum
Iron(
III) p
otas
sium
tart
rate
deh
ydra
te
(Fer
ric p
otas
sium
tart
rate
)sta
rtin
g m
ater
ial f
or
prep
arat
ion
of S
olut
io
Ferr
i com
p. an
d So
lutio
Sa
ccha
ri co
mp.
(see
ap
p. 2
.6)
Gla
ndul
a sup
rare
nalis
/Sol
utio
Fer
ri co
mp.
; Sol
utio
Fer
ri co
mp.
; Sol
utio
Sa
ccha
ri co
mp.
Glo
noin
umse
e Nitr
ogly
cerin
um
Hep
ar su
lfuris
Hep
ar su
lfuris
A su
bsta
nce,
obta
ined
thro
ugh
heat
ing
toge
ther
to g
lowi
ng a
mix
ture
of c
alciu
m
carb
onic
um H
ahne
man
ni an
d su
lfur.
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2H
epar
sulfu
ris; H
epar
sulfu
ris co
mp.
; La
ches
is co
mp.
Hyd
rarg
yri s
ulfa
sM
ercu
ry(II
) sul
fate
, 99-
100.
5% H
gSO
4ra
w m
ater
ial f
or
prep
arat
ion
of e.
g.
Visc
um M
ali c
um
Hyd
rarg
yro
(see
app.
2.
6)
Hyd
rarg
yri d
ichlo
ridum
Hyd
rarg
yrum
bi
chlo
ratu
mM
ercu
ric ch
lorid
e(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(eth
anol
90
%),
4.1.
1, 4
.1.2
Hyd
rarg
yrum
bi
cyan
atum
Mer
cury
(II) c
yani
deH
ABPh
.Eur
. 3.1
.1 (e
than
ol
50%
), 4.
1.1,
4.1
.2M
ercu
rius c
yana
tus
Hyd
rarg
yrum
biio
datu
mM
ercu
ry(II
) iod
ide
HAB
Ph.E
ur. 3
.1.1
(D3
with
et
hano
l 90%
), 4.
1.1;
4.
1.2,
star
ting
mat
eria
l fo
r pre
para
tion
of
Trab
ecul
um co
mp.
(a
pp. 2
.6)
Trab
ecul
um co
mp.
Hyd
rarg
yrum
chlo
ratu
m
Mer
curiu
s dul
cis p
phM
ercu
ry(I)
chlo
ride
HAB
; Ph.
fr.Ph
.Eur
. 4.1
.1, 4
.1.2
Lyco
podi
um co
mp.
; Mer
curiu
s dul
cis
Hyd
rarg
yrum
m
etal
licum
, M
ercu
rius v
ivus
pph
Met
allic
mer
cury
HAB
; Ph.
fr.Ph
.Eur
. 4.1
.1, 4
.1.2
Hiru
do co
mp.
; Mer
curiu
s viv
us;
Mer
curiu
s/Pu
lmo
Hyd
rarg
yrum
nitr
icum
ox
ydul
atum
Mer
cury
(I) n
itrat
e dih
ydra
teH
ABPh
.Eur
. 4.1
.1, 4
.1.2
; for
th
e pre
para
tion
of
Mer
curiu
s sol
ubili
s H
ahne
man
ni
Hyd
rarg
yri s
ulfid
um ap
hH
ydra
rgyr
um su
lfura
tum
ru
brum
, Hyd
rarg
yri
disu
lfura
tum
rubr
um ap
h Ci
nnab
aris,
Cin
naba
ris
pph
Red
Mer
cury
(II) s
ulfid
eH
AB; P
h.fr.
Ph.E
ur. 4
.1.1
; API
Echi
nace
a/Pr
unus
com
p.; O
leum
rh
inal
e
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
176
Iodu
mJo
dum
, Iod
um p
phIo
dine
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (D
2 wi
th
etha
nol 9
0% ac
c. to
m
on. H
AB);
raw
mat
eria
l for
pre
para
tion
of Su
lfur i
odat
um
Jodu
m
Kalii
bich
rom
as ap
hKa
lium
bich
rom
icum
Pota
ssiu
m d
ichro
mat
e fhp
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (D
2 wi
th
wate
r acc
. to
mon
. H
AB),
3.1.
2
Kaliu
m b
ichro
mic
um; M
yrist
ica
sebi
fera
com
p.
Kaliu
m ca
rbon
icum
Kaliu
m ca
rbon
icum
, Ka
lium
carb
onic
um p
phPo
tass
ium
carb
onat
e(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(eth
anol
18
%),
4.1.
1, 4
.1.2
; sta
rtin
g m
ater
ial f
or
prep
arat
ion
of K
aliu
m
acet
icum
com
p. an
d So
lutio
Fer
ri co
mp.
(see
ap
p. 2
.6)
Anag
allis
/Mal
achi
t com
p.;
Cham
omill
a/M
alac
hit c
omp.
; Kal
ium
ac
etic
um co
mp.
; Kal
ium
carb
onic
um;
Kaliu
m/T
eucr
ium
com
p.; S
olut
io F
erri
com
p.; S
olut
io S
acch
ari c
omp.
; Sol
utio
Si
licea
com
p.
Kalii
chlo
ridum
Kaliu
m ch
lora
tum
, Ka
lium
mur
iatic
um p
phPo
tass
ium
chlo
ride
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (E
than
ol
18%
acc.
to m
on. H
AB),
3.1.
2, 4
.1.1
, 4.1
.2
Répe
rtoire
de m
éd.
anth
r.: K
aliu
m
mur
iatic
um
Kalii
dih
ydro
geno
phos
phas
Kaliu
m p
hosp
horic
um,
Kaliu
m p
hosp
horic
um
pph
Pota
ssiu
m d
ihyd
roge
n ph
osph
ate
Ph.E
ur.
Ph.E
ur. 3
.1.1
, 4.1
.1,
4.1.
2Be
rber
is/H
yper
icum
com
p.; J
ugla
ns
regi
a com
p.; K
aliu
m p
hosp
horic
um
com
p.; L
ilium
tigr
inum
com
p.
Kalii
hyd
roge
nota
rtra
sPo
tass
ium
hyd
roge
n ta
rtra
tePh
.Eur
.Ra
w m
ater
ial f
or th
e pr
epar
atio
n of
Tar
taru
s sti
biat
us an
d So
lutio
fe
rri c
omp.
(app
. 2.6
)
Kalii
iodi
dum
Kaliu
m io
datu
m,
Kaliu
m io
datu
m p
phPo
tass
ium
iodi
de(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(eth
anol
50
%),
4.1.
1, 4
.1.2
Kalii
nitr
asKa
lium
nitr
icum
, Ka
lium
nitr
icum
pph
Pota
ssiu
m n
itrat
e(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(D2
with
et
hano
l 18%
acc.
to
mon
. HAB
), 4.
1.1;
sta
rtin
g m
ater
ial f
or
prep
arat
ion
of S
ilex
- La
pis c
ancr
i sol
utus
(a
pp. 2
.6),
excip
ient
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
177
Kalii
sulfa
sKa
lium
sulfu
ricum
, Ka
lium
sulfu
ricum
pph
Pota
ssiu
m su
lfate
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (D
1 wi
th
wate
r acc
. to
mon
. H
AB),
start
ing
mat
eria
l fo
r pre
para
tion
of
Kaliu
m su
lfuric
um
com
p. (s
ee ap
p. 2
.6)
Kaliu
m/T
eucr
ium
com
p.
Kaliu
m ca
rbon
icum
e cin
ere F
agi
Pota
ssiu
m ca
rbon
ate,
prep
ared
from
the
ash
of b
eech
wood
(Fag
us si
lvat
ica)
Ph.E
ur. 3
.1.2
Agro
pyro
n co
mp.
; Ana
galli
s com
p.;
Frag
aria
/Urt
ica c
omp.
Kaliu
m st
ibyl
tart
aric
uKa
lium
stib
ylta
rtar
icum
Pota
ssiu
m d
i-µ-
tart
rato
bis[
antim
onat
e(III
)] tri
hydr
ate,
98.0
-103
.0%
C8H
4K2O
12Sb
2, 3
H20
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2;
liqui
d so
lutio
ns ac
c. to
m
on. H
AB o
r Ph.
Eur.
3.1.
2
Phos
phor
us/T
arta
rus s
tibia
tus;
Pulm
o/Ta
rtar
us st
ibia
tus A
; Pul
mo/
Tart
arus
sti
biat
us B
; Pul
mo/
Vivi
anit
com
p.;
Tart
arus
stib
iatu
s; Ta
rtar
us st
ibia
tus
com
p.
Hep
ar su
lfuris
kal
inum
Kaliu
m su
lfura
tum
Crud
e pot
ash,
cont
aini
ng a
mix
ture
of
mai
nly p
otas
sium
trisu
lfide
and
pota
ssiu
m m
etab
isulfi
te (d
ipot
assiu
m
pyro
sulfi
te)
DAB
6AP
IKa
lium
sulfu
ratu
mVa
dem
ecum
: Kal
ium
su
lfura
tum
(ext
.)
Kaliu
m-E
isen-
Tart
rat
see F
erru
m(II
I)-ka
lium
-tart
aric
um
Kreo
sotu
mM
ixtu
re o
f gua
jaco
le, cr
eoso
le an
d cr
esol
ene o
btai
ned
thro
ugh
disti
llatio
n of
ta
r fro
m b
eech
woo
d
HAB
Ph.E
ur. 3
.1.1
(with
et
hano
l 90%
, see
m
onog
raph
)
Kreo
sotu
m; M
ajora
na/Th
uja c
omp.
Liqu
or n
atrii
silic
icise
e Nat
rii si
licici
, Liq
uor
Lith
ii ca
rbon
asLi
thiu
m ca
rbon
icum
, Li
thiu
m ca
rbon
icum
pph
Lith
ium
carb
onat
e(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(D2
with
wa
ter a
cc. t
o m
on.
HAB
), 4.
1.1,
4.1
.2
Mag
nesii
chlo
ridum
he
xahy
dric
usM
agne
sium
chlo
ratu
m,
Mag
nesia
mur
iatic
a pph
Mag
nesiu
m ch
lorid
e hex
ahyd
rate
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (e
than
ol
50%
), 4.
1.1;
raw
mat
eria
l for
the
prep
arat
ion
of H
epar
-M
agne
sium
(app
. 2.6
)
Mag
nesii
hyd
roge
noph
osph
as
trihy
dric
usM
agne
sium
ph
osph
oric
um,
Mag
nesia
pho
spho
rica
pph
Mag
nesiu
m h
ydro
gen
phos
phat
e tri
hydr
ate
(HAB
); Ph
.Eur
.Ph
.Eur
. 4.1
.1, 4
.1.2
; sta
rtin
g m
ater
ial f
or
prep
arat
ion
of C
inis
e fr
uctib
us A
vena
e cum
M
agne
sio
phos
phor
icum
(1:1
)(see
ap
p. 2
.6)
Cor/
Crat
aegu
s com
p.; F
raga
ria/U
rtic
a co
mp.
; Mag
nesiu
m p
hosp
horic
um;
Mag
nesiu
m p
hosp
horic
um co
mp.
; M
agne
sium
pho
spho
ricum
cum
cine
re
Aven
ae; V
erat
rum
com
p.
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
178
Mag
nesiu
m
hydr
oxyd
atum
Mag
nesiu
m h
ydro
xide
Ph.E
ur.
Raw
mat
eria
l for
pr
epar
atio
n of
e.g.
H
epar
-Mag
nesiu
m(s
ee
app.
2.6
)
Hep
ar-M
agne
sium
Mag
nesii
sulfa
s hep
tahy
dric
usM
agne
sium
sulfu
ricum
, M
agne
sia su
lfuric
a pph
Mag
nesiu
m su
lfate
hep
tahy
drat
ePh
.Eur
.Ph
.Eur
. 3.1
.2Be
rber
is/Pr
osta
ta co
mp.
; Ber
beris
/U
teru
s com
p.; M
agne
sium
sulfu
ricum
/O
varia
com
p.
Mag
nesiu
m m
etal
licum
Met
allic
mag
nesiu
mH
ABAP
I
Mag
nesiu
m
phos
phor
icum
acid
um
20%
Aque
ous s
olut
ion
of m
agne
sium
di
hydr
ogen
pho
spha
te (2
0%)
Ph.E
ur. 3
.1.1
, 3.1
.2Ca
ctus
/Mag
nesiu
m p
hosp
horic
um;
Mag
nesiu
m p
hosp
horic
um ac
idum
; M
agne
sium
pho
spho
ricum
acid
um/
Taba
cum
; Ono
pord
on co
mp.
/M
agne
sium
pho
spho
ricum
acid
um
Mer
curiu
s aur
atus
Gol
d-m
ercu
ry al
loy,
cont
aini
ng at
leas
t 32
.0 an
d no
t mor
e tha
n 35
.0%
Au
(Ar
196.
97) a
nd at
leas
t 65.
0 an
d no
t mor
e th
an 6
8.0%
Hg
(Ar 2
00.5
9)
Ph.E
ur. 4
.1.1
, 4.1
.2
Mer
curiu
s bijo
datu
sse
e Hyd
rarg
yrum
biio
datu
m
Mer
curiu
s cya
natu
sse
e Hyd
rarg
yrum
bic
yana
tum
Mer
curiu
s dul
cisse
e Hyd
rarg
yrum
chlo
ratu
m
Mer
curiu
s sol
ubili
s H
ahne
man
niA
mix
ture
with
86.
0-90
.0%
Hg
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2Ap
is/Be
llado
nna/
Mer
curiu
s; Ec
hina
cea/
Mer
curiu
s com
p.;
Mer
curiu
s sol
ubili
s Hah
nem
anni
Mer
curiu
s sub
limat
us
corr
osiv
usse
e Hyd
rarg
yrum
bich
lora
tum
(H
ydra
rgyr
um d
ichlo
ridum
)
Mer
curiu
s viv
usse
e Hyd
rarg
yrum
met
allic
um
Min
ium
Min
ium
[Lea
d(II,
IV) o
xide
]H
ABPh
.Eur
. 4.1
.1, 4
.1.2
Min
ium
Nat
rii ca
rbon
as d
ecah
ydric
usSo
dium
carb
onat
e dec
ahyd
rate
Ph.E
ur.
Ph.E
ur. 3
.1.1
(wat
er),
4.1.
1, 4
.1.2
; raw
m
ater
ial f
or th
e pr
epar
atio
n of
zinc
um
isova
leria
nicu
m
Levi
sticu
m co
mp.
Nat
rii ca
rbon
as m
onoh
ydric
usN
atriu
m ca
rbon
icum
, N
atru
m ca
rbon
icum
pph
Sodi
um ca
rbon
ate m
onoh
ydra
te(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(wat
er),
3.1.
2, 4
.1.1
, 4.1
.2Ce
rebe
llum
com
p.; F
raga
ria/U
rtic
a co
mp.
Nat
rii ch
lorid
umN
atriu
m ch
lora
tum
, N
atru
m m
uria
ticum
pph
Sodi
um ch
lorid
e(H
AB);
Ph.E
ur.
Ph.E
ur. 3
.1.1
(eth
anol
18
%),
4.1.
1, 4
.1.2
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
179
Nat
rii si
licici
, Liq
uor
Liqu
or n
atrii
silic
iciAq
ueou
s sol
utio
n of
sodi
um p
olys
ilica
te
with
7.5
- 8.
5% so
dium
oxi
de (N
a2O
) and
25
.5 -
28.5
% si
lcicu
m d
ioxi
de (S
iO2)
DAB
6Ra
w m
ater
iel fo
r pr
epar
atio
n of
e.g.
Uve
a co
mp.
(see
app.
2.6
)
Nat
rii su
lfas a
nhyd
ricus
Nat
rium
sulfu
ricum
, N
atru
m su
lfuric
um p
phAn
hydr
ous s
odiu
m su
lfate
Ph.E
ur.
Ph.E
ur. 3
.1.1
(D2
with
et
hano
l 18%
acc.
to
mon
ogra
ph H
AB),
3.1.
2, 4
.1.1
, 4.1
.2; r
aw
mat
eria
l for
pre
parin
g Ka
lium
sulfu
ricum
co
mp.
(see
app.
2.6
)
Lyco
podi
um co
mp.
Nat
rii te
trach
loro
aura
s di
hydr
icus
aph
Nat
rium
te
trach
loro
aura
tum
Sodi
um te
trach
loro
aura
te d
ihyd
rate
fhp
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (w
ater
, see
m
onog
raph
HAB
), 4.
1.1
Répe
rtoire
de m
éd.
anth
r.: A
urum
m
uria
ticum
na
trona
tum
Nat
rium
pho
spho
ricum
see D
inat
rii p
hosp
has d
odec
ahyd
ricus
HAB
Nat
rium
tetra
bora
cicum
see B
orax
Ph.E
ur.
Nitr
icum
acid
um p
phse
e Acid
um n
itric
um
Nitr
ogly
cerin
umG
lono
inum
, Glo
noin
um
pph
Solu
tion
of g
lyce
rol t
rinitr
ate (
1%) i
n et
hano
l 96%
HAB
HAB
: The s
ubsta
nce i
s id
entic
al w
ith D
2;
furt
her p
oten
cies w
ith
etha
nol 5
0%
Glo
noin
um
Petro
leum
rect
ifica
tum
, Pe
troleu
m p
phPe
troleu
m sp
irit d
istill
ing
betw
een
180
and
220
°C o
btai
ned
by re
ctifi
catio
n of
cr
ude o
il
(HAB
); Ph
.Eur
.Ph
.Eur
. 3.1
.1 (e
than
ol
90%
acco
rdin
g to
m
onog
raph
HAB
), AP
I
Cocc
ulus
/Oleu
m P
etra
e com
p.; O
leum
Pe
trae c
omp.
; Pet
roleu
m
Phos
phor
icum
acid
um
pph
see A
cidum
pho
spho
ricum
conc
entra
tum
Phos
phor
usYe
llow
phos
phor
usH
ABse
e Pho
spho
rus H
AB
(D3
with
anhy
drou
s et
hano
l), A
PI (e
.g. 0
.1%
in
oil)
Agar
icus
com
p./P
hosp
horu
s; Ap
atit/
Phos
phor
us co
mp.
; Ave
na co
mp.
; Br
yoni
a/Eu
pato
rium
com
p.; B
ryon
ia/
Gels
emiu
m co
mp.
; Equ
isetu
m co
mp.
; M
eliss
a/Ph
osph
orus
com
p.;
Met
eore
isen/
Phos
phor
/Qua
rz; O
leum
Pe
trae c
omp.
; Pho
spho
rus;
Phos
phor
us/M
alva
; Pho
spho
rus/
Sulfu
r; Ph
osph
orus
/Tar
taru
s stib
iatu
s; Sa
mbu
cus/
Teuc
rium
com
p.; V
aler
iana
co
mp.
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
180
Phos
phor
us m
etal
licus
(n
iger
)Bl
ack
met
allic
pho
spho
rus
Ph.E
ur. 4
.1.1
, 4.1
.2
Plat
inum
chlo
ratu
mse
e Aci
dum
hex
achl
orop
latin
icum
Plat
inum
met
allic
umM
etal
lic p
latin
HAB
Ph.E
ur. 4
.1.1
(D2)
, 4.1
.2Ré
perto
ire d
e méd
. an
thr.:
Plat
ina
Plum
bi ca
rbon
asPl
umbu
m ca
rbon
icum
Basic
lead
(II) c
arbo
nate
Raw
mat
eria
l for
pr
epar
atio
n of
Cin
is Ca
psell
ae co
mp.
APC
(s
ee ap
p. 2
.6)
Cini
s Cap
sella
e com
p.
Plum
bum
acet
icum
Lead
(II) a
ceta
te tr
ihyd
rate
HAB
Liqu
id so
lutio
n ac
c. to
m
onog
raph
HAB
and
Ph.E
ur. 3
.1.1
; 4.1
.1,
4.1.
2
Vade
mec
um: P
lum
bum
ac
etic
um/M
el co
mp.
Plum
bum
joda
tum
Lead
(II) i
odid
ePh
.Eur
. 4.1
.1, 4
.1.2
; API
Plum
bum
met
allic
umM
etal
lic le
adH
ABPh
.Eur
. 4.1
.1, 4
.1.2
; raw
m
ater
ial f
or th
e pr
epar
atio
n of
Pl
umbu
m m
ellitu
m
(see
app.
2.6
)
Cupr
um su
lfuric
um co
mp.
; Epi
phys
is/Pl
umbu
m; L
ien
com
p.; L
obeli
a com
p.;
Ono
pord
on co
mp.
/Plu
mbu
m;
Plum
bum
mell
itum
; Plu
mbu
m
met
allic
um; P
lum
bum
/Sta
nnum
Plum
bum
silic
icum
Lead
(II) m
eta s
ilica
te, o
btai
ned
by
smelt
ing
ceru
ssite
and
quar
tzPh
.Eur
. 4.1
.1, 4
.1.2
Plum
bum
silic
icum
Vade
mec
um
Sacc
haru
mSa
ccha
rum
Sac
char
iSu
cros
e obt
aine
d fro
m th
e ste
ms o
f Sa
ccha
rum
offi
cina
rum
L.
Ph.E
ur.
Ph.E
ur. 3
.1.2
, raw
m
ater
ial f
or p
repa
ratio
n of
e.g.
Plu
mbu
m
mell
itum
(see
app.
2.6
)
Anis-
Pyrit
; Arg
entu
m/Q
uerc
us co
mp.
; Ar
gent
um/R
ohrz
ucke
r; Pa
rath
yreo
idea
co
mp.
; Plu
mbu
m m
ellitu
m
Sacc
haru
m ca
ndid
umCr
ysta
ls, w
hich
dev
elop
by so
lvin
g an
d cr
ysta
llizi
ng su
cros
ePh
.Eur
. 4.1
.1, 4
.1.2
Auru
m/P
ulsa
tilla
/Spo
ngia
com
p.;
Spon
gia c
omp.
Silic
ease
e Aci
dum
silic
icum
Silic
ea co
lloid
alis
Collo
idal
silic
a, di
rect
ly o
btai
ned
in th
e m
anuf
actu
re o
f the
fini
shed
pro
duct
by
reac
tion
of ad
juste
d am
ount
s of a
queo
us
solu
tions
of s
odiu
m si
licat
e and
citr
ic ac
id
mon
ohyd
rate
.
API
Berb
eris/
Euca
lypt
us/ S
ilice
a com
p.;
Berb
eris/
Silic
ea co
mp.
; Ros
ae
aeth
erol
eum
/Sili
cea c
ollo
idal
is co
mp.
; Si
licea
collo
idal
is co
mp.
Stan
nosi
chlo
ridum
di
hydr
icum
Stan
nous
chlo
ride d
ihyd
rate
, tin
(II)c
hlor
ide
Ph.E
ur.
Star
ting
mat
eria
l for
pr
epar
atio
n of
stan
num
hy
drox
ydat
um (s
ee ap
p.
2.6,
Hep
ar-S
tann
um)
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
181
Stan
num
hyd
roxy
datu
mTi
n(II)
hyd
roxi
deRa
w m
ater
ial f
or
prep
arat
ion
of e.
g.
Hep
ar-S
tann
um (s
ee
app.
2.6
)
Corp
us vi
treum
-Sta
nnum
; Hep
ar-
Stan
num
Stan
num
met
allic
umM
etal
lic ti
nH
ABPh
.Eur
. 4.1
.1, 4
.1.2
; raw
m
ater
ial f
or p
repa
ratio
n of
Stan
num
mell
itum
(s
ee ap
p. 2
.6)
Alliu
m ce
pa/T
endo
com
p.; A
patit
/St
annu
m; A
rtic
ulat
io ta
locr
ural
is co
mp.
; Bry
onia
/Sta
nnum
; Bry
onia
/Vi
scum
com
p.; C
artil
ago
com
p.; C
ina
com
p.; C
onch
ae/Q
uerc
us co
mp.
; Disc
i co
mp.
cum
Nico
tiana
; Disc
i com
p.
cum
Pul
satil
la; D
isci c
omp.
cum
St
anno
; Disc
i/Pul
satil
la co
mp.
cum
St
anno
; Disc
i/Visc
um co
mp.
cum
St
anno
; Equ
isetu
m/S
tann
um;
Gna
phal
ium
com
p.; H
epar
/Sta
nnum
m
etal
licum
A; H
epar
/Sta
nnum
m
etal
licum
B; H
yper
icum
com
p.;
Hyp
ophy
sis/S
tann
um; J
ugla
ns re
gia
com
p.; L
ens c
rista
llina
/Visc
um co
mp.
cu
m St
anno
; Lili
um ti
grin
um co
mp.
; M
agne
sium
sulfu
ricum
/Ova
ria co
mp.
; M
enisc
us G
enus
/Sta
nnum
; Mer
curiu
s vi
vus c
omp.
; Mix
tura
Stan
ni co
mp.
; Pe
riodo
ntiu
m/S
tann
um co
mp.
; Pl
umbu
m/S
tann
um; P
runu
s/Ro
smar
inus
com
p.; S
cilla
com
p.;
Sene
cio co
mp.
; Sta
nnum
com
p.;
Stan
num
met
allic
um; S
tann
um/
Succ
inum
; Sta
nnum
/Sym
phyt
um
com
p.; U
rtic
a com
p.
Stib
ium
arse
nico
sum
Mix
ture
of e
qual
par
ts of
an
timon
y(V
)oxi
de an
d ar
seni
c(III
)oxi
deH
ABPh
.Eur
. 4.1
.1, 4
.1.2
Stib
ium
arse
nico
sum
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
182
Stib
ium
met
allic
umM
etal
lic an
timon
yH
ABPh
.Eur
. 4.1
.1, 4
.1.2
Arge
ntum
/Stib
ium
; Arn
ica/
Echi
nace
a co
mp.
; Aur
um/H
yosc
yam
us co
mp.
; Au
rum
/Stib
ium
; Bism
utum
/Stib
ium
; Ca
lendu
la/M
ercu
rialis
com
p.;
Calen
dula
/Stib
ium
; Cich
oriu
m co
mp.
; Ci
chor
ium
/Pan
crea
s com
p.; C
upru
m/
Stib
ium
; Disc
i com
p. cu
m St
ibio
; H
amam
elis c
omp.
; Mar
mor
/Stib
ium
; M
edul
la sp
inal
is co
mp.
; Mer
curia
lis
com
p.; M
ercu
rialis
/Stib
ium
com
p.;
Ova
rium
com
p.; R
hus/
Salix
com
p.;
Stib
ium
com
p.; S
tibiu
m m
etal
licum
; St
roph
anth
us co
mp.
; Tor
men
tilla
co
mp.
; Ver
atru
m co
mp.
Stib
ium
sulfu
ratu
m
aura
ntia
cum
Mix
ture
of a
ntim
ony(
V) s
ulfid
e and
su
lfur
HAB
Ph.E
ur. 4
.1.1
, 4.1
.2St
ibiu
m su
lfura
tum
aura
ntia
cum
Sulfu
r ad
usum
exte
rnal
Sulfu
r for
exte
rnal
use
(99.
0-10
1.0%
S)
Ph.E
ur.
Ph.E
ur. 4
.1.1
, 4.1
.2; A
PI
(for o
intm
ents)
Sulfu
r aph
Sulfu
rSu
lfur o
btai
ned
by su
blim
atio
nPh
.Eur
.Li
quid
solu
tions
acc.
to
mon
ogra
ph H
AB (D
4);
Ph.E
ur. 4
.1.1
, 4.1
.2;
API;
raw
mat
eria
l for
pr
epar
atio
n of
Eq
uise
tum
cum
Sulfu
re
tostu
m (s
ee ap
p. 2
.6)
Aven
a com
p.; B
etul
a/Ar
nica
com
p.;
Carb
o Be
tula
e/Su
lfur;
Disc
us
inte
rver
tebr
alis
embr
yona
lis/S
olut
io
Silic
eae c
omp.
; Equ
isetu
m cu
m Su
lfure
to
stum
; Fer
rum
side
reum
com
p.;
Ferr
um/S
ulfu
r com
p.; G
land
ula
supr
aren
alis/
Solu
tio F
erri
com
p.;
Hep
ar su
lfuris
; Pho
spho
rus/
Sulfu
r; Pu
lvis
stom
achi
cus c
um B
ismut
o pr
aepa
rato
; Sol
utio
Fer
ri co
mp.
; So
lutio
Sili
cea c
omp.
; Sul
fur;
Valer
iana
co
mp.
Sulfu
r iod
idum
Sulfu
r iod
atum
Mix
ture
of 4
par
ts of
iodi
ne an
d 1
part
of
sulfu
r car
eful
ly m
elted
toge
ther
(con
tain
s 70
-80%
I)
HAB
Liqu
id so
lutio
ns ac
c. m
onog
raph
HAB
(D3)
; Ph
.Eur
. 4.1
.1, 4
.1.2
Sulfu
r iod
idum
aph
Iode
et so
ufre
(méla
nge
d’) p
phM
ixtu
re o
f 4 p
arts
of io
dine
and
1 pa
rt o
f su
lfur c
aref
ully
melt
ed to
geth
er (c
onta
ins
75-8
2% I)
Ph.fr
.Ph
.Eur
. 4.1
.1, 4
.1.2
Sulfu
r sele
nosu
mM
ixtu
re o
btai
ned
by m
eltin
g 1
part
of
selen
with
99
part
s of s
ulfu
r.Ph
.Eur
. 4.1
.1, 4
.1.2
Vade
mec
um: S
ulfu
r se
lenos
um
Sulfu
ricum
acid
um p
phse
e Aci
dum
sulfu
ricum
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
183
Tart
arus
dep
urat
usPu
rified
tart
ar, m
ainl
y con
sistin
g of
po
tass
ium
hyd
roge
n ta
rtra
teO
nly u
sed
as a
raw
mat
eria
l for
pro
duct
ion
of T
arta
rus s
tibia
tus
Tart
arus
stib
iatu
sse
e Kal
ium
stib
ylta
rtar
icum
Tetra
mm
ine c
oppe
r(II)
su
lfate
see C
oppe
r tet
ram
min
e sul
fate
m
onoh
ydra
te
Zinc
um is
oval
eria
nicu
mZi
ncum
isov
aler
iani
cum
, Zi
ncum
valer
iani
cum
Zinc
isov
aler
ate d
ihyd
rate
with
98-
103%
Zn
(C5H
9O2)
, 2H
2OH
ABPh
.Eur
. 3.1
.1 (D
2 wi
th
etha
nol a
cc. t
o m
onog
raph
HAB
), 4.
1.1,
4.1
.2
Cupr
um ac
etic
um/Z
incu
m
valer
iani
cum
; Zin
cum
valer
iani
cum
; Zi
ncum
valer
iani
cum
com
p.
Vade
mec
um
Zinc
umZi
ncum
met
allic
um,
Zinc
um m
etal
licum
pph
Met
allic
zinc
with
97.
0-10
0.5
(HAB
) or
99.5
-101
.5%
(Ph.
fr.) Z
nH
AB; P
h.fr.
Ph.E
ur. 4
.1.1
, 4.1
.2
Zinc
um va
leria
nicu
mse
e Zin
cum
isov
aler
iani
cum
Latin
nam
e: Ph
.Eur
., H
AB
or P
h.fr.
Trad
ition
al n
ame:
H
AB
and/
or P
h.fr.
Abbr
evia
ted
defin
ition
En
glish
Nam
e in
Ph.E
ur. i
f app
licab
leRe
fere
nce
to S
tand
ard
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
185
•
Ap
pend
ix 2
.5
APPENDIX 2.5
Starting materials that have undergone special treatment Additional Information, see p. 18
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
186
Nam
e of t
he su
bsta
nce
Abbr
evia
ted
defin
ition
Re
fere
nce t
o St
anda
rd
(for t
he p
lant
)Pr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
Acon
itum
nap
ellus
Pl
umbo
cultu
mW
hole
fresh
pla
nts o
f Aco
nitu
m n
apell
us L
., col
lecte
d at
the s
tart
of fl
ower
ing,
cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
lead
cont
aini
ng
subs
tanc
e for
the t
reat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
(HAB
)Ph
.Eur
. 1.1
.3,
HAB
21
Acon
itum
nap
ellus
Plu
mbo
cultu
m
Atro
pa b
ellad
onna
Cu
pro
culta
Who
le fre
sh p
lant
s of A
tropa
bell
a-do
nna L
., with
out w
oody
lowe
r ste
m se
ctio
ns,
colle
cted
at th
e end
of fl
ower
ing,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
copp
er co
ntai
ning
subs
tanc
e for
the t
reat
men
t of t
he so
il fo
r the
1st
life
cycle
).
Ph.E
ur. 1
.1.3
Bryo
phyl
lum
pin
natu
m
Arge
nto
cultu
mFr
esh
leave
s of B
ryop
hyllu
m p
inna
tum
(Lam
.) O
ken
[Syn
. Kal
anch
oe p
inna
ta
(Lam
.) Pe
rs.],
har
veste
d in
the fi
rst y
ear o
f gro
wth,
culti
vate
d ac
cord
ing
to A
PC
Met
hod
1.1.
1 (u
sing
a dilu
ted
silve
r con
tain
ing
subs
tanc
e for
the t
reat
men
t of t
he
soil
for t
he 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.7,
HAB
21
Bryo
phyl
lum
Arg
ento
cultu
m
Bryo
phyl
lum
pin
natu
m
Mer
curio
cultu
mFr
esh
leave
s of B
ryop
hyllu
m p
inna
tum
(Lam
.) O
ken
[Syn
. Kal
anch
oe p
inna
ta
(Lam
.) Pe
rs.],
har
veste
d in
the fi
rst y
ear o
f gro
wth,
culti
vate
d ac
cord
ing
to A
PC
Met
hod
1.1.
1 (u
sing
a dilu
ted
mer
cury
cont
aini
ng su
bsta
nce f
or th
e tre
atm
ent o
f th
e soi
l for
the 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.7,
HAB
21
Bryo
phyl
lum
Mer
curio
cultu
mVa
dem
ecum
Cham
omill
a rec
utita
Cu
pro
culta
Fres
h un
derg
roun
d pa
rts o
f Cha
mom
illa r
ecut
ita (L
.) Ra
usch
ert,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a d
ilute
d co
pper
cont
aini
ng su
bsta
nce f
or
the t
reat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
Ph.E
ur. 1
.2.9
, H
AB 2
1Ch
amom
illa C
upro
culta
, Rad
ix
Cheli
doni
um m
ajus
Ferr
o cu
ltum
Fres
h rh
izom
e and
adhe
rent
root
s of C
helid
oniu
m m
ajus L
., col
lecte
d du
ring
late
autu
mn
or o
n th
e app
eara
nce o
f the
firs
t sho
ots,
culti
vate
d ac
cord
ing
to A
PC
Met
hod
1.1.
1 (u
sing
a dilu
ted
iron
cont
aini
ng su
bsta
nce f
or th
e tre
atm
ent o
f the
soil
for t
he 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.5,
HAB
21
Cheli
doni
um F
erro
cultu
mVa
dem
ecum
: Ch
elido
nium
Fer
ro
cultu
m
Cich
oriu
m in
tybu
s Pl
umbo
cultu
mW
hole
fresh
flow
erin
g pl
ants
of C
ichor
ium
inty
bus L
. (va
r. in
tybu
s and
/or v
ar.
sativ
um D
C), c
ultiv
ated
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
lead
cont
aini
ng su
bsta
nce f
or th
e tre
atm
ent o
f the
soil
for t
he 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.7,
HAB
21
Cich
oriu
m P
lum
bo cu
ltum
Cich
oriu
m in
tybu
s St
anno
cultu
mW
hole
fresh
flow
erin
g pl
ants
of C
ichor
ium
inty
bus L
. (va
r. in
tybu
s and
/or v
ar.
sativ
um D
C), c
ultiv
ated
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
tin
cont
aini
ng su
bsta
nce f
or th
e tre
atm
ent o
f the
soil
for t
he 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.7,
HAB
21
Cich
oriu
m St
anno
cultu
m
Cich
oriu
m in
tybu
s St
anno
cultu
m, R
adix
Fres
h ro
ot o
f Cich
oriu
m in
tybu
s L. (
var,
inty
bus a
nd/o
r var
. sat
ivum
DC)
, col
lecte
d at
flow
erin
g tim
e, cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
tin
cont
aini
ng su
bsta
nce f
or th
e tre
atm
ent o
f the
soil
for t
he 1
st lif
e cyc
le).
Ph.E
ur. 1
.1.7
Cich
oriu
m St
anno
cultu
m
Equi
setu
m ar
vens
e Si
licea
cultu
mFr
esh
gree
n ste
rile a
eria
l par
ts of
Equ
isetu
m ar
vens
e L., c
ultiv
ated
acco
rdin
g to
APC
M
etho
d 1.
1.2
(usin
g a d
ilute
d sil
icat
e con
tain
ing
subs
tanc
e for
the t
reat
men
t of t
he
soil
for t
he 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.7,
HAB
21
(see
m
onog
raph
!)
Equi
setu
m ar
vens
e Sili
cea c
ultu
mVa
dem
ecum
Hyp
eric
um p
erfo
ratu
m
Auro
cultu
mFr
esh
aeria
l par
ts of
Hyp
eric
um p
erfo
ratu
m L
., col
lecte
d at
flow
erin
g tim
e, cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
gold
cont
aini
ng
subs
tanc
e for
the t
reat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
(HAB
)Ph
.Eur
. 1.1
.5,
HAB
21
Aqua
Mar
is co
mp.
; Hyp
eric
um
Auro
cultu
m
Kala
ncho
e pin
natu
m
Arge
nto
culta
see B
ryop
hyllu
m p
inna
tum
Arg
ento
culta
•
Appendix 2.5
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
187
Kala
ncho
e pin
natu
m
Mer
curio
culta
see B
ryop
hyllu
m p
inna
tum
Mer
curio
culta
Meli
ssa o
fficin
alis
Cupr
o cu
ltaFr
esh
aeria
l par
ts of
Meli
ssa o
fficin
alis
L., c
ultiv
ated
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
copp
er co
ntai
ning
subs
tanc
e for
the t
reat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
(HAB
)Ph
.Eur
. 1.1
.5,
HAB
21
Meli
ssa C
upro
culta
Vade
mec
um
Nas
turt
ium
offi
cinal
e M
ercu
rio cu
ltum
Fres
h ae
rial p
arts
of N
astu
rtiu
m o
fficin
ale R
. Br.,
colle
cted
at fl
ower
ing
time,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a d
ilute
d m
ercu
ry co
ntai
ning
su
bsta
nce f
or th
e tre
atm
ent o
f the
soil
for t
he 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.5,
HAB
21
Nas
turt
ium
Mer
curio
cultu
mVa
dem
ecum
: N
astu
rtiu
m M
ercu
rio
cultu
m
Nico
tiana
taba
cum
Cu
pro
culta
Fres
h lea
ves o
f Nico
tiana
taba
cum
L., c
ultiv
ated
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
copp
er co
ntai
ning
subs
tanc
e for
the t
reat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
(HAB
)H
AB 2
1Ta
bacu
m C
upro
cultu
mVa
dem
ecum
: Ta
bacu
m C
upro
cu
ltum
Oen
othe
ra A
rgen
to
culta
Fres
h ae
rial p
arts
of O
enot
hera
bie
nnis
L., c
ollec
ted
at fl
ower
ing
time,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a d
ilute
d sil
ver c
onta
inin
g su
bsta
nce f
or th
e tre
atm
ent o
f the
soil
for t
he 1
st lif
e cyc
le).
(HAB
192
4)Ph
.Eur
. 1.1
.3Va
dem
ecum
: O
enot
hera
Arg
ento
cu
lta Ja
chen
s: D
erm
atol
ogie.
Sa
lum
ed V
erla
g 20
12,
pp 3
86-3
91.
Prim
ula v
eris
Auro
cu
ltaFr
esh
flowe
rs o
f Prim
ula v
eris
L., c
ultiv
ated
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d go
ld co
ntai
ning
subs
tanc
e for
the t
reat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.Ph
.Eur
. 1.1
.5,
HAB
21
Prim
ula A
uro
culta
; Prim
ula A
uro
culta
com
p.Va
dem
ecum
: Prim
ula
Auro
culta
Tara
xacu
m o
fficin
ale
Stan
no cu
ltum
Who
le fre
sh fl
ower
ing
plan
ts of
Tar
axac
um o
fficin
ale a
gg. F
.H. W
igg.
, cul
tivat
ed
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a dilu
ted
tin co
ntai
ning
subs
tanc
e for
the
treat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
(HAB
)Ph
.Eur
. 1.1
.3,
HAB
21
Tara
xacu
m St
anno
cultu
mVa
dem
ecum
: Ta
raxa
cum
Stan
no
cultu
m
Thuj
a occ
iden
talis
Ar
gent
o cu
ltaFr
esh,
leaf
y, on
e-ye
ar-o
ld tw
igs o
f Thuj
a occ
iden
talis
L., c
ultiv
ated
acco
rdin
g to
AP
C M
etho
d 1.
1.1
(usin
g a d
ilute
d sil
ver c
onta
inin
g su
bsta
nce f
or th
e tre
atm
ent o
f th
e soi
l for
the 1
st lif
e cyc
le).
(HAB
)Ph
.Eur
. 1.1
.5,
HAB
21
Thuj
a occ
iden
talis
Arg
ento
culta
Urtic
a dio
ica F
erro
cu
ltaFr
esh
aeria
l par
ts of
Urt
ica d
ioic
a L., c
ollec
ted
at fl
ower
ing
time,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a d
ilute
d iro
n co
ntai
ning
subs
tanc
e for
the
treat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
(HAB
)Ph
.Eur
. 1.1
.3,
HAB
21
Urtic
a dio
ica F
erro
culta
Vade
mec
um: U
rtic
a di
oica
Fer
ro cu
lta
Urtic
a dio
ica F
erro
cu
lta, C
inis
see C
inis
Urtic
ae F
erro
culta
e app
. 2.7
Urtic
a dio
ica F
erro
cu
lta, R
adix
Fres
h un
derg
roun
d pa
rts o
f Urt
ica d
ioic
a L., c
ollec
ted
at fl
ower
ing
time,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a d
ilute
d iro
n co
ntai
ning
subs
tanc
e for
the
treat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.
HAB
21;
for t
he
prep
arat
ion
of
Cini
s Urt
icae
Fe
rro
culta
e (a
pp. 2
.5)
Urtic
a dio
ica F
erro
culta
Nam
e of t
he su
bsta
nce
Abbr
evia
ted
defin
ition
Re
fere
nce t
o St
anda
rd
(for t
he p
lant
)Pr
epar
atio
n m
etho
dRe
fere
nce f
or u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.5
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
189
•
Ap
pend
ix 2
.6
APPENDIX 2.6
List of compositions Additional Information, see p. 18
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
190
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
Alka
li co
mp.
Com
mip
hora
Jacq
. spe
cies
(M
yrrh
) / K
aliu
m
carb
onic
um /
Qua
rz /
Tron
a
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Cich
oriu
m in
tybu
s, Pl
anta
tota
, Al
kali
com
p. is
mad
e fro
m: P
otas
sium
carb
onat
e / T
rona
/ Q
uart
z and
Myr
rh. P
otas
sium
ca
rbon
ate,
Tron
a and
qua
rtz a
re in
tens
ively
tritu
rate
d an
d m
ixed
with
an o
rgan
ic b
inde
r (M
yrrh
). Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Vade
mec
um: A
lkal
i co
mp.
Anis-
Pyrit
Pim
pine
lla an
isum
L. /
Py
rite /
Sac
char
um
(Sac
char
um o
ffici
naru
m L
.)
1 g
Anis-
Pyrit
is p
repa
red
from
: Pim
pine
lla an
isum
, Fru
ctus
0.3
3 g
/ pyr
ite 0
.33
g /
sacc
haru
m 0
.33
g. W
arm
ed p
yrite
pow
der a
nd m
elted
sucr
ose (
cane
suga
r) ar
e th
orou
ghly
mix
ed, t
he p
owde
red
anise
ed ad
ded,
with
fina
l tho
roug
h m
ixin
g. Th
is fo
rmul
atio
n is
dilu
ted
with
an eq
ual a
mou
nt o
f lac
tose
mon
ohyd
rate
, grin
ded
and
sieve
d. Th
e res
ultin
g pr
epar
atio
n is
nam
ed A
nis-
Pyrit
50%
. The p
oten
cy A
nis-
Pyrit
D1
is pr
epar
ed fr
om 2
Par
ts An
is-Py
rit 5
0% an
d 8
part
s lac
tose
mon
ohyd
rate
, D2
acc.
to
Ph.E
ur. 4
.1.1
.
Anis-
Pyrit
Apis
cum
Lev
istic
oAp
is m
ellifi
ca L
. /
Levi
sticu
m o
ffici
nale
W. D
. J.
Koch
1 g
Apis
cum
Lev
istic
o Ø
(= D
1) is
pre
pare
d fro
m 0
.1 g
Api
s mell
ifica
/ 0.
1 g
aque
ous
extra
ct o
f Lev
istic
um, R
adix
(dru
g to
extra
ct =
4:1
). Th
e bee
s are
kill
ed, c
omm
inut
ed an
d m
ixed
with
a fre
shly
pre
pare
d aq
ueou
s ext
ract
of L
evist
icum
, Rad
ix (d
rug
to ex
tract
=
4:1)
and
glyc
erol
85%
. The l
iqui
d is
furt
her p
roce
ssed
imm
edia
tely.
Pot
entis
atio
n ac
c. to
Ph
.Eur
. 3.1
.2 (a
nd th
en H
AB 1
1).
Apis
cum
Lev
istic
o
Arge
ntum
-Cor
pus
vitre
umAr
gent
um m
etal
licum
/ Co
rpus
vitre
um (B
os ta
urus
L.
or O
ryct
olag
us cu
nicu
lus
L.)
Fres
h ey
e bal
l (Co
rpus
vitre
um) i
s clea
ned
and
mix
ed w
ith a
solu
tion
prep
ared
of s
ilver
ni
trate
, con
cent
rate
d am
mon
ia so
lutio
n an
d pu
rified
wat
er an
d m
ixed
. Afte
r add
ition
of
a sol
utio
n of
glu
cose
mon
ohyd
rate
in p
urifi
ed w
ater
the m
ixtu
re is
gent
ly w
arm
ed so
that
th
e silv
er n
itrat
e is r
educ
ed to
the m
etal
. Afte
r filte
ring,
the r
esid
ue is
drie
d wi
th la
ctos
e m
onoh
ydra
te, b
eing
adju
sted
to g
ive a
fina
l silv
er co
nten
t of 1
%. P
oten
tisat
ion
acc.
to
Ph.E
ur. 3
.2.2
.
Arge
ntum
-Cor
pus v
itreu
m
Arni
ca-C
ereb
rum
Arni
ca m
onta
na L
. /
Cere
brum
, Cer
ebell
um,
Trun
cus c
ereb
ri
1 g
Arni
ca-C
ereb
rum
D1
cont
ains
: Arn
ica,
Plan
ta to
ta, p
ress
ed ju
ice 0
.05
g/ C
ereb
rum
0.
05 g
(Cer
ebru
m =
Cer
ebru
m, C
ereb
ellum
, bra
in st
em =
2+1
+1).
The c
leane
d in
gred
ient
s of C
ereb
rum
are m
ixed
with
the f
resh
pre
ssed
pla
nt ju
ice o
f Arn
ica m
onta
na
and
inte
nsiv
ely tr
itura
ted.
Wat
er fo
r inj
ectio
ns is
adde
d an
d th
e mix
ture
pot
entis
ed to
m
ake t
he D
1 po
tenc
y. Th
e D1
pote
ncy i
s fur
ther
pro
cess
ed im
med
iate
ly ac
c. to
Ph.
Eur.
3.1.
2.
Arni
ca-C
ereb
rum
Calci
um Q
uerc
usse
e Que
rcus
e co
rtic
e cum
Cal
cio
carb
onic
o
Calci
um si
licic
um co
mp.
Arni
ca m
onta
na L
. / C
alci
i ox
idum
/ Ca
mph
ora /
Kal
ii ca
rbon
as /
Qua
rz /
Que
rcus
ro
bur L
., Que
rcus
pet
raea
(M
att.)
Lie
bl. a
nd Q
uerc
us
pube
scen
s Will
d./ T
ritic
um
aesti
vum
L. e
men
d Fi
ori e
t Pa
ol.
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Arn
ica m
onta
na, R
adix
, Cal
cium
sil
icic
um co
mp.
is p
repa
red
from
: Sili
cate
melt
(obt
aine
d fro
m q
uart
z / p
otas
sium
ca
rbon
ate /
calci
um o
xide
) / ar
nica
late
x / d
ried
wate
r-ex
tract
of Q
uerc
us, C
orte
x /
cam
phor
/ es
sent
ial o
il fro
m A
rnic
a mon
tana
, Rad
ix /
fresh
whe
at g
lute
n. Th
e sili
cate
m
elt is
adde
d to
a m
ixtu
re o
f the
Arn
ica l
atex
and
drie
d ex
tract
of Q
uerc
us, C
orte
x an
d tr
itura
ted.
Fin
ally
the c
amph
or an
d th
erea
fter t
he es
sent
ial o
il of
Arn
ica a
re ad
ded.
The
mix
ture
is tr
itura
ted
well,
fres
h wh
eat g
lute
n ad
ded
and
the w
hole
knea
ded
to m
ake a
pa
ste. Th
is is
then
drie
d, p
owde
red
and
dilu
ted
with
lact
ose m
onoh
ydra
te. P
oten
tisat
ion
acco
rdin
g to
Ph.
Eur.
4.1.
1.
Vade
mec
um: C
alciu
m
silic
icum
com
p.
•
Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
191
Carb
o Be
tula
e cum
M
etha
noBe
tula
pen
dula
Rot
h /
Met
han
Carb
o Be
tula
e (ch
arco
al fr
om th
e birc
h) sa
tura
ted
with
met
hane
R1
(Ph.
Eur.)
is u
sed:
Po
wder
ed C
arbo
Bet
ulae
is h
eate
d un
der v
acuu
m. A
fter h
eatin
g an
d du
ring
cool
ing
Carb
o Be
tula
e is s
atur
ated
with
met
hane
. Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Carb
o Be
tula
e cum
Met
hano
Cheli
doni
um/ C
urcu
ma
prae
p.Ch
elido
nium
maju
s L. /
Cu
rcum
a xan
thor
rhiz
a Ro
xb.
Cheli
doni
um Ø
(Ph.
Eur.
1.1.
5) C
urcu
ma x
anth
orrh
iza,
Rhiz
oma Ø
(Ph.
Eur.
1.2.
12) w
ith
70%
etha
nol V
/V) a
re m
ixed
by d
ropp
ing
1 pa
rt o
f the
firs
t int
o 1
part
of t
he ro
tatin
g se
cond
mot
her t
inct
ure.
Cheli
doni
um/C
urcu
ma
Cini
s Cap
sella
e com
p.
APC
Arte
misi
a abs
inth
ium
L. /
Ca
psell
a bur
sa-p
asto
ris (L
.) M
ed. /
Cup
ri su
lfas
pent
ahyd
ricus
/ Fe
rros
i su
lfas d
esicc
ates
/ H
alite
/ Ka
lii ca
rbon
as/ P
lant
ago
lanc
eolat
a L. /
Plu
mbu
m
subc
arbo
nicu
m (C
reus
sa) /
Ro
sa ce
ntifo
lia L
. / C
rem
or
Tart
ari (
Crea
m o
f Tar
tar)
The d
ried
plan
t mat
eria
l is i
ncin
erat
ed. Th
e wat
er so
lubl
e ash
salts
obt
aine
d th
eref
rom
, po
tass
ium
carb
onat
e (ob
tain
ed fr
om cr
eam
of t
arta
r) an
d ha
lite a
re m
ixed
and
adde
d to
th
e pow
der-
mix
ture
of c
oppe
r sul
fate
and
ferr
ous s
ulfa
te. Th
is co
mbi
ned
powd
er is
gr
ound
unt
il th
e col
our c
hang
es to
redd
ish b
rown
. In
the n
ext s
tep
wine
vine
gar,
in
which
fres
h ro
se p
etal
s hav
e bee
n so
aked
, is a
dded
and
the m
ixtu
re is
hea
ted
and
mix
ed
while
the c
olou
r tur
ns to
pist
achi
o gr
een.
Whe
n th
e pas
ty m
ass g
ets m
ore s
olid
, cer
ussa
is
adde
d an
d he
atin
g is
cont
inue
d un
til th
e mix
ture
is so
lid an
d dr
y. Aft
er co
olin
g th
e su
bsta
nce o
btai
ned
is po
wder
ed. F
or ex
tern
al u
se (e
.g. o
intm
ent,
gel)
an aq
ueou
s so
lutio
n of
the w
ater
solu
ble s
alts i
s use
d as
activ
e sub
stanc
e: 9
part
s of p
urifi
ed w
ater
are
adde
d to
1 p
art o
f Cin
is Ca
psell
ae co
mp.
APC
, the
mix
ture
is ag
itate
d in
a clo
sed
cont
aine
r and
allo
wed
to st
and
at ro
om te
mpe
ratu
re fo
r at l
east
20 h
ours
. The
supe
rnat
ant i
s filte
red.
The r
esul
ting
Cini
s Cap
sella
e com
p. aq
ueou
s sol
utio
n 10
% is
clea
r an
d vi
ridia
n gr
een
(turq
uoise
blu
e to
emer
ald
gree
n) in
colo
ur an
d ha
s to
be p
roce
ssed
im
med
iate
ly. 1
par
t Cin
is Ca
psell
ae co
mp.
aque
ous s
olut
ion
10%
corr
espo
nds t
o 0.
1 pa
rts o
f Cin
is Ca
psell
ae co
mp.
APC
.
Vade
mec
um: C
inis
Caps
ellae
com
p.
Cini
s e fr
uctib
us A
vena
e sa
tivae
cum
Mag
nesio
ph
osph
orico
(1:1
)
Aven
a sat
iva L
. / M
agne
sium
ph
osph
oric
um fh
p1.
Cin
is e f
ruct
ibus
Ave
nae s
ativ
ae (a
sh o
f the
frui
t of A
vena
sativ
a, oa
ts): O
ats a
re
moi
stene
d wi
th w
ater
to st
art g
erm
inat
ion,
drie
d an
d as
hed.
2. A
sh o
f oat
s with
m
agne
sium
pho
spho
ricum
: Equ
al p
arts
of as
h of
oat
s and
mag
nesiu
m p
hosp
horic
um ar
e m
ixed
toge
ther
. 3. P
oten
tisat
ion
acco
rdin
g to
Ph.
Eur.
4.1.
1.
Arni
ca/C
actu
s com
p.; C
or/
Crat
aegu
s com
p.; F
raga
ria/U
rtic
a co
mp.
; Mag
nesiu
m p
hosp
horic
um
com
p.; M
agne
sium
pho
spho
ricum
cu
m ci
nere
Ave
nae;
Vera
trum
co
mp.
Mey
er, U
. & P
eder
sen,
P.A
. (ed
): An
thro
poso
phisc
he
Phar
maz
ie 2
016
p.
587-
590.
Ciss
us-O
ssa
Aves
varia
e, e.g
. Pha
sianu
s co
lchic
us L
. (O
ssae
) / C
issus
go
ngyl
odes
(Bak
.) Bu
rch.
1 g
Ciss
us-O
ssa i
s pre
pare
d fro
m: E
than
olic
extra
ct fr
om: C
issus
gong
ylod
es, a
eria
l roo
t 1.
5 g/
Oss
a 0.5
g. Th
e bon
es o
f par
tridg
e or p
heas
ant a
re cl
eane
d, b
oiled
, drie
d,
powd
ered
and
mix
ed w
ith eq
ual p
arts
of la
ctos
e mon
ohyd
rate
. To
this
mix
ture
add
the
mot
her t
inct
ure o
f Ciss
us go
ngyl
odes
, aer
ial r
oots
drie
d (P
h.Eu
r. M
etho
d 1.
1.7)
. Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Ciss
us-O
ssa
Vade
mec
um
Com
posit
io C
ichor
iiSe
e Com
posit
io M
iner
alis
cum
Myr
rha
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
192
Com
posit
io M
iner
alis
cum
Myr
rha A
PCQ
uarz
/ Ka
lii ca
rbon
as /
Com
mip
hora
Jaco
b sp
ecie
s (m
yrrh
) / A
cidu
m
phos
phor
icum
/ H
alite
/ Fr
ucto
sum
/ La
ctos
um
mon
ohyd
ricum
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Cich
oriu
m in
tybu
s, Pl
anta
tota
, Co
mpo
sitio
Cich
orii,
is p
repa
red
by m
eltin
g qu
artz
with
pot
assiu
m ca
rbon
ate.
After
co
olin
g, th
e pro
duct
is d
issol
ved
in w
ater
and
adde
d to
pow
dere
d m
yrrh
, swo
llen
by
addi
ng Sp
iritu
s vin
i and
wat
er. Th
en p
hosp
horic
acid
is ad
ded,
lead
ing
to p
recip
itatio
n of
sil
icic
acid
. The m
ixtu
re is
drie
d, si
eved
and
mix
ed w
ith h
alite
. A co
ncen
trate
d aq
ueou
s so
lutio
n of
cara
mel
of fr
ucto
se an
d th
en la
ctos
e mon
ohyd
rate
is ad
ded.
Afte
r dry
ing,
the
whol
e mix
ture
is g
rinde
d to
a un
iform
pow
der.
Pote
ntisa
tion
acc.
to P
h.Eu
r. 4.
1.1
Com
posit
io M
iner
alis
cum
Sac
char
o AP
CKa
lii ca
rbon
as /
Qua
rz /
Tron
a / S
acch
arum
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Cha
mom
illa (
Mat
ricar
ia re
cutit
a L.)
Radi
x, C
ompo
sitio
Min
eral
is cu
m S
acch
aro
is pr
epar
ed fr
om: P
otas
sium
carb
onat
e/qu
artz
/tron
a. Po
tass
ium
carb
onat
e and
qua
rtz a
re m
elted
toge
ther
. The m
elt is
diss
olve
d in
wat
er to
pro
duce
a cle
ar so
lutio
n, an
d sim
ulta
neou
sly w
ith a
solu
tion
of su
cros
e add
ed
to a
solu
tion
of p
otas
sium
carb
onat
e and
tron
a. Th
is m
ixtu
re is
imm
edia
tely
pot
entis
ed
with
etha
nol 1
5% to
D1.
Pot
entis
atio
n ac
c. to
Ph.
Eur.
3.1.
1
Der
Mer
kurs
tab
2012
; 65
(1):
46-5
3
Corp
us vi
treum
-St
annu
mCo
rpus
vitre
um /
Stan
num
hy
drox
atum
1 g
Corp
us vi
treum
-Sta
nnum
D1
cont
ains
: Cor
pus v
itreu
m 0
.08
g / s
tann
um
hydr
oxyd
atum
0.0
2 g.
A so
lutio
n of
tin
(II) c
hlor
ide i
n pu
rified
wat
er is
mix
ed w
ith a
solu
tion
of so
dium
carb
onat
e in
purifi
ed w
ater
. The r
esul
ting
prec
ipita
te (s
tann
um
hydr
oxat
um) i
s add
ed to
fres
h, m
ince
d co
rpus
vitre
um an
d th
orou
ghly
mix
ed. Th
e m
ixtu
re is
dilu
ted
in th
e pro
port
ion
1:10
with
wat
er fo
r inj
ectio
ns to
pre
pare
the D
1 po
tenc
y. Th
e D1
pote
ncy i
s fur
ther
pro
cess
ed im
med
iate
ly ac
c. to
Ph.
Eur.
2.1.
1 an
d 3.
1.2
Corp
us vi
treum
-Sta
nnum
Cupr
um-R
en-G
land
ula
supr
aren
alis
Gla
ndul
a sup
rare
nalis
/ Re
nes (
Bos t
auru
s L. o
r O
ryct
olag
us cu
nicu
lus L
.) /
Tetra
mm
ine c
oppe
r(II)
su
lfate
1 g
Cupr
um-R
en (=
D1)
cont
ains
: Gla
ndul
a sup
rare
nalis
0.0
23 g
/ re
n 0.
060
g /
tetra
mm
ine c
oppe
r(II)
sulfa
te 0
.017
g. Th
e fre
sh, c
leane
d an
imal
ingr
edie
nt is
mix
ed w
ith
a sm
all a
mou
nt o
f wat
er fo
r inj
ectio
ns an
d te
tram
min
e cop
per (
II) su
lfate
, and
tritu
rate
d to
geth
er. A
fterw
ards
the r
est o
f the
wat
er fo
r inj
ectio
ns is
adde
d to
mak
e the
D1
pote
ncy,
and
the s
olut
ion
is po
tent
ised.
The D
1 po
tenc
y is f
urth
er p
roce
ssed
imm
edia
tely
acc.
to
Ph.E
ur. 3
.1.2
Cupr
um-R
en-G
land
ula
supr
aren
alis
Equi
setu
m cu
m Su
lfure
to
stum
Equi
setu
m ar
vens
e L. /
Su
lfur
Equi
setu
m cu
m Su
lfure
tostu
m is
pre
pare
d fro
m E
quise
tum
arve
nse,
Her
ba an
d su
lfur.
99 p
arts
Equi
setu
m ar
vens
e, H
erba
(drie
d, h
erba
l dru
g, co
mm
inut
ed to
a
part
icle s
ize <
4 m
m) a
re m
ixed
with
1 p
art s
ulfu
r (pa
rticl
e siz
e < 0
,063
mm
) and
then
to
aste
d ac
cord
ing
to A
PC 4
.1. H
eatin
g tim
e: ab
out 5
- 15
min
utes
. Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Equi
setu
m cu
m Su
lfure
tostu
m
Equi
setu
m h
yem
ale-
Rube
llit
Equi
setu
m h
yem
ale,
Rube
llit
Fres
h ha
rves
ted
shoo
ts of
Equ
isetu
m h
yem
ale L
. are
put
into
a aq
ueou
s dilu
tion
of
Rube
llit D
6 du
ring
the d
ay an
d un
der p
rese
nce o
f day
ligh
t. In
the e
veni
ng th
e sho
ots a
re
take
n ou
t, co
mm
inut
ed an
d ex
pres
sed.
The e
xpre
ssed
juic
e is m
ixed
with
an eq
ual m
ass
of et
hano
l 96%
. Filt
er aft
er 5
to 1
0 da
ys. Th
e filtr
ate i
s Equ
isetu
m h
yem
ale-
Rube
llit Ø
. Po
tent
isatio
n ac
c. to
Ph.
Eur.
1.1.
1
Der
Mer
kurs
tab
2013
; 66
(5):
415-
438.
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
193
•
Ap
pend
ix 2
.6
Equi
setu
m li
mos
um-
Rube
llit
Equi
setu
m li
mos
um L
. (E
quise
tum
fluv
iatil
e L.)
/ Ru
belli
t
Fres
h ha
rves
ted
shoo
ts of
Equ
isetu
m li
mos
um L
. (Eq
uise
tum
fluv
iatil
e L.)
are p
ut in
to a
aque
ous d
ilutio
n of
Rub
ellit
D6
durin
g th
e day
and
unde
r pre
senc
e of d
ay li
ght.
In th
e ev
enin
g th
e sho
ots a
re ta
ken
out,
com
min
uted
and
expr
esse
d. Th
e exp
ress
ed ju
ice is
m
ixed
with
an eq
ual m
ass o
f eth
anol
96%
. Filt
er aft
er 5
to 1
0 da
ys. Th
e filtr
ate i
s Eq
uise
tum
lim
osum
-Rub
ellit
Ø. P
oten
tisat
ion
acc.
to P
h.Eu
r. 1.
1.1
Sold
ner G
, Ste
llman
n H
M. I
ndiv
idue
lle
Pädi
atrie
, 4. A
uflag
e, W
issen
scha
ftl. V
erl.
Ges
., Stu
ttgar
t, 20
11, p
. 74
3
Ferr
um h
ydro
xyda
tum
Ferr
um ap
h / V
itis v
inife
ra
L.Fe
rrum
hyd
roxy
datu
m is
pre
pare
d fro
m F
erru
m m
etal
licum
redu
ctum
and
red
wine
vi
nega
r. Iro
n th
at p
revi
ously
has
bee
n ob
tain
ed fr
om si
derit
e by r
educ
tion
is co
vere
d wi
th re
d wi
ne vi
nega
r and
ligh
tly w
arm
ed fo
r abo
ut 1
4 da
ys. Th
en th
e sol
utio
n is
filte
red,
an
d th
e res
idue
was
hed
with
wat
er an
d left
to re
act w
ith ai
r. Th
is ox
idat
ion
relea
ses h
eat,
wher
efor
e the
pre
para
tion
has t
o be
kep
t moi
st. Th
e oxi
dise
d iro
n is
redu
ced
to p
owde
r. Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Ferr
um h
ydro
xyda
tum
Ferr
um p
omat
umFe
rrum
aph
/ Malu
s do
mes
tica B
orkh
.1
g of
the D
1 co
ntai
ns: F
e 5 m
g. S
our a
pples
are p
ress
ed; 1
00 p
arts
juice
is m
ixed
with
4
part
s Fer
rum
met
allic
um. Th
e mix
ture
is le
ft fo
r sev
eral
day
s and
then
war
med
to ab
out
50 °C
. Afte
rwar
ds th
e sol
utio
n is
filte
red,
evap
orat
ed to
55-
65%
of t
he w
eigh
ed m
ass a
nd
mix
ed w
ith et
hano
l 96%
(sta
ndar
disa
tion
on 1
0% et
hano
l and
0.5
% F
e). P
oten
tisat
ion
acc.
to P
h.Eu
r. 3.
1.1
(eth
anol
18%
).
Ferr
um ro
satu
mFe
rrum
side
reum
/ Ro
sa
cent
ifolia
L.
Ferr
um ro
satu
m is
pre
pare
d fro
m R
osa c
entif
olia
and
Ferr
um si
dere
um D
1. F
resh
rose
pe
tals
are t
ritur
ated
with
1%
Fer
rum
side
reum
D1
and
the a
mou
nt o
f wat
er, c
alcu
lated
ac
cord
ing
to P
h.Eu
r. 1.
1.6,
and
then
allo
wed
to st
and
for 2
-4 d
ays a
t 15-
20 °C
. Then
the
calcu
lated
amou
nt o
f eth
anol
94%
is ad
ded
and
the p
repa
ratio
n co
ntin
ued
acco
rdin
g to
Ph
.Eur
. 1.1
.6. Th
e com
posit
ion
can
be p
oten
tised
acc.
to P
h.Eu
r. 1.
1.6.
Ferr
um ro
satu
m/G
raph
ites;
Trop
aeol
um co
mp.
Ferr
um-Q
uarz
Ferr
osi s
ulfa
s hep
tahy
dric
us
APC/
Mel,
Qua
rz /
Vinu
m
(Viti
s vin
ifera
L.)
A m
ixtu
re o
f fer
rous
sulfa
te h
epta
hydr
ate,
hone
y, wh
ite w
ine,
and
calci
nate
d qu
artz
is
prep
ared
. This
mix
ture
is h
eate
d an
d dr
ied
unde
r vac
uum
. Pot
entis
atio
n ac
c. to
Ph.
Eur.
4.1.
1 or
4.1
.2
Ferr
um/Q
uarz
Hell
ebor
us fo
etid
usH
elleb
orus
foet
idus
L.
Aque
ous e
xtra
cts p
repa
red
from
the f
resh
pla
nt p
arts
of H
elleb
orus
foet
idus
L. (
Flos
rec.
and
Foliu
m et
Rad
ix re
c., se
e app
. 2.2
) are
mix
ed 1
:1 ac
cord
ing
to A
PC 7
.5.
Der
Mer
kurs
tab
6/20
10
p. 5
65
Hell
ebor
us n
iger
Hell
ebor
us n
iger
L.
Aque
ous e
xtra
cts p
repa
red
from
the f
resh
pla
nt p
arts
of H
elleb
orus
nig
er L
. (Fl
os re
c. an
d Pl
anta
tota
rec.,
see a
pp. 2
.2) a
re m
ixed
1:1
, acc
ordi
ng to
APC
7.5
.D
er M
erku
rsta
b 6/
2010
p.
500
-566
Hep
ar su
lfuris
see a
pp. 2
.4
Hep
ar-M
agne
sium
Hep
ar /
Mag
nesiu
m
hydr
oxyd
atum
1 g
Hep
ar-M
agne
sium
D1
cont
ains
: Hep
ar 0
.06
g / m
agne
sium
hyd
roxy
datu
m 0
.04
g. A
so
lutio
n of
mag
nesiu
m ch
lorid
e in
wate
r is m
ixed
with
a so
lutio
n of
sodi
um h
ydro
xide
in
wat
er. Th
e res
ultin
g pr
ecip
itate
(Mag
nesiu
m h
ydro
xyda
tum
) is w
ashe
d se
vera
l tim
es
with
wat
er an
d th
an m
ixed
with
chop
ped
piec
es o
f liv
er an
d th
en to
geth
er w
ith h
oney
, it
is fin
ely tr
itura
ted.
The m
ixtu
re is
mix
ed w
ith w
ater
for i
njec
tions
(Ph.
Eur.
3.1.
2) o
r gl
ycer
ol 8
5% (P
h.Eu
r. 2.
1.1)
, and
pot
entis
ed to
mak
e the
D1
pote
ncy.
This
D1
pote
ncy i
s pr
oces
sed
imm
edia
tely
acc.
to P
h.Eu
r. 3.
1.2
Hep
ar-M
agne
sium
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
194
Hep
ar-S
tann
umH
epar
/ St
annu
m
hydr
oxyd
atum
1 g
Hep
ar-S
tann
um co
ntai
ns: H
epar
0.0
8 g
/ Sta
nnum
hyd
roxy
datu
m 0
.02
g. A
solu
tion
of ti
n (II
) chl
orid
e in
wate
r is m
ixed
with
a so
lutio
n of
sodi
um ca
rbon
ate i
n wa
ter.
The
resu
lting
pre
cipita
te (S
tann
um h
ydro
xyda
tum
) is w
ashe
d wi
th w
ater
. The r
esul
ting
Stan
num
hyd
roxy
datu
m is
mix
ed w
ith ch
oppe
d pi
eces
of l
iver
and
then
thor
ough
ly
tritu
rate
d wi
th h
oney
. The m
ixtu
re is
mix
ed w
ith w
ater
for i
njec
tions
(Ph.
Eur
. 3.1
.2) o
r gl
ycer
ol 8
5% (P
h. E
ur. 2
.1.1
), an
d po
tent
ised
to m
ake t
he D
1 po
tenc
y. Th
is D
1 po
tenc
y is
proc
esse
d im
med
iate
ly ac
c. to
Ph.
Eur.
3.1.
2
Hep
ar-S
tann
um
Kaliu
m ac
etic
um co
mp.
Antim
onite
/ Co
ralli
um
rubr
um L
. / C
rocu
s sat
ivus
L.
/ Ka
lii ca
rbon
as /
Acet
um
Vini
des
tillat
um (V
itis
vini
fera
L.)
/ Spi
ritus
e Vi
no
(Viti
s vin
ifera
L.)
Kaliu
m ac
etic
um co
mp.
is p
repa
red
from
: Pot
assiu
m ca
rbon
ate /
dist
illed
red
wine
vi
nega
r / an
timon
ite /
Croc
us sa
tivus
tinc
ture
1:2
0 (v
ehicl
e: sp
iritu
s e vi
no) /
spiri
tus e
vi
no /
Cora
llium
rubr
um. P
otas
sium
carb
onat
e/di
stille
d re
d wi
ne vi
nega
r / an
timon
ite /
Croc
us sa
tivus
tinc
ture
/ Cor
alliu
m ru
brum
and
spiri
tus e
vino
are s
tepw
ise co
mbi
ned
and
repe
ated
ly d
istill
ed. Th
e res
ulta
nt d
ried
resid
ue is
use
d. P
oten
tisat
ion
acc.
to P
h.Eu
r. 4.
1.1
Anag
allis
/Mal
achi
t com
p.;
Cham
omill
a/M
alac
hit c
omp.
; Ka
lium
acet
icum
com
p.
Kaliu
m su
lfuric
um
com
p.Ka
lii su
lfas /
Nat
rii su
lfas /
Li
num
usit
atiss
imum
L.
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Ana
galli
s arv
ensis
, Her
ba, K
aliu
m
sulfu
ricum
com
p. is
pre
pare
d by
mix
ing
Kalii
sulfa
s and
Nat
rii su
lfas a
nd m
akin
g a p
aste
by
grin
ding
with
muc
ilage
of l
inse
ed. Th
e mix
ture
is d
ried,
grin
ded,
siev
ed; a
nd fi
nally
di
lute
d wi
th la
ctos
e mon
ohyd
rate
. Pot
entis
atio
n ac
c. to
Ph.
Eur.
4.1.
1
Vade
mec
um: K
aliu
m
sulfu
ricum
com
p.
Lapi
s Can
cri-F
lintst
ein
Lapi
s Can
cri/
Flin
t / Sp
iritu
s e v
ino
(Viti
s vin
ifera
L.)
1 g
Lapi
s Can
cri-F
lintst
ein
cont
ains
: Lap
is Ca
ncri
0.5
g/fli
nt 0
.5 g
: Fin
ely p
owde
red
Lapi
s Ca
ncri
and
flint
are t
horo
ughl
y mix
ed w
ith sp
irito
e vi
no an
d th
e slu
rry t
reat
ed w
ith
wate
r. Th
e res
ulta
nt d
ry re
sidue
is th
e sub
stanc
e. Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Lapi
s Can
cri/F
lintst
ein
Mix
tura
Stan
ni co
mp.
Alum
en /
Cupr
um
met
allic
um /
Stan
num
m
etal
licum
/ Ac
idum
ni
tric
um (6
5 pe
r cen
tum
);
1 g
susp
ensio
n is
prep
ared
from
: 1 m
g Al
umen
/ 0.
002
mg
Cupr
um m
etal
licum
/ 2
mg
Stan
num
met
allic
um 1
0.4
mg
Acid
um n
itric
um (6
5 pe
r cen
tum
).M
ixtu
ra St
anni
com
p.D
er M
erku
rsta
b 20
11;
64(4
): 33
2-33
7
Myr
rha c
omp.
Auru
m m
etal
licum
/ Bo
swell
ia sp
ecie
s /
Com
mip
hora
Jacq
. Spe
cies
/ Sa
ccha
rum
(Sac
char
um
offici
naru
m L
.)
1 g
Myr
rha c
omp.
D1
is pr
epar
ed fr
om: M
yrrh
a 0.1
g /
Auru
m m
etal
licum
folia
tum
(gol
d lea
f) 0
.001
g an
d O
liban
um 0
.1g.
Myr
rha a
nd go
ld le
af ar
e bou
nd to
geth
er w
ith th
e aid
of
mod
erat
e hea
t; in
cens
e sm
oke (
from
Olib
anum
) is p
asse
d th
roug
h th
e mix
ture
. This
com
posit
ion
is sti
rred
into
mol
ten
sucr
ose (
cane
suga
r). A
fter c
oolin
g it
is tr
itura
ted
for
one h
our b
y han
d, re
sulti
ng th
e pot
ency
D1.
Pot
entis
atio
n ac
c. to
Ph.
Eur.
4.1.
1
Vade
mec
um: M
yrrh
a co
mp.
Ono
pord
on co
mp.
Hyo
scya
mus
nig
er L
. /
Ono
pord
um ac
anth
ium
L. /
Pr
imul
a ver
is L.
A co
mbi
natio
n of
Ono
pord
um ac
anth
ium
, Flo
s rec
., eth
anol
. Dig
estio
(1:3
.1) w
ith
0.1-
1% H
yosc
yam
us n
iger
, Her
ba re
c. Ø
and
Prim
ula v
eris,
Flo
s rec
., eth
anol
. Dig
estio
(1
:3.1
) with
0.1
-1%
Hyo
scya
mus
nig
er, H
erba
rec.
Ø
Ono
pord
on co
mp.
Ono
pord
on co
mp.
pr
aepa
ratu
m C
HO
nopo
rdum
acan
thiu
m L
. /
Hyo
scya
mus
nig
er L
. /
Prim
ula v
eris
L.
0.1
part
of P
rimul
a ver
is, F
los r
ec., e
than
ol. D
iges
tio (1
:3.1
) pre
pare
d wi
th 2
%
Hyo
scya
mus
nig
er, H
erba
rec.
Ø is
dilu
ted
with
0.3
15 p
arts
of p
urifi
ed w
ater
("m
ixtu
re
a").
0.1
part
of O
nopo
rdum
acan
thiu
m, F
los r
ec., e
than
ol. D
iges
tio (1
:3.1
) is d
ilute
d wi
th
0.31
5 pa
rts o
f pur
ified
wat
er (m
ixtu
re b
). In
a sp
ecia
l equ
ipm
ent "
mix
ture
b" i
s dro
pped
in
to th
e rot
atin
g "m
ixtu
re a"
. 0.1
7 pa
rts o
f Eth
anol
96%
are a
dded
to o
btai
n 1
part
of t
he
final
pro
duct
Ono
pord
on co
mp.
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
195
Ono
pord
um ac
anth
ium
, Fl
os re
c., et
hano
l. D
iges
tio (1
:3.1
) with
0.
1-1%
Hyo
scya
mus
ni
ger,
Her
ba re
c. Ø
Ono
pord
um ac
anth
ium
L. /
H
yosc
yam
us n
iger
L.
Dig
estio
pre
pare
d fro
m 1
par
t of t
he fr
esh
flowe
rhea
ds o
f Ono
pord
um ac
anth
ium
L. a
nd
3.1
part
s of e
than
ol o
f sui
tabl
e con
cent
ratio
n or
wat
er fo
r inj
ectio
ns an
d th
e add
ition
of
0.00
4 to
0.0
4 pa
rts (
corr
espo
ndin
g to
0.1
to 1
%) o
f Hyo
scya
mus
nig
er L
., Her
ba, m
othe
r tin
ctur
e ( P
h.Eu
r. 1.
1.3)
.
Ono
pord
on co
mp.
Peat
mos
s ext
ract
co
mpo
sitio
n I (
light
)So
lum
ulig
inos
um /
Aesc
ulus
hip
poca
stanu
m
L. /
Equi
setu
m ar
vens
e L.
98 p
arts
of p
eat m
oss e
xtra
ct in
anal
ogy t
o to
HAB
Met
hod
12c (
usin
g pu
rified
wat
er
only
), ar
e mix
ed w
ith ea
ch 1
par
t of A
escu
lus h
ippo
casta
num
e se
min
e acc
ordi
ng to
H
AB M
etho
d 12
m an
d Eq
uise
tum
arve
nse e
x he
rba a
ccor
ding
to H
AB M
etho
d 12
c. Th
e su
pern
atan
t liq
uid
is de
cant
ed an
d fil
tere
d aft
er 1
0 - 1
2 we
eks y
ieldi
ng at
leas
t 75%
Pea
t m
oss e
xtra
ct co
mpo
sitio
n I.
API o
r Pot
entis
atio
n ac
c. to
Ph.
Eur.
3.1.
2
Solu
m u
ligin
osum
com
p.
Peat
mos
s ext
ract
co
mpo
sitio
n II
(dar
k)So
lum
ulig
inos
um /
Aesc
ulus
hip
poca
stanu
m
L. /
Equi
setu
m ar
vens
e L.
The r
est l
eft fr
om th
e dec
antin
g fo
r pre
parin
g Pe
at m
oss e
xtra
ct co
mpo
sitio
n I,
(max
. 25
%) i
s Pea
t mos
s ext
ract
com
posit
ion
IISo
lum
ulig
inos
um co
mp.
Plan
tago
lanc
eolat
a, Fo
lium
rec.,
etha
nol.
Dig
estio
(1:3
.1) w
ith
1-2%
Hyo
scya
mus
nig
er,
Her
ba re
c. Ø
Plan
tago
lanc
eolat
a L. /
H
yosc
yam
us n
iger
L.
Dig
estio
pre
pare
d fro
m 1
par
t of t
he fr
esh
leave
s of P
lant
ago
lanc
eolat
a L. a
nd 3
.1 p
arts
of et
hano
l of s
uita
ble c
once
ntra
tion
or w
ater
for i
njec
tions
and
the a
dditi
on o
f 0.0
4 to
0.
08 p
arts
(cor
resp
ondi
ng to
1 to
2%
) of H
yosc
yam
us n
iger
L., H
erba
, mot
her t
inct
ure
(Ph.
Eur
. 1.1
.3).
Plan
tago
-Prim
ula c
um
Hyo
scya
mo
Plum
bum
mell
itum
Plum
bum
met
allic
um /
Mel
/ Sac
char
um
(Sac
char
um o
fficin
arum
L.)
Plum
bum
mell
itum
is p
repa
red
from
lead
, hon
ey an
d ca
ne su
gar.
Dep
ress
ions
are
intro
duce
d in
to a
shee
t of l
ead,
this
is fil
led w
ith h
oney
, and
the w
hole
cove
red
with
m
olte
n lea
d. A
fter c
oolin
g it
is gr
ated
, melt
ed ag
ain
and
then
laid
out
as a
shee
t. N
ew
depr
essio
ns ar
e int
rodu
ced
once
mor
e. Th
ese a
re fi
lled
this
time w
ith m
olte
n su
cros
e (c
ane s
ugar
) and
cove
red
with
mol
ten
lead
from
the fi
rst l
ead-
hone
y-sh
eet.
After
cool
ing
it is
finely
gra
ted
and
the D
1 po
tenc
y is p
repa
red
by tr
itura
tion
with
lact
ose
mon
ohyd
rate
. Dur
ing
the g
rindi
ng an
d tri
tura
tion
proc
ess t
he p
owde
r mus
t be
sieve
d.Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Arni
ca/B
etul
a com
p.; A
rnic
a/Ep
iphy
sis/P
lum
bum
mell
itum
co
mp.
; Arn
ica/
Hyp
ophy
sis/
Plum
bum
mell
itum
com
p.;
Arni
ca/P
lum
bum
mell
itum
; Au
rum
/Plu
mbu
m m
ellitu
m
com
p.; N
icotia
na/S
troph
antu
s co
mp.
; Plu
mbu
m m
ellitu
m
Prim
ula v
eris,
Flo
s rec
., et
hano
l. D
iges
tio (1
: 12
.35)
with
0.6
%
Hyo
scya
mus
nig
er,
Her
ba re
c. Ø
Prim
ula v
eris
L. /
Hyo
scya
mus
nig
er L
.Pr
epar
ed b
y dig
estio
n ac
cord
ing
to A
PC 3
.8.1
from
1 p
art o
f the
fres
h flo
wers
of P
rimul
a ve
ris L
. and
12.
35 p
arts
of et
hano
l of s
uita
ble c
once
ntra
tion
and
the a
dditi
on o
f 0.0
8 pa
rts (
corr
espo
ndin
g to
0.6
%) o
f Hyo
scya
mus
nig
er L
., Her
ba, m
othe
r tin
ctur
e (Ph
. Eur
. 1.
1.3)
.
Prim
ula v
eris,
Flo
s rec
., et
hano
l. D
iges
tio (1
:3.1
) wi
th 0
.1-1
% H
yosc
yam
us
nige
r, H
erba
rec.
Ø
Prim
ula v
eris
L. /
Hyo
scya
mus
nig
er L
.A
dige
stio
prep
ared
from
1 p
art o
f the
fres
h flo
wers
of P
rimul
a ver
is L.
and
3.1
part
s of
etha
nol o
f sui
tabl
e con
cent
ratio
n or
wat
er fo
r inj
ectio
ns an
d th
e add
ition
of 0
.004
to 0
.04
part
s (co
rres
pond
ing
to 0
.1 to
1%
) of H
yosc
yam
us n
iger
L., H
erba
, mot
her t
inct
ure (
Ph.
Eur.
1.1.
3).
Ono
pord
on co
mp.
Prun
usei
sen
Prun
us sp
inos
a L. /
Fer
rum
m
etal
licum
Prep
ared
acco
rdin
g to
HAB
met
hod
37a
Levi
co co
mp.
; Pru
nus s
pino
sa
cum
Fer
ro
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
196
Que
rcus
e co
rtic
e cum
Ca
lcio
carb
onic
oQ
uerc
us ro
bur L
., Que
rcus
pe
traea
(Mat
t.) L
iebl
., Q
uerc
us p
ubes
cens
Will
d.
1. C
alciu
m ca
rbon
icum
e ci
nere
Que
rcus
: oak
bar
k is
inci
nera
ted.
The a
sh is
susp
ende
d 1
part
in 1
0 pa
rts o
f pur
ified
wat
er. C
arbo
n di
oxid
e is i
nduc
ed fo
r 5 to
10
min
utes
and
then
wa
rmed
unt
il bu
bblin
g sta
rts (
75-8
5 °C
). Th
is te
mpe
ratu
re is
kep
t unt
il bu
bblin
g en
ds.
The c
ooled
susp
ensio
n is
filte
red
and
the r
esid
ue d
ried
= Ca
lcium
carb
onic
um e
cine
re
Que
rcus
. 2. C
alciu
m ca
rbon
icum
e ci
nere
Que
rcus
solu
tum
: 0.1
par
t of C
alciu
m
carb
onic
um e
cine
re Q
uerc
us is
mix
ed w
ith 6
100
part
s of p
urifi
ed w
ater
or w
ater
for
Inje
ctio
ns an
d bo
iled
for 5
min
utes
. The c
ooled
solu
tion
is fil
tere
d (fo
r sol
utio
ns fo
r in
ject
ion
it is
deca
nted
and
filte
red)
. The r
esul
t is a
satu
rate
d aq
ueou
s sol
utio
n of
Ca
lcium
carb
onic
um e
cine
re Q
uerc
us =
Cal
cium
carb
onic
um e
cine
re Q
uerc
us
solu
tum
. 2.1
. Cal
cium
carb
onic
um e
cine
re Q
uerc
us so
lutu
m sa
ccha
ratu
m: s
yrup
pr
epar
ed w
ith su
cros
e and
Cal
cium
carb
onic
um e
cine
re Q
uerc
us so
lutu
m (6
4:36
). 3.
Q
uerc
us ro
bur/
petra
ea e
cort
ice c
um C
alci
o ca
rbon
ico
solu
tion
= D
5: A
dec
octio
n of
oa
k ba
rk ac
cord
ing
to H
AB 2
3a (Ø
=D1)
is p
oten
tised
to D
5 wi
th C
alciu
m ca
rbon
icum
e ci
nere
Que
rcus
solu
tum
as a
vehi
cle. A
ppen
dix:
acco
rdin
g to
the d
osag
e for
m to
be
prod
uced
eith
er p
oten
tise f
urth
er w
ith C
alciu
m ca
rbon
icum
e ci
nere
Que
rcus
solu
tum
(e
.g. s
olut
ion
for i
njec
tion)
or w
ith C
alciu
m ca
rbon
icum
e ci
nere
Que
rcus
solu
tum
sa
ccha
ratu
m (G
lobu
li ve
lati).
Calci
um ca
rbon
icum
cum
Q
uerc
u; C
alciu
m ca
rbon
icum
/M
esen
chym
com
p.
Rose
neise
nRo
sa L
., sui
tabl
e spe
cies
of
the g
enus
/ Fer
rum
m
etal
licum
Prep
ared
acco
rdin
g H
AB m
etho
d 37
aFe
rrum
rosa
tum
/Gra
phite
s
Rube
llit c
omp.
Equi
setu
m li
mos
um
(Equ
isetu
m fl
uvia
tile L
.),
Rube
llit,
Mel
Fres
h ha
rves
ted
shoo
ts of
Equ
isetu
m li
mos
um L
. (Eq
uise
tum
fluv
iatil
e L.)
are p
ut in
to an
aq
ueou
s dilu
tion
of R
ubell
it D
6 du
ring
the d
ay an
d in
the p
rese
nce o
f day
ligh
t. In
the
even
ing
the s
hoot
s are
take
n ou
t, co
mm
inut
ed an
d ex
pres
sed.
4 p
arts
of ex
pres
sed
juic
e ar
e mix
ed w
ith 1
par
t of m
el. A
fter s
tand
ing
at 3
7 °C
for 1
2 h
durin
g th
e nig
ht, 5
par
ts of
et
hano
l 96%
are a
dded
. Filt
er aft
er 5
to 1
0 da
ys. Th
e filtr
ate i
s Rub
ellit
com
p. Ø
. Po
tent
isatio
n ac
c. to
Ph.
Eur.
1.1.
1
Der
Mer
kurs
tab
2013
; 66
(5):
415-
436,
43
9-44
2.
Silex
Lap
is ca
ncri
solu
tus
Silex
(Flin
t) / K
alii
nitra
s /
Lapi
s can
cri /
Ace
tum
Vin
i de
st. (V
itis v
inife
ra L
.)
Calci
um si
licat
e is p
recip
itate
d by
addi
ng an
aque
ous s
olut
ion
of p
otas
sium
silic
ate
(pre
pare
d fro
m fl
int a
nd p
otas
sium
nitr
ate)
to an
aque
ous s
olut
ion
of ca
lcium
acet
ate
(pre
pare
d fro
m L
apis
Canc
ri an
d di
stille
d re
d wi
ne vi
nega
r in
seve
ral s
teps
) and
di
ssol
ved
in d
istill
ed re
d wi
ne vi
nega
r to
give
a cle
ar so
lutio
n. Th
e sol
utio
n is
dilu
ted
with
wat
er to
1.0
% an
d th
en su
ccus
sed
to re
sult
the p
oten
cy D
2. P
oten
tisat
ion
acc.
to
Ph.E
ur. 3
.1.1
Vade
mec
um 2
013:
Si
lex-L
apis
Canc
ri so
lutu
s
Solu
tio al
kalin
aTa
rtar
us cr
udus
An aq
ueou
s sol
utio
n (1
0% d
ry re
sidue
) pre
pare
d fro
m as
h of
gre
en p
lant
s and
crud
e cr
eam
of t
arta
r. Po
tent
ising
acc.
to P
h.Eu
r. 3.
1.1
(eth
anol
18%
)So
lutio
alka
lina
Vade
mec
um
Solu
tio F
erri
com
p.Ka
lii ca
rbon
as /
Ferr
um(II
I)-Ka
lium
-ta
rtar
icum
/ Su
lfur /
Tro
na /
Acid
um ta
rtar
icum
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Urt
ica d
ioic
a, Pl
anta
tota
, Sol
utio
Fe
rri c
omp.
is p
repa
red
from
: Pot
assiu
m ca
rbon
ate /
ferr
ic p
otas
sium
tart
rate
/ su
lfur /
tro
na /
acid
um ta
rtar
icum
. Pot
assiu
m ca
rbon
ate,
trona
and
sulfu
r are
melt
ed to
geth
er.
The r
esul
ting
melt
is d
issol
ved
in w
ater
and
alte
rnat
ely h
eate
d an
d su
bjec
ted
to an
in
tens
ive a
ir-str
eam
. Afte
r thi
s pro
cedu
re fe
rric
pot
assiu
m ta
rtra
te an
d ac
idum
ta
rtar
icum
are a
dded
. The r
esul
ting
solu
tion
is ex
pose
d to
the l
ight
. Pot
entis
atio
n ac
c. to
Ph
.Eur
. 3.1
.1
Aqua
Mar
is co
mp.
; Gla
ndul
a su
prar
enal
is/So
lutio
Fer
ri co
mp.
; So
lutio
Fer
ri co
mp.
Vade
mec
um
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
197
Solu
tio S
acch
ari c
omp.
Acid
um su
lfuric
um /
Betu
la
pend
ula R
oth
/ Kal
ii ca
rbon
as /
Ferr
um(II
I)-Ka
lium
-tart
aric
um /
Mel
/ Q
uart
z / T
rona
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Cha
mom
illa (
Mat
ricar
ia re
cutit
a L),
Radi
x, S
olut
io S
acch
ari c
omp.
is p
repa
red
from
: Car
bo B
etul
ae /
pota
ssiu
m ca
rbon
ate /
fe
rric
pota
ssiu
m ta
rtra
te /
hone
y / q
uart
z / tr
ona.
Pota
ssiu
m ca
rbon
ate,
quar
tz an
d Ca
rbo
Betu
lae a
re m
elted
toge
ther
. The m
elt is
diss
olve
d in
wat
er to
pro
duce
a cle
ar so
lutio
n, to
wh
ich a
solu
tion
of p
otas
sium
carb
onat
e, tro
na an
d di
lute
d su
lfuric
acid
is ad
ded.
Afte
r ad
ditio
n of
furt
her d
ilute
d su
lfuric
acid
, hon
ey an
d th
en fe
rric
pota
ssiu
m ta
rtra
te ar
e ad
ded.
The r
esul
ting
solu
tion
is ex
pose
d to
the l
ight
. Pot
entis
atio
n ac
c. to
Ph.
Eur.
3.1.
1
Cini
s Arn
icae
com
p.; S
olut
io
Sacc
hari
com
p.Va
dem
ecum
Solu
tio S
ilice
ae co
mp.
Kalii
carb
onas
/ M
arm
or /
Qua
rz /
Sulfu
r / T
rona
The m
iner
al co
mpo
sitio
n ac
cord
ing
to th
e mod
el of
Equ
isetu
m ar
vens
e, H
erba
, Sol
utio
Si
licea
e com
p. is
pre
pare
d fro
m: P
otas
sium
carb
onat
e / m
arbl
e / q
uart
z / tr
ona a
nd
sulfu
r. Q
uart
z and
pot
assiu
m ca
rbon
ate a
re m
elted
toge
ther
and
diss
olve
d in
wat
er. I
n a
furt
her s
tep
mar
ble,
pota
ssiu
m ca
rbon
ate a
nd tr
ona a
re d
issol
ved
in w
ater
by a
ddin
g va
pour
from
bur
ning
sulfu
r to
a sec
ond
solu
tion.
Bot
h so
lutio
ns ar
e com
bine
d un
der
cont
inuo
s vap
our f
rom
bur
ning
sulfu
r. Ai
r is p
asse
d th
roug
h th
e res
ultin
g so
lutio
n fo
r se
vera
l hou
rs. P
oten
tisat
ion
acc.
to P
h.Eu
r. 3.
1.1
Disc
us in
terv
erte
bral
is em
bryo
nalis
/Sol
utio
Sili
ceae
co
mp.
; Sol
utio
Sili
cea c
omp.
Vade
mec
um
Stan
num
mell
itum
Stan
num
met
allic
um /
Mel
/ Sa
ccha
rum
(Sac
char
um
officin
arum
L.)
Stan
num
mell
itum
is p
repa
red
from
tin
with
hon
ey an
d ca
ne su
gar.
Dep
ress
ions
are
intro
duce
d in
to a
shee
t of t
in, t
his i
s fille
d wi
th h
oney
, and
the w
hole
cove
red
with
m
olte
n tin
. Afte
r coo
ling
it is
grat
ed, m
elted
agai
n an
d th
en la
id o
ut as
a sh
eet.
New
de
pres
sions
are i
ntro
duce
d on
ce m
ore.
Thes
e are
fille
d th
is tim
e with
mol
ten
sucr
ose
(can
e sug
ar) a
nd co
vere
d wi
th m
olte
n tin
. Afte
r coo
ling
it is
finely
gra
ted
and
the D
1 po
tenc
y is p
repa
red
by tr
itura
tion
with
lact
ose m
onoh
ydra
te. D
urin
g th
e grin
ding
and
tritu
ratio
n pr
oces
s the
pow
der m
ust b
e sie
ved.
Pot
entis
atio
n ac
c. to
Ph.
Eur.
4.1.
1
Der
Mer
kurs
tab
1992
; 45
(2):
108-
12
Trab
ecul
um co
mp.
Acid
um fo
rmici
cum
e fo
rmic
a / A
mm
onia
e sol
utio
co
ncen
trata
25%
/ Cu
pri
sulfa
s pen
tahy
dric
us /
Hyd
rarg
yrum
biio
datu
m /
Kalii
iodi
dum
/ Tr
abec
ulum
(B
os ta
urus
L.)
1 g
of T
rabe
culu
m co
mp.
(=D
1) is
pre
pare
d fro
m: 0
.1 g
Tra
becu
lum
/ 0.
1 g
acid
um
form
icicu
m e
form
ica (
5%) /
0.0
05 g
Cup
ri su
lfas /
0.0
07 g
Am
mon
iae s
olut
io
conc
entra
ta /
0.03
g H
ydra
rgyr
um b
iioda
tum
/ 0.
0225
g K
alii
iodi
dum
. Tra
becu
lum
is
treat
ed w
ith an
aque
ous s
olut
ion
of ac
idum
form
icicu
m e
form
ica t
o m
ake a
pul
p wi
th a
smoo
th co
nsist
ency
and
then
mix
ed w
ith an
amm
onia
cal s
olut
ion
of co
pper
sulfa
te.
Then
a so
lutio
n of
mer
cury
(II)
iodi
de an
d po
tass
ium
iodi
de an
d fin
ally
lact
ose
mon
ohyd
rate
is ad
ded.
Afte
r dry
ing,
the w
hole
mix
ture
is ru
bbed
to a
unifo
rm p
owde
r. Po
tent
isatio
n ac
c. to
Ph.
Eur.
4.1.
1
Trab
ecul
um co
mp.
Uve
a com
p.Ac
idum
form
icicu
m e
form
ica /
Acid
um
asco
rbic
um /
Liqu
or n
atrii
sil
icici
DAB
6/ F
erro
si su
lfas /
Hyo
scya
mus
nig
er L
. / M
agne
sium
pho
spho
ricum
ac
idum
/ U
vea (
Bos t
auru
s L.
)
1 g
Uve
a com
p. co
ntai
ns: U
vea b
ovis
1.00
g /
Mag
nesiu
m p
hosp
horic
um ac
idum
0.1
0 g
/ Ac
idum
asco
rbic
um 0
.10
g / F
erru
m su
lfuric
um 0
.33
g / S
olut
io n
atrii
silic
ici 1
.00
g /
Hyo
scya
mus
nig
er, P
lant
a tot
a Rh
Ø (H
AB, M
etho
d 21
) 1.0
0 g.
Uve
a is t
reat
ed w
ith an
aq
ueou
s sol
utio
n of
Acid
um fo
rmici
cum
e fo
rmic
a to
mak
e a p
ulp
with
a sm
ooth
co
nsist
ency
and
then
mix
ed w
ith a
solu
tion
of m
agne
sium
pho
spha
te d
ihyd
rate
and
sodi
um si
licat
e. Th
en an
aque
ous s
olut
ion
of fe
rrou
s sul
fate
and
asco
rbic
acid
are a
dded
, an
d fin
ally
Hyo
scya
mus
, Pla
nta t
ota R
h Ø
is ad
ded.
Afte
r dry
ing,
the s
ubsta
nce i
s po
wder
ed. P
oten
tisat
ion
acc.
to P
h.Eu
r. 4.
1.1
Visc
um A
biet
isVi
scum
albu
m ss
p. ab
ietis
(W
iesb
.) Ja
nch.
Aque
ous e
xtra
cts f
rom
fres
h pl
ants
of V
iscum
albu
m ss
p. ab
ietis
(Wie
sb.)
Janc
h.,
prep
ared
acco
rdin
g to
APC
7.2
.2.
Visc
um al
bum
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
198
Visc
um al
bum
(Abi
etis)
e pl
anta
tota
KVi
scum
albu
m ss
p. ab
ietis
(B
eck)
(Wie
sb.)
Abro
m.
Aque
ous e
xtra
ct p
repa
red
from
the d
ried
plan
t inc
ludi
ng fr
uit a
nd h
austo
rium
of
Visc
um al
bum
ssp.
abie
tis (B
eck)
(Wie
sb.)
Abro
m. (
Hos
t tre
e: Ab
ies a
lba M
ill.)
prep
ared
ac
cord
ing
to H
AB 3
8
Visc
um al
bum
Visc
um al
bum
(Cra
taeg
i) e p
lant
a tot
a KVi
scum
albu
m ss
p. al
bum
L.
Aque
ous e
xtra
cts p
repa
red
from
drie
d pl
ants
inclu
ding
frui
t and
hau
storiu
m o
f Visc
um
albu
m ss
p. al
bum
L. (
Hos
t tre
e: Cr
atae
gus L
.) pr
epar
ed ac
cord
ing
to H
AB 3
8Vi
scum
albu
m
Visc
um al
bum
(Mal
i) e
plan
ta to
ta K
Visc
um al
bum
L. s
sp. a
lbum
Aque
ous e
xtra
ct p
repa
red
from
the d
ried
plan
t inc
ludi
ng fr
uit a
nd h
austo
rium
of
Visc
um al
bum
L. s
sp. a
lbum
(hos
t tre
e: M
alus
dom
estic
a Bor
ck.)
prep
ared
acco
rdin
g to
H
AB 3
8
Visc
um al
bum
Visc
um al
bum
(Pin
i) e
plan
ta to
ta K
Visc
um al
bum
ssp.
au
stria
cum
(Wie
sb.)
Vollm
.Aq
ueou
s ext
ract
pre
pare
d fro
m d
ried
plan
ts in
cludi
ng fr
uit a
nd h
austo
rium
of V
iscum
al
bum
L. s
sp. a
ustr
iacu
m (W
iesb
.) Vo
llm. (
Hos
t tre
e: Pi
nus s
peci
es) p
repa
red
acco
rdin
g to
HAB
38
Visc
um al
bum
Visc
um al
bum
(Pop
uli)
e pl
anta
tota
KVi
scum
albu
m L
. ssp
. alb
umAq
ueou
s ext
ract
pre
pare
d fro
m d
ried
plan
ts in
cludi
ng fr
uit a
nd h
austo
rium
of V
iscum
al
bum
L ss
p. al
bum
(Hos
t tre
e: Po
pulu
s L.)
prep
ared
acco
rdin
g to
HAB
38
Visc
um al
bum
Visc
um al
bum
(Que
rcus
) ex
her
ba K
Visc
um al
bum
L ss
p. al
bum
Aque
ous e
xtra
ct p
repa
red
from
drie
d pl
ant i
nclu
ding
frui
t and
exclu
ding
hau
storiu
m o
f Vi
scum
albu
m L
. ssp
. alb
um (H
ost t
ree:
Que
rcus
L.)
prep
ared
acco
rdin
g to
HAB
met
hod
38
Visc
um al
bum
Visc
um al
bum
(Sal
icis)
e pl
anta
tota
KVi
scum
albu
m L
. ssp
. alb
um
L.Aq
ueou
s ext
ract
s of d
ried
plan
ts in
cludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m ss
p.
albu
m L
. (H
ost t
ree:
Salix
L.)
prep
ared
acco
rdin
g to
HAB
38
Visc
um al
bum
Visc
um al
bum
(Tili
ae) e
pl
anta
tota
KVi
scum
albu
m L
. ssp
. alb
umAq
ueou
s ext
ract
of d
ried
plan
ts in
cludi
ng fr
uit a
nd h
austo
rium
of V
iscum
albu
m ss
p.
albu
m L
. (H
ost t
ree:
Tilia
L.)
prep
ared
acco
rdin
g to
HAB
38
Visc
um al
bum
Visc
um M
ali
Visc
um al
bum
ssp.
albu
m L
.Fe
rmen
ted
aque
ous e
xtra
ct p
repa
red
from
the f
resh
pla
nts e
xclu
ding
hau
storiu
m o
f Vi
scum
albu
m ss
p. al
bum
L. (
Hos
t tre
e: M
alus
dom
estic
a Bor
kh.; a
pple
tree)
, pre
pare
d ac
cord
ing
to A
PC 7
.2.3
.
Visc
um al
bum
Visc
um M
ali
Visc
um al
bum
ssp.
albu
m L
.pr
epar
ed ac
cord
ing
to A
PC 7
.2.2
.
Visc
um M
ali c
um
Arge
nto
Visc
um al
bum
L. s
sp.
albu
m /
Arge
nti c
arbo
nas
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d wi
th ad
ditio
n of
silv
er ca
rbon
ate (
2x10
-5 m
g pe
r 10
0 m
g fre
sh p
lant
), ac
cord
ing
to A
PC 7
.2.4
.Vi
scum
albu
m c.
Arg
Visc
um M
ali c
um C
upro
Visc
um al
bum
ssp.
albu
m
L./ M
alac
hite
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d wi
th ad
ditio
n of
copp
er ca
rbon
ate (
mal
achi
te)
(2x1
0-5
mg
per 1
00 m
g fre
sh p
lant
), ac
cord
ing
to A
PC 7
.2.4
.Vi
scum
albu
m c.
Cu
Visc
um M
ali c
um
Hyd
rarg
yro
Visc
um al
bum
ssp.
albu
m
L. /
Hyd
rarg
yri s
ulfa
sFe
rmen
ted
aque
ous e
xtra
ct w
ith ad
ditio
n of
mer
cury
sulfa
te (2
x10-
5 m
g pe
r 100
mg
fresh
pla
nt),
prep
ared
acco
rdin
g to
APC
7.2
.4.
Visc
um al
bum
c. H
g
Visc
um P
ini
Visc
um al
bum
L. s
sp.
austr
iacu
m (W
iesb
.) Vo
llm.
prep
ared
acco
rdin
g to
APC
7.2
.3.
Visc
um al
bum
Visc
um P
ini
Visc
um al
bum
ssp.
au
stria
cum
(Wie
sb.)
Vollm
.pr
epar
ed ac
cord
ing
to A
PC 7
.2.2
.Vi
scum
albu
m
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
199
Visc
um P
ini c
um
Hyd
rarg
yro
Visc
um al
bum
ssp.
au
stria
cum
(Wie
sb.)
Vollm
ann
/ Hyd
rarg
yri
sulfa
s
Ferm
ente
d aq
ueou
s ext
ract
with
addi
tion
of m
ercu
ry su
lfate
(10-
5 m
g pe
r 100
mg
fresh
pl
ant),
pre
pare
d ac
cord
ing
to A
PC 7
.2.4
.Vi
scum
albu
m c.
Hg
Visc
um Q
uerc
iVi
scum
albu
m ss
p. al
bum
L.
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d ac
cord
ing
to A
PC 7
.2.3
.Vi
scum
albu
m
Visc
um Q
uerc
i cum
Ar
gent
oVi
scum
albu
m ss
p. al
bum
L.
/ Ar
gent
i car
bona
sFe
rmen
ted
aque
ous e
xtra
ct w
ith ad
ditio
n of
silv
er ca
rbon
ate (
10-8
mg
per 1
00 m
g fre
sh
plan
t), p
repa
red
acco
rdin
g to
APC
7.2
.4.
Visc
um al
bum
c. A
rg
Visc
um Q
uerc
i cum
Cu
pro
Visc
um al
bum
ssp.
albu
m
L. /
Mal
achi
teFe
rmen
ted
aque
ous e
xtra
ct w
ith ad
ditio
n of
copp
er ca
rbon
ate (
mal
achi
te) (
10-5
mg
per
100
mg
fresh
pla
nt),
prep
ared
acco
rdin
g to
APC
7.2
.4.
Visc
um al
bum
c. C
u
Visc
um Q
uerc
i cum
H
ydra
rgyr
oVi
scum
albu
m L
. ssp
. alb
um
L. /
Hyd
rarg
yri s
ulfa
sFe
rmen
ted
aque
ous e
xtra
ct w
ith ad
ditio
n of
mer
cury
sulfa
te (1
0-5
mg
per 1
00 m
g fre
sh
plan
t), p
repa
red
acco
rdin
g to
APC
7.2
.4.
Visc
um al
bum
c. H
g
Visc
um U
lmi c
um
Hyd
rarg
yro
Visc
um al
bum
ssp.
albu
m
L./ H
ydra
rgyr
i sul
fas
Ferm
ente
d aq
ueou
s ext
ract
with
addi
tion
of m
ercu
ry su
lfate
(10-
5 m
g pe
r 100
mg
fresh
pl
ant),
pre
pare
d ac
cord
ing
to A
PC 7
.2.4
.Vi
scum
albu
m c.
Hg
Nam
e of c
ompo
sitio
nSc
ient
ific n
ames
of
ingr
edie
nts
Prep
arat
ion
met
hod
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
201
•
Ap
pend
ix 2
.7
APPENDIX 2.7
Stocks with special manufacturing methods
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
202
Nam
e of t
he su
bsta
nce
Defi
nitio
nPr
epar
atio
n m
etho
dRe
fere
nce
to S
tand
ard
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
Arni
ca m
onta
na, P
lant
a tot
a re
c. 1:
1,1
Etha
nolic
extra
ct o
f who
le pl
ants
of
Arni
ca m
onta
na L
.W
hole,
fres
h flo
werin
g pl
ants
of A
rnic
a mon
tana
L. a
re
com
min
uted
and
mac
erat
ed fo
r 10-
30 d
ays w
ith 1
.1 p
arts
of et
hano
l, gi
ving
an E
than
ol co
ncen
tratio
n of
36%
V/V
, th
en p
ress
ed an
d fil
trate
d.
HAB
Arni
ca, P
lant
a tot
a
Bryo
phyl
lum
pin
nata
1:1
,1Aq
ueou
s ext
ract
of B
ryop
hyllu
m
pinn
atum
(Lam
.) O
ken
Fres
h lea
ves o
f Bry
ophy
llum
pin
natu
m ar
e mac
erat
ed
unde
r occ
asio
nal s
tirrin
g wi
th 1
.1 p
arts
of w
ater
for
1.5-
2.5
h, p
ress
ed an
d th
e flui
d lat
er fi
ltrat
ed.
HAB
Bryo
phyl
lum
Carb
o Be
tula
eCa
rbon
obt
aine
d fro
m w
ood
of B
etul
a pe
ndul
a Rot
h or
B. p
ubes
cens
Ehr
h.Ca
rbon
pre
pare
d fro
m w
ood
of B
etul
a pen
dula
or B
. pu
besc
ens a
ccor
ding
to A
PC 4
.2 (c
f. Ph
.Helv
. 17.
7.4.
2).
Pote
ntisa
tion
acc.
to P
h.Eu
r. 4.
1.1
HAB
; Ph.
fr.Ba
rium
/Pan
crea
s com
p.; C
arbo
Be
tula
e; Ca
rbo
Betu
lae c
um M
etha
no;
Carb
o Be
tula
e/Ca
rvi a
ethe
roleu
m;
Carb
o Be
tula
e/Cr
atae
gus;
Carb
o Be
tula
e/Su
lfur
Carb
o Co
ffeae
Prod
uct w
ith m
in. 1
.0%
caffe
ine,
obta
ined
by i
nten
sive r
oasti
ng o
f rip
e, dr
ied
seed
s of C
offea
arab
ica L
.
Inte
nsiv
e roa
sting
of r
ipe,
drie
d se
eds o
f Coff
ea ar
abic
a H
AB. P
oten
tisat
ion
acc.
to P
h.Eu
r. 4.
1.1
(HAB
)
Carb
o Pt
erid
ii aq
uilin
iCa
rbon
obt
aine
d fro
m le
aves
of
Pter
idiu
m aq
uilin
um (L
.) Ku
hnLe
aves
of P
terid
ium
aqui
linum
are d
ried
and
the c
arbo
n is
prep
ared
acco
rdin
g to
APC
4.2
. Pot
entis
atio
n ac
cord
ing
to
Ph.E
ur. 4
.1.1
Carb
ones
/Pan
krea
s/W
ither
it
Care
x ar
enar
ia, e
than
ol.
Dec
octu
m 1
:4Et
hano
lic d
ecoc
tion
of th
e drie
d rh
izom
e of C
arex
aren
aria
L.
The c
omm
inut
ed d
ried
rhiz
ome i
s mix
ed w
ith 3
.14
part
s of
wat
er an
d 0.
86 p
arts
of et
hano
l 96%
. Afte
r 12-
18 h
, the
m
ixtu
re is
hea
ted
for 3
0 m
in u
nder
reflu
x to
get a
n et
hano
lic d
ecoc
tion
1:4
(DEV
) (cf
. Ph.
Eur.
1.2.
12).
The
mix
ture
is p
ress
ed an
d lat
er fi
ltere
d.
Cini
s Glec
hom
atis
Ash
from
drie
d flo
werin
g pl
ant o
f G
lecho
ma h
eder
acea
L.
Ash
obta
ined
from
drie
d flo
werin
g pl
ant o
f Glec
hom
a he
dera
cea a
cc. t
o AP
C 4.
3. P
oten
tisat
ion
acc.
to P
h.Eu
r. 4.
1.1
Cini
s Urt
icae
Fer
ro cu
ltae
Ash
obta
ined
from
drie
d, ae
rial p
arts
of
Urtic
a dio
ica F
erro
culta
Urtic
a dio
ica F
erro
culta
(app
. 2.5
) is d
ried
and
the a
sh
prep
ared
acco
rdin
g to
Ph.
Helv
. 17.
7.4.
3 (c
f. AP
C 4.
3).
Pote
ntisa
tion
acc.
to P
h.Eu
r. 4.
1.1.
Urtic
a dio
ica F
erro
culta
Vade
mec
um
Citr
us li
mon
, Fru
ct. r
ec.,
1:0.
41Et
hano
lic ex
tract
of f
resh
frui
t of C
itrus
lim
on (L
.) Bu
rman
fil.
Fres
h fr
uit o
f Citr
us li
mon
is ex
tract
ed w
ith et
hano
l 36%
(D
ER =
1:0
.41)
Hyp
eric
um p
erfo
ratu
m; F
los;
Extr.
oleo
s 1:2
Oil
extra
ct o
f fre
sh fl
ower
s of
Hyp
eric
um p
erfo
ratu
mFr
esh
flowe
rs o
f Hyp
eric
um p
erfo
ratu
m ar
e ext
ract
ed w
ith
2 pa
rts o
f refi
ned
sesa
me o
il.H
yper
icum
Lac T
arax
aci
Fres
h lat
ex o
f Tar
axac
um o
ffici
nale
(fres
h un
derg
roun
d pa
rts)
colle
cted
in
sprin
g (v
erna
le)
Ph.E
ur. 1
.1.2
Laur
ocer
asus
100
%Aq
ueou
s dist
illat
e of t
he fr
esh
leave
s of
Prun
us la
uroc
eras
us L
. with
0.0
9-0.
11%
H
CN
See m
onog
raph
; adj
ustm
ent o
f the
dist
illat
e to
0.1%
HCN
by
addi
ng et
hano
l 4.8
%H
AB; P
h.
Helv
.Sp
iritu
s con
tra tu
ssim
•
Appendix 2.7
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
203
Muc
ilago
Lev
istici
D1
Aque
ous e
xtra
ct o
f the
drie
d ro
ot o
f Le
visti
cum
offi
cinal
e Koc
hTh
e drie
d ro
ot is
com
min
uted
(200
0) an
d 1
part
is
mac
erat
ed fo
r 12-
18 h
with
8.4
par
ts of
wat
er an
d th
en
pres
sed
and
filte
red.
To
one p
art o
f the
flui
d 0.
1905
par
ts of
etha
nol 9
6% ar
e add
ed to
get M
ucila
go L
evist
ici D
1 wi
th 1
8% et
hano
l. La
ter,
the e
xtra
ct is
filte
red.
Ph.E
ur.
Levi
sticu
m
Sepi
a Gru
neris
Drie
d se
cret
ion
from
ink
glan
d fro
m
Sepi
a offi
cinal
is L.
Acc.
to G
rune
r: 1
part
of t
he d
ried
secr
etio
n is
extra
cted
un
der s
tirrin
g wi
th 5
.24
part
s of w
ater
for a
t lea
st 5
h, th
en
mix
ed w
ith 4
.76
part
s of e
than
ol 9
6%, p
oten
tised
and
filtra
ted.
Pot
entis
atio
n ac
c. to
Ph.
Eur.
1.1.
9
HAB
Sepi
a com
p.
Visc
um al
bum
, Ext
ract
um
resin
osum
An ex
tract
of t
he li
poph
ilic,
resin
ous
subs
tanc
es o
f the
gre
en p
arts
of V
iscum
al
bum
L.
Fres
h gr
een
part
s (ste
ms,
leave
s and
gre
en ge
nera
tive
orga
ns) o
f Visc
um al
bum
are c
omm
inut
ed an
d ex
tract
ed
with
supe
rcrit
ical
CO
2 at
700
-900
bar
.
Phyt
omed
icine
201
5;
22. S
uppl
. 1 S
. S28
. An
thro
poso
phisc
he
Phar
maz
ie S
alum
ed
Verla
g Be
rlin
2016
Nam
e of t
he su
bsta
nce
Defi
nitio
nPr
epar
atio
n m
etho
dRe
fere
nce
to S
tand
ard
Refe
renc
e for
use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
Oth
er
•
Ap
pend
ix 2
.7
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
205
•
Ap
pend
ix I
I
APPENDIX II
Correlation table: Ph.Eur./HAB manufacturing methods used in anthroposophic pharmacy and corresponding manufacturing methods in the HPUS
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
206
•
Ph. E
ur. /
HA
B m
etho
ds u
sed
in
anth
ropo
soph
ic p
harm
acy
Cor
resp
ondi
ng m
anuf
actu
ring
Met
hods
in th
e H
PUS
Ph. E
ur. M
etho
d 1.
1.1
(HA
B 1a
)Ph
. Eur
. Met
hod
1.1.
2 (H
AB
1b)
Cla
ss O
Ph. E
ur. M
etho
d 1.
1.3
(HA
B 2a
)Ph
. Eur
. Met
hod
1.1.
4 (H
AB
2b)
Cla
ss M
Ph. E
ur. M
etho
d 1.
1.5
(HA
B 3a
)Ph
. Eur
. Met
hod
1.1.
6 (H
AB
3b)
Ph. E
ur. M
etho
d 1.
1.7
(HA
B 3c
)
Cla
ss N
Ph. E
ur. M
etho
d 1.
1.8
(HA
B 4a
)C
lass
C
Ph. E
ur. M
etho
d 1.
1.9
(HA
B 4b
)C
lass
E
Ph. E
ur. M
etho
d 1.
1.10
(Ph.
fr.)
No
corr
espo
ndin
g H
PUS
met
hod
for a
ttenu
atio
ns, t
houg
h C
lass
C is
the
sam
e pr
oces
s for
the
first
step
1
Ph. E
ur. M
etho
d 1.
1.11
(Ph.
fr.)
No
corr
espo
ndin
g H
PUS
met
hod
for a
ttenu
atio
ns, t
houg
h C
lass
D is
the
sam
e pr
oces
s for
the
first
step
2
Ph. E
ur. M
etho
d 3.
1.1
(HA
B 5a
)C
lass
A o
r Cla
ss B
, dep
endi
ng o
n so
lubi
lity
Cha
ract
erist
ics o
f the
star
ting
mat
eria
l
Ph. E
ur. M
etho
d 3.
1.2
(HA
B 5b
)C
lass
A o
r Cla
ss B
, dep
endi
ng o
n so
lubi
lity
Cha
ract
erist
ics o
f the
star
ting
mat
eria
l
Ph. E
ur. M
etho
d 4.
1.1
(HA
B 6)
Cla
ss F
Ph. E
ur. M
etho
d 4.
1.2
(Ph.
fr.)
Cla
ss F
Ph. E
ur. M
etho
d 4.
2.1
(HA
B 7)
“Med
icat
ion:
Med
icat
ed P
owde
rs” a
pplie
s for
cent
esim
al, b
ut n
ot fo
r dec
imal
atte
nuat
ions
3
Ph. E
ur. M
etho
d 3.
2.1
(HA
B 8a
)Ph
. Eur
. Met
hod
3.2.
2 (H
AB
8b)
Cla
ss H
1 Th
e Ph
. Eur
. Met
hod
1.1.
10 p
rodu
ces a
1:1
0 pr
epar
atio
n fr
om w
hich
the
D1
or C
1 is
mad
e. Th
e H
PUS
Cla
ss C
also
pro
duce
s a 1
:10
prep
arat
ion.
But
this
is co
nsid
ered
the
sam
e as
a D
1. Th
us, P
h. E
ur. M
etho
d 1.
1.10
D1
= H
PUS
D2.
For
this
reas
on, t
he m
etho
ds d
o no
t cor
resp
ond.
2 Th
e Ph
. Eur
. Met
hod
1.1.
11 p
rodu
ces a
1:2
0 pr
epar
atio
n fr
om w
hich
the
D1
or C
1 is
mad
e. Th
e H
PUS
Cla
ss D
also
pro
duce
s a 1
:20
prep
arat
ion.
But
the
Cla
ss D
pr
epar
atio
n is
then
atte
nuat
ed 2
par
ts +
8 p
arts
veh
icle
to p
rodu
ce th
e D
2. Th
e pr
epar
atio
n by
Ph.
Eur
. Met
hod
1.1.
11 is
atte
nuat
ed 1
par
t + 9
par
ts v
ehic
le to
pro
duce
th
e D
1. F
or th
is re
ason
, the
met
hods
do
not c
orre
spon
d.3
HPU
S “M
edia
ted
Pow
ders
” are
spec
ified
to b
e m
ade
from
1 p
art l
iqui
d pr
epar
atio
n +
100
part
s veh
icle
.
•
Appendix II
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
207
•
Ap
pend
ix I
I
Ph. E
ur. /
HA
B m
etho
ds u
sed
in
anth
ropo
soph
ic p
harm
acy
Cor
resp
ondi
ng m
anuf
actu
ring
Met
hods
in th
e H
PUS
HA
B M
etho
d 9
“Med
icat
ion:
Tab
lets”
HA
B M
etho
d 10
“Med
icat
ion:
Glo
bule
s”
HA
B M
etho
d 11
“For
ms o
f veh
icle
s for
disp
ensin
g”
HA
B M
etho
d 12
a“F
orm
s of v
ehic
les f
or d
ispen
sing”
HA
B M
etho
d 12
bC
lass
M
HA
B M
etho
d 13
“For
ms o
f veh
icle
s for
disp
ensin
g”
HA
B M
etho
d 14
“For
ms o
f veh
icle
s for
disp
ensin
g”
HA
B M
etho
d 15
“For
ms o
f veh
icle
s for
disp
ensin
g: O
phth
alm
ic S
olut
ions
”
HA
B M
etho
d 16
New
Sec
tion
39, a
nd “I
ntro
duct
ion
to th
e H
omoe
opat
hic P
harm
acop
oeia
of t
he U
nite
d St
ates
: St
atem
ent r
egar
ding
com
bina
tions
of h
omoe
opat
hic d
rugs
”H
AB
Met
hod
17“A
ttenu
atio
ns: F
ifty
Mill
esim
al S
cale
of A
ttenu
atio
n”
Ph. E
ur. M
etho
ds 1
.2.1
-2 (H
AB
18a-
b)C
lass
M, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: I
ncub
atio
n”
Ph. E
ur. M
etho
ds 1
.2.3
-5 (H
AB
18c-
e)C
lass
N, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: I
ncub
atio
n”
Ph. E
ur. M
etho
d 1.
2.6
(HA
B 18
f)C
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: I
ncub
atio
n”
Ph. E
ur. M
etho
ds 1
.2.7
-8 (H
AB
19a-
b)C
lass
M, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: D
ecoc
tion”
Ph. E
ur. M
etho
ds 1
.2.9
-11
(HA
B 19
c-e)
Cla
ss N
, “Ti
nctu
res o
f bot
anic
al su
bsta
nces
: Dec
octio
n”
Ph. E
ur. M
etho
d 1.
2.12
(HA
B 19
f)C
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: D
ecoc
tion”
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 4.0
208
•
Ph. E
ur. /
HA
B m
etho
ds u
sed
in a
nthr
opos
ophi
c ph
arm
acy
Cor
resp
ondi
ng m
anuf
actu
ring
Met
hods
in th
e H
PUS
Ph. E
ur. M
etho
d 1.
2.13
(HA
B 20
)C
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: I
nfus
ion”
HA
B M
etho
d 21
Cla
ss O
, fer
men
ted
HA
B M
etho
d 22
Cla
ss P
Ph. E
ur. M
etho
d 1.
4.3
(HA
B 23
a)C
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: D
ecoc
tion”
Ph. E
ur. M
etho
d 1.
4.2
(HA
B 23
b)C
lass
N, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: D
ecoc
tion”
Ph. E
ur. M
etho
d 1.
4.4
(HA
B 24
a)C
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: I
nfus
ion”
HA
B M
etho
ds 3
3C
lass
P
HA
B M
etho
ds 3
4C
lass
P
HA
B M
etho
ds 3
5C
lass
P
HA
B M
etho
ds 3
6C
lass
P
Ph. E
ur. M
etho
d 5.
1.1
(HA
B 40
a)Ph
. Eur
. Met
hod
5.1.
2 (H
AB
40b)
Ph. E
ur. M
etho
d 5.
1.3
(HA
B 40
c)
No
corr
espo
ndin
g m
etho
d
Ph. E
ur. M
etho
d 2.
1.1
(HA
B 42
a)Ph
. Eur
. Met
hod
2.1.
2 (H
AB
42b)
Cla
ss L
, Met
hod
II
Ph. E
ur. M
etho
d 2.
1.3
(Ph.
fr.)
No
corr
espo
ndin
g m
etho
d
Ph. E
ur. M
etho
d 2.
2.1
(HA
B 41
a)Ph
. Eur
. Met
hod
2.2.
2 (H
AB
41b)
Ph. E
ur. M
etho
d 2.
2.3
(HA
B 41
c)Ph
. Eur
. Met
hod
2.2.
4 (H
AB
41d)
Cla
ss L
, Met
hod
II (a
ltern
ate
met
hodo
logy
)
HA
B M
etho
ds 4
5“F
orm
s of
veh
icle
s for
disp
ensin
g: N
asal
Sol
utio
ns”
HA
B M
etho
ds 5
1C
lass
P
•
Appendix II